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An Evaluation of Evidence-Based Prescribing Support from Primary Care 
Prescribing Advisers on GP Prescribing Behaviour 
 
 
Evidence-based prescribing is promoted in national policy and is an essential 
component of good quality, effective and safe healthcare.  Promotion of evidence-
based prescribing is fundamental to the pharmacist prescribing advisor’s professional 
role in primary care.   
 
The aim of this study was to evaluate the impact of an intervention delivered by 
pharmacist prescribing advisers on GP prescribing.  The intervention involved 
promotion of evidence-based prescribing utilising several approaches, which are 
known to be successful in influencing professional behaviour.  Management of Type 2 
diabetes and use of non-steroidal anti-inflammatory drugs were clinical areas targeted 
within the intervention. 
 
The study was designed and powered through quantitative methods to determine, the 
impact of the intervention on prescribing outcomes as measured using ePACT 
prescribing data.  The impact on measurable patient-orientated outcomes was also 
assessed.   
 
The qualitative evaluation explored GP perceptions, attitudes and beliefs regarding 
evidence-based medicine and considered the impact of the intervention from the GP 
perspective through semi-structured interviews. 
 
The results provide clear evidence for the impact of primary care pharmacists in 
influencing GP prescribing behaviour.  Statistically significant differences in 
achievement of primary prescribing outcome measures aimed at improving uptake of 
evidence-based prescribing (including reduction in diclofenac prescribing, p<0.05) were 
demonstrated in the intervention group compared with control.   
 
Statistically significant differences in patient-oriented outcomes were also 
demonstrated (HbA1c target ≤7.5%, p<0.01).  This finding challenges a main criticism 
of evidence-based medicine in that evidence is lacking to demonstrate that 
incorporation of evidence-based research into clinical decision-making improves 
outcomes for patients.  
 
Both qualitative and quantitative evaluations indicated that GPs had internalised and 
incorporated key evidence-based messages into their clinical decision-making as 
promoted and supported by the pharmacists. 
 
The intervention was shown to be effective in promotion and implementation of 
evidence-based prescribing in practice and provides an indication of how primary care 
pharmacists might develop their future role. 
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Introduction   
 
Provision of prescribed medication for patients is fundamental to the management of 
many acute and chronic conditions.  The most common healthcare intervention in 
the NHS is issue of a prescription.  Evidence based prescribing is promoted in 
national policy and is essential in providing good quality, effective and safe 
healthcare to patients.1,2,3 
 
Promotion of evidence-based prescribing is fundamental to the pharmacist 
prescribing advisor’s professional role in primary care.  However, prescribing 
decisions are often encountered in practice, which are contrary to current best 
evidence.  Inappropriate prescribing and lack of an evidence-based approach may 
not only result in ineffective treatment but may also be associated with potentially 
serious safety related issues.   
 
There are a number of external influences which clearly have an impact on general 
practitioner (GP) prescribing decisions including the pharmaceutical industry, 
requests from specialists, pressure from peers and not least, patients themselves.4  
Such influences do not necessarily represent an evidence-based perspective and 
may in fact contradict the available evidence or prescribing recommendations.  
Questions therefore arise around what does influence prescribing choices and why 
clinicians make the choices they do particularly in the light of available evidence to 
inform clinical decision-making in practice. 
 
The absence of a sound clinical evidence base underpinning many clinical decisions 
is widely suggested.5  However, compared with some other areas of clinical practice, 
evidence from large well designed randomised controlled trials of medicines in study 
populations have repeatedly demonstrated that those who receive evidence-based 
therapies have better outcomes than those who do not.6,7  Despite the availability of 
high quality research from large well-designed trials however, incorporation of 
evidence into the decision-making process and translation into routine practice 
remains an important goal.8 
 
Despite initiatives to promote evidence-based prescribing, evidence is also lacking 
to demonstrate that incorporation of evidence-based information into prescribing 
decisions improves patient care or patient outcomes.8   Additionally, prescribing 
patterns of many GPs indicate that they do not embrace the principles of evidence-
based practice.  Certain prescribing decisions may be considered irrational at best, 
potentially dangerous at worst. 
 
Medicines Management Services in NHS Primary Care Trusts (PCTs) fulfil 
widespread roles influencing decision-making processes and affecting provision of 
medicines related services across primary, secondary and tertiary care.9,10  A key 
principle embraced is promotion of evidence-based prescribing, influencing GP 
prescribers and extending initiatives across the primary/secondary care interface.   
 
Typically, Medicines Management functions include provision of prescribing support 
at practice and organisational level, as well as working across primary, secondary 
and tertiary care interfaces.10  Pharmacists are the key professionals involved in 
developing and achieving prescribing initiatives.9  In order to facilitate prescribing 
change, Medicines Management activities often involve GP practice visits, audit and 
provision of prescribing feedback as well as provision of synthesised evidence-
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based information often disseminated as guidelines, newsletters and PCT policies.  
Organisational level activities include facilitation and involvement in local therapeutic 
networks, primary/secondary care decision-making committees and educational 
initiatives for local healthcare professionals. 
 
Approaches adopted by pharmacists for influencing prescribing are often 
multifaceted and may be employed with varying success.  They may involve 
activities identified above and incorporate specific strategies to promote uptake of 
evidence-based medicine in prescribing.11  Although not strictly defined as a 
strategy, the resulting approach may be considered as integration of known 
successful approaches with social influence strategies for promoting evidence 
based medicine in prescribing.  This approach however has not been tested. 
 
Various interventions have been shown to be effective in changing professional 
behavior although evidence is inconclusive.  Interventions which are targeted at 
changing behaviour are defined as complex interventions, in other words comprising 
a number of separate elements consisting of a number of interacting components.  
Evaluation of complex interventions is by definition difficult because of problems of 
developing, identifying, documenting and reproducing the intervention.  In order to 
evaluate a complex intervention it is therefore necessary to define as clearly as 
possible each element of the intervention and standardise delivery of it in practice. 
 
Some of the methods known to be successful in influencing professional behaviour 
are utilised by prescribing advisers as part of their role in influencing prescribing 
change.   However, there is no clearly defined approach (for which the component 
parts are described) adopted for promotion and implementation of evidence-based 
prescribing in practice, and there is currently little evidence that such an approach, if 
adopted, works. 
 
The purpose of this research is to define, implement and evaluate an intervention 
delivered by pharmacist prescribing advisers in primary care, which is intended to 
influence GP prescribing behaviour.   The intervention which is by nature complex, 
will incorporate approaches which are known to be successful in influencing 
professional behaviour.  It is intended to demonstrate that the defined evidence-
based intervention works by changing GP prescribing behaviour.   
 
The study seeks to establish, through a mixed methods approach whether suitably 
skilled primary care pharmacists can promote the uptake of evidence-based 
prescribing by general practitioners.  The research seeks to provide quantitative 
evidence to demonstrate that the intervention improves prescribing by 
demonstrating changes in GP prescribing patterns.  It also seeks to establish 
whether improved outcomes which matter to patients can be demonstrated.   
 
Qualitative methodologies are also employed in order to explore concepts of 
incorporation of evidence into the clinical decision-making process by professionals 
in practice.  They seek to provide further evidence in order to gain greater 
understanding regarding the processes of internalisation of evidence-based 
medicine into decision-making by clinicians and by contributing to knowledge in an 
area which is little understood.  
 
This study is exploratory in nature and aims to ensure thorough development of the 
intervention in order to establish its application as intended in practice.  It is hoped 
that the results obtained may inform future medicines management strategies for 
influencing prescribing behaviour, and ultimately provide the basis for further 
research. 








The initial part of the literature review describes the principles and development of 
Evidence Based Medicine and its application in practice.  It explores how clinicians 
make clinical decisions and obtain information to inform those decisions.  It 
describes means of getting research evidence into practice and identifies barriers to 
the uptake of research evidence into the clinical decision-making process.  The 
particular importance of evidence-based prescribing is also considered here.  
 
Translation of evidence into practice and incorporation into the process of making 
prescribing decisions is fundamental to the prescribing adviser role in influencing GP 
prescribing behaviour.  The literature review therefore explores the evidence for 
interventions which are known to promote behaviour change in practice, in 
particular, academic detailing which is the method underpinning the intervention in 
this study.  It summarises the evidence for approaches that are known to work and 
what does not work in influencing behaviour change.  The evidence for the impact of 
pharmacists on influencing prescribing behaviour is then specifically explored as 
part of the review.  
 
The systematic literature search methodology is summarised in Appendix 1. 
 
2.1.1 Prescribing Advisers in Primary Care 
 
Pharmacists are the key professionals employed in influencing prescribing in 
primary care and are fundamental to this project in terms of their role in delivering 
the intervention which is to be evaluated.  This chapter therefore describes the basis 
of the role, functions and skills of the pharmacist prescribing adviser, set within the 
context of the Medicines Management function in primary care and identifies the 
approaches typically adopted in supporting GPs in prescribing objectives.  It also 
summarises the provision and availability of clinical and professional support for the 
primary care pharmacist role in practice. 
 
2.1.2 Theoretical Basis of Study Evaluation 
 
The evaluation of any intervention intended to change behaviour is by nature 
complex.  This study is based on the evaluation of a complex intervention.  This 
section describes the characteristics of complex interventions and highlights the 
difficulties which may be encountered in evaluating complex interventions.  It also 
summarises the principles which should be considered when developing and 
evaluating a complex intervention, in particular, clear definition of its component 
parts and standardisation of approach. 
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2.2 Evidence Based Medicine 
 
The underlying philosophy of evidence-based medicine (EBM), was first described 
in 1992 as representing a new paradigm and new approach in the teaching and 
practice of medicine.  It de-emphasised intuition, unsystematic clinical experience 
and pathophysiological rationale as sufficient basis for clinical decision-making.  
Instead, it favoured new skills (of question formulation, search and retrieval of the 
best available evidence, and critical appraisal of studies to ascertain validity of 
results) which practitioners need in accessing, appraising and applying best 
available evidence for incorporation into the decision-making process.   
 
Traditionally, the focus of teaching and the practice of EBM was based on training 
individuals how to seek answers to questions themselves by following a five step 
model. (Table 2.1)5,12,13,14 
 
 
The five steps involved in practicing evidence based medicine 
 
1. To convert information needs into an answerable question 
2. Access, with maximum efficacy, current best evidence to answer the question 
3. Critically appraise the evidence 
4. Integrate critical appraisal with clinical expertise and patient factors 
5. Evaluate effectiveness and efficiency 
 
 
Table 2.1 The Traditional Five Step Model Approach to the Practice of Evidence  
    Based Medicine 
 
It was recognised that in order to practice and incorporate EBM into clinical 
decision-making processes, clinicians would need to develop and apply skills in 
accessing most relevant and up to date evidence-based information.12,13,15  This 
assumption however relies on the fact that the individual will adopt the approach in 
order to seek appropriate answers and depends on the individual being able to 
determine relevant clinical questions in practice.  One study exploring questioning 
behaviour in GPs concluded that doctors would need to become more questioning in 
their routine practice if EBM and associated self-directed learning were to be 
successful.13,16  
 
A large number of publications on the subject of evidence-based practice are 
available in the literature.  Many texts intended to guide practitioners, particularly 
doctors, in how to develop and apply skills in developing answerable clinical 
questions, accessing the current best evidence, critically appraising the evidence 
and getting research into practice also exist.5,14 
 
The most widely used definition of Evidence Based Medicine is probably that 
expressed by Sackett and colleagues in 1996.17  
 
“Evidence Based Medicine is the conscientious, explicit and judicious use of current 
best evidence in making decisions about the care of individual patients.  The 
practice of evidence based medicine means integrating individual clinical expertise 
with the best available evidence from systematic research.” 
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Much has been published on the benefits of EBM and discussions have stimulated 
both positive and negative reaction from clinicians and academics.  
EBM has been described as promoting ‘Cookbook’ medicine, a term used to 
describe the practice of medicine by strict adherence to practice guidelines and 
which may not be an appropriate substitute for clinical judgement.  EBM has also 
been depicted as denigrating clinical expertise and ignoring patient values.18  Critics 
also argued that application of evidence from randomised controlled trials (RCTs), 
which form the basis of EBM as well as many guidelines, is not necessarily 
generalisable to the general population, and may potentially lessen the focus from 
patient-centred medicine.19  These misperceptions may have arisen initially because 
of a failure to appreciate step four in the five-step model described previously.8 
 
Criticisms regarding the limitations of EBM were summarised along with commonly 
held misperceptions concerning EBM in a commentary published in 2000 and are 





Universal to the practice of medicine 
 Shortage of coherent, consistent and relevant scientific evidence 
 Difficulties in applying the evidence to individual patients 
 Barriers to the practice of high-quality medicine (e.g lack of resources, costs) 
 
Unique to the practice of evidence-based medicine 
 Requirement to develop new skills in finding and accessing the evidence 
 Limited time and resources to seek out information 






 Evidence-based medicine denigrates clinical expertise 
 It ignores patient values and preferences 
 It promotes a ‘cookbook’ approach to medicine 
 It is a cost-cutting tool 
 EBM is an ivory tower concept 
 It is limited to clinical research 




Table 2.2  Commonly cited limitations and misperceptions of evidence-based 
medicine (Adapted from ‘Occasional Essay’ Straus and McAlister, 2000) 
 
Early in the EBM movement, it’s proponents sought to allay perceived 
misinterpretations that practicing EBM may ignore certain aspects of more traditional 
medicine such as clinical training, clinical experience, intuition and clinical problem 
solving.17  They challenged the view that EBM is ‘cookbook’ medicine and indicated 
that doctors need to use both clinical expertise and the best available external 
evidence and that neither alone is enough.  
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The concepts of EBM have continued to evolve as criticisms and limitations of 
earlier models were addressed. The emphasis being that research evidence alone is 
not adequate to guide action and that clinicians must apply their expertise to assess 
the patient and incorporate patient preferences or values before making a 
management recommendation.18,21  
 
EBM involves the active incorporation of relevant evidence into the clinical decision-
making process, and is therefore regarded as integration of best research evidence 
with clinical expertise and patient values.5,13  
 
In 2004, a series of articles in the BMJ sought to reflect on the challenges of 
practicing and teaching EBM, highlighting the work that had been done in the field 
and providing an opportunity to point the way forward.  It was noted that as an 
intervention, not only had EBM been difficult to define, but it was also difficult to 
evaluate.  It pointed out that whilst changes in knowledge and skills are relatively 
easy to detect, changes in attitudes and behaviours were harder to confirm, with 
changes in patient outcomes being even more challenging to detect.22,23  
 
A number of themes emerged from the articles.  Research had demonstrated that 
educational interventions involving EBM had improved knowledge, skills and self-
reported behaviours.  EBM was being incorporated more widely into learning 
environments with the principles of EBM becoming core concepts.8,24  One 
systematic review of educational interventions concluded that whilst critical appraisal 
and EBM skills can be taught through standalone courses, improvements in skills, 
attitudes and behaviour are more effective when taught in clinical practice.24  
 
Important developments in EBM included improved access to evidence through 
availability and popularity of structured abstracts and secondary journals 
summarising studies of high relevance and methodological quality.  The availability 
and accessibility of regularly updated evidence based information from credible 
sources such as the Cochrane Library with its systematic reviews and BMJ ‘Clinical 
Evidence’ were cases in point.   
 
The importance of and ongoing requirement to produce evidence from high quality 
research to inform clinical practice remained.  However, because of the sheer 
volume of published information available requiring review and evaluation, 
knowledge translation was highlighted as a major challenge to ensure that clinicians 
have access to relevant and current best evidence.25  
 
2.2.1 Hierarchy of Evidence 
 
Different research study designs carry different ‘weight’ in terms of the reliability of 
the evidence obtained and there is broad agreement on the relative strength of the 
main types of research in the ‘hierarchy of evidence’ which is fundamental to the 
practice of EBM.  Well conducted prospective double-blind randomised controlled 
trials are regarded as ‘gold standard’ although systematic reviews or meta-analyses 
of RCTs are placed higher in some hierarchies.  Non-blinded studies are more 
reliable than retrospective studies.  Observational studies followed by expert opinion 
and clinical experience are ranked lowest.14,26,27,28 
 
Recommendations from different guidelines however, may differ or even disagree 
despite citing the same studies.  One study demonstrated that less than a third of 
recommendations based on evidence from RCTs were actually based on high 
quality evidence, indicating that guideline recommendations should not necessarily 
be assumed to provide high quality evidence for therapy recommendations.29  
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A number of grading schemes have been developed to assess the quality and 
hence the strength of evidence from primary research (e.g. SORT, GRADE).  Levels 
of evidence may therefore be allocated to published research findings or guidelines 
to help clinicians determine the quality of evidence in order to facilitate incorporation 
of EBM into their clinical decisions.30  
 
2.2.2 Progress in Evidence Based Medicine 
 
Understanding of and implementation of EBM in practice has come a long way since 
its inception and few would argue that the principles of EBM be rejected.  It is widely 
accepted that considerable progress has been made.25,31  
 
The term Evidence Based Practice (EBP) is now employed to encompass 
healthcare and healthcare professionals (HCPs) from all disciplines and is regarded 
as a key skill.8,13,32  Teaching EBP has become an integral part of undergraduate 
and post-graduate curricula for many healthcare professionals.8,13  The emphasis on 
EBP in many medical schools and training programmes is also shifting from 
development of skills in individual evidence appraisal towards focus on 
implementation of evidence in practice.31  
 
Despite advances in EBM, a number of challenges still remain.8  Provision of high 
quality evidence from clinical research is not alone sufficient to change behaviour.  
Knowledge translation and interventions which aim to address implementation of 
evidence in practice as well as having effective means of measuring effectiveness 
are all deemed necessary.8,25  
 
2.2.3 Application of EBM in Practice 
 
Despite availability of high quality evidence from large well-designed RCTs, and the 
evolution of evidence based medicine, medical research is constantly producing 
evidence-based findings which are not routinely incorporated into clinical decision-
making or translated into healthcare practice.33,34,35  Clinical practice in many 
instances appears at odds with even clear cut research results.36,37   
 
There is currently no clear evidence which demonstrates that incorporation of 
evidence-based research into clinical decision-making improves outcomes for 
patients.  Getting research into practice remains an important objective.   
 
It has been suggested that the most basic assumptions of EBM remained unproven 
and largely untested.  A key factor is lack of understanding of how the process of 
EBM is adopted and internalised by practitioners.  It is not known whether 
convincing information leads to optimal decision-making or whether clinicians base 
their decisions on best evidence, or whether EBM ultimately affects patient care.8,38  
Evidence of improved patient outcomes remains lacking.   
 
Moreover, many clinicians may not embrace the evidence-based paradigm or adopt 
the principles in practice.  For research-based evidence to be incorporated into 
practice may still require HCPs to change long-held patterns of behaviour.3,12,39  
 
2.2.4 Clinical Decision Making 
 
One factor in considering the incorporation of EBM into practice is an understanding 
of what influences clinical decision-making.  Despite a number of studies which have 
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sought to establish why clinicians fail to incorporate evidence into the clinical 
decision-making process, the reasons remain unclear.   
 
One key ethnographic study explored how primary care clinicians derive individual 
and collective healthcare decisions.  The authors concluded that:  
 
‘Clinicians rarely accessed and used explicit evidence from research or other 
sources directly, but relied on ‘mindlines’ - collectively re-enforced internalised tacit 
guidelines’.  These were informed by brief reading but mainly by their own and 
colleagues’ experience, their interactions with each other and with opinion leaders, 
patients and pharmaceutical representatives and other sources of largely tacit 
knowledge - resulting in socially constructed “knowledge in practice”’.40  
 
Although in no way providing evidence for incorporation of EBM into practice, this 
study highlighted the potential for exploiting existing formal and informal networking 
as a key means of disseminating evidence to practitioners.  
 
Coumou considered how primary care physicians seek answers to clinical questions 
in reaction to the increase of greater availability of online journals, bibliographic 
databases and the internet during 1992-2005 (which also corresponded with the 
evolution of EBM).  He also concluded that despite the enormous increase and 
better accessibility of electronic information sources, primary care clinicians seek 
answers only to a limited number of questions about which they first consult 
colleagues and paper sources.41  
 
Pharmaceutical representatives, hospital consultants, hospital prescribing and 
patients have all been shown in other studies to be primary influences on the uptake 
of new drugs by GPs.4,42,43  One study concluded that ‘GPs are largely reactive and 
opportunistic recipients of information, rarely actively searching information, 
influenced more by ‘who says what’.4  The patient, practitioner-patient relationship, 
verbal and non-verbal communication have also been identified at practitioner level 
as factors relevant to the decision-making process.  Importantly, however, the 
available evidence suggests that evaluation and critical appraisal of the evidence 
are not key elements of the decision-making process.   
 
Conclusions from these and other studies reinforce the concept of the ‘mindline’ 
model and its significance in how clinicians seek information to answer clinical 
questions in practice.  They also highlight the challenge in that barriers to 
implementation of EBM remain.   
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2.2.5 Barriers to the Uptake of Translating Evidence into Practice 
 
Scott suggests that it is necessary to understand better the determinants of clinician 
behaviour and a clinician’s view of compelling evidence to improve evidence-uptake. 
Understanding of integration into the process of clinical decision-making is also 
necessary.36  Barriers to and incentives for evidence uptake may also be mapped 
out at micro, (individual physician and patient), meso (social and organisational) and 
macro (economic and political) level.  It may then be possible to devise suitable 
methods for optimising behaviour which can then be tested.3,36  
 
Barriers towards evidence-based thinking and acting have been explored and 
reviewed in a number of qualitative studies.43,44,45  One study explored barriers as 
perceived by GPs at micro, meso and macro level through grounded approach.41  
Themes identified by GPs themselves as barriers to implementation of evidence into 
practice in primary care include GP personal/professional experiences, patient-
doctor relationship, perceived tensions between primary/secondary care, feelings 
about the evidence, logistical problems, competencies, time and EBM resources.44,45  
Some GPs regard clinical evidence as a square peg to fit in the round whole of the 
patient’s life.45  
 
In addition, physicians frequently feel overwhelmed with information.  Although they 
may have a positive attitude towards EBM, they lack time and skills to appraise 
scientific papers and have difficulty finding, assessing, interpreting and applying 
current best evidence.46,47  Many appear well aware of the gaps in their knowledge, 
their problem being, to get adequate information quickly.48  
 
In order to practice EBM effectively, clinicians today cannot hope to obtain the 
information they need by searching and evaluating it themselves.  Better transition 
of information making it focussed and accessible to them is required.  Proposed 
solutions include services that abstract and synthesise information, and improving 




2.2.6 Evidence Based Prescribing 
 
Evidence-based prescribing is an essential component of good quality, effective and 
safe healthcare for patients which underpins national healthcare policy and 
guidance.1,2,3  
 
Inappropriate prescribing and lack of evidence-based approach may result in 
ineffective treatment and serious safety related issues.  Between 5-17% of hospital 
admissions in the elderly are known to be medication related.1   Incorporation of 
evidence in prescribing decisions is therefore a key intervention in clinical decision-
making.1,2  It cannot be assumed however that dissemination of information or even 
awareness of evidence-based research leads to incorporation of knowledge into 
clinical decision-making or, that it will ultimately bring about a change in practice.    
 
There is currently little evidence to demonstrate that incorporation of evidence into 
clinical decision-making improves outcomes for patients although results from robust 
randomised controlled trials has repeatedly demonstrated that those who do receive 
evidence based therapies have better outcomes than those who do not.5,6,7  
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Provision of evidence-based prescribing support from a reliable and trusted source 
using a combination of methods which are known to work in influencing behaviour 
change may be an effective approach to incorporation of the evidence base into 
clinical-decision making relating to prescribing.  By understanding the barriers faced 
by clinicians, it is possible to develop a tailored approach intended to overcome the 
barriers and encourage change in behaviour.3,49  This study seeks to address 
identified barriers by means of an intervention which will engage practitioners and 
promote integration of evidence-based prescribing into the clinical decision-making 
process. 
 
The term ‘evidence-based’ often precedes many recommendations and guidelines 
which are not transparently linked to the underlying evidence base and which is not 
necessarily accessed from credible sources.31  There are often commercial interests 
behind promotion of much information.  Unsophisticated users of the medical 
literature may incorrectly assume that such reports are based on current best 
evidence and advocate implementation in practice.31  There therefore remains a 
requirement for the promotion of EBM through access to and dissemination of 
robust evidence-based information.  It is necessary that clinicians have access to 
appropriate sources of evidence, evidence summaries and guidelines that 
acknowledge the most current EBM thinking.  Primary care pharmacists are in an 
ideal position not only to access the evidence but also communicate evidence-
based prescribing information to other health care professionals. 
 
 
2.2.7 Evaluation of Evidence-Based Practice 
 
The EBM paradigm is multifaceted and complex in nature and despite the volume of 
published papers on the subject, demonstration of the success of the EBM 
movement is not straightforward.  Clear evidence is lacking in relation to various 
domains of EBP including uptake by professionals, change in clinical behaviour and 
translation of evidence into practice and not least the impact on the healthcare of the 
patient.8  
 
One systematic review designed to identify measures for assessing practice change 
in practitioners following an intervention aimed at increasing uptake of evidence into 
practice concluded that most studies measured the effect of the intervention at the 
level of the practitioner.  Few actually measured whether any change in practice 
resulted in a change which affected patient health status.  Most did not report 
validity or reliability of the measures used.50  
 
Another systematic review of studies on tools designed to evaluate education in 
EBP indicated that most concentrated on EBP knowledge and critical appraisal skills 
rather than objectively documenting behaviours in actual practice.  The authors 
concluded that further development and testing of instruments to test attitudes, 
behaviours and other aspects of EBP were necessary.51  
 
More recently, a classification for standardising the components and development of 
EBP learning assessment tools which includes practitioner attitudes, values, 
behaviours and potential benefits to patients has been proposed,. However, the 
focus in practice remains evaluating skills in formulating and answering clinical 
questions rather than assessing attitudes and actual behaviours.52   
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2.3 Evidence for Interventions to Influence Behaviour Change in Practice 
 
Many studies and reviews have sought to identify interventions which influence HCP 
behaviour and bring about change in practice.35,39  Specific interventions, 
interventions targeted at improving specific behaviours (patient management, 
disease management, preventative care, prescribing, service utilisation) and broad 
strategies (guideline implementation, continuing medical education) have all been 
considered.   
 
The NHS Centre for Reviews and Dissemination reported an overview of forty-four 
systematic reviews of different dissemination and implementation intervention 
approaches to changing professional practice.39  
 
Specific interventions which have been shown to be consistently (but generally 
moderately) effective are interactive educational meetings, educational outreach 
visits (academic detailing), opinion leaders, patient mediated interventions and 
reminders/prompts issued during consultation.39,53  Multifaceted interventions and 
those assessing potential barriers to change were more likely to be effective than 
single interventions.  Multifaceted interventions tended to effect changes in 
performance but less consistently in health outcomes.   
 
Review of interventions specifically intended to improve prescribing indicated that 
educational outreach approaches and ongoing feedback were generally effective.  
However, inadequately controlled reporting of some studies highlighted a need for 
rigorous evaluation of the dissemination and implementation strategies.  Educational 
outreach was considered as potentially a promising approach for modifying 
professional behaviour, especially prescribing. 
 
One systematic review of 235 studies specifically explored the effectiveness of 
guideline development, dissemination and implementation strategies.  Single 
interventions included reminders, dissemination of educational materials and audit 
and feedback.  Multifaceted interventions, (twenty-three involving educational 
outreach), were included in the review.  The majority of interventions observed 
modest to moderate improvements in care.54  
 
Results indicated that reminders are potentially effective, and that educational 
outreach may result in modest improvements in the process of care.  The evidence 
for educational materials, audit and feedback and patient directed interventions was 
less robust as there were fewer interventions, nevertheless, these may result in 
modest or moderate effects.  
 
The authors highlighted difficulties in interpretation of the results, arising as a result 
of differences in context, barriers and targeted behaviour in the studies assessed.  
Most studies used process measures for their primary endpoint, rather than 
measures of care and only three of the guidelines were explicitly evidence based.  
The overall quality of the studies was also described as poor.  Some of the results 
were at odds with other reviews.54  It was suggested however, that dissemination of 
educational materials and short educational meetings may be an appropriate 
circumstance in which to engage with practitioners.  The conclusions overall were 
largely tentative, indicating that further well designed robust evaluations were 
required.  They also seemingly emphasise recognised difficulties encountered in the 
evaluation of complex interventions.  
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Barriers to guideline adherence have been identified as lack of awareness, lack of 
familiarity, lack of agreement, lack of self-efficacy, lack of outcome expectancy, and 
inertia of previous practice.55  Clinical decision support systems using prompts 
based on patient-specific characteristics may suggest potential for improving patient 
care.56  However, computerised decision support systems intended to increase 
adherence to evidence-based guidelines have been shown to be ineffective.57,58  
Guidelines were however more likely to be effective if they took account of local 
circumstances and were disseminated by active educational interventions such as 
educational outreach.39  
 
Audit and feedback on performance, local opinion leaders, rules and incentives have 
been shown as sometimes effective.  Didactic educational meetings and 
dissemination only strategies such as conferences and distribution of unsolicited 
materials including clinical guidelines demonstrated little or no effect.35,39,53,54  
 
A Cochrane review assessing audit and feedback as a strategy to improve 
professional practice and healthcare outcomes, concluded that audit and feedback 
can be effective in improving professional practice, the effects being small and 
moderate but may be worthwhile.59  Effects may be larger when HCPs are actively 
involved with responsibilities for implementing change.  Provision of printed 
education materials, might also modify the effect of audit and feedback.59  Audit and 
feedback involving comparison with peers has also been shown to be effective.59  
 
Interventions relying solely on passive information transfer are ineffective whilst 
active knowledge translation strategies are usually effective.  Educational outreach 
and delivery of targeted educational messages by a credible messenger is most 
consistently effective.60  
 
A systematic review of 102 studies indicated that dissemination only strategies such 
as conferences and mailing unsolicited materials demonstrated little or no change in 
health care professional behaviour or health outcome.  More complex interventions 
such as outreach visits or opinion leaders ranged from ineffective to highly effective 
with most being moderately effective.  The authors concluded that ‘there are no 
magic bullets for provider behaviour change.  A range of interventions can lead to 
provider change but no single intervention is always effective’.35  A similar 
systematic review by the same authors specifically on the effect of continuing 
medical education (CME) strategies also concluded that effective interventions 
included reminders, patient-mediated interventions, outreach visits, opinion leaders 
and multifaceted activities.  Audit and feedback and educational materials were less 
effective and formal CME conferences or activities without practice reinforcing 
strategies had little impact.61  
 
Overall, evidence for interventions aimed at changing health professionals 
behaviour remains limited and in many cases inconclusive, largely because it is 
based on evaluation of diverse interventions in terms of the intervention settings, the 
behaviours or quality improvement targeted and methodological aspects of the 
studies reported.47  Interventions aimed at bringing about behaviour change are 
complex in nature and cannot necessarily be generalised to other situations.  The 
paucity of available evidence for effectiveness reflects difficulties encountered in the 
evaluation of such complex interventions.62,63,64  
 
Effectiveness of different methods to facilitate implementation of evidence in 
practice are summarised in Table 2.3. 
 




















 Reminders or 
prompts (patient-
specific) 
 Audit with feedback 
and follow-up review 
 Use of local/national 




 Audit with feedback 
only 
 Local consensus 
process 
 Patient mediated 
interventions 
 Interventions 





 Educational materials 










Table 2.3. Effectiveness of Methods to facilitate implementation of evidence in 
       practice 
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2.3.1 Academic Detailing (Educational Outreach)  
 
The evidence for interventions which influence behaviour change in practice 
suggests that the most consistently effective approach is through academic 
detailing.  The approach is based on ‘social marketing’ theory, or, the selling of 
ideas rather than physical products to achieve health and social solutions.39,60 
 
Soumerai and Avorn originally defined the principles of ‘academic detailing’, also 
known as ‘educational outreach’.65  They noted that a number of theories and 
principles of communication and behaviour change underlay the success of the 
pharmaceutical industry in influencing prescribing practices.  Despite this, there was 
little in the literature at the time about the approaches adopted by pharmaceutical 
representatives or how these may be adapted to the non-profit sector to reduce 
inappropriate prescribing.  They therefore set out to determine the aspects of 
detailing which could be utilised in supporting physicians in making better 
therapeutic decisions. 
 
They focused on approaches to improving prescribing behaviour for example by 
using drugs with better safety profile, decreasing use of marginal therapies, reducing 
prescribing in vulnerable groups and making more cost effective prescribing choices 
and ultimately demonstrated changes in prescribing behaviour. 65  In their study two 
brief visits to physicians by clinical pharmacists reduced inappropriate prescribing of 
a number of drugs by 14% compared with control (p≤0.0001).66  
 
Soumeri and Avorn consequently defined the key techniques or elements 
incorporated in the academic detailing approach, which necessarily, involves face to 
face communication with the practitioner.66,67  
 
These include: 
 Investigating the baseline knowledge and motivation for current prescribing 
patterns 
 Focusing detailing programmes on specific categories of physicians 
 Defining clear educational and behavioural objectives 
 Establishing credibility through a respected organisational identity, referencing 
authoritative and unbiased information sources 
 Stimulation of active physician participation in educational interactions 
 Use of concise graphic educational materials 
 Highlighting and repeating essential messages 
 Providing positive reinforcement of improved practices in follow-up visits.   
 
Elements of an outreach visit may vary.  However, selection and training of 
academic detailers is crucial to the success of this approach.66 
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2.3.1.1 Evidence for the Effectiveness of Educational Outreach Visits  
 
Educational Outreach Visits (EOVs) have been identified as having the potential to 
improve the practice of healthcare professionals.  EOVs rely on a personal visit by a 
trained person to health care professionals (HCPs) in their practice environment.  
This face-to-face communication may also be referred to as academic detailing or 
educational detailing.   It may include feedback on performance. 
 
The Cochrane EPOC Review Group specifically assessed the effects of educational 
outreach visits on professional outcomes.  In the review, an EOV was defined as a 
personal visit by a trained person to healthcare professionals in their own settings.68  
The review included 69 studies involving more than 15,000 HCPs.  Effects varied 
depending on types of behaviour being evaluated.  However, the results were 
consistent in demonstrating effects relating to prescribing but varied for other types 
of performance.  
 
For interventions aimed at changing prescribing behaviour, the authors concluded 
that EOVs alone or when combined with other interventions have effects that are 
relatively consistent and small to moderate, but potentially important.68,35 
 
They recommended six aspects for consideration for future research into EOVs: 
 It is important that investigators report each of the components of the 
intervention in detail, including the type of visitor and the content of the visits.  
(Sustained efforts to improve practice might be more effective and efficient than 
one-time efforts).   
 As effects of EOVs are generally small/moderate, studies should be powered 
sufficiently to detect small but important effects. 
 Process evaluation embedded in trials should support determination of  the 
extent to which the intervention was implemented and how it improved practice 
 Including patient outcomes as well as professional performance should be 
considered.   
 Evaluation should consider the number and nature of behaviours targeted for 
improvement as targeted behaviours requiring a large number of steps may be 
too complex to interpret. 
 If found to be effective, where possible, studies should measure use of 
resources and include economic analyses.   
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2.3.2 Evidence for the Impact of Pharmacists in Influencing Prescribing 
Behaviour 
 
Pharmacists are experts in medicines use.  Numerous studies have reported the 
impact of pharmacists from differing backgrounds and experience on prescribing 
and medicines use in various settings and circumstances.   
 
Community Pharmacists have long influenced prescribing behaviour at individual 
patient level through initiatives such as medication review, repeat prescribing and 
disease management.69,70,71,72  Community pharmacists undertaking sessional work 
in practices have been shown to influence practice prescribing through assessing 
their clearly documented interventions including patient review.69  Case conferences 
involving community pharmacists with GPs resulted in uptake of significantly more 
clinically relevant recommendations compared with written feedback alone.70  
Improvement in patient knowledge, medication use and clinical measures have been 
demonstrated when community pharmacists have been instrumental in delivering 
structured pharmaceutical care plans for patients with long term conditions.72  
 
Early evidence for primary care clinical pharmacists has also demonstrated their 
impact working within GP practices and influencing prescribing behaviour.  Although 
changes have often been measured by cost savings, promotion of more rational or 
cost-effective prescribing was the foundation of many initiatives.73,74  Despite initial 
reservations, (Canadian) physician perspectives of pharmacists integrated into 
family practice, providing medication assessment, drug information, academic 
detailing and practical enhancements are positive and benefits of collaborative 
working have been realised.75,76,77  Primary care pharmacist led disease 
management and patient consultations have also improved medication use and 
influenced patient care at both individual and practice levels.78,79,80,81 
 
As PCTs emerged through NHS reforms, PCT prescribing advisers became the 
mainstay of prescribing support to GPs locally, promoting high quality prescribing 
and value for money within the context of wider healthcare.82  As PCT 
responsibilities in development and delivery of local services increased, primary 
care pharmacists now embrace a broad range of roles across a wide range of 
agencies.83,84 
 
Practice visits to promote rational cost effective prescribing and providing 
prescribing feedback became an established means of communicating with GPs.  
UK studies have demonstrated that such practice (outreach) visits by pharmacists 
providing feedback specifically on prescribing cost and volume indicators using 
comparative ePACT data had some influence on prescribing behaviour.85,86,87,88  
Additional elements of some interventions included discussion around rational drug 
use and prescribing recommendations.  Face to face discussions appeared more 
successful in reducing inappropriate prescribing than printed information. 85,86,87  
Limitations regarding these studies were that outcome measures were generally 
based on cost rather than the appropriateness of prescribing based on available 
evidence. 
 
A limited number of studies have specifically evaluated the effect of educational 
outreach (or academic detailing) by pharmacists on prescribing behaviour.  The 
majority were conducted in the southern hemisphere.  Most also evaluated 
compliance with guidance/guideline recommendations or reduction in costs rather 
than incorporation of evidence-based practice into clinical decision-making.  Many 
have documented limitations relating to design and evaluation of the intervention.   
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2.3.2.1 Evidence for the Impact of Pharmacists Using Academic Detailing 
 
In one Australian study, educational mailing plus project pharmacist visits delivering 
campaign messages to GPs, demonstrated significantly improved compliance with 
antibiotic guideline recommendations in the intervention group compared with 
control.89  Another Australian study providing antibiotic prescribing guidelines plus a 
brief visit from a clinical pharmacist demonstrated a significant difference in 
prescribing of preferred antibiotics in the intervention group compared with control.90  
 
Three Tasmanian studies by the same authors, separately evaluated appropriate 
prescribing of allopurinol, NSAID and antibiotics.91,92,93  Each involved provision of 
educational material on the specified topic.  A pharmacist then visited to discuss 
rational prescribing of the medications with each GP.  Statistically significant 
differences in prescribing were demonstrated in each study.  The authors concluded 
that educational programmes utilising academic detailing by clinical pharmacists can 
modify prescribing practices within the community setting.  A further Tasmanian 
study demonstrated that a multifaceted approach employing educational outreach 
visit plus educational materials, guidelines, feedback and reminders also produced 
statistically significant increase in the use of osteoporosis therapy in long term oral 
corticosteroid users.94  
 
Educational outreach by clinical pharmacists providing prescription analysis and 
feedback, report interpretation, therapeutic bulletin plus locally preferred prescribing 
list in New Zealand resulted in reduced prescribing of benzodiazepines and a 
significant increase in use of preferred medicines.95   
 
One Australian study in which GPs received academic detailing visits from 
experienced teaching-hospital clinical pharmacists who developed evidence-based 
presentations on the pharmacological management of heart failure and osteoarthritis 
demonstrated improvements in prescribing of appropriate medications.  However, 
the small sample size limited comprehensive statistical analysis.96  
 
Asthma symptom scores were significantly improved (p<0.03) in a more recent 
South African disease management study.  Intervention practices received two 
EOVs from pharmacists trained in academic detailing, who also left materials 
describing key interventions to improve asthma care.  Control practices received 
written copies of the guidelines.97  
 
Relatively few studies in the UK have investigated the effects of pharmacists in 
improving prescribing behaviour.  None explicitly investigated uptake of evidence-
based practice.  One early study investigated the use of academic detailing using 
detail aids to encourage rational approach to prescribing of NSAIDs.  The 
intervention produced a significant increase in prescribing (costs) of the preferred 
NSAID in the intervention group compared with control.98  A cluster RCT in twenty 
GP practices of mailed guidelines versus mailed guidelines plus educational 
outreach visits from trained community pharmacists on prescribing of recommended 
NSAIDs, showed no significant differences between groups.99  One small UK study 
(two practices) indicated that provision of therapeutics advice by a clinical 
pharmacist and consultant pharmacologist using educational outreach improved 
management of hypertension, atrial fibrillation and guideline adherence.100  Another 
study assessing the impact of an educational outreach campaign (IMPACT) led by 
primary care pharmacists on depression management influenced prescribing 
behaviour in terms of adherence to NICE guidance and cost-effective prescribing of 
antidepressants.101  
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In the UK, the larger EBOR study evaluated acceptability and effectiveness of 
outreach visits by community pharmacists using evidence-based practice guidelines 
to promote change in prescribing.  Pharmacists trained in guideline content and 
detailing techniques performed two visits on guideline topics for four commonly used 
interventions.  Overall there was an (5.2%) improvement in number of patients 
treated according to the guidelines.  Results ranged from +7% (aspirin) to -3% 
(NSAIDs) depending on the guideline.102  The study design and interpretation has 
however been open to criticism.  Guideline compliance was evaluated by practice 
level data collection (not ePACT).  A post hoc evaluation of EBOR reported complex 
interactions between pharmacists, GPs and guideline topics with many influences 
and barriers affecting uptake of each guideline.103  The authors recommended that 
future interventions use a range of methods to explore steps leading to behaviour 
change. 
 
The Norwegian RaPP study evaluated a multifaceted intervention (educational 
outreach, audit and feedback, computerised reminders) delivered by pharmacists to 
support guideline implementation and promote uptake of evidence-based research 
findings into clinical decision-making.  There was an increase in adherence to 
guideline recommendations on choice of antihypertensive drug but no difference in 
secondary patient-oriented outcomes.104,105  An economic evaluation of RaPP 
however predicted modest savings over two years, as the preferred drug was 
cheaper.106  
 
In an attempt to address current lack of evidence, two Italian RCTs were proposed 
to test evidence-based methods, academic detailing and pharmacist outreach visits 
on a large scale and to make independent and evidence-based information available 
to GPs.107  One study aimed to evaluate one-to-one (pharmacist–GP) meetings plus 
information format (the other, to evaluate small group meetings).  One hundred and 
fifty primary care groups were to be randomised to primary care pharmacist 
outreach visits on one of two topics, aiming for a 10%-15% decrease in prescribing 
of targeted drugs.  GP knowledge and attitudes were to be assessed through a 
questionnaire.  There was however no control (non-intervention) group and it is 
possible that confounding may have occurred because each group received one 
intervention.  Further details are not accessible, however, comment by the authors 
provided in an abstract published since the original literature review suggested that 
the feasibility and acceptance of the proposed Italian strategy may have been high 
with significant impact on certain prescribing outcomes.108  
 
Only one RCT has specifically evaluated individual versus group detailing and 
demonstrated that both individual and group visits decreased prescribing of highly 
anticholinergic antidepressants in elderly people compared with control (no visits).109   
Practice visits engaging GPs as a group (as typically occurs in practice) is 
considered to be a suitable and more cost effective approach to influencing 
prescribing behaviour than visits with individual GPs and will be employed in this 
study. 
 
Evidence for influencing prescribing behaviour by pharmacists using outreach visits 
and academic detailing remains weak, particularly in the UK.  However, the 
evidence does suggest that pharmacists with clearly stated clinical and 
communication skills are most likely to be successful at bringing about behaviour 
change in prescribing.110  Targeted visits are more likely to be effective than 
untargeted visits.110,111  It is therefore intended in this study to address 
inconsistencies in study design and lack of rigour apparent in the currently published 
studies. 
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In general, studies evaluating the impact of pharmacists or other health care 
professionals on prescribing behaviour are quantitative, focusing on prescribing data 
and identifying shifts in prescribing.  Most qualitative studies however, tend to focus 
on physicians perceptions of and barriers to EBM.44,45,46,47,48  As far as the 
researcher is aware, only one (Israeli) qualitative study has evaluated the impact of 
an EBM teaching intervention on primary care physicians’ point of care behaviour.112  
The teaching emphasised accessing, appraising and integration of best evidence 
into practice.  Although it affected attitudes and knowledge it had little impact on the 
physicians’ ability to use pre-appraised resources at the point of care because of the 
complexity and impracticality of use in a busy setting.  Constantly changing 
evidence was also perceived as hindering the practice of EBM.  The study identified 
a need to improve ease of access to evidence-based resources.  
 
This study will use pre-appraised evidence-based information in face-to-face 
communication with primary care pharmacists thus removing the burden for GPs of 
seeking evidence at the point of prescribing.   
 
Not all sources of information (including guidelines) are transparently linked to the 
underlying evidence base and they do not necessarily represent a critical appraisal 
of the evidence.  It is important to ensure that clinicians continue to have access to 
appropriate sources of evidence, evidence summaries and guidelines that 
acknowledge the most current EBM thinking.  Primary care pharmacists are in an 
ideal situation to access the evidence and communicate the most up to date 
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2.4 Primary Care Pharmacists 
 
Pharmacists are key players in the management of medicines.   They are highly 
skilled and trained professionals possessing greater expertise in medicines than any 
other health professional as highlighted by the RPSGB.113   
 
The most visible face of the pharmacy profession is the community pharmacy 
situated in the high street, with most if not all members of the public accessing 
pharmacy professional services through their local community pharmacist.  Hospital 
pharmacists are also pivotal members of the healthcare team where their clinical 
role has become increasingly extensive and specialised, involving direct 
management of patient’s medicines and, in making independent prescribing 
decisions.113,114  Other pharmacists work within the pharmaceutical industry and in 
academia playing a crucial role in the discovery and development of new drugs and 
medicines.   
 
A more recent development in the professional role of the pharmacist has been the 
evolution of primary care pharmacists also known as ‘prescribing advisers’.  In 2008, 
out of 25,243 registered pharmacists who were actively working in the UK, just 7.2% 
of pharmacists were actively employed in primary care.  The majority (71%) were 
working in community pharmacy, 21.4% in hospital, 4.1% in industry, 2.8% in 
academia and 3.8% elsewhere.115 
 
Pharmacist’s skills have long been recognised.  However, it has been acknowledged 
that in many areas, pharmacists’ knowledge and skills have been 
underutilised.116,117,118,119    
 
Government has increasingly sought to utilise pharmacist skills more effectively in 
both hospital and primary care.  In primary care however, the emphasis to date has 
largely focussed on greater integration of community pharmacists in activities to 
meet national policy objectives by improving access to medicines, medicines 
services and medicines advice through the national community pharmacy 
contractual framework.117,119   
 
The government acknowledges that primary care PCT prescribing advisers are 
increasingly active in promoting cost effective use of medicines both at PCT and 
practice level.  It also notes that PCT pharmaceutical advisers make a significant 
contribution to local prescribing strategies, are involved in commissioning of drug 
treatments, are increasingly working with secondary care pharmacists and have a 
role in implementation of the community pharmacy contractual framework.118   
 
2.4.1 Evolution of the Primary Care Pharmacist 
 
Historically, Health Authority medical and pharmaceutical advisers have been the 
mainstay of prescribing support to GPs at local level.   The evolution of Primary 
Care Trusts (PCTs) as part of NHS reform in 2000 has meant that cost effective 
prescribing has become high priority requiring professional support.120  
Consequently, since the 1990’s, the role and function of primary care pharmacists 
has evolved markedly within the NHS.83,84   
 
The NHS requires that emphasis is placed on high quality, evidence based medicine 
including prescribing.1,2  As the prescribing adviser role has expanded, this has 
involved evolution of comprehensive Medicines Management Services within PCTs.  
Pharmacists because of their training are equipped to support delivery of this 
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agenda and are the professional leads within the function.  They also fulfil a 
strategic role, focusing on maximising benefit and minimising risk of medicines, as 
well as making the best use of resources allocated for medicines. 
 
Early resources intended to define PCT Medicines Management responsibilities and 
to support prescribing advisers in achieving quality prescribing objectives in primary 
care were issued by the National Prescribing Centre and other sources.9,121  Many 
prescribing advisers also used the National and Primary Care Trust Development 
Programme (NatPaCT) Competency Framework self-assessment and support tool 
to develop and evaluate their PCT Medicines Management strategies.122  The NPC 
has continued to be an important resource for individual prescribing advisers, 
prescribers and commissioning and provider organisations on prescribing and 
medicines management issues impacting on primary care. (Section 2.5)   
 
2.4.2 Medicines Management Role and Function 
 
PCTs should have an appropriate infrastructure in place to manage prescribing in 
primary care and across the primary and secondary care interface.  An essential 
aspect of successful medicines management involves promotion of rational, cost-
effective prescribing in line with local and national priorities such as National Service 
Frameworks (NSFs) and NICE Guidance in order to maximise health gain.123  
 
Key Medicines Management functions involve promotion of evidence-based 
prescribing and influencing prescribing behaviour.  Medicines Management activities 
may be implemented at practice and organisational level, as well as spanning 
primary, secondary and tertiary care interfaces.   
 
In order to facilitate prescribing change, Medicines Management activities frequently 
involve GP practice visits, audit and provision of prescribing feedback as well as 
provision of synthesised evidence-based information often disseminated as 
guidelines, newsletters and PCT policies and may involve prescribing support from 
pharmacists / pharmacy technicians, working directly with and within practices.  
 
Organisational level activities include facilitation and involvement in local therapeutic 
networks and primary/secondary care decision-making committees and educational 
initiatives for local healthcare professionals. 
 
In England, primary care pharmacists also play a significant part in Practice Based 
Commissioning (PBC).  Evolution of the role is set to continue.  As the NHS 
embarks on further reorganisation, Local Commissioning Groups will control the 
commissioning of services as well as taking responsibility for the integration of 
medicines management functions into the new commissioning organisations.   
 
2.4.3 Influencing Primary Care Prescribing 
 
The National Audit Office (NAO) report ‘Influencing Prescribing Cost and Quality in 
Primary Care’ published in 2007 provided prescribing advisers in PCTs with 
suggestions on how to drive clinical and cost effective prescribing initiatives through 
more effective planning of communication and targeting of clinicians.11  Results from 
a separate qualitative study into GP prescribing behaviour based on interviews with 
PCT managers and focus groups with GPs also contributed to the report.124  
 
The NAO report advises that the most effective method of communicating with 
physicians is to visit them, and by making the most of each visit.  This involves 
building relationships, monitoring performance and following up with them in order to 
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facilitate change.  A number of the more effective approaches adopted by 
pharmaceutical industry are highlighted in the report with suggestions on how they 
may be adapted by prescribing advisers in order to influence prescribing behaviour 
and drive change in primary care (although evidence for their success is not 
provided in the report).   
 
The report addresses areas such as effective communication, targeting effort 
effectively to the practices that need it most, building relationships and getting plans 
adopted by clinicians in order to bring about change in line with the Medicines 
Management agenda.  The NAO stresses that visits have more impact if 
communication materials such as prescribing data and ‘communication pieces’ (or 
‘detail aids’) are available to reinforce the prescribing strategy.  Examples of written 
materials which may be used to support communication of key messages 
(developed by the Department of Medicines Management, Keele) are included.  
 
In summary, the methods embraced by pharmacists in influencing prescribing within 
their role are multifaceted and may be employed with varying success.  Although not 
strictly defined as a strategy, the resulting model may be considered as integration 
of known successful approaches with social influence strategies for promoting 
evidence-based medicine in prescribing.  Evidence for the impact of this approach 
as such is lacking and remains to be tested and therefore forms the basis of this 
study.   
 
2.4.4 Primary Care Pharmacist Competencies 
 
In order to support the development and functions of primary care pharmacists, the 
National Prescribing Centre (NPC) has developed a Core Competency Framework 
for Primary Care Pharmacists.  First published in 2000 it identified the skills and 
behaviours individual pharmacists need to in order to contribute effectively within 
primary care.83  Updated in 2003 it was incorporated in the ‘NPC PCT 
responsibilities around prescribing and medicines management scoping and support 
guide’.9,84   
 
The core competency framework is regarded as generic in that the competencies 
can be applied to all pharmacists working in primary care.   However, it is possible to 
define primary care pharmacist roles into three general levels as described in the 
framework, in order to apply the competency framework to individuals.  These are 
broadly defined as: 
 
 Level 1 -  A practice based pharmacist 
 Level 2 - A senior primary care pharmacist 
 Level 3 -  A Chief Pharmacist / Head of Medicines Management 
    
Primary care pharmacists involved in delivering initiatives as described in the NAO 
report require considerable clinical and communication skills and would therefore be 
expected to demonstrate skills defined at Level 2 and to be operating at that level.   
Key competencies required at this level include sound clinical therapeutic 
knowledge, communication and other interpersonal skills, knowledge of health policy 
and priorities, and skills in the management of change. 
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2.5 Prescribing and Medicines Management Support 
 
2.5.1 The National Prescribing Centre 
 
The National Prescribing Centre (NPC) has been one of, if not the main provider of 
robust evidence-based prescribing, therapeutics and medicines management 
information across the NHS.  Since its formation in 1996 by the Department of 
Health, the NPC evolved from its early beginnings to provision of wide based 
support of Medicines Management functions, predominantly in primary care, whilst 
adapting to continuing structural, policy and priority changes occurring within the 
NHS.  Its aim being, to support individuals and the NHS to deliver rational, evidence-
based, safe and cost-effective use of medicine for the benefit of patients and the 
public.125 
 
The NPC had developed a wide range of resources, including e-learning and 
organisation of learning events and activities which support and promote evidence 
based Medicines Management across the NHS.    
 
More recently, as new NHS structures have emerged and transferred to GP 
Commissioning Consortia, the NPC has been instrumental in defining key functions 
and organisational competencies in relation to prescribing and medicines 
management and in developing associated resources.  The NPC published several 
significant guidance documents in order to support achievement of key Medicines 
Management objectives in primary care.10,125,126,127  
 
The NPC also traditionally supported the therapeutic training for pharmacists 
working in primary care by cascaded delivery of local therapeutic workshops. 
 
From 2003, specific training was commissioned and delivered through the ‘NPC 
Plus’ programme, launched to extend the support offered to local NHS organisations 
and providers of NHS healthcare.  The aims and objectives of NPC Plus include 
delivery of high quality, effective healthcare by supporting healthcare practitioners 
and service providers, including the provision of individual and organisational 
training for Prescribing and Medicines Management.128  From 2006, NPC Plus 
operated from within the Faculty of Health, Keele University. 
 
2.5.1.1 NPC Plus Therapeutic Workshops 
 
NPC Plus Therapeutic workshops have supported an evidence-based approach to 
healthcare and up-to-date evidence-based education, on a wide range of 
therapeutic topics delivered by a team of NPC Plus Therapeutic Trainers operating 
across the UK.128  They are highly knowledgeable healthcare professionals who 
have been trained, assessed and supported by the National Prescribing Centre’s 
Evidence-based Therapeutics Team, thus maintaining the high level of competency 
required of an NPC Plus trainer. 
  
NPC trainers (usually pharmacists) have a unique combination of knowledge, 
experience and expertise and can tailor workshops to local need and context.  
Training is underpinned by evidence-based materials produced by the NPC and 
which are also subject to rigorous quality assurance procedures.129  
 
In April 2011, the NPC became part of the National Institute for Health and Clinical 
Excellence, and from May 2012, became integrated in the NICE Medicines and 
Prescribing Centre.  The NPC’s activities are now incorporated within the NICE work 
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programme.  Following merger with NICE, the original NPC resources, publications 
and e-learning materials have been made accessible from a separate NPC Legacy 
website.130  NPC Plus closed in July 2012 following review between NICE and Keele 
University.  The trainer programme is pending further review before being 
incorporated into the work of NICE.131  All NPC resources and training accessed for 
the purposes of this study were accomplished before the formal transfer of NPC 
activities to NICE. 
 
2.5.2 Information Mastery 
 
It is becoming increasingly difficult to access relevant and evidence-based 
information to inform clinical decision-making with an ever increasing volume of 
available information, fuelled partly by the expansion of the internet.  Clinicians 
cannot hope to keep abreast of current published evidence by searching and 
evaluating it themselves. They require some means of developing effective and 
efficient ways of accessing and evaluating useful information in order to keep up to 
date.132,133 
 
A probable confounding factor involves an educative system whereby clinicians 
(doctors in particular) initially learn through a directed pedagogical process but lack 
and are not taught the necessary skills to be able to access and discriminate 
relevant information in order to further learn and update themselves.134 
 
The concept of Information Mastery, as a means to combat ‘information overload’ 
was first described by Slawson and Shaughnessy and has been defined as the 
“applied science that allows clinicians to harness resources in the information 
age”.134,135  Information Mastery depends on using strict criteria, so that clinicians 
can focus on obtaining information which will be most useful to them for clinical 
situations.136  In order to establish usefulness, information sought must be relevant 
to everyday practice, it must be correct (valid) and should be easy to obtain.136,137  
 
Techniques for accessing relevant and valid information are based on ‘hunting’, 
foraging and ‘hot-synching’.133  Hunting relies on having a reliable system for 
accessing relevant and valid data to answer a question specifically and quickly.  
Foraging requires having a reliable system to highlight new, important, relevant and 
valid information which may require a change in practice.  Hot-synching involves 
actively checking and updating personal knowledge and skills periodically for the 
main conditions seen in practice. 
 
In adopting these techniques, HCPs should use trustworthy, pre-appraised 
summaries of information.  Reliable sources in the UK are regarded as NICE, NHS 
Evidence, Cochrane Library, Clinical Evidence, InfoPoems, MeReC and the Drug 
and Therapeutics Bulletin (DTB).133  
 
The NPC promotes the principles of Information Mastery and offers a variety of tools 
to help professionals cope with information overload. It supports busy practitioners 
in keeping up to date with the clinical evidence base, health policy and other types 
of information.133  It produces pre-appraised, synthesised information including 
MeReC publications which are available electronically.  MeReC Rapid Review is a 
’foraging’ tool, providing critiques of key clinical trials or guidance as soon as they 
are published.  MeReC Monthly provides a compilation of key MeReC Rapid 
Reviews.  The quarterly MeReC Bulletin, focuses on key therapeutic dilemmas, 
collating and summarising the available evidence and guidance.  MeReC Extra, 
(also quarterly) summarises other MeReC publications and highlights new e-
learning materials on the NPC website. 
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2.5.3 Electronic Updates 
 
‘Foraging’ involves accessing evidence from trusted sources, typically by receiving 
electronic alerts and updates from reliable sources such as the NPC electronic 
Current Awareness Bulletin (eCAB) and the National electronic Library of Medicine 
(NeLM) as soon as information is published.  eCAB accesses information from other 
relevant websites (including NeLM, NICE, Cochrane,) and collates information for 
dissemination through its daily and weekly alerts to subscribers.138  It also provides 
links to the original websites where more detailed information can be accessed.   
 
NeLM is the largest medicines information portal for healthcare professionals in the 
NHS and is updated daily.  It promotes safe and efficient use of medicines and 
provides evidence based reviews on drugs and drug therapy.  It also critically 
reviews evidence and produces specific drug reviews, drug class reviews and 
disease-focused reviews.139  Much of the content is developed by pharmacists 
working in the NHS UK Medicines Information Service. 
 
All pharmacists involved in the study subscribed to eCAB e-mail alert services as 
part of their role in primary care and would have been alerted to newer evidence and 
publications relevant to the study therapeutic topics arising during the intervention 
period. 
 
In general, doctors remain unskilled in Information Mastery.134  In contrast, it is 
believed that many primary care pharmacists (including those involved in the study), 
have developed and honed their Information Mastery skills in supporting rational and 
evidence based prescribing as a core part of their role.9  Many have taken 
advantage of NPC Information Mastery training and employ these skills, including 
critical appraisal, which involves evaluating available evidence to inform all aspects 
of the Medicines Management function from development of medicines 
management policy to individual patient decision-making. 
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2.6 Complex Interventions 
 
Interventions intended to change health professionals’ behaviour are by definition 
complex.  In health care, Complex Interventions may be targeted at individual 
patient or health care professional level.  Alternatively, they may be targeted at an 
organisational or service modification, or delivered at a population level as often 
implemented in public health campaigns. 
 
Complex Interventions are defined as comprising a number of separate elements 
containing several interacting components.63,64  There are also several dimensions 
of complexity which may relate to:  
 number of and interactions between components within the intervention 
 number of and difficulty of the behaviours required by those delivering or 
receiving the intervention 
 group or organisation targeted  
 number and variability of outcomes  
 whether a degree of flexibility or tailoring of the intervention is permitted.63,64   
 
Consequently, evaluation of a complex intervention may present difficulties relating 
to standardisation of the design and delivery of the intervention.62,63,64  Evaluation 
frequently requires application of quantitative and qualitative approaches. 
 
The Medical Research Council (MRC) has developed a framework to provide 
guidance on the development and evaluation of complex interventions.  The 
framework re-emphasises key messages and addresses limitations of earlier 
guidance and considers more recent experience and evidence for the 
implementation of complex interventions.64  One aim of the guidance is to support 
researchers in choosing and implementing appropriate methods to evaluate an 
intervention.   
 
The intervention being tested in this research is the impact of primary care 
prescribing advisers in influencing GP prescribing behaviour and is regarded as a 
complex intervention because of the level of complexity inherent in influencing 
prescribing behaviour.  The approach described in the MRC Guidance was therefore 
adopted as a basis for developing, defining and evaluating the intervention to be 
tested in this study.64   
 
When developing and evaluating complex interventions it is important to ensure 
sufficient development and pilot work, and consideration of the practicalities of its 
implementation.63,64  It is important to clearly define each of the individual 
components of the intervention, prospectively and, as far as possible, to standardise 
the approach adopted by the individuals involved in delivering the intervention in 
order to ensure consistency and reproducibility.  It is also necessary to define who 
the intervention is aimed at and any change expected to be achieved.  Ideally, an 
exploratory trial should be randomised to allow assessment of the size effect which 
will provide sound basis for calculating sample sizes for any larger trial.64  It is not 
unusual to also include a qualitative assessment in order to gain insight from the 
individuals involved, including identification of barriers to participation and adoption 
of the intervention.  
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Chapter 3 
 
Theoretical Basis and Study Rationale 
 
This chapter describes the rationale for conducting the study and why it constitutes 
an evaluation of a complex intervention.  It explains the hypothesis to be tested in 
evaluating the defined complex intervention.  The aims and objectives of the 
research are summarised here.  The methods applied in the evaluation and the 
main outcome measures are introduced here, as is the basis for the study design, 
which adopts a mixed methods approach.  The latter part of this chapter also 
contains a summary of the evidence underpinning the two therapeutic topics which 
were defined for evaluation of the intervention.   
 
Evidence for efficacy in influencing prescribing behaviour is limited, and is not 
necessarily generalisable to the UK healthcare system.68  Evidence for pharmacists 
influencing prescribing behaviour specifically using outreach visits and academic 
detailing is also lacking, particularly in the UK.  However, available evidence does 
suggest that pharmacists with clearly stated clinical and communication skills are 
most likely to be successful at bringing about behaviour change in prescribing.110  
 
Not all sources of information available to clinicians are evidence-based.  Published 
information claiming to provide clinical evidence has frequently not been critically 
evaluated and there is often a lack of transparency relating to the underlying claims 
for efficacy.29  It is appropriate that clinicians have access to relevant sources of 
evidence, evidence summaries and guidelines that acknowledge the most current 
EBM thinking.  
 
Typically, primary care pharmacists are skilled in accessing and evaluating evidence 
about effectiveness and safety of medicines and already have a responsibility in 
influencing prescribing behaviour.  They are in an ideal situation, to communicate 
key clinical messages and promote the uptake of evidence-based findings a role 
which many currently undertake.  The effect of their influence on incorporation of the 
evidence-base into prescribing related decision-making however remains less clear.  
 
The hypothesis for this study is that implementation of an intervention utilising 
strategies which are known to work in changing healthcare professional behaviour 
and aimed at bringing about change in practice will influence prescribing behaviour 
according to the EBM paradigm.  The intervention, aimed at general practitioners is 
multifaceted in nature.  The intervention is based on outreach visits conducted by 
trained clinical pharmacists employing an academic detailing approach.  The 
components of this complex intervention will also incorporate interactive discussion 
around evidence-based therapeutic topics supported with provision of topic 
summaries highlighting key messages and audit data and feedback on practice 
prescribing trends.   
 
This study aims to address Cochrane recommendations by utilisation of effective 
strategies (multifaceted approach involving interactive rather than didactic 
educational meetings, audit, feedback and summaries of key messages) in 
influencing behaviour change and by employing sustained efforts to improve 
prescribing behaviour, rather than individual visits and by clearly defining the type of 
visitor and visit content.59,68  Pre-appraised evidence-based information will be 
utilised in face-to-face communication by primary care pharmacists thus removing 
the burden for GPs of seeking evidence at the point of prescribing.  It is intended 
that this study also address inconsistencies in study design and lack of rigour 
apparent in the currently published studies. 
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A mixed methods approach will be adopted for evaluation of the intervention.   
A quantitative evaluation of changes in prescribing relating to two predetermined 
therapeutic topics will be made.  Cochrane also recommends consideration of 
patient outcomes as an evaluation measure and a further quantitative evaluation will 
be performed in an attempt to identify any change in patient related outcomes.68  
 
A qualitative evaluation of GP perceptions, attitudes and beliefs will be undertaken 
to provide greater insight into intervention delivered.  It aims to establish whether the 
intervention influenced the way GPs worked.  It will also assess pastoral aspects, 
whether the GPs valued the intervention and whether they developed as a result.  It 
is hoped that the results obtained through this mixed methods approach may inform 
future medicines management strategies for influencing prescribing behaviour.  
 
This study adopts the principles described in the guidance on developing and 
evaluating complex interventions.63,64  It is therefore exploratory in that it aims to 
describe the individual components of a replicable intervention, testing feasibility 
and delivery of the intervention in everyday practice, and its impact on and 
acceptability to participants.  It seeks to demonstrate that the intervention can be 
delivered as intended.  Pragmatically, as the sample size is relatively small, this 
study will also enable assessment of size effect and sample size for any future 
studies.   
 
 
3.1 Study Aims and Objectives 
 
An Evaluation of Evidence-Based Prescribing Support from Primary Care 




To evaluate a complex intervention utilising primary care pharmacists intended to 
influence GP prescribing behaviour by promoting uptake and integration of evidence 




 To assess the impact of evidence-based prescribing support delivered by 
primary care pharmacist prescribing advisers on GP prescribing outcomes 
compared with non-intervention practices. 
 
 To assess the impact of evidence-based prescribing support on measurable 
patient-orientated outcomes and to determine whether the intervention leads to 
improved patient care. 
 
 To explore GP perceptions, attitudes and beliefs regarding prescribing support 
both before and after delivery of the intervention. 
 
 To consider the feasibility of implementing the intervention more widely. 
 
The study also seeks to define a consistent, reproducible intervention (and its 
components) for evaluation and potential implementation.  The evaluation seeks to 
confirm the reproducibility and fidelity of the intervention in practice and that it was 
delivered as intended.
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3.2 Description of the Intervention  
 
The purpose of the intervention was to influence prescribing behaviour by adopting 
a number of known (evidence-based) approaches for influencing behaviour change.  
The intervention centred on regular interactive practice meetings (outreach visits) 
conducted by pharmacist prescribing advisers with GPs in their practices.  Academic 
detailing techniques were adopted in the promotion of evidence-based prescribing.   
 
A fundamental objective of the study was to develop and deliver a clearly defined 
complex intervention for evaluation.  The intervention and its components were 
defined in line with MRC Guidance on Complex Interventions.  It was important 
therefore to define the individual components of the intervention and to standardise 
the approach adopted by the individuals involved in its delivery in order to ensure 




 Pharmacist Prescribing Advisers instrumental in delivery of the intervention 
 
 Regular Practice Visits during 12 months 
o Baseline visit. 
o Three Follow-up visits – each approximately 3-4 months apart.       
 
 Academic Detailing Approach 
o Engagement of healthcare professionals in interactive discussion 
focussing on pre-determined therapeutic topics (T2DM, NSAIDs) 
o Use of Detail Aids 
o Re-enforcement of key messages 
 
 Provision of evidence-based prescribing support 
o Clinical pharmacists supporting evidence-based prescribing in 
predetermined therapeutic topics 
o Use of Detail Aids  - Content based on best available evidence 
o Provision of evidence-based summaries on therapeutic topics  
o Access to and dissemination of appropriate evidence-based resources 
 
 Audit and feedback to practitioners during study period 
o Provision of regular and updated comparative prescribing data 
o Written Visit Report from pharmacist following each practice visit.  To 
highlight visit content, discussion and agreed actions 
 
 Pharmacists involved in the intervention  
o Meet NPC Level 2 competencies for pharmacists working in primary care 
o Trained in Academic Detailing techniques 
o Sound clinical and therapeutic knowledge  
o Updated training in therapeutic topics and Information Mastery 
o Communication and interpersonal skills 
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3.3 Therapeutic Topics 
 
The latter part of this chapter also contains here, a summary of the evidence 
underpinning the two therapeutic topics which were defined for evaluation of the 
intervention.  These were: 
 
 Therapeutic management of patients with Type 2 diabetes (T2DM) 
 Use of non-steroidal inflammatory drugs (NSAIDs) in musculoskeletal 
conditions. 
 
Background and rationale for their inclusion as a component of the study 
intervention is summarised in this section with reference to the main published 
evidence supporting therapeutic interventions to improve patient outcomes. 
 




Diabetes is an increasing problem in the UK.  In 2006, approximately 1.9 million 
people diagnosed with diabetes were recorded on practice registers in England.  An 
estimated half million remained undiagnosed.140  In addition to the human cost, the 
financial burden of diabetes is estimated to be as high as 10% of the NHS 
expenditure which equates to approximately £9 billion a year.140 
 
Prevalence of diabetes in the UK is estimated between 3.5%-5.0%.  Approximately 
85% of diabetics have Type 2 diabetes (T2DM), which affects approximately 4% of 
the population. 
 
Despite sharing a similarity of disordered glucose metabolism, manifested by raised 
glucose levels, Type 1 diabetes (T1DM) and T2DM possess different aetiologies 
and consequently, different approaches to management.  T1DM is an autoimmune 
disease characterised by pancreatic beta-cell destruction leading to an absolute 
insulin deficiency requiring exogenous insulin.  T2DM is a long-term condition 
associated with increasing obesity and an aging population usually manifested by 
insulin insensitivity plus a failure of pancreatic secretion to compensate for 
increased insulin requirements.  
 
Although characterised by raised blood glucose, T2DM is essentially a 
cardiovascular disease, associated with increased cardiovascular morbidity and 
mortality.  The three commonest complications are angina, cardiac failure and 
myocardial infarction.  It is also a leading cause of blindness, end-stage renal failure 
and lower limb amputation.  There is evidence that effective management of the 
disease and associated risk factors increases quality of life and life expectancy.  
Complications of T2DM can be limited or prevented with good, early intervention.  
Management of patients with T2DM is multifactorial in approach. 
 
Lifestyle interventions (diet, exercise) are key in the prevention and treatment of 
T2DM, which aim to correct obesity, improve glycaemic control, blood pressure and 
blood lipid control.   After stopping smoking, successful management of blood 
pressure is the most effective means of reducing cardiovascular risk in T2DM.141  
Blood lipid management and use of aspirin are the next most effective 
interventions.141  The main aims of treatment are therefore to manage symptoms, 
reduce life threatening or disabling complications (MI, stroke) and manage renal 
disease, retinopathy and foot disease. 
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Figure 3.1. Reduction of Cardiovascular Risk in T2DM.  Extract from MeReC Bulletin 
     Vol 21 No.5 
 
 
3.3.1.2 Blood Glucose or Blood Pressure 
 
The landmark United Kingdom Prospective Diabetes Study (UKPDS) was 
conducted over 20 years in 5012 patients with newly diagnosed T2DM.  Key findings 
were reported and published relating to different study sub-groups. 
 
Intensive control of blood glucose with sulphonylureas or insulin was shown to be 
important in terms of managing symptoms and reducing microvascular 
complications (single retinopathy endpoint).  The benefit on macrovascular 
outcomes (MI, stroke) however, was not proven.142  
 
In contrast, metformin was shown to have an effect on reducing macrovascular 
complications which is independent of its blood glucose lowering effect.143  
Metformin is therefore the preferred firstline hypoglycaemic drug in T2DM (NICE).   
 
UKPDS 38 determined whether intensive (lower) blood pressure (BP) control 
prevents macrovascular and microvascular complications in T2DM.  It demonstrated 
that intensive BP control achieved clinically important reduction in risk of deaths and 
T2DM related complications.144  The authors concluded that reducing BP needs to 
have high priority for patients with T2DM.144  Intensive control of BP is therefore 
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regarded as, if not more important than intensive blood glucose control in managing 
the cardiovascular risks associated with T2DM.   
 
Concerns have been raised however suggesting that data from UKPDS have been 
distorted by other authors and reviewers continuing to promoting an aggressive 
approach to glucose control.145,146,147 
 
One meta-analysis showed no association between degree of HbA1c reduction and 
magnitude of risk reduction.  The authors concluded that improving BG control 
without addressing other abnormalities, most importantly hypertension, 
dislipidaemia, and platelet activity may only produce limited benefit.148 
 
Evidence also suggests that Health Care Professionals (HCPs) frequently focus on 
blood glucose control rather than emphasising the importance of aggressively 
managing cardiovascular risk factors and that the ‘glucocentric’ approach to 
management is prominent.149,150  T2DM patients are also often unaware of the 
importance of BP and cardiovascular risk management.151 
 
3.3.1.3 Management of Blood Glucose 
 
More recently evidence from three studies (ACCORD, ADVANCE and VADT) has 
demonstrated that intensive blood glucose lowering failed to show any reduction on 
cardiovascular events compared with standard treatment and raised concerns that 
intensive BG control is actually harmful.141,152,153,154 
 
The evidence for improved patient outcomes with newer drugs is also lacking as all 
recently introduced hypoglycaemic agents have been licensed on the basis of their 
blood glucose lowering ability rather than effect on patient outcomes.   
 
Self-Monitoring of Blood Glucose (SMBG) is crucial in the management of patients 
with T1DM and T2DM patients on insulin.  Evidence also suggests that T2DM 
patients on oral therapies or who are diet-controlled are unlikely to gain benefit from 
SMBG as it may result in lower quality of life because of increased level of 
anxiety.155,156,157 
 
Recommended treatment choices for management of blood glucose and target 
HbA1c levels are summarised in NICE Guidance on management of T2DM.158 
 
 




Several large RCTs have proven the importance of managing hypertension in both 
diabetics and non-diabetic patients.6  In general, there is no compelling evidence of 
any clinically significant, drug specific effects to distinguish between 
antihypertensive agents (diuretics, calcium channel-blockers and ACE-Inhibitors) in 
terms of BP lowering effect (although renin-angiotensin drugs are preferred firstline 
because of renoprotective effects in diabetics).6,159,160 
 
The main focus of therapy is therefore to reduce blood pressure in order to improve 
cardiovascular outcomes.  Greater risk reductions are produced by regimens 
targeting lower BP goals.159  Recommended drug choices, sequence of use and BP 
target levels are summarised in NICE Guidance.158 
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3.3.1.4.2 Blood Lipids  
 
Evidence for management of blood lipids in diabetics largely comes from the Heart 
Protection Study (HPS) where simvastatin reduced cardiovascular event rates in 
high risk patients, including diabetics whose cholesterol levels were not raised.161,162  
Evidence from the CARDS study also provided evidence for reduction in 
cardiovascular events in people with T2DM.163 
 
In most patients withT2DM, lipid lowering therapy (usually simvastatin 40mg) should 
be initiated as first line blood lipid lowering therapy.  Target lipid levels are defined in 
NICE Guidance.158 
 
3.3.1.4.3 Antiplatelet Therapy 
 
NICE Guidance, recommends initiation of aspirin in higher risk patients and those 
aged 50 or older as long as blood pressure is controlled.158  More recent evidence 
indicates that aspirin may only be effective in secondary prevention of 
cardiovascular events rather than as primary prevention.164   
 
 
3.3.1.5 Renal Function 
 
Management and prevention of renal deterioration is an important goal in the 
management in patients with T2DM.  Renin-Angiotensin System (RAS) drugs 
constitute a key therapeutic intervention for the management and prevention of 
diabetic nephropathy. 
 
Although classified as antihypertensive medicines, RAS drugs are also licensed for 
use in heart failure, left ventricular dysfunction, post-myocardial infarction, chronic 
kidney disease (CKD) and in diabetes.  They act by slowing down the development 
of microalbuminuria and protenuria, reduce progression and hence subsequent 




3.3.1.5.1 Use of Reno-Angiotensin Drugs in T2DM 
 
The two main classes of RAS drugs are ACE-Inhibitors (ACE-I) and Angiotensin-
Receptor Antagonists (A-II-A or ARB).   
 
ACE inhibitors have a more robust evidence base across all indications than A-II-As 
and there is no evidence that A-II-As are more effective or safer than ACE-Inhibitors 
in any indication.  A-II-As however remain an alternative to ACE-inhibitors if ACE-Is 
are not suitable.    
 
A Cochrane review concluded that both ACE-Is and ARBs had similar effects on 
renal outcomes.  At maximum tolerated doses however, ACE-Is reduced all-cause 
mortality but A-II-As did not, providing some evidence for reduced cardiovascular 
outcomes with ACE-Is but not for A-II-As.165 
 
The evidence-based position and current NHS policy is that ACE inhibitors are first-
line choice if RAS drugs are indicated.158,166,167,168  
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3.3.1.5 Rationale for Inclusion of T2DM Management as Part of the Intervention 
 
Management of blood glucose is important in patients with T2DM, however, in 
isolation is not the key to reducing morbidity and mortality.141,169  
 
Management of T2DM was included as a therapeutic topic because it is a chronic 
condition requiring a multifaceted approach.  Improved management should ideally 
lead to appropriate therapeutic intervention for various aspects of the condition, 
achievement of related targets and improved clinical outcomes. 
 
The key messages underpinning the evidence base relating to management of 
T2DM delivered within the study intervention were therefore about prioritising 
management by targeting the most effective approaches in order to minimise 
cardiovascular risk and to reduce adverse cardiovascular and cardio-renal 
outcomes.  Other key messages revolved around safety and efficacy of newer drugs 
in diabetes (including glitazones), and assessment of the benefits and risks in using 






                                                                                                                                         35 
 




Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have wide ranging applications in 
the management of musculoskeletal anti-inflammatory conditions and pain and may 
be used in both acute and chronic conditions.  Their principle pharmacological 
effects are analgesic, anti-inflammatory and antipyretic.  Serious side effects 
associated with NSAIDs include gastrointestinal complications (e.g. perforation, 
ulcer, bleeding), cardiovascular effects (e.g. stroke, myocardial infarction) and 
cardio-renal effects (e.g. oedema, hypertension, heart failure).   
 
NSAIDs inhibit cyclo-oxygenase (COX) enzymes.  There are two main types of COX 
enzymes, COX-1 which produces prostaglandins which help maintain gastric 
mucosal integrity and platelet induced blood clotting, and COX-2 which mediates 
pain and inflammation. 
 
Traditional NSAIDs including ibuprofen, naproxen, diclofenac and indomethacin 
were developed before the mechanism of action of NSAIDs and COX selectivity was 
understood.  Because of their association with potentially serious gastrointestinal 
effects, COX-2 selective NSAIDs (also known as coxibs) were subsequently 
developed with the intention of targeting inflammation and reducing gastrointestinal 
risk.  The first selective COX-2 Inhibitors (celecoxib, rofecoxib) were licensed based 
on results from two randomised trials.170,171  However, coxibs were not 
recommended routinely in patients with cardiovascular disease, because of safety 
concerns regarding adverse cardiovascular effects.172,173  
 
Several traditional NSAIDs were subsequently found to differ in their COX- 1 and 
COX-2 selectivity with meloxicam and etodolac being regarded as ‘partially 
selective’, and diclofenac arguably, now qualifying as a ‘coxib’ as it preferentially 
inhibits COX-2 rather than COX-1.174 
 
Evidence subsequently emerged however, demonstrating that selective COX-2 
Inhibitor use is associated with a considerably higher incidence of adverse 
cardiovascular events than other traditional NSAIDs (thrombotic risk).174,175  
Consequently, the MHRA has issued a number of warnings on cardiovascular 
effects of COX-2 selective inhibitors.176  Rofecoxib, valdecoxib and lumaricoxib have 
since been withdrawn from the market. 
 
Both traditional NSAIDs and COX-2 Inhibitors have also been the subject of MHRA 
warnings regarding serious gastrointestinal toxicity, with the elderly and those on 
aspirin being identified as at greater risk.177,178 
 
3.3.2.2 Thrombotic versus Gastrointestinal Risk 
 
Most available evidence relates to diclofenac, COX-2 Inhibitors, ibuprofen and 
naproxen.  Less evidence is available regarding the cardiovascular safety or efficacy 
of the partially selective NSAIDs.   
 
Evidence has now evolved demonstrating that diclofenac is associated with a similar 
level of cardiovascular risk as COX-2 Inhibitors.  Further MHRA advice re-iterates 
concerns regarding cardiovascular risk associated with COX-2 Inhibitors, including 
diclofenac use.179,180  Naproxen and (low dose) ibuprofen are not associated with 
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increased cardiovascular risk although higher dose ibuprofen may be associated 
with a small increase in thrombotic risk.   
 
Ibuprofen is known to be associated with lower gastrointestinal risk than diclofenac 
or naproxen.174  Other traditional NSAIDs are known to carry higher gastrointestinal 
risk.180  Proton pump inhibitors (PPIs) may be co-prescribed in order to reduce 
adverse gastrointestinal effects associated with NSAID use. 
 
All non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 Inhibitors are 
associated with a range of adverse effects on gastrointestinal, cardiovascular and 
renal systems which can be serious and life threatening.   
 
Evidence continues to emerge highlighting safety concerns regarding these drugs, 
particularly in the elderly.174  The MHRA has continued to monitor NSAID use, 
issuing issue both warnings and advice regarding use of NSAIDs and COX-2 
Inhibitors.181,182,183  The MHRA has advised using the lowest dose for the shortest 
duration possible if prescribed.  It also advises against using these drugs in patients 
at risk of renal impairment (particularly the elderly).182,183 
 
 
3.3.2.3 Clinical Management   
 
The key approach to management of patients where prescribing of NSAIDs is being 
considered, is to focus on minimisation of risk to the patient, taking into 
consideration individual patient factors.  Gastrointestinal and cardiovascular toxicity 
are the two most important safety concerns as well as potential drug interactions.  
Aspirin and selective serotonin reuptake inhibitors (SSRIs) for depression may 
significantly increase bleeding risk when co-prescribed with NSAIDs.  
 
Current NICE Guidance on the management of osteoarthritis (OA) and rheumatoid 
arthritis (RA) largely supports the evidence base and MHRA advice, with NSAIDs 
(including COX-2 Inhibitor) being considered only after alternative forms of 
intervention have been attempted.  There is however no clear distinction made 
between preferential use of traditional NSAIDs compared with COX-2 selective 
inhibitors for people with pre-existing cardiovascular risk (as in RA) other than to 
take into consideration individual patient factors.184,185   
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3.3.2.4 Rationale for Inclusion of NSAID Use as Part of the Intervention 
 
Despite repeated safety warnings and recommendations to consider carefully the 
use of NSAIDS (including COX-2 Inhibitors), as also summarised in the BNF, the 
number of prescriptions issued for these drugs remains extremely high.186  Between 
April–June 2007, 4.3 million prescriptions for NSAIDs were issued with 45.9% being 
for diclofenac, 6% for coxibs and 8% for meloxicam and etodolac.  Sheer volume of 
prescriptions for these drugs translates to an estimated 240 additional premature 
cardiovascular events in England alone with most being attributable to diclofenac.174  
 
Even where authoritative guidance exists advising against their use, historically, 
many clinicians have not followed it indicating that significant barriers to 
incorporating research findings into practice remain.174 
 
The rationale for including NSAID prescribing as a therapeutic topic was based on 
the fact that NSAIDs continue to be widely prescribed despite evidence-based 
recommendations to carefully consider the benefit versus risk profile in relation to 
individual patients. 
 
The key messages underpinning the evidence base, to be delivered as part of the 
intervention therefore, relate to patient safety and the risks associated with NSAID 
use.  The importance of assessing an individual’s cardiovascular, gastrointestinal 
and other risk factors in order to make an appropriate prescribing choice in the 











This section describes the basis of the study design and the rationale for the 
methodologies adopted.  The data sources accessed for evaluation of the 
intervention are described. 
 
4.1 Study Design 
 
A randomised controlled trial (RCT) design is generally regarded as the gold 
standard and most robust means of evaluating the impact of a defined 
intervention.63,64,187,188,189  Randomisation is the most robust method of preventing 
selection bias.  For an exploratory trial it also enables assessment of the size effect 
and provides a more solid basis for calculating sample sizes for any larger trial.63,64  
 
Ideally, a study design whereby practices are randomly allocated to intervention and 
non-intervention (control) groups would have been preferred.  However, because of 
the small sample size and exploratory nature of this study, this was not feasible.  
Instead, a quasi-experimental design (also known as a pre-test, post-test design) 
was adopted whereby a control group was also identified for comparison.189,190,191   
 
The most common and preferred (robust) design is a controlled before and after 
study where a control (business as usual) or non-intervention population is identified 
which has similar or the same characteristics to the study population.189,190  Data are 
collected in both groups before and after implementation of the intervention.  A 
comparative analysis is then performed between the groups and any observed 
differences assumed to be due to the intervention.  
 
In order to analyse data from a pre-post test design, it is essential to collect 
quantitative outcome data.  It is also important to collect multiple forms of data 
where possible.  MRC guidance suggests involving different methodologies and 
combining evidence from a variety of sources in the evaluation of complex 
interventions.64  In addition to the quantitative evaluation, the study also involves a 
qualitative component, in order to gain greater understanding of the implementation 
of the intervention in practice.   
 
This study therefore involves a pre-test, post-test design comparing the intervention 
group with control group.  A mixed methods approach, combining both quantitative 
and qualitative methodologies was adopted.   
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4.2 Mixed Methods Adopted in the Evaluation of the Intervention 
 
4.2.1 Quantitative Evaluation of Prescribing Change 
 
NHS prescribing information is available as ePACT (Prescribing Analysis and CosT) 
data.   Data is uploaded monthly (six weeks after the dispensing month) following 
prescription returns from community pharmacists.  ePACT.net is an application 
which allows nominated users in the NHS to electronically access prescription data.  
Its facility enables PCT prescribing advisers to access and analyse the previous 
sixty months prescribing data held on the NHS Prescription Services Prescribing 
Database.   The data is used to measure and compare prescribing and is frequently 
shared openly between practices.192 
  
Practice and GP prescribing data can be analysed and compared using a variety of 
patient denominators.193  Prescribing data can also be weighted to take into account 
practice populations and demographics as well as therapeutic class of drugs.  One 
such weighting is ADQ per ASTRO-PU (Average Daily Quantities weighted by 
ASTRO-PU) and is a preferred unit of measurement.  ADQ is a measure of 
prescribing volume based upon prescribing behaviour.  It is an analytical unit 
defined by the Prescribing Support Unit used to compare prescribing activity.  
ASTRO-PU (Age-Sex and Temporary Residence Originated Prescribing Unit) is a 
weighting which takes into consideration differing practice populations.  STAR PUs 
(Specific Therapeutic group Age-sex weightings Related Prescribing Units) are an 
alternative weighting which, also takes into consideration usage of drugs in certain 
therapeutic classes.  Where ADQs are not appropriate, items and cost-based 
denominators weighted by ASTRO-PUs or STAR-PUs also provide comparative 
data. 
 
A tagging facility is available in ePACT, enabling specific or tailored information 
requests.194  A set of predefined tags is available within ePACT.  However, selection 
of data can also be tailored to the requirements of the user by setting up specific 
tags.  Selection and download of data can be grouped by specific practices (e.g. 
rural, dispensing, locality) or according to specific BNF categories (e.g. practice 
formulary, specialist drugs).  BNF tags can be shared between users to enable 
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4.2.1.1 Pre-Post Intervention Evaluation - Prescribing Outcomes 
 
The primary aim of the study is to determine whether prescribing support from 
prescribing advisers influences GP prescribing behaviour and promotes the uptake 
of evidence-based prescribing.  The primary quantitative measure is intended to 
detect and evaluate any change in prescribing patterns following the intervention 
compared with baseline and to compare with non-intervention practices.   
 
The main evaluation therefore assesses the impact on pre-defined prescribing 
indicators following delivery of the intervention compared with baseline.  Data for the 
quarter following delivery of the intervention was compared with prescribing data for 
the quarter immediately preceding implementation of the intervention (baseline).  
The study was powered to detect statistically significant differences in defined 
prescribing measures between intervention and control groups. 
 
4.2.1.2 Prescribing Trend Data 
 
In addition to the quarter on quarter comparison, monthly prescribing data was also 
collated for each practice in order to detect any obvious differences in prescribing 
trends throughout the intervention period in the intervention practices compared with 
control practices.  The data is presented in graphical format.  
 
 
4.2.2 Quantitative Evaluation - Patient Outcomes 
 
Evidence is lacking that interventions intended to change clinical behaviour improve 
outcomes for patients or improve patient care.54  Therefore, a separate quantitative 
pre-test post-test evaluation was conducted in order to establish whether the 
intervention intended to improve GP prescribing had a corresponding effect on 
measurable patient-orientated outcomes.   
 
This quantitative evaluation assesses the impact of the intervention on pre-defined 
patient related outcomes by assessing the difference in the proportion of patients 
meeting predefined audit standards both before and after implementation of the 
intervention.  Patient-orientated outcomes were defined, based on indicators which 
are predicted to reflect the appropriate management of T2DM and musculoskeletal 
conditions.  Specific clinical outcome measures (HbA1c, BP) were also included in 
this group of indicators.  
 
Patient-related outcome data are only available through individual practice systems.  
It was not possible to access all control practices.  However, a group of practices 
within the control group permitted access to their data which provided a benchmark 
by which to compare intervention practices. Practices in this sub-set of the control 
group are referred to as ‘benchmark’ practices for the purposes of this evaluation. 
Patient related outcome data was collated from all intervention practices and all 
benchmark group of practices both at baseline and then again following the 
intervention.   
 
Key prescribing and patient orientated outcomes for each therapeutic topic and 




                                                                                                                                         41 
 




The purpose of the qualitative evaluation was to collect descriptive and contextual 
data in order to evaluate the experience and perspectives of participants at whom 
the intervention was targeted.  It explores GP perceptions, attitudes and beliefs both 
before and after the intervention in order to provide greater insight to the intervention 
and its impact on behaviour in practice.  It seeks feedback on delivery and 
acceptability of the intervention in influencing GP prescribing behaviour. The 
clinician perspective is also explored in terms of delivery of the intervention to 
improve uptake and incorporation of evidence into the clinical decision-making 
process. 
 
Data collection for the qualitative evaluation was achieved through pre-intervention 
and post intervention semi-structured interviews with GPs in participating practices.  
Interviews were transcribed and analysed using accepted qualitative methodologies.  
 
 
4.2.3.2 Methodological Approach 
 
It is not possible to explore and provide a detailed review and evaluation of the 
various practical approaches or theoretical underpinnings of qualitative research in 
this section.  Many standard texts exist for reference.195,196,197  However, the main 
concepts, principles and rationale adopted in approach to the qualitative evaluation 
in this study are summarised briefly here.  
 
Much qualitative analysis falls under the general heading of ‘Thematic Analysis’, in 
effect a ‘generic’ tool which is often adopted within different methods.  It involves a 
series of stages including organising and indexing data, extracting and coding 
elements of the data, developing themes and categories and potentially progressing 
to further theoretical analysis.198  Categories may be derived inductively that is, 
obtained from the data, or used deductively as a way of approaching the data.199  
 
Grounded Theory, is one such methodology used and accepted in qualitative 
research.200  The aim is to generate theory and a higher level of understanding that 
is ‘grounded’ in or derived from analysis of the data, rather than testing theory as in 
a positivist approach.   It is inductive in nature although deductive elements may be 
incorporated in the analysis.201,202,203  Individuals sharing common circumstances, 
experiencing common perceptions, thoughts and behaviours are also the essences 
of grounded theory and on which its epistemological underpinnings are based.204 
 
In grounded theory, the analytical process begins during data collection, shaping 
ongoing data collection through an iterative process.  Constant comparative 
methodology allows the researcher to further refine questions, and pursue emerging 
themes in more depth.200,204  
 
There is a lack of evidence or existing theory regarding incorporation of evidence-
based findings into clinical decision-making hence there is no preconceived 
theoretical perspective in this situation.  Grounded theory was deemed an 
appropriate basis for this study in order to generate theory that addresses a 
conceptual area of enquiry around professional behaviour.204  
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4.2.3.3 Framework Analysis 
 
Framework Analysis is a more recent approach to qualitative analysis, explicitly 
developed in the context of applied policy research.  It shares many common 
features of much qualitative analysis, including ‘thematic analysis’.198  
 
The general approach to framework analysis remains inductive as in grounded 
theory.  However, it also allows for the inclusion of ‘a priori’ as well as emergent 
concepts.198  There are five key stages of Framework Analysis, familiarisation with 
the data, identifying the thematic framework, indexing, charting and mapping and 
interpretation. 
 
There is no one right way to analyse qualitative data, however, it is important to 
describe the approach adopted in the analysis and its relevance to the 
methodology.198,203,205,206  In this study, there were clearly aspects of the data which 
related to pre-existing aspects of local and national policy, as well as patient care.   
 
Framework analysis was therefore deemed a relevant and suitable method of data 
analysis for this study.  The principles of grounded theory however were 
incorporated in the methodology during data collection. 
 
The methods adopted in data collection and analysis are described in Section 4.12. 
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4.3 Pharmacist Preparation and Training 
 
One crucial component of the complex intervention being delivered in practices was 
the pharmacists themselves.  In order to deliver the intervention as intended, it was 
necessary that they were equipped with the necessary skills, knowledge and 
expertise.  All participating pharmacists were therefore required to meet at least 
NPC Level 2 competencies for pharmacists working in primary care.   Key 
competencies included sound clinical therapeutic knowledge, excellent 
communication and interpersonal skills, knowledge of health policy and priorities 
and skills in the management of change as well as experience working in primary 
care with GPs. 
 
All pharmacists involved in delivering the intervention were employed within the PCT 
with job role functions ranging between Band 8a and 8d as defined in the NHS 
Knowledge and Skills Framework.207  All were fulfilling roles requiring clinical 
expertise with sound knowledge of prescribing, pharmacy and medicines 
management issues.  All had experience working in primary care and with GPs.   
 
It was desirable that each pharmacist should have a Postgraduate MSc/Diploma in 
clinical pharmacy or equivalent as part of their role specification.  All pharmacists in 
the study had at least one postgraduate qualification.  (Pharmacist details - 
Appendix 4). 
  
Although all the pharmacists involved in the study, were operating at a relatively 
senior level and were experienced health care professionals, it was necessary, for 
the purposes of the study to ensure that all were equipped with an appropriate 
knowledge and skill set and which was consistent across the group.  To this end, 
therapeutic update training and personal development training was commissioned 
for completion before delivery of the intervention in practices. 
 
Pre-study preparation focussed on three areas: 
 Information Mastery 
 Therapeutic Updates 
 Academic Detailing 
 
Most if not all pharmacists had previously attended NPC training on Information 
Mastery, Diabetes and Non-steroidal Anti-inflammatory drugs.  For the purposes of 
the study however, the pharmacists attended relevant NPC training updates.  




4.3.1 Information Mastery 
 
The NPC ‘Information Mastery for Local Decision Makers’ Workshop was 
commissioned and delivered by an NPC PlusTraining Adviser.  All pharmacists 
involved in delivering the study intervention attended.  The workshop was also open 
to members of the local prescribing sub-groups, interested GPs and to other 
members of the Medicines Management Team.  NB: None of the GPs from 
practices subsequently involved in the study intervention attended the training. 
 
The aim was to update participants with the necessary skills to adopt an evidence-
based approach in practice and incorporate relevant information into clinical 
decision-making.  The course plan and content were discussed and agreed between 
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the trainer and the chief investigator prior to the delivery, in order to tailor the 
content to the needs of the attendees, in particular the pharmacists. 
 
The interactive workshop involved didactic sessions and small group workshops.  
It included techniques in accessing most recent and relevant information from 
trusted sources, how to interpret statistical data, determining robustness of clinical 
trials and critical appraisal of published studies. 
 
 
4.3.2 Therapeutic Workshop - Type 2 Diabetes and NSAIDs 
 
NPC Plus training was commissioned to provide updates for the pharmacists 
involved in the study on the therapeutic topics chosen as the focus for the study 
intervention.  An NPC trainer/facilitator who had previously provided PCT training 
was contacted to discuss training requirements and the feasibility of bespoke 
therapeutics training to support the pharmacists delivering the study intervention.  
 
The aim was to provide pharmacists delivering the intervention with updated 
therapeutics training focussing on T2DM and NSAIDs with relevant Information 
Mastery included.  The workshop was also open to other members of MMT. 
 
The course plan and content were discussed and agreed between the chief 
investigator and NPC Plus trainer, and the content tailored to attendee requirements 
of the, in particular the pharmacists.  Copies of draft documents summarising the 
evidence and key messages for NSAIDs and T2DM prepared during ongoing 
development of the detail aids were provided to the trainer for information in 




Key messages and supporting evidence relating to NSAIDs focussed on managing 




The focus in T2DM was on management of cardiovascular risk (BP, blood lipids and 
aspirin), newer drugs for the management of blood glucose, appropriate use of RAS 
drugs (for management of hypertension and diabetic nephropathy) and self-
monitoring of blood glucose.  Knowledge of and reference to original clinical studies 
providing the evidence to support the key messages was a crucial aspect of the 
therapeutics training.  
 
The training was also tailored to consider academic detailing techniques and the use 
of detail aids in the delivery of key messages as an element of the intervention.  To 
this end a dedicated session on action planning was included.  This incorporated 
development and utilisation of a Detail Aid Matrix and use of the Detail Aid Matrix in 
selling key messages and influencing behaviour as part of the planned interactive 
meetings with GPs.  (Refer to Section 4.4). 
 
A comprehensive Lesson Plan was developed by the trainer which was agreed prior 
to implementation. (Appendix 5)  The training session covering both therapeutic 
topics was delivered over one day.  NPC Plus hand-outs reinforced the key 
messages and background references and resources for pharmacists to utilise if 
required when delivering the intervention visits. 
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4.3.3 Therapeutics Workshop – Renin-Angiotensin Drugs 
 
Management of renal disease (using RAS drugs) is an important aspect of 
management of T2DM.  Prior to the intervention, a free NPC workshop on Renin-
Angiotensin System (RAS) Drugs was offered and therefore commissioned to 
supplement the evidence-based therapeutics training (relating to T2DM) for 
pharmacists delivering the study intervention.  Other members of MMT and local 
primary care clinicians were invited to attend. 
 
Appropriate prescribing of RAS drugs is a national QIPP (Quality, Innovation, 
Productivity and Prevention) agenda Medicines Management option for local 
implementation.  Despite the evidence base and policy approach, there continues to 
be a relatively high use of A-II-As in preference to ACE-Is.   
 
The RAS drug update session covered factors guiding the evidence-based practice 
approach influencing choice of RAS drug, therapeutic dilemmas and a review of 
local prescribing patterns from ePACT data. 
 
The pharmacist training, aims, learning objectives and expected outcomes for the 
Information Mastery training and the therapeutic updates (T2DM, NSAIDs and RAS 
drugs) are summarised in Appendix 6. 
 
                                                                                                                                         46 
 
4.4 Provision and Development of Academic Detailing Training and Aids 
 
The pharmacists involved in delivery of the intervention, by virtue of their existing 
roles and competencies, arguably already exhibited skills in influencing behaviour 
change and in implementing academic detailing techniques.  However, the majority 
had not previously been introduced to the concept of academic detailing or received 
formal training in the approach.  Bespoke training was therefore commissioned to 
ensure that they were familiar with the principles of academic detailing and able to 
conduct educational outreach visits using relevant skills in order to facilitate change 
in prescribing behaviour.   
  
Investigation revealed that NHS training dedicated to academic detailing was lacking 
and that little commercially available training was available at the time including from 
the NPC (other than the dedicated session included in the therapeutic training 
workshop).  Other options to access bespoke detail training were therefore explored.   
 
The company commissioned to provide academic detailing training, (Focus Games 
Ltd.) was recommended by the acting Chief Pharmacist in a neighbouring PCT (an 
independent Healthcare Consultant with experience in both the pharmaceutical 
industry and the NHS).  It describes itself as ‘a clinical engagement, benefits 
realisation and change management consultancy specialising in front line 
communication work primarily within the healthcare sector’.  It had experience of 
working with the Department of Health, the Pharmaceutical Industry and in 
delivering clinical engagement programmes within the NHS. 
 
The course leaders had practical experience of drug detailing and communication 
techniques and in pharmaceutical marketing and training involving provision of detail 
training for outreach visits as well as development of communication skills.  They 
had clinical (nursing) background qualifications.  
 
 
4.4.1 Development of Academic Detailing Training 
 
Several meetings were held between the Chief Investigator and the Company to 
discuss and finalise the training.  Discussions focussed on development of a training 
package to meet the requirements for delivering the study intervention and 
establishing that the trainer would be able to meet the required objectives.  
 
Training was developed on the understanding that the academic detailing approach 
was part of a complex intervention based on practice visits, which involved engaging 
the group in discussion about specific therapeutic topics using detail aids, 
incorporating presentation and feedback on prescribing data, additional written 
support material, and implementation of agreed actions. 
 
The training addressed development and utilisation of structured Detail Aids which 
were evidence-based, focussing on the key messages to be delivered and 
reinforced by the pharmacists during practice visits.  Draft study detail aids were 
utilised during training as the focus of exercises on detail aid development and 
building the detail “story board”.  This approach also enabled the pharmacists to 
familiarise themselves with the detail aids (and content), which were relevant to 
practice visits that they would be conducting.  The emphasis on skills development, 
involved communication of the detail and key messages, agreement and 
quantification of actions with the GPs and applying pharmacists analytical skills in 
order to adapt to the visit dynamics.   
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The Aims and learning outcomes from the academic detail training are summarised 
in Appendix 7. 
 
Two pre-workshop teleconference sessions were conducted plus pre-course work in 
developing an adoption ladder and question bank.  Course activities involved 
identifying key messages, developing associated detail aids and using the adoption 
ladder and question bank in pre-prepared scenarios.  The Detailing Skills 
Workshops ran over two consecutive days with a single day follow-up a week later.  
Funding was approved from the MMT training budget.  Training approach, detailing 
skills principles and pre-course preparation are summarised in Appendix 8. 
 
The training also provided opportunity to practice detailing techniques using pre-
prepared vignettes.  Role play sessions were included to enable pharmacists to 
practice under mentored conditions.  Supplementary written training materials were 
also provided.  
 
 
4.4.1.1 Academic Detailing Review Session 
 
A separate review session was organised by the chief investigator for pharmacists 
delivering the study intervention, before baseline practice visits began, in order to 
ensure that they were clear on the visit objectives, intervention components and 
outcome measures as well as being familiar with the finalised detail aids, supporting 
slides and other materials including planning matrices and key reference 
documents. It also provided an opportunity to raise any outstanding queries.   
A detailing skills presentation was included as revision and circulated to the 
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4.4.2 Detail Aids 
 
Detail aids specific to the intervention therapeutic topics, required for delivery of the 
intervention were developed and prepared by the Chief Investigator.  Examples of 
existing detail aids were sought for reference.  A limited number of examples were 
obtained from the Northern and Yorkshire Regional Drug and Therapeutic Centre 
(NYDTC) Website, plus examples published in the NAO Report.  A formal query to 
the UK Medicines Information Service (UKMI) identified no additional resources. 
 
Key messages to be delivered within the intervention for each therapeutic topic were 
initially collated in summary documents in preparation for development of the detail 
aids.  References supporting the evidence base were documented and potential 
points for discussion highlighted.   (Appendix 10) 
 
Trusted, validated evidence-based resources such as NICE and the NPC were 
accessed and utilised to distil the key messages for incorporation in the detail aids.  
(Appendix 11).  The key evidence-based messages were integral to and consistent 
with the therapeutics update training organised for the purposes of the study.  This 
approach ensured that detail aids were relevant and study specific. 
 
Draft study detail aids were made available to academic detailing and therapeutics 
trainers for training purposes, and to support learning objectives relating to 
development of detail aids.  A dual outcome was that key messages delivered by as 
part of the intervention were reinforced, and enabled the Pharmacists to practice 
detailing skills, using documents which would ultimately form part of the detailing 
package in practice.  
 
The detail aids were prepared using Microsoft Office PowerPoint, presented in slide 
format.  Key messages were distilled and supporting evidence based references 
included on the slides. 
 
The NSAID and musculoskeletal pain detail aid consisted of twelve ‘slides’  The key 
messages targeted appropriate use and choice of NSAID, the importance of safety 
and minimisation of the clinical risk associated with individual drug choices.  The 
main T2DM detail aid consisted of sixteen slides.  The key messages targeted 
prioritisation of the multifaceted approach to management, reduction of 
cardiovascular risk and improving benefits for patients.  The Detail Aids are included 
as Appendix 12. 
 
Because T2DM is a long term condition and its management is complex and 
multifaceted, a set of (sixty) supporting slides was prepared in addition to the main 
detail aid.  These focussed on specific aspects of management, highlighting key 
messages and the supporting evidence base within each topic.  Its purpose was to 
provide further evidence for use by the pharmacists if required in tailored 
discussions during practice visits.  (Appendix 13).  
 
Additional slides were prepared during delivery of the intervention in response to 
queries, further topics raised during practice visits and in the light of new evidence. 
 
 
4.4.3 Academic Detail Planning Matrix 
 
A detail planning matrix is an extremely useful supporting tool for use when 
preparing delivery of an academic detailing session.  The document is prepared 
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prospectively, enabling the person developing or delivering the detail to collate the 
relevant information to the key messages in one summary.  It describes the aims of 
the detail, highlighting areas of controversy and identifies key supporting sources of 
information that the detailer should be familiar with before the visit.   
 
The planning matrix template contains two elements which are completed as part of 
the detail development.  One element focuses on, and lists the key messages to be 
delivered during the detailing session.  Any important features associated with each 
key message are identified and any benefits associated with implementation are 
also listed.  Credible sources of information which underpin each message are 
identified and suitable questions relating to each message are considered. 
 
The second element of the planning matrix focuses on the main aims of the detailing 
session.  Any known areas of controversy are documented.  Mandatory literature or 
policies that the detailer requires and should be familiar with before the visit are 
listed.   Possible opening questions to initiate discussion and to ascertain closure 
are documented and any support materials that the detailer should take with them 
are listed.   
 
Completed Academic Planning Matrices (prepared by the Chief Investigator) for 
T2DM and NSAIDs using the planning matrix template from the NPC therapeutics 










4.5 Study Approval 
 
The research study received the following Research Ethics and Research 
Management and Governance approvals prior to commencement: 
 
 Local (NHS) Research Ethical Approval – Cambridgeshire 4 Research Ethics 
Committee 
 University of Bath, School for Health School Research Ethics Approval Panel  
 PCT Research Management and Governance Approval - Peterborough and 
Cambridgeshire NHS Trusts (Primary Care) 
 
 
4.6 Sample Size 
 
Sample size calculations were based on the quantitative evaluation of retrospective 
prescribing data assessed over a twelve month period. 
 
There was some uncertainty as to which prescribing indicator(s) would ultimately be 
'primary' (as external factors may influence prescribing during the study).  Some 
uncertainly also surrounded the sizes of effects that should be both worthwhile and 
achievable.  Therefore, sample-size calculations proceeded by taking first a 
'practical' sample-size -10 intervention and 10 control practices - and working out 
the consequences for power of that choice.  Principal prescribing outcome 
measures were intended to include increase in metformin and reduction in total 
glitazones, reduction in diclofenac and reduction in overall NSAIDs.  
 
Sample size calculations were carried out for these indicators using a two-tailed 5% 
level of significance for the effect of the intervention with 80% power.  The variance 
estimates needed were obtained from regression analysis on the log scale of 
ePACT data for the financial quarter (July, August, September), 2008 on the 
corresponding data for 2007 for all 75 practices in NHS Cambridgeshire.   
 
With 10 practices in the intervention group and 10 practices in the control group, this 
strategy would be able to detect a 10% increase in the prescribing of metformin, a 
29% decrease in the prescribing of glitazones, 14% reduction in total NSAIDs and a 
23% reduction in diclofenac.   
 
Allowing for a 30% practice response rate and a potential further 10% loss of 
practices to follow up, 66 practices would need to be approached to participate in 
the study.  As this is close to total number of practices in the PCT, all 75 practices 
were invited to participate.   
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4.7 Recruitment   
 
The overall recruitment process for both the quantitative and qualitative elements of 
the study is summarised in the Recruitment Process Summary Flowchart.   
(Appendix 16). 
 
4.7.1 Practice Recruitment  
 
A routine Medicines Management newsletter was utilised to raise awareness about 
the study.  It was distributed approximately one month before letters of invitation 
were sent to practices inviting them to participate in the study. (Appendix 17) 
 
A letter providing study details was then sent to each practice GP prescribing lead, 
Senior Partner and copied to the Practice Manager.   Copies of the Study 
Information Sheet and Expression of Interest form containing the researcher contact 
details and reply slip were included.  (Appendices 18,19)   Duplicate details were 
also e-mailed direct to each prescribing lead and practice manager.  Interested 
practices were invited to contact the chief investigator for further information and, if 
required, to request a visit from the researcher to discuss the study design and 
participation requirements.  Several practices requested a visit from the chief 
investigator to discuss participation. 
 
Practices which did not respond either to express an interest or to decline 
participation were sent a follow-up invitation letter approximately two months later.  
Non-responders to this letter were deemed not to wish to participate. 
 
Participating practices were required to provide signed consent before practice visits 
could commence.  The senior partner or designated deputy (eg practice GP 
prescribing lead) acted as signatory for consent on behalf of all GPs in the practice 
(Appendix 20). 
 




Where practices agreed to participate, a further letter was sent to the GP 
Prescribing lead, and copied to the Practice Manager.  The Qualitative Evaluation 
Study Information Sheet was enclosed for dissemination to practice GPs.  
(Appendices 21,22)  The purpose of this letter was to recruit interested GP 




Following implementation of the intervention and completion of the practice visits,  
Participating GP Prescribing Leads were e-mailed in order to recruit interested GP 
volunteers to participate in post-intervention semi-structured interviews.  The 
Qualitative Evaluation Study Information Sheet was attached for dissemination to 
practice GPs.  
 
GPs who expressed an interest and agreed to participate in pre- or post- study 
semi-structured interviews were required to provide signed consent, prior to 
participation.  (Appendix 23) 
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All Study Information Sheets and Consent Forms were approved for use as part of 
the NRES Local Research Ethics Approval Process.   
 
 
4.7.2.3 Follow Up Communication with GP Practices 
 
Following completion of the pre-intervention and post-intervention semi-structured 
interviews, letters were sent to GP practice prescribing leads and to individual GPs 
who participated in interviews thanking them for their time and commitment to 
participation in the study.  They were advised that feedback would be available to 











                                                                                                                                         53 
 
4.8 Allocation to Groups Strategy 
 
Because of the small sample size and exploratory nature of this study, it was not 
feasible to randomise practices to intervention and control groups.  Instead, as a 
quasi-experimental design was adopted, it was necessary to define the intervention 
group and matched control group.   
 
Cambridgeshire PCT was formed in 2007 following reconfiguration of three smaller 
PCTs with differing demographic patterns.   These were Huntingdonshire, 
(predominantly town and residential), Cambridge City (high professional and student 




Practices which consented to participate in the study were automatically enrolled to 
receive the study intervention.  This group constituted the intervention group (twelve 




Prescribing (ePACT) data is available for all practices in the PCT.  It was therefore 
possible to define a group of practices of similar size and demographics to the 
intervention group In order to obtain a matched control group (no intervention) of 
equal sample size to the intervention group for the purposes of prescribing data 
analysis and statistical evaluation and in order to enable prescribing comparisons 
between intervention and non-intervention practices.   
 
In addition to participating (intervention) practices, a number of practices (for various 
reasons unable to commit to study participation), granted access to the chief 
investigator to collect patient outcome data.  These practices constituted the 
benchmark group against which intervention group patient-orientated outcome data 
was compared.  
 
The number of benchmark practices (seven) was less than the number of 
intervention practices (twelve).  Nevertheless, it was believed that they would 
constitute a benchmark for comparison against which it would be possible to detect 
some differences in achievement of patient outcomes in intervention group 
practices. 
 
The study control group therefore consisted of the seven benchmark practices plus 
five additional non-intervention practices.  Intervention and Control groups were 
matched as closely as possible for practice population size, locality and 
demographics in order to provide two equal sized groups with similar characteristics 
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4.9 Practice Visits 
 
4.9.1 Pharmacist Allocation 
 
Each pharmacist prescribing adviser conducting intervention visits was allocated to 
several participating practices.  Where possible, pharmacists were allocated to 
practices where they were already known to the GPs, or working within the locality, 
in order to capitalise on pre-existing relationships as a credible source of 
information.  
 
4.9.2 Intervention Visits 
 
The intervention was conducted over a twelve month period.  Four practice visits 
were conducted with each practice.  Practice nurses, and practice managers were 
also invited to attend.   
 
 Academic detailing approach involved:  
o Face to face meetings, engaging the GPs in discussions focussing on 
pre-determined therapeutic topics.   
o Identification of needs and issues of participants and presentation of 
cohesive arguments backed up by referenced facts.   
o Re-enforcement of Key messages.   
o Visit Outcome - that GPs agree a course of action which would be 
followed up in future meetings. 
 
 Baseline visit.  The prescribing adviser introduced themselves and provided a 
brief summary of the study (and therapeutic topics) to participants.  Baseline 
prescribing data containing anonymised comparative PCT practice prescribing 
data was presented for discussion. 
 
 Follow-up visits.  Three follow up visits were conducted approximately 3-4 
months apart.  Meeting agendas were based on the pre-determined therapeutic 
topics, previous discussions and agreed actions.  Previous messages were 








The detail aids were prepared in three formats to allow for flexibility in individual 
pharmacist presentation style. 
 
Each pharmacist received one individual A4 size presentation folder containing hard 
copy Detail Aids.  Two A3 folders were prepared for shared use for pharmacists 
preferring to utilise larger copy detail aids during practice visits.  Pharmacists were 
also issued with a USB memory stick loaded with the PowerPoint detail aids for 
individuals or practices preferring electronic presentation during practice visits.   
 
During the course of the intervention, new and updated detail aids produced in 
response to queries and on availability of new evidence were prepared, 
disseminated and added to all relevant folders.    
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4.9.4 Prescribing Data for Practice Visits 
 
4.9.4.1 Baseline Visits 
 
Prior to conduct of the baseline visits, the previous 12 month data were downloaded 
from ePACT.net for each therapeutic topic:  
 Drug Group BNF Chapter 6.1.2 Endocrine – Drugs used in Diabetes  
 Drug Group BNF Chapter 10.1.1 Musculoskeletal - NSAIDs 
 
Total Items, Total Cost and Total ADQ data for each practice and for the PCT at 
individual drug level were downloaded into an Excel spreadsheet.   
 
In order to provide comparisons, percentage items, cost and ADQs were calculated 
for the drugs listed, to show prescribing of each drug as a proportion of total 
prescribing within each therapeutic group.  Differences between individual practice 
data and the PCT mean were then calculated in order to demonstrate how the 
practice prescribing compared with PCT averages.  Data comparing use of topical 
NSAIDs compared with oral NSAIDs was also presented at baseline. 
 
Graphs (pie-charts) of percent prescription items for each practice compared with 
the PCT average were prepared.  (Example in Appendix 25)  The data was 
presented in tabular and graphical format for presentation to practices by the 
pharmacists during the baseline visits. 
 
 
4.9.4.2 Follow Up Visits 
 
Because there is approximately 6-8 weeks delay in ePACT data availability, updated 
baseline prescribing data was unavailable for the second scheduled practice visits.   
 
When available, data for the quarter following baseline was downloaded to identify 
any obvious differences in individual practices compared with PCT averages.  Data 
manipulation was performed as for baseline.  Data summaries were presented as 
previously in tabular and graphical (pie chart) format for the pharmacists to highlight 
and discuss any changes during practice visits.   
 
Throughout the intervention period, the Chief Investigator also downloaded and 
prepared data to demonstrate prescribing trends for NSAIDs and drugs used in 
T2DM.  Prescribing data was updated prior to each practice visit and provided to the 
allocated pharmacist for discussion with the GPs.  It was presented in tabular and 
graphical format.  The purpose was to provide feedback for GPs, and to 
demonstrate any shifts in prescribing during the study period and to monitor 
prescribing patterns in relation to agreed practice actions.  The trend data was 
incorporated into the ‘Visit Summary’ for follow-up visits three and four.  (Section 
4.9.5) 
 
Hard copies of practice e-PACT data were prepared for each pharmacist.  Original 
copies were filed electronically in dedicated MMT folders and were available for 
uploading on to the pharmacist USB sticks if that was their preference. 
 
4.9.4.3 Additional Prescribing Data Requirements  
 
Following practice visits, several practices required additional prescribing 
information to inform further discussion or in order to support achievement of agreed 
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actions.  In such situations, the data was downloaded and prepared for presentation 
by the nominated practice pharmacist themselves (depending on their ePACT skills) 
or, by request for required data to the Chief Investigator. 
 
Pharmacists allocated to practices were aware that the Chief Investigator had 
collected patient-orientated outcome data from practice searches.  Baseline practice 
data (e.g. renal data) was also shared by the pharmacist with certain practices to 
further inform discussion and achievement of agreed actions.   
 
4.9.5 Visit Summaries  
 
Visit summaries were prepared by the Chief Investigator on behalf of the other 
pharmacists prior to the third and fourth practice visits for use during practice visits 
and for dissemination within the practice if required. 
 
The report included most recent prescribing data for feedback to the practice with a 
written summary of any changes which had occurred since the previous visits and 
study start.  Shifts in prescribing trends were highlighted and documented.  It also 
incorporated a review of agreed actions from previous meetings and evidence of 
progress.  In addition, possible areas for follow-up discussion or actions for the 
following meeting were highlighted.  
 
The Visit Summary specifically served as a pre-visit discussion document for those 
pharmacists who wished to discuss the upcoming visit with Chief Investigator prior 
to each meeting.  An example is included in Appendix 26. 
 
 
4.9.6 Visit Support Materials 
 
Various support materials were collated to support the pharmacists in conducting 
the practice visits and to facilitate easy access to study related documents including 
evidence-based reference materials.  
 
Support materials were provided for the pharmacists in two resource ‘packages’.   
Individual study folders were prepared for each pharmacist containing core study 
documents for reference (Appendix 27).  
 
Written evidence-based information summaries and core references supporting key 
messages were also collated, and disseminated to the pharmacists delivering the 
intervention.   Additional copies of evidence-based summaries were also available 
for dissemination to GP practice participants.   
 
A central repository containing all study related documents, key references and 
additional resources was also maintained by the Chief Investigator. 
 
During the course of the study, the Chief Investigator continued horizon scanning 
and evaluating more recent publications which may have been relevant to the topics 
discussed during the practice visits.  Any new evidence was circulated to the 
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4.9.7 Visit Reports 
 
Following each practice visit, it was the pharmacist’s responsibility to summarise the 
meeting, documenting discussions and any agreed actions in a visit report.   The 
visit report was sent to the practice GPs following each practice visit. 
 
A template was shared and adopted by the pharmacists as the approach to 
recording study practice visits, meeting discussions and agreed actions.   Aspects of 
the visit which were routinely documented included attendees, main discussion 
points, topics discussed, resources supplied, agreed actions and responsibilities and 
arrangements for the next meeting. 
 
Pharmacists were requested to send visit reports back to the practices within two 
weeks of conducting the practice visit.  Copies of the visit reports were sent to the 
Chief Investigator.  (Example visit reports included as Appendix 28). 
 
 
4.9.8 Study Folders 
 
All documentation relating to practice visits was held electronically in a central study 
folder in the MMT computer system.   In addition, a central repository containing 
individual practice study folders (hard copy) was maintained by the Chief 
Investigator in a dedicated study cabinet.  The study folders contained copies of all 
documents relating to the study visits, filed in date order, maintained on file for 
reference.  The study folders therefore contained copies of the visit reports, practice 
data, visit summary reports and examples of evidence based reference materials 
used during the practice visits. 
 
 
4.9.9 Review of Baseline Visits 
 
Following completion of all baseline visits, a formal meeting was held with the 
pharmacists to review and discuss the visit process, share experiences and raise 
any issues which may require further action.  
 
The Chief Investigator prepared a summary of the agreed actions from the baseline 
visits in order to identify any consistent themes or queries and to ensure that the 
pharmacists were fully supported in achieving their own agreed actions (such as 
provision of additional ePACT data).  The Agenda, Discussion Points and meeting 
summary are included in Appendix 29. 
 
The meeting provided an opportunity to review the conduct of the study and ensure 
that the intervention was being delivered in a consistent manner according to the 
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4.10 Data Evaluation 
 
4.10.1 Prescribing Outcome Measures 
 
The primary outcome measures defined for statistical analysis and which determine 
the power of the study are based on differences between pre-intervention (baseline) 
prescribing volume and post-intervention prescribing volume (following completion 
of the study visits) for the intervention group compared with the control group.  
Primary and secondary prescribing outcome measures are based on evaluation of 
ePACT data. 
 
The primary outcome prescribing measures for T2DM are based on an increase in 
prescribing of metformin and overall reduction in prescribing of glitazones.   
Secondary outcome measures include potential effects of the intervention on overall 
diabetic drug use and use of newer drugs in diabetes. (Table 4.1) 
 
Primary outcome prescribing measures for NSAIDs are based on a reduction in the 
prescribing of diclofenac (and COX-2 Inhibitors) and an overall reduction in 
prescribing of NSAIDs.  Secondary prescribing outcome measures anticipated for 
NSAIDs are aimed to identify shifts towards prescribing of alternative medications 
(ibuprofen and naproxen) which are associated with lower cardiovascular risk than 
diclofenac and COX-2 Inhibitors.  (Table 4.1) 
 
Prescribing Outcome Measures are summarised in Table 4.1 
 
Therapeutic Topic Prescribing Outcome Measure 
Diabetes  Overall Antidiabetic Drug Usage  
      (All hypoglycaemic agents,excludes insulin) 
 Metformin Usage 
 Glitazone Usage 
 Other Antidiabetic Drugs   
      (Newer drugs in diabetes, GLP-1 agonists,  
      DPP-4 Inhibitors) 
NSAIDs 
 
 Diclofenac Usage 
 COX-II Inhibitor Usage 
 Overall NSAIDs Usage 
 Naproxen Usage 
 Ibuprofen Usage 
 
Table 4.1 Study Prescribing Outcome Measures  
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4.10.1.1 Prescribing Data – Plan of Analysis  
 
The plan of analysis compares the level of pre-intervention prescribing from ePACT 
data in a quarter (as measured by ADQs per ASTRO-PUs) compared with the same 
quarter one year later, (post-intervention) for each of the defined outcome 
measures.  The effect of the intervention on prescribing will be evaluated by testing 
the null hypothesis that no prescribing differences exist between the intervention 
and control groups for each of the prescribing outcome measures.  Evidence for 
statistically significant differences will be sought. 
 
Descriptive statistics will also be performed on the data in order to describe the 
sample characteristics and check for violation of the underlying statistical techniques 
applied in analysis of the data. 
 
 
4.10.1.2 Prescribing Data Collection 
 
Pre-intervention prescribing data (as measured by ADQ Usage Per Items based 
ASTRO-PUs), was accessed and downloaded from ePACT for the financial quarter 
immediately preceding implementation of the intervention (July, August, and 
September) and for the same post-intervention time period the following year to 
enable before and after comparison.  (2nd Quarter 2010/2011 compared with 2nd 
Quarter 2011/2012). 
 
Data was grouped, selected and downloaded for intervention group practices and 
control practices by setting up and applying separate tags for each study group.  
(Data was downloaded for individual practices and for NHS Cambridgeshire as a 
whole in case access was necessary for comparison or perusal at a later date).   
NB: Creating Tags for Indicators – Refer to Section 4.2.1. 
 
Prescribing data relating to each therapeutic topic was downloaded into separate 
Microsoft Excel spreadsheets for data manipulation and analysis.  Data for each of 
the outcome measures was transferred to a separate sheet within in each workbook.   
The differences between pre-intervention prescribing volume and post-intervention 
prescribing volume were calculated for each prescribing measure (indicator) within 
Excel. 
 
Data files were further prepared within Excel so that they could be directly imported 
in the appropriate format into the SPSS Statistics software package for statistical 
analysis (IBMs Statistical Package for the Social Sciences).208  
 
SPSS Version 18 (downloaded from Bath University Secure Downloads) was 
utilised for statistical analysis of study prescribing data. 
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Methods 
 
4.10.2 Prescribing Trend Data 
 
In addition to collection and analysis of prescribing outcome data, (used to 
determine statistically significant differences between intervention and control 
practices), prescribing trend data over the study period was collated for all of the 
intervention practices, all ‘control’ practices and the PCT as a whole.   
 
Data from ‘control’ practices (non-intervention) would reflect general or background 
trends  in prescribing patterns (local or national) and would be used as a benchmark 
by which to compare intervention practice prescribing patterns over the study period. 
 
The purpose was to identify and establish whether there were any demonstrable 
trends or shifts in the prescribing of drugs used in T2DM and musculoskeletal 
disorders which might be attributable to the intervention in the intervention practices 
during the study period by comparing with background prescribing patterns in non-
intervention practices.  
 
Monthly prescribing data was downloaded from ePACT for each of the individual 
drugs in the BNF Sections indicated below:186 
 
 BNF Chapter 6, Endocrine System 
Section 6.1.2  Antidiabetic Drugs   
Sulphonylureas (6.1.2.1), Biguanides (6.1.2.2) and Other Antidiabetic 
Drugs(6.1.2.3) 
 
 BNF Chapter 10, Musculoskeletal and Joint Diseases 
Section 10.1.1  Non-steroidal anti-inflammatory drugs (including COX-Inhibitors) 
 
 
4.10.2.1 Prescribing Trend Data Collection 
 
Prescribing data, based on ‘total items’ for each drug prescribed each month in the 
defined BNF Sections was downloaded from ePACT for the twenty-one month 
period from April 2010 to December 2011.  This time period therefore included 
approximately five months pre-baseline data and approximately four months post-
study data. 
 
Data was downloaded from ePACT and imported into a Microsoft Excel spreadsheet 
for further manipulation and analysis.  Separate workbooks were used for 
intervention and benchmark practices and NHS Cambridgeshire.  A separate work 
sheet was allocated for each practice. 
 
Prescribing of each drug as a proportion of the monthly total items was then 
converted to a percentage figure, expressed as percentage of total items in the 
relevant BNF Section for that month.   
 
Data manipulation involved further collation of figures so that certain classes or 
groups of drugs could be presented collectively (e.g sulphonylureas, COX-2 
Inhibitors, combination products, ‘Others’).  Data was further manipulated within the 
spreadsheets so that overall prescribing trends could be presented graphically as 
demonstrated in the Results Section. 
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4.10.3 Practice Data - Patient Orientated Outcome Measures 
 
4.10.3.1 Type 2 Diabetes  
 
Thirteen patient-orientated outcome measures for patients with T2DM were defined 
focusing on three areas.  These were, clinical outcomes, (recommended targets), 
appropriate prescribing of medication in T2DM and renal care measures, as follows: 
 
Type 2 Diabetes Patient Orientated Outcome Measure 
Recommended Target Measures 
 
 
Proportion of patients achieving: 
 Blood pressure  (≤ 140/80mmHg) 
 Blood lipids  (TC ≤ 5mmol/l) 
 HbA1c (≤ 7.5%) 
 HbA1c (≤ 9.0%) 




 Proportion of patients on metformin,  
 Proportion of patients on lipid lowering 
therapy 
 Proportion of patients on aspirin 
 Proportion of patients prescribed a Renin-
Angiotensin drug 
o Proportion of patients specifically 
prescribed an ACE-Inhibitor 
Renal Care Measures 
 
 Proportion of patients tested for 
microalbuminuria 
 Proportion of patients with 
microalbuminuria on a RAS drug 
 Proportion of patients with 
microalbuminuria attaining recommended 
BP target (≤ 130/80mmHg) 
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4.10.3.2 Non-Steroidal Anti-inflammatory Drugs 
 
Six patient-orientated outcome measures for patients on NSAIDs were defined 
focusing on three areas These were prescribing of NSAIDS in patients with clinical 
risk factors, concomitant prescribing of ‘other’ drugs (including drugs which increase 
GI risk and those which provide gastro-protection) and general prescribing of 
NSAIDs, as follows: 
 
NSAIDs Patient Orientated Outcome Measure 
Risk Factor Measures  Proportion of elderly patients (≥65) on 
NSAID 
 Proportion of patients with documented 
clinical risk factors (combined) 
o Cardiovascular risk factors 
o Gastrointestinal risk factors 
o Cardio-renal Risk factors 




o PPI (gastro-protection) 
NSAIDs Prescribing Measures 
 
 Proportion of patients on NSAIDs 
o NSAIDs (overall) as proportion of 
practice patient population 
 
Table 4.3 Patient-Oriented Outcome Measures NSAIDs 
 
 
4.10.3.3 Patient-Orientated Outcome Data - Plan of Analysis 
 
Practice outcome data was subjected to two separate analyses. 
 
4.10.3.3.1 Statistical Analysis 
 
The main statistical evaluation of the intervention on which the power of the study is 
calculated is based on evaluation of prescribing data and comparison between 
intervention and control groups.  However, the effect of the intervention on defined 
patient-oriented outcomes will also be evaluated by performing an analysis on the 
patient outcome data to establish whether a statistically significant difference in 
patient outcomes exists between the intervention and benchmark groups. 
 
This statistical analysis will test the null hypothesis that no differences exist between 
the intervention and benchmark groups for each of the prescribing outcome 
measures.  Evidence for statistically significant differences will be sought. 
 
4.10.3.3.2 Comparison between Intervention and Benchmark Group Practices 
 
Patient outcome data will also be reviewed and presented at individual practice 
level.  This analysis will establish whether any obvious differences exist in 
achievement of outcome measures between intervention and benchmark practices. 
 
For patients with T2DM, the plan of analysis compares proportion of patients 
achieving recommended treatment targets and receiving appropriate medication in 
the management of T2DM post-intervention compared with pre-intervention figures 
for each of the defined outcome measures. 
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For patients on oral NSAIDs, the plan of analysis compares proportion of patients 
with concomitant clinical risk factors or medication which may increase (or reduce) 
patient risk post-intervention compared with pre-intervention figures.  Comparisons 
between pre-intervention and post-intervention proportions of patients on NSAID 
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4.11 Collection of Quantitative Patient Orientated Outcome Data 
 
GP practices hold patient medical records and associated information on dedicated 
practice computer systems which are an integral part of GP practice.  A variety of 
commercially available systems are available and utilised in practice.  Although 
systems may vary in layout, functionality and additional features, all perform the 
same basic functions. 
 
A large amount of information is held on practice computer systems, covering all 
aspects of patient care including prescribing and chronic disease management.  It is 
possible to extract information from the practice system in order to audit, track and 
monitor changes in health outcomes.  Read Codes are a coded thesaurus of clinical 
terms used to record data (such as diagnosis, investigations, medication) on clinical 
systems in the UK.  Data extraction from GP practice systems is facilitated by the 
use of Read coded information, irrespective of the commercial computer system 
implemented in the practice. 
 
4.11.1 Patient Orientated Outcome Data Collection 
 
For the purposes of the study, patient-oriented measures were defined for the two 
patient populations, those with T2DM and patients on NSAIDs.  Data was collected 
from intervention and control practices according to the predetermined outcomes as 
summarised in Table 4.2 and Table 4.3. 
 
Data sets were collected from all twelve intervention practices and seven 
benchmark practices prior to implementation of the intervention and the data 
searches were repeated approximately twelve months later following completion of 
the intervention study visits. 
 
The data sets collected for T2DM and NSAIDs are summarised in Appendix 30 and 




Patient-orientated outcome data was collected from nineteen practices in total.  
Three different practice systems were employed by the Intervention practices. All 
benchmark practices utilised the EMIS LV system.    A summary of Intervention and 
Benchmark practice systems is provided in Table 4.4.   
 
 Number of Practices 
Practice System Intervention Benchmark 
EMIS 7 7 
System One 3 0 
Torex (RepAid Software) 2 0 
Total 12 7 
 
Table 4.4 Practice System Summary 
 
 
4.11.2 Practice Data Collection Strategy 
 
Building up each practice search requires a methodical and stepwise approach.   
Data collection was performed by employing the appropriate search strategy 
applicable to each practice system in order to achieve the specified data set.  
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Despite the differences in practice systems, it is possible to collect consistent data 
sets from each practice.     
 
It was necessary at the outset to establish the overall practice population and 
calculate disease prevalence (proportion of patients with T2DM and proportion of 
patients on NSAID) both before and after the intervention in order to account for any 
possible increase or decrease in the study populations and in order to calculate pre-
intervention and post-intervention differences.   
 
It was also necessary to ensure that no major unanticipated changes in practice 
population had occurred during the intervention period.  Otherwise, the figures may 
have required further adjustment in order to perform the required assessments.   
 
Most practices utilised the EMIS-LV system.  All Baseline and Post-intervention 
EMIS practice searches were performed by the chief investigator. 
The EMIS search methodology and subsequent preparation of the Excel 
spreadsheets for T2DM data is described in Appendix 32.  The EMIS search 
strategy and data collection process for NSAIDs is summarised in Appendix 33. 
 
Baseline searches in System One practices were performed by the chief investigator 
with support from a pharmacy technician experienced in using the System One 
clinical system, to ensure that the required data set was collected.  Post intervention 
searches which were essentially re-runs of the baseline searches were performed 
by the Chief Investigator twelve months later. 
 
Practices using the Torex system also employ RepAid software which facilitates 
downloading of data according to the defined search strategy.  The Torex system is 
not used widely in the PCT.  The Torex searches were therefore performed in one of 
the intervention practices with support from the practice manager who had 
considerable IT experience to ensure that the required data set was collected.  
These searches were copied onto an encrypted memory stick in order to repeat the 
exact searches in the other participating Torex study practice and so ensuring 
consistent data collection. 
 
In all cases, once the search had been performed, the resulting report was 
downloaded into a Microsoft Excel spreadsheet.  Each Excel spread sheet was 
tidied, and each column was given an appropriate title labelling the data in it.   
 
It was extremely important at this stage, and whilst still in the practice, to check that 
all of the columns had data entered (if available) as some practices may use 
different Read Codes or different descriptors (terms) for the same parameter.  If 
there were differences, it was necessary to amend the report using the relevant 
Read Code or descriptors used by the practice and rerun the report and re-export 
the data into Excel.  The file was then saved as an Excel workbook and filed on the 
practice system in appropriate folders.  The spreadsheets were then forwarded for 
storage and analysis using a secure route via an nhs.net e-mail account and were 
also backed up on an encrypted memory stick. 
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4.11.3 Analysis of Patient-Orientated Outcome Data  
 
The tidied Excel spread sheets required further adaptation and manipulation prior to 
analysis to ensure that presentation of data sets were consistent between each 
practice and each practice system.  Superfluous exported data was deleted (for 
example where systolic blood pressure and diastolic blood pressure values have 
duplicated date columns, one requires deletion).  
 
NB: Missing Data.  Where individual values were missing from exported data, 
calculations were still based on total practice population as a missing value was 
regarded as non-achievement of the target. 
 
The data analysis was an intensive process requiring exploration and extraction of 
the information in each spreadsheet.  A data recording form was prepared for each 
therapeutic topic in order to record the main results from the Excel data 
manipulation and to facilitate further analysis and reporting. (Appendix 35). 
 
The summary data for each practice was further analysed within Excel and 
presented as a Data Collection and Analysis Summary for each therapeutic topic. 
 
 
4.11.3.1 Statistical Data Analysis 
 
The differences between the proportions of patients achieving pre-intervention 
patient outcome measures compared with proportions of patients achieving post-
intervention outcome measures were calculated for each patient-orientated measure 
(indicator) within Excel. 
 
Data files were further prepared within Excel so that they could be directly imported 
in the appropriate format into the SPSS Statistics software package for statistical 
analysis (IBMs Statistical Package for the Social Sciences).208  
 
SPSS Version 18 was utilised for statistical analysis of patient outcome data.  
 
 
4.11.3.2 Comparison between Intervention and Benchmark Group Practices 
 
The purpose of the additional analysis was to determine whether it was possible to 
detect any obvious differences in patient-orientated outcomes between practices 
which had participated in the study and received the intervention, compared with 
non-intervention practices. 
 
Data is presented in tabular form and key findings summarised in Section 5.4.2. 
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4.12 Qualitative Evaluation 
 
Semi-structured in-depth interviews were conducted in order to obtain rich data.  
GPs from participating practices were invited to take part in semi-structured 
interviews both before and after implementation of the intervention to explore their 
perception of and attitudes towards the delivery and acceptability of the intervention 
and their perspective on the intervention to improve uptake and incorporation of 




Purposeful sampling was employed.  The main inclusion criterion was that GPs from 
participating practices were willing to participate.  Participating GPs represented a 
balanced sample from a range of practices.  At least one, in some cases two GPs 
from each practice participated in a semi-structured interview.   
 
4.12.2 Semi-Structured Interviews 
 
Interviews were audio-taped and subsequently transcribed.  Signed consent was 
obtained from GPs in order to tape record the interview and for permission to quote 
anonymised excerpts of transcripts in any potential publications or presentations 
arising from the study.   
 
Seven pre-intervention semi-structured interviews lasting up to one hour were 
conducted with GPs in their practice base according to a pre-determined topic 
guide.  (Appendix 36)    Pre-intervention interviews were conducted using a Philips 
analogue recording device (Pocket Memo 381) and transcription equipment.  
Interview tapes were stored securely in a locked cabinet.   
 
Thirteen post-intervention interviews were conducted with GPs in their practice base 
according to a pre-determined topic guide.  (Appendix 37)   GPs participating in 
post-intervention interviews had to have attended most if not all of the practice 
intervention meetings.  Post-intervention interviews were recorded using an 
Olympus Digital Voice Recorder (DS-5000) and transcription device.  
 
Each participant was identified by a pseudonym in order to maintain anonymity and 
confidentiality.  Interview tapes and transcripts were identified by code so that 
participants were not identifiable from the transcripts.  Interview tapes were 
destroyed once the data had been transcribed and verified.   
 
4.12.2 Qualitative Evaluation – Data Analysis 
 
Transcriptions were read whilst listening to the tape recordings and re-read before 
coding in order to become thoroughly familiar with the data.  Data was then coded 
and grouped into concepts and further categorised to explore key themes arising 
from the interviews, in order to generate theory from the data.  Constant 
comparative analysis was employed to compare emerging categories enabling 




Transcripts of one pre-intervention and two post-intervention interviews were also 
coded and emergent themes identified by two independent individuals experienced 
in qualitative research methodologies, in order to ensure validity and reliability of the 
thematic analysis as conducted by the researcher for all interview transcripts. 








All seventy-five practices within the PCT were invited to participate in the study. 
Sixty-three practices responded to the letters of invitation (84% response rate).  
Twelve practices (16%) elected to participate in the study. Forty-one practices (55%) 
declined. 
 
Details of the intervention and control practice populations and their localities are 
summarised in Table 5.1.    
 
Summary - Practice Populations, Location and PCT Locality 
  
Intervention Group  Control Group  
  
** Practice 
Population Location   
** Practice 
Population Location 
CH Surgery 13,942 Town  CH Centre 13,662 Town  
SE Centre 11,758 Town  BU Surgery 7,868 Rural^ 
SG Surgery 3,124 Rural^ OR Surgery 4,325 Town^  
PH Surgery 4,504 Rural^ MK Centre 6,276 Rural^ 
PF Surgery 10,713 Town RH Centre* 7,492 Rural^ 
WS Surgery 6,740 Rural^ WL Surgery* 7,074 City Centre 
RH Surgery 15,349 City Centre SY Surgery* 9,238 City Centre 
TS Surgery 10,998 City Centre CH Surgery* 10,646 City Centre 
CM Centre 9,008 Rural SM Surgery* 15,054 Rural/Town^ 
DM Centre 3,495 Rural^ PF Surgery* 5,794 Rural^ 
HJ Centre 8,246 Rural/Town^  BW Surgery* 7,883 Rural^ 
SM Centre 18,488 Rural/Town^  BN Surgery 18,048 Rural/Town^ 
Total 116,365   Total 113,360   
Key:  * Benchmark Practice (Outcome Data) 
Practice Locality:   Huntingdonshire 
    Cambridge City 
    East Cambs and Fenland 
* Benchmark practices for comparison of patient orientated outcomes data 
** Practice Population Figures from August 2011 
^ Dispensing Practice 
 
Table 5.1 Practice Profile Summary    
 
 
Details of Practice computer systems for Intervention and Benchmark practices are 
summarised in Table 5.2.   
 
Allocation of Practice Pharmacists is summarised in Table 5.3 
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Summary – Practice Computer Systems  (Intervention and Benchmark) 
Intervention Group  Control Group  
 Practice System    Practice System  
CH Surgery EMIS-LV  CH Centre   
SE Centre EMIS-LV  BU Surgery   
SG Surgery EMIS-LV  OR Surgery   
PH Surgery EMIS-LV  MK Centre   
PF Surgery EMIS-LV  RH Centre* EMIS-LV  
WS Surgery Torex (Rep-Aid)  WL Surgery* EMIS-LV  
RH Surgery EMIS-LV  SY Surgery* EMIS-LV  
TS Surgery System One  CH Surgery* EMIS-LV  
CM Centre System One  SM Surgery* EMIS-LV  
DM Centre System One  PF Surgery* EMIS-LV  
HJ Centre EMIS-LV  BW Surgery* EMIS-LV  
SM Centre Torex (Rep-Aid)  BN Surgery   
Key:  * Benchmark Practice - Outcome Data 
Practice Locality:   Huntingdonshire 
    Cambridge City 
    East Cambs and Fenland 
* Benchmark practices for comparison of patient orientated outcomes data 
 
Table 5.2 Practice Computer System Summary 
 
 
Summary – Practice Allocated Pharmacists Intervention Group  
 Practice Pharmacist  
CH Surgery Pharmacist 5 
SE Centre Pharmacist 2 
SG Surgery Pharmacist 5 
PH Surgery Pharmacist 3 
PF Surgery Pharmacist 2 
WS Surgery Pharmacist 4 
RH Surgery Pharmacist 4 
TS Surgery Pharmacist 4 
CM Centre Pharmacist 1 
DM Centre Pharmacist 1 
HJ Centre Pharmacist 1 
SM Centre Pharmacist 2 
Practice Locality:   Huntingdonshire 
    Cambridge City 
    East Cambs and Fenland 
 
Table 5.3 Practice Pharmacist Allocation Summary 
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5.2 Prescribing Data – Outcome Measures 
 
5.2.1 Non-Steroidal Anti-Inflammatory Drugs 
 
There were five NSAID prescribing outcome measures defined.  These were 
difference in pre-intervention and post-intervention prescribing volume (as measured 
by ADQ per ASTRO-PUs) for the quarter (July, August, September), 2011 
compared with the corresponding quarter 2010 for:  
 Total NSAIDs 
 Diclofenac 
 COX-2 Inhibitors 
 Ibuprofen 
 Naproxen  





Summary descriptive statistics for the study sample (intervention and control) 
practices are summarised in Table 5.4.  The Statistic values referenced represent 
the difference in prescribing volume (as measured by ADQ per ASTRO-PUs) 






















NSAIDDiff 24 -83.3 8.3 -10.823 20.0271 -2.238 0.472 6.749 0.918 
DicDiff 24 -76.6 5.2 -14.079 17.7234 -2.008 0.472 5.872 0.918 
COXDiff 24 -6.4 2.9 -0.693 2.6223 -0.853 0.472 -0.377 0.918 
IbuDiff 24 -10.2 11 -0.679 5.5472 0.393 0.472 0.004 0.918 
NapDiff 24 -42 62.3 7.53 18.4541 0.287 0.472 4.314 0.918 
IbNapDiff 24 -50.8 57.6 6.797 18.2739 -0.461 0.472 5.644 0.918 
Table 5.4 Summary Descriptive Statistics - NSAIDs  
 
More detailed summary statistics for each NSAID indicator are summarised in 
Appendix 38. 
 
5.2.1.1 Testing for Significant Difference between Intervention and Control  
Groups 
 
A number of assumptions are made about the population, from which the sample 
has been drawn when applying parametric techniques, including whether the data is 
normally distributed.  Non-parametric techniques have less stringent assumptions 
and are often more suitable techniques for smaller samples or when the data is 
measured only at the ordinal (ranked) level.209  It was therefore necessary to 
determine whether the data was normally distributed in order to apply an appropriate 
test for statistical significance. 
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5.2.1.1.1 Assessing Normality 
 
Histogram plots were produced in order to assess the normality of distribution of the 
data for each measure (Appendix 38) Normal Q-Q Plots were reviewed in 
conjunction to assess deviation of the scores from the straight line.  Box Plots were 
also produced for each measure enabling identification of specific outliers.  Tests of 
normality were also produced as part of the data output. 
 




Statistic df Sig. Statistic df Sig. 
NSAIDDiff 0.171 24 0.067 0.79 24 0 
DicDiff 0.147 24 0.194 0.821 24 0.001 
COXDiff 0.216 24 0.005 0.894 24 0.016 
IbuDiff 0.127 24 0.200* 0.963 24 0.503 
NapDiff 0.214 24 0.006 0.884 24 0.01 
IbNapDiff 0.165 24 0.088 0.854 24 0.003 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
Table 5.5 Tests for Normality Summary for NSAID Prescribing Measures 
 
Review of the histograms indicated that Overall NSAIDs, COX-2 Inhibitors, 
Ibuprofen Naproxen and Ibuprofen indicators may conform to normal distribution of 
the data.  However, sample sizes were relatively small.  Normality tests indicated 
that not all indicators were associated with normally distributed data.  (Table 5.5) 
NB: A non-significant result from normality tests (i.e.>0.05) indicates normality  
 
Kolmogorov-Smirnov indicated that NSAIDs, Diclofenac Ibuprofen and 
Ibuprofen/Naproxen indicators may be normally distributed.  However, Shapiro-Wilk 
Test (more appropriate for smaller sample sizes) indicated that the COX-2 Inhibitor 
indicator may be normally distributed. 
 
It was therefore deemed appropriate to apply a non-parametric Mann-Whitney U test 
(used to test for differences between two independent groups on a continuous 
measure) to all NSAID indicators.  Test statistics are summarised in Table 5.6 
  
5.2.1.1.2 Mann-Whitney U Tests 
 
Test Statisticsa 
  NSAIDDiff DicDiff COXDiff IbuDiff NapDiff IbNapDiff 
Mann-Whitney U 39 34 26 67 46 37 
Wilcoxon W 117 112 104 145 124 115 
Z -1.905 -2.194 -2.656 -0.289 -1.501 -2.021 
Asymp. Sig. (2-tailed) 0.057 0.028 0.008 0.773 0.133 0.043 
Exact Sig. [2*(1-tailed Sig.)] .060b .028b .007b .799b .143b .045b 
a Grouping Variable: Group 
b Not corrected for ties. 
 
Table 5.6 Test Statistics Summary Mann-Whitney U Tests NSAID Prescribing 
                 Measures 
 
 





ADQ / ASTRO-PU 
Change –  
Intervention Practices 
(n=12) 
ADQ / ASTRO-PU 
Change –  
Control Practices 
(n=12) 
Mann-Whitney U Tests 
  
Median IQR Median IQR 
Test 
Statistic p-value 
NSAID All -13.1 17.8 -2.245 12.8 39 0.057 
Diclofenac -17.755 18.6 -2.13 14.3 34 0.028* 
COX-2 Inhibitors -0.56 4.4 1.145 1.5 26 0.008** 
Ibuprofen -0.95 7.4 -0.67 6.6 67 0.773 
Naproxen 11.81 20.4 2.93 11 46 0.133 
Ibuprofen/Naproxen 12.8 11.8 1.32 14.9 37 0.043*  
*   Significant at the 5% Level 
** Significant at the 1% Level 
 
Table 5.7  Statistical Significance Summary Mann-Whitney U Tests Prescribing 
  Indicators 
 
The results therefore indicate that statistically significant differences exist between 
intervention and control practices for the indicators diclofenac, COX-2 Inhibitors and 
combined ibuprofen and naproxen as summarised in Table 5.7 and as follows: 
 
 Decrease in prescribing of diclofenac    (p<0.05) 
 
 Decrease in prescribing of COX-2 Inhibitors   (p<0.001) 
 
 Increase in prescribing of ibuprofen and naproxen (combined)  (p<0.05) 
 
Therefore, the null hypotheses that no difference exists in prescribing of diclofenac, 
COX-2 Inhibitors and naproxen plus ibuprofen between intervention and control 
groups are rejected. 
 
 
5.2.1.2 Effect Size 
 
The effect size (r) was calculated by using the reported value for z, where  
r = z / square root of N where N = total number of cases as summarised in Table 
5.8. 210   
 





Diclofenac r = -2.194/4.899 0.4478 Medium  
COX-2 Inhibitors r = -2.656/4.899 0.5422 Large 
Ibuprofen and Naproxen r = -2.021/4.899 0.4125 Medium 
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It was noted that there were a limited number of outliers (cases with values well 
above or below the majority of other cases) for Total NSAIDs (Intervention Practice, 
20), Diclofenac (Intervention Practice, 10), Ibuprofen (Control Practice, 01), 
Naproxen (Intervention Practices 10 and 20) and Ibuprofen/Naproxen (Intervention 
Practices 10 and 20).  Refer to Appendix 38. 
 
Outliers may affect the normality of the distribution and distort the statistics.  It is 
possible to remove extreme outliers and adjust their value to a less extreme value 
so that the score does not distort the statistics.  However, 5% trimmed mean values 
for all the indicators were similar to the actual means, indicating that the outliers 
were not distorting the statistics or causing a problem in terms of the analysis.   
 
Nevertheless, it was decided to perform an additional analysis of the data excluding 
outliers to confirm statistical significance. 
 
 
5.2.1.3.1 Tests of Normality 
 
Tests of Normality 
 Measure 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
NSAIDDiff 0.144 23 .200* 0.931 23 0.117 
DicDiff 0.13 23 .200* 0.944 23 0.224 
COXDiff 0.216 24 0.005 0.894 24 0.016 
IbuDiff 0.112 23 .200* 0.972 23 0.734 
NapDiff 0.155 22 0.181 0.962 22 0.534 
IbNapDiff 0.091 22 .200* 0.967 22 0.646 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 5.9 Tests for Normality Summary Excluding Outliers - NSAIDs 
 
Normality tests (Table 5.9) indicated that data for all indicators (excluding outliers) 
with the exception of COX-2 Inhibitors complied with a normal distribution.  
Therefore, an independent t-test (the parametric alternative to Mann-Whitney U test) 
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5.2.1.3.2 Independent Samples T-tests 
 
Independent Samples Test 
 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 













Interval of the 
Difference 
Lower Upper 
NSAIDDiff 0.187 0.67 -1.424 21 0.169 -7.586 5.3277 -18.6655 3.4936 
DicDiff 0.05 0.825 -2.139 21 0.044 -9.897 4.6278 -19.521 -0.273 
COXDiff 1.759 0.198 -2.295 22 0.032 -2.2567 0.9832 -4.2957 -0.2176 
IbuDiff 0.671 0.422 0.235 21 0.816 0.5092 2.165 -3.993 5.0115 
NapDiff 0.109 0.744 1.986 20 0.061 8.4708 4.2643 -0.4244 17.366 
IbNapDiff 2.035 0.169 2.559 20 0.019 8.9795 3.5084 1.6612 16.298 
NB: Significance values for Levin’s test for equality of variances are all > 0.05 indicating that variances for the two 
groups are the same.   
 
Table 5.10 Statistical Significance Summary - Independent Tests for NSAID 
  Prescribing Indicators 
 
 
Results indicate that statistically significant differences exist between intervention 
and control practices for the indicators diclofenac, COX-2 Inhibitors and combined 
ibuprofen and naproxen as summarised in a Table 5.10 and as follows: 
 
 Decrease in prescribing of diclofenac    (p<0.05) 
 Decrease in prescribing of COX-2 Inhibitors   (p<0.05) 
 Increase in prescribing of ibuprofen and naproxen (combined)  (p<0.05) 
 
Therefore, the null hypotheses that no difference exists in prescribing of diclofenac, 
COX-2 Inhibitors and naproxen plus ibuprofen between intervention and control 
groups are rejected.  The results therefore support the conclusions from non-
parametric tests on the individual outcome measures.    
                                                                                                                                         75 
5.2.2 Type 2 Diabetes 
 
There were four T2DM prescribing outcome measures defined.  These were 
difference in pre-intervention and post-intervention prescribing volume (as measured 
by ADQ per ASTRO-PUs) for the quarter (July, August, September), 2011 
compared with the corresponding quarter 2010 for:  
 Total drugs in T2DM 
 Metformin 
 Total Glitazones 
 ‘Other’ (newer drugs) in T2DM.  
 
Summary descriptive statistics for the study sample (intervention and control) 
practices are summarised in Table 5.11  The Statistic values referenced represent 
the difference in prescribing volume (as measured by ADQ per ASTRO-PUs) 





















AllDiff 24 -157.6 26.8 -1.303 35.8153 -3.893 0.472 17.105 0.918 
MetDiff 24 -87.8 27.5 8.977 21.7448 -4.128 0.472 18.772 0.918 
GlitDiff 24 -19.5 6.7 -8.28 7.1058 0.257 0.472 -0.274 0.918 
OtherDiff 24 -16.4 5.8 0.928 4.1143 -3.365 0.472 14.38 0.918 
Table 5.11 Summary Descriptive Statistics – Type 2 Diabetes 
 




5.2.2.1 Testing for Significant Difference between Intervention and Control  
Groups 
 
5.2.2.1.1 Assessing Normality 
 
Histogram plots were produced in order to assess the normality of distribution of the 
data for each measure (Appendix 39).  Normal Q-Q Plots were reviewed in 
conjunction to assess deviation of the scores from the straight line.  Box Plots were 
also produced for each measure enabling identification of specific outliers.   
Tests of normality were also produced as part of the data output.                    
 




Statistic df Sig. Statistic df Sig. 
AllDiff 0.259 24 0 0.543 24 0 
MetDiff 0.327 24 0 0.5 24 0 
GlitDiff 0.096 24 .200* 0.966 24 0.571 
OtherDiff 0.243 24 0.001 0.644 24 0 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
Table 5.12 Tests for Normality Summary for T2DM Prescribing Measures 
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Review of the histograms suggested that Overall (total) Drugs in T2DM, Metformin, 
and ‘Other’ Drugs indicators may conform to normal distribution of the data.  
However, sample sizes were relatively small.  Normality tests indicated that only 
glitazones were associated with normally distributed data.  (Table 5.12) 
NB: A non-significant result from the normality tests (i.e.>0.05) indicates normality. 
 
It was therefore decided to apply non-parametric Mann-Whitney U tests (used to test 
for differences between two independent groups on a continuous measure) to all 
T2DM prescribing indicators. Test statistics are summarised in Table 5.13. 
  
 
5.2.2.1.2 Mann-Whitney U Tests 
 
Test Statisticsa 
  AllDiff MetDiff GlitDiff OtherDiff 
Mann-Whitney U 56 69 55 68 
Wilcoxon W 134 147 133 146 
Z -0.924 -0.173 -0.981 -0.231 
Asymp. Sig. (2-tailed) 0.356 0.862 0.326 0.817 
Exact Sig. [2*(1-tailed Sig.)] .378b .887b .347b .843b 
a Grouping Variable: Group 
b Not corrected for ties. 
 




ADQ Change - 
Intervention Practices 
(n=12) 
ADQ Change - 
Control Practices 
(n=12) 
Mann-Whitney U Tests 
  
Median IQR Median IQR Test Statistic p-value 
T2DM All 1.1775 33.7 10.605 10.4 56 0.356 
Metformin 14.86 11.1 12.655 9.7 69 0.862 
Glitazones -10.12 11.6 -6.985 6.7 55 0.326 
Other 1.755 2.1 1.325 3.1 68 0.817 
*   Significant at the 5% Level 
** Significant at the 1% Level 
 
Table 5.14 Statistical Significance Summary Mann-Whitney U Tests Prescribing 
  Indicators 
 
The results therefore indicate that no statistically significant differences exist 
between intervention and control practices for the indicators Total drugs in diabetes, 
Metformin, Total glitazones or ‘Other’ drugs in T2DM.  (Table 5.14)  
 
Therefore, the null hypotheses that no difference exists in prescribing of Total drugs 
in T2DM, Metformin, Total glitazones and ‘Other’ drugs in T2DM, between 
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It was noted that for all the indicators (except for glitazones, where tests had 
suggested normal distribution) there was one intervention practice which appeared 
to be an outlier for each indicator (3, CMC).  Refer to Appendix 39. 
 
As indicated earlier, outliers may affect the normality of the distribution and distort 
the statistics.  5% trimmed mean values for all the indicators were relatively close in 
value to the actual means, indicating that the outliers were not distorting the 
statistics or causing a problem in terms of the analysis.   
 
Nevertheless, it was decided to perform an additional analysis of the data excluding 
outliers for the one intervention practice.  
 
 
5.2.2.2.1 Tests of Normality 
 
Tests of Normality 
 Measure 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
AllDiff 0.161 23 0.125 0.942 23 0.195 
MetDiff 0.096 23 .200* 0.97 23 0.682 
GlitDiff 0.096 24 .200* 0.966 24 0.571 
OtherDiff 0.113 23 .200* 0.971 23 0.703 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 5.15 Tests for Normality Summary Excluding Outliers – T2DM 
 
Normality tests suggested (Table 5.15) that data for all indicators (excluding outliers) 
complied with a normal distribution.  Therefore, an independent t-test (the 
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5.2.2.2.1 Independent Samples T-tests 
 
Independent Samples Test 
  
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 












Interval of the 
Difference 
Lower Upper 
AllDiff 7.08 0.015 -0.956 14.1 0.355 -5.5548 5.8125 -18.0165 6.9069 
MetDiff 0.004 0.951 -0.154 21 0.879 -0.4648 3.0252 -6.7561 5.8264 
GlitDiff 0.721 0.405 -1.127 22 0.272 -3.2508 2.884 -9.2319 2.7303 
OtherDiff 0.244 0.627 0.831 21 0.416 0.6552 0.7888 -0.9852 2.2955 
NB: Significance values for Levin’s test for equality of variances were > 0.05 for three indicators (metformin, 
glitazones and ‘Other’ i)ndicating that variances for the two groups are the same.  Alternative t-value output figures 
from SPSS were therefore substituted for Total Drugs in T2DM (AllDiff). 
 
Table 5.16 Statistical Significance Summary - Independent t-Tests for T2DM 
      Prescribing Indicators 
 
 
The results therefore indicate that no statistically significant differences exist 
between intervention and control practices for the indicators Total drugs in diabetes, 
Metformin, Total glitazones or ‘Other’ drugs in T2DM.  (Table 5.16)  
 
Therefore, the null hypotheses that no difference exists in prescribing of Total drugs 
in T2DM, Metformin, Total glitazones and ‘Other’ drugs in T2DM, between 
intervention and control groups is retained.  The results therefore support the 
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5.3 Prescribing Trend Data 
 
This section consists of a series of graphs demonstrating prescribing trends in each 
practice for non-steroidal drugs and drugs used in diabetes throughout the study 
period.  Prescribing trend data are presented for individual Control practices 
followed by Intervention practice data. 
 
At the end of each section, aggregated data for specific NSAIDs and drugs used in 
T2DM are presented to enable overall comparisons between Intervention and 
Control practices. 
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5.3.1 Non-Steroidal Anti-inflammatory Drugs  
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Graph 5.2. NSAIDs Trend Control Practice – BW Surgery 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Graph 5.4.  NSAIDs Trend Control Practice – CH Surgery 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Diclofenac Sodium Ibuprofen Naproxen Celecoxib
 
Graph 5.6.  NSAIDs Trend Control Practice – BN Surgery 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 





























































Diclofenac Ibuprofen Naproxen Coxibs
 


























































Diclofenac Ibuprofen Naproxen Coxibs
 




                                                                                                                                         87 
Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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Non-Steroidal Anti-Inflammatory Drugs Prescribing Trend Data – Individual 
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5.3.1 Non-Steroidal Anti-inflammatory Drugs (Cont) 
 
Individual Practices (Graphs 5.1 to 5.24) 
 
Overall, there were no major changes in individual or general NSAIDs usage over 
the intervention period in the Control practices.  Diclofenac usage ranged from as 
low as 10% in one practice (MK Centre, Graph 5.5) to as high as 40% in others.  
Naproxen usage ranged from approximately 25% in some practices to 
approximately 50% in one practice (MK Centre) 
 
One practice, BW Surgery showed an increase in naproxen from approximately 20% 
to 40% with a corresponding decrease in diclofenac although this shift occurred 
towards the end of and following the study intervention period.  It most likely 
reflected specific activity in the practice to address high diclofenac usage.   Other 
practices also showed slight reductions in diclofenac usage with corresponding 
increases in naproxen following study completion and may have reflected local 
activities to address NSAID usage. 
 
In contrast, a number of intervention practices showed dramatic reductions in 
diclofenac usage with corresponding increases in naproxen use during the 
intervention period, which appeared to continue, and were sustained on study 
completion (CH, SE, SG, HJ, PH, PF, RH, TS, and WS practices).  In particular, HJ 
Centre, RH Surgery, TS Surgery and WS Surgery (Graphs 5.18, 5.21, 5.23, 5.24) 
demonstrated marked opposing shifts in use of the two drugs. 
 
Pre-intervention Diclofenac usage in intervention practices ranged from 10%-55% 
and naproxen usage from approximately 10% to 40%.  By study completion, 
naproxen use was 40% or more of total NSAID usage in ten of the twelve 




5.3.1.1 Aggregated Prescribing Trend Data 
 
Graph 5.25 shows a clear trend of reduction in prescribing of diclofenac in 
intervention practices compared with Control (Graph 5.26).  There is also an 
increased trend in prescribing of naproxen in Intervention practices (Graph 5.27) 
compared with Control (Graph 5.28).  
 
There are no obvious differences in prescribing of Ibuprofen (Graphs 5,29, 5.30) or 
COX-II Inhibitors (Graphs 5.30, 5.31) in Intervention compared with Control 
Practices. 
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5.3.2 Drugs Used in Type 2 Diabetes 
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Graph 5.34.  T2DM Drugs Trend Control Practices – BW Surgery 
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5.3.2 Drugs Used in Type 2 Diabetes (Cont) 
 
Individual Practices (Graphs 5.33 to 5.56) 
 
Overall there were no major shifts demonstrated in prescribing of drugs in T2DM 
between Intervention and Control practices.  There were very slight increases in 
Metformin in several individual intervention and control practices 
 
5.3.2.1 Aggregated Prescribing Trend Data 
 
Aggregated data suggests that overall prescribing of metformin was slightly higher 
and within a narrower range in intervention practices, with a possible slight overall 
upward trend compared with control.  (Graphs 5.57, 5.58) 
 
There are no obvious differences in prescribing trends of glitazones or other anti-






                                                                                                                                         114 
 
5.4 Practice Data – Patient-Orientated Outcome Measures 
 
5.4.1 Statistical Analysis 
 
5.4.1.2 Non-Steroidal Anti-Inflammatory Drugs 
 
Six different outcome measures were defined relating to patients receiving NSAIDs 
in each practice.  The proportion of patients coded for each parameter was 
calculated at baseline and following completion of the intervention visits.  Each 
outcome measure was based on the difference in post-intervention value compared 
with pre-intervention value.  (Summarised in Table 5.17) 
 
NSAIDs Patient Orientated Outcome Measure 
Risk Factor Measures  Proportion of elderly patients (≥65) on NSAID 
 Proportion of patients with documented clinical 
risk factors (combined) 
o Cardiovascular risk factors 
o Gastrointestinal risk factors 
o Cardio-renal Risk factors 
Concomitant Medication Measures  Proportion of patients on concomitant drugs 
o Aspirin 
o SSRI 
o PPI (gastro-protection) 
NSAIDs Prescribing Measures 
 
 Proportion of patients on NSAIDs 
o NSAIDs (overall) as proportion of 
practice patient population 
 










N Minimum Maximum Mean 
Std. 
Deviation Skewness Kurtosis 





Overall NSAIDs 19 -0.4 0.2 -0.011 0.1912 -0.846 0.524 0.107 1.014 
Over 65 19 -8 7.7 -0.545 4.2375 -0.131 0.524 -0.292 1.014 
Total Risk 19 -8.1 4.8 -0.647 3.6234 -0.879 0.524 0.237 1.014 
Proportion on PPI 19 -6 13.5 2.474 4.4237 0.493 0.524 1.172 1.014 
Proportion on Aspirin 19 -6.3 3.4 -1.137 2.5303 -0.085 0.524 -0.258 1.014 
Proportion on SSRI 19 -3.1 4.7 1.037 2.3005 -0.088 0.524 -0.641 1.014 
Valid N (listwise) 17                 
 
Table 5.18 Summary Descriptive Statistics – NSAID Patients 
 
Summary descriptive statistics for the study sample (intervention and benchmark) 
practices are summarised in Table 5.18.  The Statistic values referenced represent 
the difference between baseline value and post intervention value in the proportion 
of patients coded for each outcome measure/indicator  
 
More detailed summary statistics for each NSAID indicator are provided in  
Appendix 40. 
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5.4.1.2.1 Testing for Significant Difference between Intervention and Control 




Histogram plots were produced in order to assess the normality of distribution of the 
data for each measure (Appendix 40).  Normal Q-Q Plots were reviewed in 
conjunction to assess deviation of the scores from the straight line.  Box Plots were 
also produced for each measure enabling identification of specific outliers.   
Tests of normality were also produced as part of the data output.   
 
 
Tests of Normality 
 Measure 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Overall NSAIDs 0.206 19 0.033 0.869 19 0.014 
Over 65 0.112 19 .200* 0.974 19 0.855 
Total Risk 0.175 19 0.127 0.916 19 0.095 
Proportion on PPI 0.124 19 .200* 0.964 19 0.655 
Proportion on Aspirin 0.126 19 .200* 0.979 19 0.932 
Proportion on SSRI 0.087 19 .200* 0.967 19 0.722 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 5.19 Tests for Normality Summary for NSAID Patient-Orientated Outcome 
Measures 
 
Review of the histograms and Normal Q-Q Plots indicated that the majority of the 
patient outcome indicators conformed with normal distribution of the data although 
normality tests suggested that data relating to overall NSAIDs, was not normally 
distributed. (Table 5.19)  
NB: A non-significant result from normality tests (i.e.>0.05) indicates normality.  
 
Independent t-tests were therefore performed in order to establish whether results 
for parametric data were statistically significant.  Mann-Whitney U tests were also 























5.4.1.2.1.1 Independent Samples t-test (Parametric) 
 
Independent Samples Test 
Measure 
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 









Interval of the 
Difference 
Lower Upper 
Overall NSAIDs 0.062 0.806 -0.926 17 0.367 -0.0845 0.0913 -0.2771 0.1081 
Over 65 0.03 0.864 1.508 17 0.15 2.9378 1.9475 -1.1711 7.0466 
Total Risk 0.601 0.449 -0.093 17 0.927 -0.1655 1.7728 -3.9057 3.5748 
Proportion on PPI 0.003 0.956 0.614 17 0.547 1.3155 2.1412 -3.2021 5.8331 
Proportion on Aspirin 0.231 0.637 -0.889 17 0.386 -1.0762 1.2105 -3.6301 1.4777 
Proportion on SSRI 1.157 0.297 0.853 17 0.405 0.9405 1.1025 -1.3856 3.2665 
NB: Significance values for Levin’s test for equality of variances were > 0.05 for all indicators except ibuprofen, 
indicating that variances for the two groups are the same.  Alternative t-value output figures from SPSS were 
therefore substituted for the ibuprofen output. 
 
Table 5.20  Statistical Significance Summary - Independent t-Tests for NSAID      
        Patient- Orientated Outcome Indicators 
 
Parametric test results indicate that no statistically significant differences exist 
between intervention and benchmark practices for any of the patient-orientated 
outcome indicators relating to NSAIDs for the measures for which the data was 
regarded as normally distributed (or indeed the measures for which the data was not 





It was noted that there were a limited number of outliers (cases with values well 
above or below the majority of other cases) for clinical risk factor, and PPI 
indicators.  However, it was noted that 5% trimmed mean values for all of the 
indicators were very similar to the actual mean values, indicating that the outliers 
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NSAIDs Over 65 Total Risk PPI Aspirin SSRI 
Mann-Whitney U 29.5 27 41 37.5 31.5 35 
Wilcoxon W 107.5 55 119 65.5 109.5 63 
Z -1.086 -1.268 -0.085 -0.38 -0.888 -0.592 
Asymp. Sig. (2-tailed) 0.278 0.205 0.933 0.704 0.374 0.554 
Exact Sig. [2*(1tailedSig.)] .299b .227b .967b .711b .384b .592b 
a Grouping Variable:Group  b Not corrected for ties. 
 
Table 5.21 Test Statistics Summary Mann-Whitney U Tests NSAID Patient Outcome 






Intervention Practices  
(n=12)  
Indicator Change 




Median IQR Median IQR 
Test 
Statistic p-value 
Overall NSAIDs 0.0 0.2 0.0 0.2 29.5 0.278 
Over 65 0.469 6.1 -2.4 7.5 27.0 0.205 
Total Risk 0.2 3.6 -0.4 7.5 41.0 0.933 
 PPI 2.6 5.1 0.5 6.3 37.5 0.704 
Aspirin -1.7 2.2 0.6 4.2 31.5 0.374 
SSRI 1.1 3.6 0.6 5.2 35.0 0.554 
       
*   Significant at the 5% Level 
** Significant at the 1% Level 
 
Table 5.22 Statistical Significance Summary Mann-Whitney U Tests Patient 
      Outcome Indicators 
 
The results indicate that no statistically significant differences exists between 
intervention and benchmark practices for non-parametric indicators as none of the 
p-value figures reach statistical significance <0.05.  (Tables 5.21 and 5.22).   
 
Therefore, the null hypotheses that no difference exists for any of the NSAID patient 
outcome indicators between intervention and benchmark groups are retained. 
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5.4.1.3 Type 2 Diabetes 
 
Thirteen different outcome measures were defined relating to patients diagnosed 
with T2DM in each practice.  The proportion of patients coded for each parameter 
was calculated at baseline and following completion of the intervention visits.  Each 
outcome measure was based on the difference in post-intervention value compared 
with pre-intervention value.  (Summarised in Table 5.23) 
 
Type 2 Diabetes Patient Orientated Outcome Measure 
Recommended Target Measures 
 
 
Proportion of patients achieving: 
 Blood pressure  (≤ 140/80mmHg) 
 Blood lipids  (TC ≤ 5mmol/l) 
 HbA1c (≤ 7.5%) 
 HbA1c (≤ 9.0%) 




 Proportion of patients on metformin,  
 Proportion of patients on lipid lowering 
therapy 
 Proportion of patients on aspirin 
 Proportion of patients prescribed a Renin-
Angiotensin drug 
o Proportion of patients specifically 
prescribed an ACE-Inhibitor 
Renal Care Measures 
 
 Proportion of patients tested for 
microalbuminuria 
 Proportion of patients with 
microalbuminuria on a RAS drug 
 Proportion of patients with 
microalbuminuria attaining recommended 
BP target (≤ 130/80mmHg) 
 





Summary descriptive statistics for the study sample (intervention and benchmark) 
practices are summarised in Table 5.24.  The Statistic values referenced represent 
the difference between baseline value and post intervention value in the proportion 
of patients coded for each outcome measure/indicator  
 
More detailed summary statistics for each T2DM indicator are provided in   
Appendix 41. 










Statistic Statistic Statistic Statistic Statistic Statistic Std. Error Statistic 
Std. 
Error 
Metformin 19 -8.2 6.1 0.135 3.1749 -0.917 0.524 1.948 1.014 
RAS Drug 19 -3.8 3.8 -0.437 1.7765 0.58 0.524 0.614 1.014 
ACE-I 19 -5.1 4 0.163 2.251 -0.58 0.524 0.78 1.014 
LLA 19 -8.2 5.8 -1.042 3.1565 -0.066 0.524 0.94 1.014 
Aspirin 19 -16.6 0.9 -3.784 4.4873 -1.607 0.524 2.734 1.014 
BP Target 19 -9.7 11.4 0.137 5.5696 0.312 0.524 -0.148 1.014 
Cholesterol 17 -2.8 7 1.506 3.1364 0.412 0.55 -1.015 1.063 
HbA1c (7.5%) 19 -9.3 5.5 -1.421 3.9973 0.051 0.524 -0.505 1.014 
HbA1c (9.0%) 19 -10.3 5.7 -1.432 4.0594 -0.812 0.524 1.057 1.014 
ACR Measured 19 -5 35.4 2.974 8.3952 3.491 0.524 13.794 1.014 
M/A Detected 19 -5.4 7.9 0.253 2.8133 0.846 0.524 2.352 1.014 
m/a on RAS 19 -18.1 47.1 3.842 15.7286 1.489 0.524 2.549 1.014 
m/a BP target 19 -14.1 11.5 -1.526 8.8618 -0.03 0.524 -1.478 1.014 
Valid N (listwise) 17                 
 
Table 5.24 Summary Descriptive Statistics – T2DM Patients 
 
 
5.4.1.3.1 Testing for Significant Difference between Intervention and Control 
   Groups 
 
 
Assessing Normality  
 
Histogram plots were produced in order to assess the normality of distribution of the 
data for each measure (Appendix 41).  Normal Q-Q Plots were reviewed in 
conjunction to assess deviation of the scores from the straight line.  Box Plots were 
also produced for each measure enabling identification of specific outliers.   
Tests of normality were also produced as part of the data output.    
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Tests of Normality 
 Measure 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Metformin 0.145 19 .200* 0.934 19 0.208 
RAS Drug 0.172 19 0.142 0.96 19 0.574 
ACE-I 0.155 19 .200* 0.946 19 0.34 
LLA 0.12 19 .200* 0.986 19 0.988 
Aspirin 0.173 19 0.139 0.841 19 0.005 
BP Target 0.141 19 .200* 0.97 19 0.771 
Cholesterol 0.177 17 0.16 0.939 17 0.303 
HbA1c (7.5%) 0.112 19 .200* 0.967 19 0.722 
HbA1c (9.0%) 0.148 19 .200* 0.923 19 0.129 
ACR Measured 0.285 19 0.0 0.57 19 0.0 
M/A Detected 0.195 19 0.054 0.927 19 0.15 
m/a on RAS 0.217 19 0.019 0.86 19 0.01 
m/a BP target 0.174 19 0.134 0.917 19 0.1 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
Table 5.25 Tests for Normality Summary for T2DM Patient Outcome Measures 
 
 
Review of the histograms and Normal Q-Q Plots indicated that the majority of the 
patient outcome indicators conformed with normal distribution of the data although 
sample sizes were relatively small.  Exceptions appeared to relate mainly to renal 
outcome indicators (proportion of patients with ACR measured, patients with 
microalbuminuria on a RAS Drug and proportion of patients with microalbuminuria 
reaching recommended BP target). 
 
Normality tests, in particular Shapiro-Wilk (more appropriate for smaller sample 
sizes) indicated that data may not be normally distributed in two of the renal 
indicators (ACR measured, m/a on RAS) and for proportion of patients on aspirin. 
(Table 5.25)  
NB: A non-significant result from normality tests (i.e.>0.05) indicates normality  
 
Independent t-tests were therefore performed in order to establish whether results 
for parametric data were statistically significant.  Mann-Whitney U tests were also 




It was noted that there were a limited number of outliers (cases with values well 
above or below the majority of other cases) for various indicators.  However, it was 
noted that 5% trimmed mean values for all of the indicators were relatively close to 
the actual mean values, indicating that the outliers were not distorting the statistics 
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5.4.1.3.1.1 Independent Samples T-tests 
 




for Equality of 




















Interval of the 
Difference 
                Lower Upper 
Metformin 2.38 0.141 2.189 17 0.043* 3.0037 1.3724 0.1083 5.8992 
RAS Drug 1.939 0.182 2.309 17 0.034* 1.7512 0.7586 0.1508 3.3516 
ACE-I 1.218 0.285 1.397 17 0.181 1.4571 1.0434 -0.7442 3.6584 
LLA 1.934 0.182 0.221 17 0.828 0.3405 1.5425 -2.914 3.595 
Aspirin 3.144 0.094 0.301 17 0.767 0.6583 2.1902 -3.9626 5.2792 
BP Target 2.604 0.125 -0.311 17 0.759 -0.8464 2.7179 -6.5807 4.8879 
Cholesterol 0.159 0.695 1.361 15 0.194 2.05 1.506 -1.16 5.26 
HbA1c (7.5%) 0.696 0.416 3.317 17 0.004** 5.056 1.5242 1.8402 8.2717 
HbA1c (9.0%) 0.004 0.953 2.239 17 0.039* 3.9083 1.7459 0.2248 7.5918 
ACR Measured 1.662 0.215 0.992 17 0.335 3.9619 3.9945 -4.4658 12.3896 
M/A Detected 1.145 0.3 0.126 17 0.901 0.1738 1.3762 -2.7296 3.0772 
m/a on RAS 0.522 0.48 1.216 17 0.241 8.9786 7.3828 -6.5979 24.555 
m/a BP target 0.527 0.478 -0.281 17 0.782 -1.2179 4.3267 -10.3465 7.9107 
NB: Significance values for Levin’s test for equality of variances are all > 0.05 indicating that variances for the two 
groups are the same.   
*    Significant at the 5% Level 
**  Significant at the 1% Level 
 
Table 5.26 Statistical Significance Summary - Independent Tests for T2DM Patient  
              Outcome Indicators 
 
The results demonstrate that statistically significant differences exist between 
intervention and benchmark practices for four indicators.   They indicate a relative 
increase in the proportion of patients being prescribed both metformin and renin-
angiotensin drugs, in the intervention group compared with the benchmark group 
over the intervention period.  There is also a statistically significant difference 
indicating a relative increase in proportion of patients achieving both HbA1c targets 
(7.5%, 9.0%) at study completion in the intervention group compared with 
benchmark practices.   
 
Results are summarised in Table 5.26 and as follows: 
  
 Proportion of patients prescribed metformin    (p<0.05) 
 Proportion of patients prescribed a Renin-Angiotensin drug (p<0.05) 
 Proportion of patients achieving HbA1c target ≤ 7.5%  (p<0.01)  
 Proportion of patients achieving HbA1c target ≤ 9.0%  (p<0.05) 
  
 
Therefore, the null hypotheses that no difference exists in achievement of patient-
oriented outcomes between intervention and control groups are rejected.   The null 
hypothesis that no difference exists in achievement of patient clinical outcomes 
(HbA1c target) between intervention and control groups is also rejected.    
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5.4.1.3.1.2 Mann-Whitney U Tests 
 
Test Statisticsa 
  Metformin RAS ACE-I LLA Aspirin 
Mann-Whitney U 22.5 17.5 36.5 40.5 25 
Wilcoxon W 50.5 45.5 64.5 68.5 53 
Z -1.649 -2.072 -0.466 -0.127 -1.437 
Asymp. Sig. (2-tailed) 0.099 0.038 0.641 0.899 0.151 
Exact Sig. [2*(1-tailed Sig.)] .100b .036b .650b .902b .167b 
a Grouping Variable: Group       


















Mann-Whitney U 36 21.5 12 9 23.5 41.5 25 37.5 
Wilcoxon W 114 49.5 40 37 51.5 69.5 53 115.5 
Z -0.507 -1.318 -2.537 -2.79 -1.567 -0.042 -1.437 -0.381 
Asymp. Sig. (2-tailed) 0.612 0.187 0.011 0.005 0.117 0.966 0.151 0.703 
Exact Sig. [2*(1-tailed 
Sig.)] .650b .193b .010b .004b .120b .967b .167b .711b 
a Grouping Variable: Group             
b Not corrected for ties. 
 
Table 5.27 Test Statistics Summary Mann-Whitney U Tests T2DM Patient Outcome 





Intervention Practices  
(n=12)  
Indicator Change 




Median IQR Median IQR 
Test 
Statistic p-value 
Metformin 1.05 3.0 -1.5 7.1 22.5 0.099 
RAS Drug 0.35 2.8 -1.5 1.7 17.5 0.038* 
ACE-I 0.5 3.8 0.7 4.8 36.5 0.641 
LLA -0.7 4.2 -1.1 3.3 40.5 0.899 
Aspirin -1.05 5.7 -4.5 4.3 25.0 0.151 
BP Target -1.45 9.8 -0.1 6.2 36.0 0.612 
Cholesterol 2.2 5.4 -0.6 4.7 21.5 0.187 
HbA1c (7.5%) 1.25 5.2 -5.2 4.1 12.0 0.011* 
HbA1c (9.0%) 0.2 2.6 -2.9 4.6 9.9 0.005** 
ACR Measured 1.5 6.4 -0.8 3.0 23.5 0.117 
M/A Detected -0.3 4.2 -0.5 2.7 41.5 0.966 
m/a on RAS 2.05 14.0 -0.1 15.1 25.0 0.151 
m/a BP target -1.25 18.7 -6.2 19.3 37.5 0.703 
*   Significant at the 5% Level 
** Significant at the 1% Level 
 
Table 5.28 Statistical Significance Summary Mann-Whitney U Tests T2DM Patient
 Outcome Indicators 
 
                                                                                                                                         123 
The Mann-Whitney U tests do not suggest that there are additional indicators 
demonstrating statistical significance.  (Tables 5.27 and 5.28).  However, they do 
support the results of independent t-tests in that prescribing of RAS drugs and that 
both HbA1c target indicators demonstrate statistical significance. 
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5.4.2 Comparison Between Intervention and Benchmark Group Practices 
 
Data from non-intervention practices provided a benchmark by which to compare 
the intervention practice group data and to also establish whether there were any 
underlying influences on prescribing affecting all practices in the PCT, which may 
have affected achievement of outcome targets.  
 
It is acknowledged that the comparison reported here is a relatively crude one.  
However the comparison is made to detect and identify any differences or differing 
trends in the intervention group practices (which may be attributable to the 
intervention) compared with non-intervention practices. 
 
5.4.2.1 Type 2 Diabetes 
 
Summary data for the patient outcome-orientated prescribing indicators, clinical 
outcomes and renal outcomes at practice level (summarised in Table 5.23) are 
presented in tabular form in the following section.  Significant post-intervention shifts 
from baseline are highlighted in green.  
 
5.4.2.1.1 Prescribing Outcome Indicators 
 




The results in the benchmark group indicate that two practices (CH and PF) may 
have increased the proportion of patients who have received metformin.  However, 
four practices have a relative decrease in metformin prescribing (one has no 
change) suggesting a trend towards a relative decrease. 
 
In all but two practices (PF, WS), in the intervention group the trend is towards an 
increase in metformin use.  One other practice shows no change (HJC), however, 
this practice demonstrates the highest metformin prescribing at baseline suggesting 
limited capacity to maximise further.  
 
 
5.4.2.1.1.2 Renin-Angiotensin Drugs 
 
Overall RAS Drugs 
 
All of the practices in the Benchmark Group indicate a relative decrease in 
prescribing of RAS drugs.  For two practices (CH, PF) the figure is marginal. 
 
In the intervention group, seven of the twelve practices demonstrate a relative 
increase in overall prescribing of RAS drugs in patients with T2DM, suggesting an 
overall increase during the intervention period (as promoted during the intervention).  
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 Percentage of Patients 
 Metformin RAS Drugs ACE-I / RAS Drugs LLA Aspirin 
Practice Pre Post % Diff Pre Post % Diff Pre Post % Diff Pre Post % Diff Pre Post % Diff 
BENCHMARK                
BW Surgery 63.1 63.3 0.2 56.2 54.7 -1.5 79.2 74.1 -5.1 74.8 73.7 -1.1 46.4 41.9 -4.5 
CH Surgery 66.8 69.3 2.5 59.0 58.7 -0.3 69.0 70.0 1.0 76.0 75.1 -0.9 49.0 42.6 -6.4 
PF Surgery 61.9 63.8 1.9 63.8 63.5 -0.3 64.0 63.7 -0.3 76.7 78.4 1.7 40.1 35.1 -5.0 
RH Centre 65.7 57.5 -8.2 57.2 55.2 -2.0 77.2 78.7 1.5 77.5 75.6 -1.9 46.9 43.4 -3.5 
SM Surgery 62.1 56.9 -5.2 61.0 59.8 -1.2 75.6 76.3 0.7 78.7 75.9 -2.8 46.7 39.7 -7.0 
WL Surgery 72.8 71.3 -1.5 61.8 58.0 -3.8 82.1 78.3 -3.8 73.5 69.2 -4.3 30.1 28.0 -2.1 
SY Surgery 73.4 71.4 -2.0 60.4 58.7 -1.7 82.8 83.5 0.7 71.4 71.9 0.5 44.8 43.9 -0.9 
INTERVENTION                
CM Centre 59.9 61.6 1.7 57.1 57.8 0.7 62.4 66.4 4.0 70.1 73.5 3.4 41.8 29.9 -11.9 
CH Surgery 66.0 68.3 2.3 59.8 60.3 0.5 73.8 77.2 3.4 72.0 71.8 -0.2 43.1 41.8 -1.3 
DM Centre 60.6 63.6 3.0 58.9 60.3 1.4 74.8 75.2 0.4 66.5 64.4 -2.1 47.9 46.2 -1.7 
SE Centre 60.4 60.8 0.4 62.2 62.4 0.2 73.3 73.9 0.6 75.7 76.7 1.0 47.1 46.5 -0.6 
SG Surgery 65.0 66.2 1.2 67.5 66.2 -1.3 81.9 84.9 3.0 68.3 63.1 -5.2 35.0 35.4 0.4 
HJ Centre 75.7 75.4 -0.3 65.6 67.7 2.1 75.6 75.8 0.2 76.5 78.0 1.5 44.5 43.7 -0.8 
PH Surgery 58.4 61.3 2.9 55.2 56.5 1.3 77.6 78.9 1.3 77.3 74.4 -2.9 29.2 22.6 -6.6 
PF Surgery 66.8 65.4 -1.4 64.2 63.1 -1.1 76.1 75.8 -0.3 79.4 78.2 -1.2 51.9 35.3 -16.6 
RH Surgery 66.2 72.3 6.1 60.1 63.9 3.8 86.7 85.1 -1.6 66.5 72.3 5.8 33.8 33.6 -0.2 
SM Centre 61.9 62.8 0.9 68.2 66.8 -1.4 80.9 81.5 0.6 77.9 75.1 -2.8 57.3 53.5 -3.8 
TS Surgery 66.1 66.1 0.0 55.4 53.9 -1.5 62.9 61.3 -1.6 82.1 73.9 -8.2 31.3 32.2 0.9 
WS surgery 59.8 58.0 -1.8 60.5 58.3 -2.2 75.8 74.2 -1.6 68.1 68.0 -0.1 42.9 42.6 -0.3 
 
Table 5.29   Movement in Prescribing of Patient-Orientated Prescribing Outcome Indicators from Baseline to Post Intervention 





Proportion of ACE-I as a Total of RAS Drug Prescribing 
 
The benchmark group shows a range of prescribing of ACE-I and A-II-A (two 
practices (WL and SY) already have high baseline prescribing of ACE-Is.  Overall 
there is a mixture of relative increase, relative decrease and marginal shifts in 
proportions of drug in each class with no major trends apparent.   
 
Eight practices in the intervention group show a relative increase in ACE-I.  Two of 
these, SMC and SG, also had very high baseline prescribing rates (as did RH).  
Otherwise, intervention practice trends are towards a relative increase.  Three 
practices, CMC, CH and SG have relatively higher proportionate increases of ACE-I 
prescribing). 
 
5.4.2.1.1.3 Lipid Lowering Agents (Statins) 
 
The benchmark group shows a range of relative positive and negative variation. No 
obvious trend is apparent. 
 
Similarly, the Intervention group has a range of relative differences.  Two practices 
(SG and TS) have relatively large decreases (5.2% and 8.2 %) however only 
represented seven and two patients respectively as practice T2DM populations were 
relatively small.  No major conclusions can be drawn from these figures although it 
is believed that statin prescribing in T2DM may have been managed within overall 
practice hypercholesterolemia management.  Also, practice visit discussions 
generally focussed on management of blood pressure rather than blood lipids, 





All Practices in the Benchmark group demonstrate a trend towards a decrease in 
prescribing of aspirin or other antiplatelet drug.  Similarly, all but two intervention 
practices demonstrated a trend towards decreased prescribing of 
aspirin/antiplatelet,  
 
The PCT wide trend in reduction of aspirin/antiplatelet is believed to relate to widely 
published evidence for lack of benefit of aspirin in primary prevention of 
cardiovascular events compared with evidence in secondary prevention during the 
intervention period.  Several practices actively stopped initiation of aspirin for 
primary prevention during this period. 
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5.4.2.1.2 Patient Clinical Outcome Indicators 
 
Summarised in Table 5.30 
 
5.4.2.1.2 .1 HbA1c 
 
For both HbA1c targets the difference for all benchmark practices demonstrated 
negative values, indicating a relative reduction in achievement of the targets. 
 
In the intervention group, seven intervention practices achieved greater proportion of 
patients achieving the 7.5% target and seven practices achieved higher proportion 
of patients with HbA1c less than 9.0%, reflecting results demonstrated in the 
statistical analysis that more patients in intervention practices were achieving 
reductions in HbA1c. 
 
 
5.4.2.1.2 .2 Blood Pressure 
 
Benchmark figures do not suggest any clear trend in increase or decrease in 
proportion of patients with T2DM meeting recommended blood pressure target 
(140/80mmHg) with figures ranging between negative and positive values. One 
practice (RMC), indicates a moderate increase (6.3%). 
 
Similarly, there is no obvious trend in terms of increase or decrease in achievement 
of targets in the intervention group.  However, two practices (DMC, TS) show large 
increases in proportion of patients achieving BP target of 9.5% and 11.4% 




5.4.2.1.2 .3 Blood lipids 
 
Benchmark practice figures range from negative to positive values and no obvious 
trend is demonstrated.  One large practice (SM) suggests a moderate increase. 
 
Similarly, intervention practice values range from negative to positive values.  Three 
practices have values which may suggest moderate increases.  There is no major 
shift in increased proportion of patients achieving total cholesterol targets (5mmol/l) 
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 Percentage of Patients 




Practice Pre Post % Diff Pre Post % Diff Pre Post % Diff Pre Post % Diff 
BENCHMARK             
BW Surgery 65.0 59.5 -5.5 91.6 81.3 -10.3 81.4 78.2 -3.2 51.5 50.9 -0.6 
CH Surgery 61.6 61.0 -0.6 87.4 86.1 -1.3 51.3 52.4 1.1 43.8 43.6 -0.2 
PF Surgery 66.5 64.9 -1.6 87.5 86.2 -1.3 77.8 76.2 -1.6 41.2 39.4 -1.8 
RH Centre 57.2 52.0 -5.2 81.9 79.6 -2.3 69.3 75.6 6.3 39.6 38.5 -1.1 
SM Surgery 66.1 60.4 -5.7 90.3 87.4 -2.9 71.6 71.5 -0.1 40.3 45.7 5.4 
WL Surgery 75.0 65.7 -9.3 91.9 86.0 -5.9 44.1 48.3 4.2 41.2 44.1 2.9 
SY Surgery 65.5 61.2 -4.3 85.9 82.1 -3.8 50.0 48.0 -2.0 50.5 48.0 -2.5 
INTERVENTION             
CM Centre 53.1 58.3 5.2 80.8 82.0 1.2 67.8 64.0 -3.8 35.6 N/A N/A 
CH Surgery 57.3 58.6 1.3 81.6 81.7 0.1 62.1 67.0 4.9 32.9 37.4 4.5 
DM Centre 65.3 66.8 1.5 86.4 85.8 -0.6 86.9 96.4 9.5 26.7 27.5 0.8 
SE Centre 54.5 60.0 5.5 81.0 84.9 3.9 66.2 56.5 -9.7 40.9 42.9 2.0 
SG Surgery 52.0 50.0 -2.0 90.2 80.0 -10.2 43.1 47.7 4.6 37.4 34.6 -2.8 
HJ Centre 47.7 48.9 1.2 77.1 76.7 -0.4 62.4 54.0 -8.4 45.6 45.0 -0.6 
PH Surgery 59.7 57.7 -2.0 81.2 86.9 5.7 64.3 64.3 0.0 32.5 36.3 3.8 
PF Surgery 52.9 56.5 3.6 78.4 78.9 0.5 48.8 46.5 -2.3 42.0 41.7 -0.3 
RH Surgery 63.9 61.7 -2.2 81.0 80.7 -0.3 53.6 48.2 -5.4 30.4 32.8 2.4 
SM Centre 65.5 66.9 1.4 81.9 84.2 2.3 81.2 79.4 -1.8 N/A N/A N/A 
TS Surgery 73.2 70.4 -2.8 92.0 89.6 -2.4 61.6 73.0 11.4 32.1 39.1 7.0 
WS surgery 63.1 57.7 -5.4 89.0 89.3 0.3 41.2 40.1 -1.1 59.8 66.5 6.7 
 
  Table 5.30 Movement in Achievement of Patient Outcome Indicators from Baseline to Post Intervention
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5.4.2.1.3 Patient Renal Clinical Outcome Indicators 
 
Summarised in Table 5.31 
 
 Proportion of patients with ACR measured 
 Proportion with documented microalbuminuria   
 Proportion with documented microalbuminuria prescribed a RAS drug  




5.4.2.1.3.1 ACR Measured 
 
There are no major shifts in proportion of patients having ACR measured at pre-
intervention and post-intervention time points in Benchmark or Intervention 
practices, except for DMC (Intervention) which shows an increase of 35.4% of 
patients being tested for microalbuminuria.  However, the general trend appears to 
be an increase in proportion of patients having ACR measured in intervention 
practices. 
 
5.4.2.1.3.2 Microalbuminuria Detected 
 
There are no major differences in proportion of patients with microalbuminuria 
detected in Benchmark or Intervention practices, except for TS (7.9% increase). 
 
5.4.2.1.3.3 Proportion of Patients on RAS Drug and Achievement of BP Targets 
 
Only one (small) Benchmark practice (PF,) shows a relatively substantial increase in 
the number of patients with microalbuminuria on a RAS drug (21.1%).  There is 
however a relative reduction (6.3%) in proportion of patients meeting the 
recommended blood pressure target.  One other (small) practice (BW) indicates a 
marginal increase in patients on a RAS drug (two patients only).  However, there is 
a slight increase (eight patients) in patients achieving the recommended BP target.  
All other benchmark practices show a relative reduction in the number of patients 
with microalbuminuria on a RAS drug ranging from -0.5% to -18.1%.   
 
Other practices (except RMC and BW) also show a relative reduction in proportion 
of patients achieving the recommended blood pressure target.  There are no 
practices which indicate an overall improvement in management of renal outcomes 
in the benchmark group. 
 
In contrast, six practices in the intervention group, (CH, CMC, SG, PH, RH and WS) 
demonstrate an overall improvement on the management of renal care in the T2DM 
population.  All of them show an increase in prescribing of RAS drugs ranging from 
0.2% to 34.2%.   Five of them show a significant increase in achievement of blood 
pressure target ranging from 2.7-10.1% in patients with microalbuminuria.  Three 
further practices (DMC, HJC, TS) all also demonstrate an increase prescribing of 
RAS drugs in microalbuminuria.  The percentage figures may suggest that these 
practices have a relative reduction in number reaching recommended BP targets.  
However, the figures reflect differences of only one or two patients per practice.  
Additionally, achievement of BP targets in a group of patients with newly diagnosed 
microalbuminuria would take time to achieve.    
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 Percentage of Patients 
 ACR Measured Microalbuminuria 
Detected 
Patients with m/a on 
RAS 
Patients with m/a BP 
Target (≤130/80mmHg) 
Practice Pre Post % Diff Pre Post % Diff Pre Post % Diff Pre Post % Diff 
BENCHMARK             
BW Surgery 83.2 82.0 -1.2 25.9 25.7 -0.2 55.9 57.4 1.5 50.8 62.3 11.5 
CH Surgery 83.5 85.4 1.9 28.4 27.4 -1.0 66.3 52.7 -13.6 32.6 38.7 6.1 
PF Surgery 78.2 83.7 5.5 20.9 20.3 -0.6 64.3 85.4 21.1 50.0 43.8 -6.2 
RH Centre 91.3 90.5 -0.8 26.2 24.3 -1.9 71.7 53.6 -18.1 41.4 51.5 10.1 
SM Surgery 84.0 82.9 -1.1 23.3 25.0 1.7 69.6 69.1 -0.5 59.2 50.0 -9.2 
WL Surgery 88.2 87.4 -0.8 31.7 35.2 3.5 73.7 72.7 -1.0 47.4 40.9 -6.5 
SY Surgery 84.9 84.7 -0.2 27.6 27.1 -0.5 80.0 77.8 -2.2 33.3 22.2 -11.1 
INTERVENTION             
CM Centre 92.7 91.9 -0.8 21.3 21.1 -0.2 42.9 77.1 34.2 40.0 46.3 6.3 
CH Surgery 89.4 94.7 5.3 22.1 25.3 3.2 71.6 71.8 0.2 43.1 45.8 2.7 
DM Centre 59.3 94.7 35.4 35.7 30.3 -5.4 30.0 77.1 47.1 60.0 46.5 -13.5 
SE Centre 91.4 91.6 0.2 18.4 16.0 -2.4 72.4 72.2 -0.2 69.7 55.6 -14.1 
SG Surgery 90.2 90.8 0.6 23.4 22.9 -0.5 65.4 70.4 5.0 26.9 37.0 10.1 
HJ Centre 28.0 29.9 1.9 59.0 61.9 2.9 72.6 75.7 3.1 43.5 34.3 -9.2 
PH Surgery 90.9 93.5 2.6 15.7 15.3 -0.4 68.2 79.2 11.0 22.7 29.2 6.5 
PF Surgery 89.3 88.6 -0.7 20.7 18.8 -1.9 87.4 82.1 -5.3 32.6 31.1 -1.5 
RH Surgery 76.0 82.1 6.1 26.5 27.1 0.6 73.6 80.3 6.7 32.1 31.1 -1.0 
SM Centre 92.7 87.7 -5.0 24.5 23.3 -1.2 87.7 80.8 -6.9 55.6 53.5 -2.1 
TS Surgery 91.1 92.2 1.1 15.7 23.6 7.9 75.0 76.0 1.0 50.0 36.0 -14.0 
WS surgery 84.1 90.6 6.5 15.4 16.6 1.2 87.2 77.1 -10.1 23.1 29.2 6.1 
 
     Table 5.31 Movement in Patient Outcome Indicators from Baseline to Post Intervention






The remaining three practices in the intervention group, (SE, PF, SMC) show no 
improvement in any of the renal outcome measures.   Interestingly, these practices 
all received the intervention from the same pharmacist.  Visit reports for these 
practices indicated that renal outcomes were not covered during the intervention 
visits whereas all other pharmacists reviewed renal care with their practices at some 
time during the intervention period. 
 
The overall trends for the patient-orientated T2DM outcomes discussed here 
(improvements highlighted in green) are suggestive of better management of 











5.4.2.2 Non-Steroidal Anti-inflammatory Drugs 
 
Summary data for patient-orientated clinical outcomes (risk factors) and for patient-
orientated prescribing indicators (concomitant medication), (Summarised in Table 
5.17) are presented in tabular form in the following section.  Significant post-
intervention shifts from baseline are highlighted in green. 
 
 
5.4.2.2.1 Proportion of Practice Population on NSAID 
 
Summarised in Table 5.32  
 
Proportion of patients on NSAIDs as a total practice population ranged from 1.4% 
(WL) to 3.2% (SM) at Baseline in benchmark practices.  During the intervention 
period, only one practice (RMC) slightly reduced proportion of patients on NSAIDs 
by 0.3%.   
 
Proportion of patients on NSAIDs in the intervention group, ranged from 0.8% (TS) 
to 4.5% (SE) at Baseline.  During the intervention period, five practices (CMC, HJC, 
RH, SMC and WS) demonstrated slight decreases in overall NSAID prescribing 
ranging from 0.2% to 0.4%.  Three practices showed no change in percentage of 
patients on NSAIDs.  Four practices showed slight increased proportion of patients 
on NSAIDs of between 0.1-0.2%.   
 
The results suggest no major increase or decrease in overall trend in NSAID 
prescribing in either group.  However, trends are suggestive of a greater reduction in 
the intervention group with RH and WS practices having greater overall decreases 
than other practices.  It is not feasible to demonstrate major shifts in numbers of 
patients prescribed NSAIDs from this data as proportion of patients on NSAIDs 
represent a relatively small proportion of each practice population. 
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5.4.2.2.2 Patients over 65  
 
Proportion of patients over the age of 65 years on an NSAID ranged from 30.5% to 
45.5% of patients in six of the seven benchmark practices.  Only one practice (WL) 
had a relatively low proportion of elderly patients on an NSAID (14.4%), possibly 
because it was a city practice with a high young (student) population.  During the 
intervention period, (with the possible exception of SY practice) there was no major 
change in patients over 65 years on NSAIDs in benchmark practices. 
 
The proportion of patients on NSAIDs over the age of 65 in intervention practices at 
baseline ranged from 21.1% to an exceptional 72.2% in one practice.  During the 
intervention period, only one practice (TS) demonstrated a moderate reduction in 
proportion of patients over 65 years on an NSAID. 
 
There was no observable difference between intervention and benchmark for 
reduction in proportion of elderly patients on and NSAID. 
 
 
5.4.2.2.3 Total (Clinical) Risk Factors 
 
Total risk factor figure is a composite of gastrointestinal (peptic ulcer), renal 
insufficiency (as indicated by chronic kidney disease classification), cardiovascular 
and cerebrovascular risk.  To an extent, reliability of this data relies on accuracy of 
the documented Read Code on the practice system.  Where Read Codes were 
documented, this should alert the prescriber to any potential risk related to 
prescribing of NSAIDs. 
 
Only three patients in the benchmark group (RMC) and one patient in the 
intervention group (WS) were coded for peptic ulcer, suggesting that there was 
awareness of NSAID-associated gastrointestinal risks and that NSAIDs were not 
generally being prescribed in this high-risk group.  Of concern perhaps, is that three 
patients with documented PU were registered in one practice.  All other data was 
based on documented cardiovascular and renovascular Read Codes. 
 
The proportion of patients prescribed an NSAID with pre-intervention documented 
risk factors ranged from 4.1% (WL) to 22.4% (SY, high student population) in the 
benchmark group and 1.9% to 27.8% in the intervention group.  In reality, actual 
numbers of patients with documented risk factors were generally small in both 
benchmark and control groups thus not enabling clear conclusions to be drawn from 
this data.   
 
There are no major increases or decreases in proportions of patients with 
documented risk factors in intervention practices.  Possible exceptions are PH, 
practice with a reduction of 6.1% and HJC with a total risk reduction (mainly renal) of 
8.0% and are believed to reflect specific practice actions to address NSAID 




                                                                                                                                         134 
 Percentage of Patients 
 % Practice Population 
on NSAIDs 
% Patients >65 on 
NSAIDS 
% Patients with Risk 
Factor (CV, CR, GI) 
Practice Pre Post % Diff Pre Post % Diff Pre Post % Diff 
BENCHMARK          
BW Surgery 2.6 2.8 0.2 34.5 32.1 -2.4 21.2 17.4 -3.8 
CH Surgery 1.7 1.9 0.2 45.5 41.3 -4.2 16.3 15.9 -0.4 
PF Surgery 2.6 2.6 0.0 30.5 33.3 2.8 13.9 12.7 -1.2 
RH Centre 2.3 2.0 -0.3 27.4 27.8 0.4 14.0 15.2 1.2 
SM Surgery 3.2 3.2 0.0 44.5 45.4 0.9 19.5 24.3 4.8 
WL Surgery 1.4 1.6 0.2 14.4 7.8 -6.6 4.1 7.8 3.7 
SY Surgery 1.9 1.9 0.0 43.1 35.4 -7.7 22.4 14.3 -8.1 
INTERVENTION          
CM Centre 1.2 1.1 -0.1 25.0 29.3 4.3 1.9 2.0 0.1 
CH Surgery 2.7 2.8 0.1 29.7 27.2 -2.5 15.0 16.7 1.7 
DM Centre 3.2 3.2 0.0 51.4 51.7 0.4 8.8 8.3 -0.5 
SE Centre 4.3 4.5 0.2 40.4 41.5 1.1 27.8 26.1 -1.7 
SG Surgery 4.0 4.1 0.1 48.4 45.2 -3.2 8.7 11.1 2.4 
HJ Centre 2.5 2.4 -0.1 34.6 42.3 7.7 25.0 17.0 -8.0 
PH Surgery 2.4 2.6 0.2 21.1 21.7 0.6 21.1 15.0 -6.1 
PF Surgery 3.2 3.2 0.0 34.7 37.5 2.8 11.4 13.4 2.0 
RH Surgery 2.1 1.7 -0.4 42.5 42.2 -0.3 24.5 24.8 0.3 
SM Centre 3.9 3.8 -0.1 37.4 42.3 4.9 25.0 25.9 0.9 
TS Surgery 0.8 0.8 0.0 43.2 35.2 -8.0 12.6 11.0 -1.6 
WS surgery 3.2 2.8 -0.4 72.2 70.9 -1.3 17.0 19.0 2.0 
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 Percentage of Patients 
 %PPI % ASPIRIN % SSRI 
Practice Pre Post % Diff Pre Post % Diff Pre Post % Diff 
BENCHMARK          
BW Surgery 51.7 51.8 0.1 9.9 8.5 -1.4 14.3 13.8 -0.5 
CH Surgery 38.8 39.3 0.5 10.1 7.5 -2.6 12.4 9.5 -2.9 
PF Surgery 37.7 38.0 0.3 7.9 8.7 0.8 10.6 15.3 4.7 
RH Centre 31.3 33.8 2.5 7.3 7.9 0.6 16.2 18.5 2.3 
SM Surgery 43.0 49.4 6.4 12.5 15.0 2.5 10.0 12.0 2.0 
WL Surgery 32.0 39.7 7.7 6.2 7.8 1.6 13.4 10.3 -3.1 
SY Surgery 44.3 38.3 -6.0 17.8 13.1 -4.7 6.3 6.9 0.6 
INTERVENTION          
CM Centre 45.2 44.4 -0.8 6.7 10.1 3.4 6.7 11.1 4.4 
CH Surgery 32.7 37.7 5.0 9.8 9.5 -0.3 9.0 12.7 3.7 
DM Centre 26.1 29.3 3.2 19.8 15.5 -4.3 3.6 6.0 2.4 
SE Centre 31.0 33.0 2.0 18.1 15.4 -2.7 10.7 10.7 0.0 
SG Surgery 50.0 46.0 -4.0 10.3 4.0 -6.3 8.7 9.5 0.8 
HJ Centre 29.8 43.3 13.5 13.5 12.4 -1.1 8.7 12.9 4.2 
PH Surgery 39.4 39.2 -0.2 11.0 9.2 -1.8 12.8 14.2 1.4 
PF Surgery 46.9 53.8 6.9 14.0 12.8 -1.2 11.1 10.8 -0.3 
RH Surgery 36.7 37.0 0.3 13.5 11.9 -1.6 5.5 5.9 0.4 
SM Centre 48.0 51.6 3.6 21.0 22.9 1.9 18.0 19.9 1.9 
TS Surgery 40.0 45.1 5.1 9.5 7.7 -1.8 5.3 4.4 -0.9 
WS surgery 25.0 25.9 0.9 13.2 10.6 -2.6 22.6 21.2 -1.4 
 





5.4.2.2.4 Prescribing Indicators Concomitant Medication 
 
Summarised in Table 5.33 
 
Several drugs (aspirin and SSRIs) may increase bleeding risk in patients on 
NSAIDs.  Co-prescription of PPIs, is recommended for gastroprotection in patients 
with a higher bleeding risk on NSAIDs. 
 
There were no obvious trends to suggest an increased use of PPIs or decreased 
use of aspirin or SSRIs in patients prescribed NSAIDs in the benchmark group.   
Data from WL and SM practices may suggest a limited increase in the use of PPIs 
with a reduction in SY.   
 
In the intervention group, there were moderate increases in the use of PPIs in seven 
of the twelve practices (CH, DMC, SE, HJC, PF, SMC and TS).  There was also an 
indication of reduction in concomitant prescribing of aspirin in SG, SE, DMC and WS 
practices. 
 
No obvious differences in prescribing of SSRIs were detected. In general, the 
differences in numbers may generally have been too small to detect any major shifts 
or to be able to draw any significant conclusions regarding prescribing of 













This section summarises the qualitative study evaluation and is divided into two 
parts.  Firstly, GP perceptions, attitudes and beliefs regarding EBM, (essentially 
collated from pre-intervention interviews), are summarised and discussed in the 
context of the GP curriculum requirements and with reference to the current 
literature on what is known on the subject.  The second element focuses on post-
intervention feedback from GPs on the impact of the intervention itself and whether 
and how it influenced the way GPs worked.  It also considers the value GPs 
themselves placed on the intervention and whether it was beneficial as a working 
model.  Table 6.1 provides a summary of GPs participating in pre-intervention and 





M / F Years  
as GP 
Practice SP PL GP  
Trainer 
Colour / Code 
Pre-
Intervention 
       
1      M 22 SGS √   Pre 1     Quote 
2 *    M 12 (22) DMC √ √  Pre 2*    Quote 
3 *    M  8 SMC  √  Pre 3*    Quote 
4      M  7 (12) CHS  √  Pre 4     Quote 
5      F 10 SEC    Pre 5     Quote 
6      F  5 TSS    Pre 6     Quote 
7      F 12 PFS    Pre 7     Quote 
Post-
Intervention 
       
1      F 25 PHS √ √  Post 1    Quote 
2      M 7 SEC  √  Post 2    Quote 
3      M 12 PFS  √ √ Post 3    Quote 
4 *    M 12 (22) DMC √ √  Post 4*   Quote 
5      M 15 WSS  √  Post 5    Quote 
6    F 12 (30) SMC   √  + Post 6    Quote 
7 *    M 8 SMC  √  Post 7*   Quote 
8      M 3 HJC    Post 8    Quote 
9      F 11 PFS    Post 9    Quote 
10    F 11 CMC  √  Post 10  Quote 
11    F 24 TSS    Post 11  Quote 
12    M 22 (31) RHS √ √  Post 12  Quote 
13    M 12 SGS  √  Post 13  Quote 
* Denotes GPs interviewed pre-intervention and post-intervention 
()  – Years Qualified 
SP - Senior Partner 
PL – Nominated GP Practice Prescribing Lead 
+ - Medical School Teacher 
 





6.2 GP Knowledge and Perceptions of EBM 
 
6.2.1 GP Knowledge and Training 
 
‘Evidence-Based Practice’ is a fundamental component of the RCGP Curriculum. 
The RCGP adopts the principles of the Sicily Statement (2005), and endorses the 
five-step model of EBP in teaching individuals how to formulate an answerable 
question and, to access, critically appraise, apply and evaluate the evidence in 
practice.211,212  
 
Key RCGP Evidence-Based Practice learning outcomes are summarised in  
Table 6.2 
 
GPs participating in pre-intervention interviews indicated that none had received 
specific training in Evidence-Based Medicine as a topic or as a ‘discipline’ during 
their medical training.  However, several indicated that the local MRCGP course 
contained a formal component involving critical appraisal and evaluation of a clinical 
research paper.  Consequently, most GPs appreciated the principles and 
importance of critical evaluation of clinical studies although several clearly regarded 
the training more a means to an end (passing the exam) than something they would 
routinely incorporate in practice. 
 
The GPs concurred in that a considerable amount of decision-making in medicine is 
not necessarily evidence-based and that evidence to support rational decision-
making is often lacking, creating a void in terms of informing best practice.  GPs 
often relied instead on traditional and habitual practice in their decision-making. 
 an awful lot of what we do particularly in primary care, but for medicine generally is not necessarily 
evidence based, an awful lot of interventions that nobody knows whether they really work, it is just 
we have always done them. (Pre-1) 
 
Apparently, prescribing decisions were not necessarily based on sound knowledge 
either. 
 I mean it’s ‘cookbook’ medicine.  I mean you look it up and think ‘that looks alright, I’ll have one of 
them’. (Post-1) 
 
GPs described several influences on their routine prescribing including patient 
factors, personal prescribing habits, familiarity with particular drugs, because they 
‘had always done it that way’ and a reluctance to move out of their perceived 
‘comfort zone’. 
 
The GPs recognised that for evidence to bring about change in their practice, 
individuals needed to actively change and move from established habitual practice, 
to incorporating known evidence into decision-making.  The personal process 
involved ‘taking the message on board’ (or internalising the relevant information). 
 it’s that habits are habits and to change habits you need to actually actively change otherwise you 
slip back into the habits, and evidence comes along and you start to make changes. (Pre-1) 
 And actually it’s quite difficult to change some of those things if you’ve always done it one way. 
(Pre-2) 
 
The main inference, however, was that changing prescribing habits was not 







Royal College of General Practitioners Curriculum 
 
Statement 3.5 Evidence-Based Practice 
 
 ‘Evidence-based care as a discipline requires GPs to find the best evidence, 
subject it to critical appraisal, understand its relevance and application in specific 
circumstances and then to communicate this knowledge appropriately and 
effectively both to individual patients as well as the wider healthcare team.’ 
 
 
Core evidence-based practice competencies 
All GPs should be able to: 
 Ask the ‘right questions’, to enable an efficient search to: 
o Find the appropriate literature from the widest available sources 
o Apply rigour in appraising the literature 
o Place the answers in the appropriate context 
o Demonstrate relevant skills so as to instigate change in practice 
effectively 
o Show an ability to design and initiate appropriate evaluation 
 
 
Primary Care Management 
GPs should be able to: 
 Demonstrate that they base their treatment and referral decisions on best 
available evidence 
 Apply rigour to scientific research to decide whether evidence is applicable to 
the primary care setting and appropriate to the individual 
 Demonstrate sufficient knowledge of the breadth of scientific evidence in order 
to provide best information for the individual 
 Use their knowledge of the ‘best possible evidence’ to inform a patient of the 
‘best possible’ way to navigate the healthcare system. 
 
 
A Comprehensive Approach 
The GP should have the ability to: 
 Demonstrate an understanding of what the limitations of evidence are in patients 
with chronic disease or the very elderly (often excluded from trials) in primary 
care. 
 Demonstrate an understanding that trials looking at therapeutic interventions 




The GP should have the ability to: 
 Demonstrate that evidence needs to be gathered from the most appropriate, 
rather than the most readily available source.  GPs should be able to determine 
whether the evidence presented to them is sufficient and rigorous enough to be 
analysed in the context of a patient. 
 
 




6.2.2 Definition of Evidence Based Practice 
 
Overall, the GPs believed that clinical decision-making should be objective and 
informed by the best and strongest available research evidence.  However, they 
found Evidence-Based Medicine a difficult and complex concept to define. 
 Oh that’s difficult isn’t it? (Pre-3) 
 I think its probably fairly difficult. (Pre-6) 
 
None of the GPs proffered the ‘recognised’ Sackett definition (Section 2.2) or 
suggested that EBM involved the traditional ‘Five-Step model ‘for finding answers to 
clinical questions as the basis for clinical decision-making.  Rather, their 
understanding of EBM focused on the principle of incorporation of best research 
evidence from clinical trials into clinical decision-making for individual patients.   
 
One definition representing the general view was:  
 I suppose looking at the whatever the best evidence is, or making a rational decision and then, I 
still think the key, which is what we probably do best as GPs is trying to, make the best fit of our 
patient to, say a different patient group. (Pre-2)  
 
 
6.2.3 What Constitutes the Evidence Base 
 
Generally, GPs considered that the ‘evidence base’ for prescribing largely results 
from studies or clinical trials, conducted in clearly defined populations for the 
purposes of research.  Results from clinical trials were considered not normally 
generalisable to the general population as seen by GPs because studies are 
typically conducted in highly selected groups of individuals, generally excluding 
those with a more complicated clinical picture.   
 Well I treat 100% of patients, so I don’t exclude people with IHD or people with diabetes or people 
who have had a stroke or people who are obese or people who smoke.  I treat all of those and 
therefore I am sceptical that the evidence that they say, you should do this from a single trial 
doesn’t necessarily apply to the patients that I’m treating. (Pre-2) 
 
The elderly population in particular was regarded by several GPs as being quite 
different from the general population where recommended treatments were often 
clinically inappropriate for individual elderly patients.   
 
GPs were therefore generally aware of limitations associated with research 
evidence obtained from clinical trials as highlighted in the RCGP curriculum.  
Several also regarded studies providing patient-orientated outcomes-based 
evidence (e.g. UKPDS) as more relevant than those with narrow disease-orientated 
outcomes.  Others realised that conclusions drawn from robust evaluation of several 
studies by reputable groups (e.g. Cochrane) contributed to the evidence-base, 
making it stronger. 
 
Despite availability of evidence-based recommendations, individual patient factors 
were regarded as a key influence in determining the most appropriate therapies.  
GPs also felt that they often have a wider picture and hence, a more holistic 
approach to patient management.  Tension between EBM and the perception of 
medicine as an art, was also implied, there being no substitute for experience, tacit 






The GPs were therefore familiar with two accepted criticisms associated with EBM, 
that is, the reductionist nature of evidence derived from clinical studies and the need 
to acknowledge patient values and subjective experience, as well as physicians 
‘tacit’ knowledge in clinical decision-making.213 
 
6.2.3.1 Evidence Based Medicine as an Event 
 
GPs observed that availability of evidence to inform practice was continually 
evolving and changing.  The whole process was perceived as dynamic and not 
permanent.   
 
Two concepts of evidence influencing clinical practice emerged from the interviews.  
One was described as ‘evidence-based’, resulting from well researched and well 
documented studies and tied in with GP views on what constitutes ‘the evidence 
base’.  The other, more nebulous, possibly unwritten, founded on traditional or long-
standing practice, was described as ‘practice-based’. 
 I guess the other side of it is a bit more woolly side of it, the things that have been done for a long 
time, so, aspirin and the kind of things that don’t necessarily have written evidence-base but have 
that practice-base. (Pre-5)   
 
It was suggested that, as information accumulates, evidence often ‘comes about’ 
ultimately resulting in changes in practice, a notion which perhaps conforms to the 
GP ‘practice-based’ concept of evidence influencing practice but which mainly fits 
the ‘passive diffusion’ model of evidence transition.36,214   
 
6.2.3.2 Benefits of Evidence Based Medicine 
 
The evolution of EBM overall was generally perceived as supporting a less nebulous 
approach in medicine by providing firmer evidence on which to base clinical 
decisions.  Consequently, benefits of EBM were regarded as cleansing of 
inappropriate historical practice, removal of nebulous practice and better 
standardisation of care. 
 
6.2.3.3 Motivations for Practicing EBM 
 
All of the GPs interviewed considered themselves as evidence-based practitioners.  
Their motivations for practicing EBM included keeping up-to-date with best-practice 
recommendations, to inform and justify clinical decision-making, and where 
necessary, to ensure value for money.  GPs were conscious that there is a potential 
for doctors, to do more harm than good.  Therefore, principles of beneficence and 




6.2.4 GP Skills and Information Management 
 
GPs felt that they were inundated with large volumes of information and believed 
that it was impossible to keep up to date with everything as they did not have time to 
read or access it all. 
 you know there are so.., there are too many resources actually. (Pre-3)   
 
The complexity of freely available information, often from conflicting sources, and 
difficulties encountered in dissecting all the contributing factors were difficult for GPs 
to assess. 
 This is the problem you see, it is so difficult to unpick. (Pre-3) 
 
It was felt that a ‘humble’ GP has no means of judging how robust evidence is as 
presented to them in articles or journals and that much of what they read, they may 
take on trust.   
 
All of the interviewees believed that the average GP has neither the knowledge nor 
the skills to perform a literature search, or to review and evaluate the evidence-base 
themselves.  Accessing and evaluating research evidence was regarded as a highly 
skilled job, reserved for individuals with appropriate skills. 
 It takes time and it takes skill.  And I’m sure somebody else could do that. I mean I can’t.  
Erm and that’s, that’s (laughs) it’s your job. (Pre-6) 
 
Despite general enthusiasm for EBM, GP feedback supported other findings in that 
physicians rarely report using evidence-based guidelines or studies identified from a 
focussed literature search to guide their clinical decisions, and that most GPs are 
not confident in even the basic skills of EBM including literature searching and 
critical appraisal.215,216 
 
The feedback also suggests that most GPs are actually unable to demonstrate the 
required ‘Core evidence-based practice competencies’ as defined in the RCGP 
Curriculum and are consequently unable to apply those competencies in practice. 
 
GPs believed that even if they had relevant skills, they did not have time to search 
for information themselves, generally ‘picking up’ information as they went along, 
and only actively seeking information if they had to.  GPs preferred information 
aimed at them to constitute the ‘bottom-line’ with key messages and salient points, 
preferably condensed on one A4 sheet. 
 Even things like the NICE Guidance, I only ever read the kind of you know, summaries, because 
my brain can’t take in all the other stuff you know.  Just put it down to one side of A4. (Pre-1) 
 
6.2.4.1 Keeping Up to Date 
 
Lack of awareness of available evidence was regarded as a barrier to incorporation 
of evidence into practice.  Unless GPs were made aware of evidence, their 
knowledge of emergent evidence ultimately depended on serendipity. 
 My barriers would be not knowing about it.  My ignorance or lack of awareness of things. (Pre-4) 
 
Only two interviewees indicated that they specifically attempted to keep up to date 
with the most recent evidence-base by attending regular (RCGP accredited) ‘GP 
Update’ courses  which addressed ‘current issues, in general practice’. Both utilised 
and relied significantly on pre-appraised information collated by GP trainers as part 
of the course.   
 a bunch of GPs have read through all the articles and all the journals and put all the current 
evidence based management of everything and anything into a book.(Pre-4) 





Several GPs accessed Web-based tutorials of their choosing.  Others attended 
consultant-led ‘hot topics’ courses co-ordinated by the local Trust post-graduate 
medical centre.  Most did however not indicate that they actively sought up-to-date 
evidence-based information to inform their practice. 
 
6.2.4.2 Background Reading  
 
The British Medical Journal (BMJ) was considered gold standard and read regularly 
by most GPs.  Several read other GP ‘magazines’ distributed opportunistically.   
 The ones I get sent. (laughs)    GP magazines often have a round of the latest sort of studies and 
things, which is quite helpful. (Pre-5) 
 
Several GPs were clearly aware of the potential for manipulation of information 
presented to them in any source of information.  Some were sceptical of information 
presented to them, particularly where product advertising was included.  Others did 
not apparently discriminate or question the quality or validity of the evidence-base in 
their reading materials.   
 
6.2.4.3 GP Colleagues 
 
The interviews confirmed that an informal network of verbal communication existed 
between GPs in seeking information from each other to inform their clinical decision-
making.  They frequently asked specific questions of their GP colleagues, usually 
when they met informally during the working day (e.g. break times) or during regular 
informal meetings.   
 We, meet, every morning and have sort of informal discussions about patients, and that came up 
as very informal. (Pre-5) 
 
Several practices organised educational and clinical meetings with the stated 
intention of information-sharing and ‘book-club’ type discussion and which were also 
regarded as an opportunity for GPs to share current issues in practice with each 
other.   
 
6.2.4.4 Consultant Specialists  
 
GPs also contacted consultants when they had clinical queries regarding the 
management of individual patients.  They observed however that consultant 
opinions frequently conflicted with each other.  
 
Overall, feedback indicated that in line with other studies, GPs preferred to rely on 
clinical experience, opinion of colleagues and brief reading as a means of 
information-gathering to inform their clinical practice, which ultimately would serve to 




6.2.4.5 Medicines Management Team 
 
Several GPs utilised MMT for obtaining prescribing advice, particularly relating to 
prescribing policy.  Consultant requests often prompted GPs to seek further advice 
to inform prescribing decisions.  Responses were generally considered evidence-
based although cost-effectiveness was assumed to have been a major 
consideration.    
 presumably you lot have all looked at the drugs, decided what the evidence base behind, how 




Depending on the query, community pharmacists, hospital pharmacists and hospital 
doctors were often contacted in preference to MMT.  Several GPs were unaware of 
the skill-base within MMT or of the prescribing advice it could provide. 
 I didn’t really know we could do that.  And we’ve probably been using much less skilled people 
than you.  We’ll often be phoning up sort of registrars in hospital and probably you lot are a lot 
better to talk to than nurses. (Pre-6) 
 
This observation should perhaps raise questions if not concerns regarding GP 
perceptions of the role and functions of MMT.  It suggests that MMT may not have 
been successful, active (or even interested) in communicating itself as a medicines 
resource available to support GPs in practice. 
 
6.2.4.6 Guidelines in Practice  
 
GPs generally accessed clinical guidelines to inform practice.  However, they 
preferred summaries only and were unlikely to access and read full guidance 
documents.  Guidelines were regarded predominantly as working models to guide 
practice in line with clinical knowledge and expertise, rather than an instruction to be 
followed slavishly.  Although constantly changing, guidelines were considered to be 
the best influence available at any one time to inform decision-making. 
 
Most, if not all GPs used NICE Guidance to inform their clinical practice.  NICE and 
(its Scottish equivalent) SIGN guidance (Scottish Intercollegiate Guideline Network) 
were regarded as gold standard evidence-based guidelines. SIGN, was considered 
to be the more evidence-based by those GPs who used it.  Frustration was also 
expressed that NICE and SIGN were often inconsistent.  
 
Several GPs were sceptical about the ‘evidence-base’ on which NICE had based 
several therapeutic recommendations in its guidance (e.g. neuropathic pain). 
 
Some GPs were cynical about the NICE cost-effectiveness stance, sometimes 
perceived as a rationing exercise whilst on others, recommending expensive drugs 
without supporting evidence.  NICE Guidance was also often open to interpretation, 
which generated uncertainty, ultimately making it more difficult to implement. 
 
Several GPs suggested that some clinicians agree with and trust NICE guidance 
unquestioningly whilst others (including several interviewees) were more sceptical.  
Several GP comments are summarised in Table 6.3. 
 




 So, You have to question why the national organisation like NICE actually 
permitted itself to write a national guideline not based on any evidence at all.  
And I think that is something that they have got to be very, very wary of, it 
devalues a lot of the good things that they have done because it is so 
patently wrong.  (Pre-4) 





 I do believe in NICE guidelines, I do believe in SIGN guidelines and 
sometimes despair that the two don’t necessarily agree with each other 
because they should reflect each other exactly. (Pre-4) 
 Yes, lots of different ways of interpreting actually what should be a very 
straightforward guideline.  (Pre-3) 
 




British Society Guidelines such as the British Thoracic Society (BTS), British Heart 
Foundation (BHF) and The British Hypertension Society (BHS) were regarded by 
several GPs as evidence-based sources, which they accessed to inform specialist 
areas of practice.  However, GPs who used these sites did not acknowledge that 
these sources were not independent and may not have been evidence-based or 
unbiased.  
 
6.2.4.7 Triggers for Seeking Information 
 
Various triggers may have prompted GPs actively to seek information.  Typically, 
where ‘evidence-based’ guidelines were poor or not relevant to practice and when 
GPs were pursuing personal professional development.  The main and most 
frequent trigger, for GPs in seeking information however, were patients, typically the 
‘informed patient’.  Seeking and accessing information was often conducted during 
patient consultations and usually via the internet. 
 
 
6.2.5 The Internet 
 
The Internet (regarded as a ‘wonderful’, and incredibly powerful tool) was the main 
means by which GPs accessed information.  Several GPs acknowledged that there 
is little control in terms of access and no guarantee of the credibility or validity of 
information available from it.  Overall, GPs determined individually which websites to 
access although in one practice, GPs shared information on internet sites amongst 
themselves.   
 on our Monday educational meeting we have a regular slot on the internet where we just discuss 
what people are using because it’s just so powerful  and it’s so important now.  You can’t ignore. 
(Pre-3) 
 
GPs routinely worked throughout the day with numerous preferred websites open 
and ready to use.  Accessing information via the internet was an integral and routine 
part of patient consultations. Many GPs during their interview demonstrated 
(unprompted) how they would use the internet. 
 I do it all day, every day.  It’s constant.  Yep. I do it with the patient there. (Pre-3) 
 
 
6.2.5.1 Frequently Used Websites  
 
Websites were frequently used by GPs to access information and to guide patients 
to further information.  One GP even directed patients to physiotherapy exercises on 
YouTube. 
 They feel empowered because actually they can use the internet in a way which is focussed by 
someone for them rather than just trying to fish. (Pre-3) 
 
GP Notebook (independently managed, online encyclopaedia of medicine for GPs) 
was routinely accessed by many GPs to inform their practice.  It was perceived as a 
‘well researched and validated’ information site.  Patient.co.uk, aimed at non-
medical individuals (EMIS funded), was frequently accessed during consultations 
with patients, often used for directing patients to further information and for 
accessing patient information leaflets issued during consultations.  
 It’s a good sort of one stop thing. (Pre-1) 
 
Neither website was acknowledged as commercially funded, or that the information 
posted had not necessarily been validated or subject to evaluation through a 




GPs mainly accessed British websites, particularly when seeking guidelines, clinical 
advice and patient-orientated information.  Foreign websites were accessed more 
for clinical knowledge-based information than for evidence to inform decision-
making.   
 
If GPs had specific information requirements unavailable through routinely used 
links, Google was undoubtedly the first and main route to actively seek and access 
further information. 
 Well you Google things for finding them don’t you?  It’s where you find everything these days.  
(Pre-4) 
 Oh crikey. I could look one (definition of EBM) up for you on Google if you like.  That’s what I 
would normally do. (Pre-3)  
 
Use of the internet as a tool during GP consultations has apparently coincided with 
the internet revolution and expansion.  In this situation, GPs are relatively time 
limited.  However, they appear to be using the internet to obtain quick answers to 
questions or as a means to provide patient support.  Although patients often come 
with information obtained from the internet, (a source of frustration for many GPs) 
GPs were conversely using the technology to manage patient queries during 
consultations.  
 
6.2.6 Trusting Information 
 
A major theme emerging from the interviews related to trust.  Trust in the evidence 
itself, trust in ‘evidence-based’ guidance, and trust in the original studies.  Trust was 
also a factor mentioned in relation to other sources of information including the 
pharmaceutical industry, internet websites and the Medicines Management Team. 
 
There was a disparity amongst GPs regarding their questioning the validity of 
evidence-based sources (including NICE), some GPs were clearly more questioning 
than others.  Several GPs assumed, (based on trust), that guidelines, websites 
aimed at GPs and patients and other resources were reliable sources of evidence-
based information.   
 
Other GPs were more cynical and appreciated that information may be distorted in 
the way it is presented to them.  Understanding motivations behind ‘evidence’ as 
presented for example by drug companies compared with NICE was regarded as 
important in discriminating between what may or may not be evidence-based 
information.   
 
 
6.2.7 Evidence Based Sources of Information 
 
Cochrane, Clinical Evidence, NICE, SIGN, Clinical Knowledge Summaries (CKS) 
and the NPC are all organisations with robust and transparent methodologies for the 
production of high quality evidence summaries.217 
 
CKS (formerly Prodigy) is an accredited ‘NHS Evidence’ based service provided by 
NICE which provides GPs with a readily accessible summary of the current 
evidence base and practical guidance on best practice for common and significant 
primary care presentations.  Several GPs used it as a source of information to 
inform clinical practice, including prescribing, however, others were completely 




A limited number of GPs did discriminate between information sources which were 
regarded as providing reliable evidence-based summaries, such as the Drug and 
Therapeutics Bulletin (DTB), Bandolier, MeReC, and Cochrane.  Several GPs also 
exercised discretion in preferentially accessing NHS or DH websites, whereas 
others did not. 
 
The majority of GPs however, did not preferentially access recognised evidence-
based sources of information routinely, possibly because many GPs have not been 
educated in accessing reliable sources as a component of information management. 
 
A selection of interviewee comments on discriminating between and trusting 








 my assumption is that its (NICE) always evidence based and I haven’t thought 
any more about it.  (Pre-4) 
 I think with the sites that I know, is that I trust them and perhaps I shouldn’t, 
(laughs)  But you know, I have never really thought about it to be honest.  (Pre-5) 
 I’m a great questioner.  But I think a lot of GPs aren’t.  Mainly really because they 
haven’t got the time.  I guess I’m very passionate about what I do so, I always… I 
love to know  (Pre-7) 
 I suppose for things like GP notebook, you just have to take a leap of faith don’t 
you?  You just, you know you have to trust your peers to some extent.  (Pre-6) 
 I think I would, describe myself as an eternal sceptic when it comes to a lot of 








 I would, trust Bandolier DTB and NICE because I don’t think these people have 
got axes to grind one way or another, they just want to give the best advice and 
they are independently funded.  (Pre-1) 
 ...have been, appraised by Cochrane or NICE or, the MHRA.  There is always a 
conclusion by reference to one of those big bodies, who have appraised those 
studies and the articles.  (Pre-4) 
 because you know, a website that’s dot nhs dot uk or dot gov dot uk is hopefully 
going to be more evidence, more sound, than you know, some website (laughs) 






 Nobody sits you down and says, you know, these are the most effective sources 
of information to use, everyone is groping around trying to find sort of relevant 
sources of information.  (Pre-6) 
 
 






6.3.1 GP Perceptions of EBM 
 
There was widespread acceptance of the concept of EBM.  However, there remains 
a diversity of approach to EBM in clinical practice involving different interpretations 
and understanding.  Since the introduction of EBM as new paradigm for practice and 
teaching in medicine, various conceptual models have evolved.  Initially focussing 
on using research evidence as a basis for clinical decision-making, later models 
incorporated components such as patient values, clinical expertise, clinical state and 
setting.218  
 
Critics argue however, that EBM is not well developed and articulated in terms of 
defining model components, justifying their inclusion or suggesting ways to integrate 
them in clinical practice.218  Essentially, although EBM is a desirable aim, the ‘how 
to’ practice it is not specified.218  
 
Even early proponents of EBM no longer believe that it represents a new or special 
theory of knowledge.  They acknowledge that there exists an inadequate framework 
for successful problem-solving and decision-making and concede that there remains 
a lack of evidence that EBM improves patient outcomes.213  They suggest that rather 
than being construed as a scientific or philosophical theory that changes the nature 
of medicine, that EBM should be considered as a continuously evolving heuristic 
structure for optimising clinical practice.213  
 
In the clinical context, EBM may therefore be regarded as having two different but 
related meanings.  Firstly, as a method to access and evaluate research evidence 
on clinical effectiveness of treatments, which requires highly developed skills in 
accessing evidence to answer clinical questions and secondly, as a model of 
practice in the clinical encounter, equated with ‘best practice’ in clinical decision-
making.218  
 
Another perhaps related classification has also been suggested whereby EBM may 
be regarded as being applied to improve healthcare at two different levels.219,220  
Evidence-Based Healthcare (EBHC) practiced at an organisational level focuses on 
population-based policies and individual decisions, which are consistent with 
evidence of effectiveness and benefits.  In this model, evidence-based research 
findings are embedded into national systems and processes through the use of 
guidelines and audit.219,221  Evidence-based guidance (EBG) is produced by teams 
using rigorous methods to produce generic guidelines and policies that address 
needs of groups of people. (e.g. Cochrane, Clinical Evidence).219  This model also 
fits the ‘Implementation’ approach to spreading research findings in practice or 
‘making it happen’ by mainstreaming innovation within an organisation.214   (Section 
7.3.4) 
 
Evidence-based Individual Decision-Making (EBID) however, is the practice of EBM 
by individual clinicians making decisions about individual patients and their care.  
EBID involves filtering and interpretation of information coming from EBG within 
clinical decision-making. 219  In this model EBID also focuses on incorporation of 






Despite stated aspirations to practice as evidence-based practitioners, the GP 
interviewees found EBM a very difficult and complex concept to define and were 
unable to offer a clear and agreed definition of what constitutes EBM.  
 
In many people’s minds, EBM is about formulating questions, literature search and 
critical appraisal or the traditional five-step approach to EBP.222  The RCGP 
Curriculum also requires that GPs should be able to demonstrate these 
competencies.  This was not however the participants’ perception of practicing EBM 
or an activity which any would normally apply in their clinical practice.   
 
Rather, application of EBM in practice as described by the GPs focussed on the 
principle of incorporation of best research evidence into clinical decision-making for 
individual patients, or, applying it as a model of practice in the clinical encounter, 
equated with ‘best practice’ in clinical decision-making.218  This perception is also 
congruent with the EBID approach described by Eddy and others.219,221 
 
Feedback suggests that whichever classification of EBM is inferred, GP 
understanding and application of EBM in practice fits in with the use of ‘best 
available evidence’ to inform decision-making at the individual patient level.   
 
Interestingly, GPs perception, that changes in practice often occur as a result of an 
accumulation of evidence which happens over time, conforms with the ‘passive 
diffusion’ model of evidence transition. 36,214  However, the EBID approach, (informed 
by EBG) is consistent with ‘implementation’ at an organisational or policy level. 
36,214,219   
 
6.3.2 Skills and Knowledge 
 
Despite positive attitudes towards EBM, GPs indicated that they simply did not have 
the basic (traditional) skills to practice EBM.  GPs seeking evidence-based answers 
to clinical questions was not an option for them.  Rather, it was someone else’s 
responsibility or role.  As reported earlier, GPs relied mainly on clinical experience, 
opinion of colleagues and brief reading to inform their decision-making. 215,216  
 
Information gathering in this way is consequently likely to reinforce GP reliance on 
‘mindlines’ to support their clinical decision-making.4,40,41  Most information doctors 
use when seeing patients is therefore kept in their heads, which may be appropriate 
if the ‘mindlines’ reflect best evidence but not if they serve to reinforce outdated and 
sub-optimal practices.223  Unfortunately, much of that information is out of date and 
wrong and studies evaluating markers of clinician knowledge have demonstrated 
severe deficiencies in doctors’ knowledge.216   
 
The GPs in this study also found the volume and complexity of information around 
them overwhelming and without appropriate skills were unable to evaluate or judge 
the quality of ‘evidence’ presented to them, taking much of what they read on trust.  
Most GPs did not search for information themselves, generally ‘picking up’ 
information as they went along, only actively seeking information when they had to.   
 
Unfortunately, information management is not generally taught to medical students 
as a critical professional skill.216,222,224  Paradoxically the EBM movement has 
concentrated much resource on teaching the more difficult traditional ‘Five-Step 
model approach for finding answers to clinical questions as the basis for clinical 
decision-making, and which evidence from this study suggests is not applied in 




The EBM movement has attempted to make it easier for clinicians to access 
evidence-based information to inform clinical decision-making.217  Despite high 
quality syntheses of evidence, and despite continued efforts, research evidence still 
does not translate into practice.225,226  In many therapeutic areas, existing 
prescribing data is different from anticipated prescribing patterns if prescribing 
decisions were based on available evidence.223  
 
Cardiovascular risk associated with NSAIDs use is just one example.  The 
statistically significant differences achieved in influencing prescribing of NSAIDs in 
this study, also suggests that there remains a wider problem to be addressed in 
raising awareness of research findings with GPs and then persuading them to adopt 
a change in prescribing behaviour.  
 
Adoption of evidence into practice ultimately depends on decisions to change made 
by individual people.224  The GPs recognised that to bring about change in 
prescribing practice, individuals needed to actively change and move from 
established habitual practice, to incorporating known evidence into decision-making.   
There was however, reluctance for GPs to move from their ‘comfort zone’ and 
instigate change in personal prescribing habits themselves.   
 
In an environment of information overload, questions therefore arise as to whether 
practitioners recognise when they do not have the best evidence for clinical 
decision-making.  Too often practitioners don’t know what they don’t know and are 
unaware of important advances.216  In this study, very few GPs acknowledged their 
own knowledge gaps because they were unaware of current advances or evidence-
based recommendations.  
 
GPs need to be aware how information reaching them can be flawed.211,223  
However, this review demonstrates that although several GPs discriminated 
between sources from which they accessed information, others took information that 
they sought or received on trust, frequently unquestioningly.   
 
The RCGP Curriculum is quite clear in its requirements that GPs should be able to 
find and critically appraise the best evidence and understand its relevance and 
application in clinical practice. (Table 6.2)  Whilst GPs were aware of limitations of 
evidence obtained from clinical trials, they were not apparently conversant with even 
the basic competencies of the traditional approach to EBM. 
 
Based on the findings of this study, although many GPs are aware of the concept of 
EBM, perhaps worryingly, the majority do not actively seek, find or evaluate the best 
evidence with which to inform their clinical decision-making.  Critical appraisal is not 
a skill routinely applied in practice by the majority of GPs.  Many prescribing 
decisions were not based on the most recent evidence, or even on sound 
knowledge. 
 
The RCGP Curriculum requires that GPs demonstrate that evidence is gathered 
from the most appropriate, rather than the most readily available source.   Results 
from this review indicate that GPs actually adopt the opposite approach. 
 
Study findings suggest that most of GPs activities in seeking information involve 
finding rapid answers to questions.  Significantly, in the age of modern technology, 
when finding answers to questions (including during patient consultations), GPs 
often rely on rapid access to information available from the internet.  Although GPs 
have preferred websites and several GPs are discriminatory in the sources from 
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which they seek information, many rely on information sought and received 
opportunistically and base their personal evaluation on trust. 
 
It is suggested here that the ‘Evidence-Based Practice’ skills and competencies as 
outlined in RCGP curriculum aimed at ensuring evidence-based decision-making in 
every day practice are not routinely demonstrated or applied by the majority of GPs. 
It is of concern that GPs do not necessarily use evidence or up to date knowledge in 
their decision-making.  GPs are not apparently equipped with certain traditional skills 
promoted by the EBM movement.  Neither, are they trained in information 
management skills, which are aimed at managing information overload.   
 
The GPs recognised that they do not have the time or the skills to access the 
evidence to inform their clinical decision-making.  Instead, as suggested elsewhere, 
they tend to rely on unstructured reading, professional networks and advice of 
experts for information.223 
 
Despite efforts to improve availability of synthesised evidence-based information, to 
inform clinical decision-making, many GPs still do not utilise information summaries 
which may never even reach them.  GPs remain largely inactive, not actively 
seeking information unless prompted by a trigger into action, continuing to rely 
instead, on ‘mindlines’ as the basis for much decision-making.225 
 
6.3.3 Potential Barriers to Implementation of EBM 
 
Several factors were identified which may constitute barriers to implementation of 
EBM in practice.  There was clearly reluctance on the part of many GPs actively to 
change and move out of their comfort-zone in relation to prescribing.  Many were 
overwhelmed by amount of information available to them and were not able to 
manage it effectively because they lacked both traditional skills in EBM and 
information management skills.  GPs remained recipients of information rather than 
seeking out the best information to inform their prescribing decisions. 
 
A major factor was GP reliance on trust in the information they received or accessed 
opportunistically.  Whilst several discriminated between the sources they accessed 
(using trusted websites and sources of information) and were sceptical of the 
evidence, others were apparently unquestioning about the credibility of the 
information reaching them.  Many were unaware of validated information sources 
which also raises a question about how aware GPs are that the information they 
receive may be flawed.  Lack of awareness of the evidence-base (blind spots) was 
also barrier to implementation of EBM.   
 
Several aspects of this review are explored further in the discussion section of 






6.4 Post-Intervention GP Interviews and Analysis 
 
6.4.1 Traditional Interactions with Medicines Management Team 
 
The intervention approach was regarded by GPs interviewees as being very 
different from traditional interactions with MMT about which they expressed several 
frank views.  
 
Prior to the intervention, GP exposure to MMT, ranged from no personal contact to 
regular interaction with MMT staff.  GP Prescribing Leads generally had greater 
contact because of their lead role responsibilities.  Most GPs found the MMT Bulletin 
disseminated periodically to practices useful in raising awareness of general 
prescribing issues. 
 
Annual Prescribing Meetings (APMs) typically involving a ‘senior’ MMT pharmacist 
meeting one-to-one with the nominated practice GP Prescribing Lead was the only 
direct contact several practices had with MMT.  The meeting tone was generally 
considered dictatorial, with MMT telling the practice where they should concentrate 
efforts to achieve financial balance and make savings. 
 
6.4.1.1 Prescribing Objectives 
 
GPs expressed frustration regarding the many prescribing schemes ‘imposed’ on 
practices by MMT and the work and time demands that it generated for them.  They 
felt inundated with prescribing data, reflecting at least five different prescribing 
schemes, all ultimately targeting cost-reduction. 
   
‘Point-in-time’ listings of various prescribing indicators for all practices were 
disseminated regularly to each prescribing lead.  Data was untargeted and did not 
provide feedback on prescribing trends.  The volume and complexity of the 
information were considered overwhelming.  Guidance on data interpretation and 
management to address MMT prescribing objectives was not provided.  There was 
no personal contact as all communications were electronic.   
 
Prescribing leads were expected to communicate relevant information to their 
partners, develop practice audits and to feed information back to MMT.  GPs 
perceived little value in what they were being asked to do, believing it demonstrated 
completion of a task rather than providing useful information on practice prescribing 
activities.  GPs believed that cold dissemination of large volumes of prescribing data 
did not persuade or help them to change prescribing behaviour.  
 
6.4.1.2 MMT Culture 
 
The overriding GP perception of MMT was that its raison d’être was based on 
minimising, if not reducing prescribing costs.  GPs frequently felt pressurised to 
make prescribing decisions which were cost-based.  The MMT approach to 
influencing prescribing behaviour was regarded as prescriptive, and restricting 
clinical freedom to prescribe.  Existing tensions between MMT and GPs were 
implicit.  MMT was also perceived as being inconsistent in promoting evidence-
based arguments manipulating evidence to support its argument when the 
underpinning motive was likely to be based on cost.  A selection of interviewee 









 The meetings are, basically, ‘We’re telling you, you’ve got to do this, 
you’ve got to change your budget’.  (Post-1) 





 Yes, within the Medicines Management, they are kind of focused to 
cost.  (Post-8) 
 If we look at the quality prescribing programme, ‘quality’ in inverted 
commas, it’s not really about quality, it’s about efficiency, you know.  
We have to be a bit more honest about it  (Post-7) 
 Well actually I’ve never met with people from Medicines Management, 
it’s usually all done by e-mail and you’re just being told what to 
prescribe  (Post-6) 
 Sometimes I’ve felt a little bit let down when I’ve looked into it a bit 
more myself to feel that it’s not entirely unbiased.  That the cost side of 
things comes to influence what the final decision is.  You get the 
evidence that supports the MMT argument but if there is evidence that 






 And you think ‘for goodness sake, you know, please be consistent with 
evidence-base because if you’re telling us there’s no evidence and 
then suddenly we’re going to make a switch across to it, because 
suddenly the evidence is there, you suddenly become incredibly 
cynical.  (Post-7) 
 It does feel like it’s all about decreased cost.  So I’m feeling a bit 
bruised about having swapped everyone to candesartan and now I’ve 
got to swap people back to losartan. I’m looking at these people who 
are looking at me as if I’m mad.  (Post-11) 
 
 




 There are four different areas that Medicines Management decides we 
have to do, which is ridiculous.  Plus this, it’s five different sticks you 
feel like you’re being beaten with and you think ‘Oh **** I should just 
go home’.  (Post-7) 
 Sometimes there’s so much to attack that you just think well where do 
I start with this, it’s one list after another and it’s a bit overwhelming.  
And it’s a bit demoralising…  (Post-11)  
 You know, my brain is not big enough to hold it all in, and I’m not 
stupid.  It’s a complete overload.  I’ll just keep seeing the patients.  
(Post-1) 
 But then once you get to a year, they just cut off the end, so you can’t 
see a trend. You know, I want to see this three or four years ago  
(Post-7)    
 I would love to have the data set to see how we’ve changed over the 
years  (Post-6) 
 it’s the ‘how do we go about sorting this out?’ really.  (Post-1) 
 You know it’s all very much just get on and do it and we’ll let you know 
once a year which I think you need a bit more feedback than that  
(Post-5) 
 I know this Medicine Management dashboard comes through to us, 
but even that, it’s not giving you all the, all the data that you kind of 
need um, to work out what your, where you should be changing.  
 I mean I just feel as though that’s almost like being marked.  I don’t 
know what that means.  (Post-3) 
 We’re supposed to have produced plans.  We’ll produce a report.  But 
this isn’t going to be a proper reflection, this is going to be tick-box 
stuff, isn’t it?  (Post-1) 
 
 
Table 6.5 Summary of GP Comments on Interactions with MMT 
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6.4.2 Impact of the Intervention 
 
6.4.2.1 On Prescribing Behaviour 
 
Virtually all GPs interviewed expressed their belief that the intervention had 
influenced their personal prescribing behaviour (and that of their colleagues).   
 
All believed that overall prescribing practice had changed within their practices as a 
result of the intervention.  Most were aware that prescribing changes had been 
demonstrated during the intervention, the main impact being on prescribing of 
NSAIDs.  External influences on prescribing in diabetes care were believed to have 
tempered the impact in T2DM although several GPs were aware of changes 
resulting from agreed actions within their practices. 
 
Interviewee comments on impact on prescribing are summarised in Table 6.6 
 
 





 Oh, absolutely, because like I said, you know, we’re now using um, 
naprosyn and ibuprofen and metformin a lot more.  (Post 6) 
 ...had shown that our prescribing had actually er, had improved...(Post-3) 
 I can only imagine it probably improved a bit, even if it was just tidying 
round the edges  (Post-11) 
 I do think probably our prescribing in diclofenac has significantly 
dropped...  (Post-9) 
 Yeah I think it showed it (diclofenac) was going down.  (Post-5) 
 And I think that has made a difference actually, especially to anti-
inflammatory prescribing  (Post-7) 
 It changed, I think overall it was very successful  (Post 8) 
 Yes, prescribing Ibuprofen, Naproxen quite a lot.  And gels.  We 
prescribe a lot of gels  (Post 2) 
 But really just I think what the best thing, we reduced the prescribing of 
non-steroidals...  (Post 10) 







 I never started people on Metformin like I do now.  (Post 6) 
 I’ve changed some of my prescribing, you know, um, based on that 
feedback  (Post 8) 
 Um, personally I prescribe less diclofenac.  (Post 9) 






 I don’t think we’d have had any of the discussions we had around 
prescribing had we not been prompted by the pharmacist.  (Post 4) 
 Having her expertise definitely I think helped with my individual 
prescribing decisions.  (Post 3) 
 
Table 6.6 Summary of GP Comments on Impact of Intervention on Prescribing 
 
The GPs believed that through the intervention, pharmacists had influenced their 
prescribing habits in a way, which traditional communications with MMT pharmacists 






6.4.2.2 GP Knowledge and Behaviour 
 
During interviews GPs recognised and reported that they had very limited 
pharmacology or therapeutics knowledge, topics which were apparently not included 
as key components of the medical training syllabus, the focus being on diagnostics.  
The intervention highlighted GPs lack of knowledge and understanding about 
medicines, (particularly new chemical entities with novel mechanisms of action) and 
the pharmacological basis of many interactions.  Without basic pharmacology 
knowledge, the GPs were often unable to assess the clinical implications of 
prescribing new drugs in practice themselves.  Many GPs believed that, their basic 
knowledge and education about drugs had increased because of the intervention, 
essentially filling a void in their knowledge.   
 
Most GPs believed that their knowledge and awareness of the evidence base had 
increased because of the intervention, and that their underlying knowledge and 
understanding of the rationale underpinning prescribing decision-making had 
improved.  The emphasis on promotion of research evidence was apparent 
throughout the visits.  GPs were confident that the evidence presented to them was 
robust and they believed that they were prescribing in a more evidence-based 
manner because of the intervention. 
 
6.4.2.3 Raised Awareness, Safety and Efficacy 
 
In addition to increased awareness of safety and efficacy issues, there also arose 
greater GP understanding, not only of the benefits that medication may bring but 
also of the harms, which may be caused by medication use in general.   
 
GPs realised that NSAIDs in particular were not the safest drugs to prescribe in the 
way that they had been and that patient safety and quantification of risk were key 
factors to be considered when prescribing NSAIDs.  Several GPs indicated that 
following the intervention, they were more likely to consider medication to be the 
cause of a serious adverse event (such as NSAID related MI) which previously they 
would not have been aware of or even considered attributing to the drug.   
 
GPs also became more aware of the evidence-base supporting holistic 
management of T2DM, prioritisation of interventions in reducing cardiovascular risk, 
key therapeutic interventions and prescribing recommendations.   
 
6.4.2.4 Wider Impact of the Intervention 
 
The intervention was also believed to have had wider-reaching impacts on 
secondary care prescribing and patient care.   
 
As well as informing decision-making, improved evidence-based knowledge 
apparently empowered GPs and they became more assured of their own prescribing 
decisions, and taking ownership of them.  GPs felt better informed and equipped 
with accurate knowledge with which they could confidently challenge consultant 
prescribing recommendations and inappropriate patient requests.  
 
GPs were able to convey relevant information underpinned by the evidence-base to 
patients when decision-making (in a manner patients could understand) and felt that 




There was a considerable benefit on patient safety perceived, particularly because 
of a reduction in inappropriate use of oral NSAIDs. GP Comments on the wider 
impact of Intervention are summarised in Table 6.7 
 
 







 Depending on your age, but the pharmacy, the therapeutics that you get as a 
doctor is very basic…  I mean I’ve never had any therapeutics training…  Since I 
qualified really, apart from what you pick up.  (Post-1) 
 I think therapeutics is actually something very badly taught to medical students 
and something that’s quite dear to my heart.  Up until this year ***** University 
weren’t even getting any pharmacology lectures   (Post-6) 
  I don’t have that diabetic experience to…  it’s, you know, new medications are 
coming onto the market, are you comfortable with managing this within General 
Practice?  (Post-9) 
 I’m sure we’re better and more evidence-based in those areas  (Post-5) 
 Yeah, it did. It definitely did come out that it was evidence-based.   (Post-7) 
 it probably renewed my vigour for finding alternative ways of treating people.  







 But then things like, you know if it has increased the risk of heart disease you 
wouldn’t necessarily have noticed that.  I mean the GI bleeds are a fairly obvious 
link but…  (Post 5) 
 It was really the Pharmacist stressing the cardiovascular, you know, effects and, 
so I think I’m much stricter with my Type 2 diabetics about getting that under 
control because I, you know, now that I’m aware that that is the prime, the 
number one thing to do really.  (Post-9) 
 I remember her ‘hand’.  That’s always stuck in my mind, so, you know, that was 
useful and actually sticking in my mind thinking, made me think, “What is the 







 When (the consultant) diabetologist came to present his community diabetes 
project it was all about HbA1c and I said, “Oh but the UK study showed that 
actually blood pressure’s more important and you haven’t even mentioned that, 
and that shut him up for a bit”.  (Post-11) 
 I feel much more confident within my practice of saying to a patient, for example, 
with the topical non-steroidals the evidence is this is as good as that.  (Post-9) 
 for instance having the evidence base, for instance an ACE-inhibitor probably 
would be more protective against a sartan, is a very useful thing to be able to say 
to a patient  (Post-11) 
 Of course with the diclofenac I mean it made us aware of the risks… …and we 
improved in a way, improved their care because we took a lot of patients off, or 
we are just prescribing naproxen if needed.  (Post 10) 
 
 




6.4.3 GP Reflection 
 
6.4.3.1 Reflection on Prescribing Practice 
 
A number of factors had undoubtedly contributed to collective behaviour change.  
The process involved in generating individual behaviour change was less clear. 
The GPs believed that changing individual ‘habitual’ prescribing practice was not 
necessarily an easy thing to do.  However, interactive discussions and the group 
dynamic apparently supported the individual in ‘breaking the habit’ and changing 
prescribing behaviour.  
 it’s because there’s a habit you have to break  (Post-7) 
 
The GPs frequently referred to reflection as being part of the process involved in 
assimilating a complex array of facts and information resulting from intervention 
visits.  They clearly reflected on their personal prescribing behaviour whilst 
collectively exploring justifications and motivations for prescribing change.   
 
The opportunity to reflect on prescribing practice, consider options and ultimately to 
agree and take action collectively, was regarded as a more rigorous approach in 




Several GPs indicated that following personal reflection, they had ‘taken on board’ 
or internalised key messages and consequently had changed their prescribing 
behaviour.  Individual GPs indicated that the intervention process had resulted in 
incorporation of evidence-based information into their personal prescribing 
decisions.  Several GPs believed that they had become ‘better prescribers’ as a 
consequence. 
 
GPs interactions with each other appeared to reinforce reflection, collective 
decision-making, and actions agreed by all, which may ultimately have created a 










 Sitting around a table and actually, you know, dissecting it like that, you 
know, it makes us reflect on our practice so it has been useful.  (Post 8) 
 as a consequence, you can be convinced or otherwise and therefore, we can 
make much rigorous action as a team to take it forward  (Post-7) 
 
Reflection 




 But you know, this study allowed me to be reflective about it (EBM) and think 
well these are, this is the evidence base and maybe I should, you know, take 
that seriously and have a little look at that and, and try re-prescribing in a 
different way.  (Post-9) 
 Yes, I think it has because it’s made us... all just a little bit more thoughtful, in 
terms of our prescribing decisions.  (Post-1) 
 
 






6.4.3.3 Reflection about EBM 
 
In addition to raising awareness of the evidence relating to NSAIDs and T2DM, the 
intervention also apparently promoted some self-reflection on the principles of EBM 
and incorporation of evidence in decision-making in general.  Increased awareness 
about availability of research evidence to inform prescribing decision-making 
encouraged several GPs to contemplate the importance of considering ‘all the facts’ 
when making individual prescribing decisions rather than prescribing routinely or 
based on habit. 
 




6.4.4 Benefits of the Intervention Approach  
 
There were several factors inherent in the intervention model which GPs found 
beneficial in support provision of prescribing support. 
 
6.4.4.1 Independent Review 
 
Having an ‘’external’ person with the skills and expertise to provide independent 
review and interpretation of practice prescribing data who could also facilitate and 
support the practice in implementing change was also regarded as an important 
factor.  GPs appreciated that the intervention was tailored to the practice 
requirements and that the pharmacist was instrumental in evaluating their needs 
and providing relevant support.   
 
6.4.4.2 Face-to-Face Meetings 
 
Face-to-face meetings were regarded as a more effective means of communication 
than traditional interactions with MMT.   
 
A dedicated forum, facilitated by a ‘specialist’ in prescribing issues enabled GPs and 
pharmacists to participate in regular dialogues about prescribing practice which GPs 
would not normally have considered themselves and otherwise simply would not 
have happened.   
 I don’t think we’d have had any of the discussions we had around prescribing had we not been 
prompted by the Pharmacist  (Post-4) 
 
The GPs were able to explore prescribing issues in more depth and complexity than 
they would have done themselves or during APMs, which they believed added 
another dimension to their knowledge and understanding of issues and the topics 
discussed.  The interactive nature of the meetings was also considered important in 
aiding the learning process and retention of information. The group dynamic was 
fundamental to the process.  
 
Practice visits enabled clinically orientated discussions.  GPs clearly valued the 
opportunity to ask, and have questions answered at the time by someone with the 
appropriate knowledge.  GPs acknowledged that the pharmacists also possessed 
skills (which they did not), in accessing further information and relevant evidence, 
which also relieved GPs of having to seek information to answer clinical questions 
themselves.   
 
6.4.4.3 Prescribing - Data 
 
Benchmarking data enabled GPs to compare their prescribing with other practices, 
identify differences and to consider where to focus discussions on prescribing 
issues.  Individual practice prescribing data raised awareness of GP prescribing, 
providing a true indication of prescribing within the practice.  Many GPs discovered 
that they were not prescribing as they thought, either individually or as a group.  
Much greater understanding of practice GP prescribing habits and decisions 








6.4.4.4 Ongoing Feedback  
 
Ongoing feedback, particularly regular trend data was considered crucial in enabling 
the GPs (and pharmacists), to target efforts at improving prescribing practice, to 
monitor against agreed actions and to demonstrate prescribing change over time.  
Both ‘positive’ and ‘negative’ feedback was considered useful as it was either 
motivational or enabled them to target further action. 
 
6.4.4.5 Supporting Information 
 
The GPs noted that clear and relevant presentation materials (referenced) were 
used in delivering key evidence-based messages.  They observed that there was a 
breadth and depth of information incorporated in the presentation materials (detail 
aids), which had probably involved considerable effort to compile. 
 
Several GPs received visit reports and read the pre-appraised evidence summaries 
provided by the pharmacists (e.g. MeReC).  These were regarded as very useful 
summaries of the evidence-base underpinning the topics discussed. 
 
A selection of interviewee comments on the benefits of the intervention to them are 
summarised in Table 6.9 
 
6.4.4.6 A Different Experience for GPs 
 
The GP experience of the intervention was considerably different from traditional 
communications with members of the MMT.  Provision of prescribing advice as 
delivered through the intervention was a form of prescribing support which none of 
the GPs had previously experienced. 
 Well, we didn’t have anything like that before.  (Post-4) 
 Well we haven’t had any prescribing advisors in before, not in this way  (Post-13) 
 As I said, that we felt more supported  (Post-10) 
 
Several GPs indicated that they believed they were actually being convinced to 
change their prescribing practice rather than being told what to prescribe.  Overall, 
intervention visits were regarded as a positive experience.   










 And, an outside person can, if they get you together, you can alter 
how you do things as a practice really.  (Post-1) 
 having a Pharmacist really look at our prescribing and the way it is 






 It’s a face-to-face meeting, so that, in itself, is a very valuable thing for 
all people.  We work so much better in that situation rather than just 
being sent an e-mail  (Post-7) 
 I’ll just come back to the um, sort of the way it was interactive.  That’s 
what was different  (Post-3) 
 I don’t think we’d have had any of the discussions we had around 
prescribing had we not been prompted by the Pharmacist  (Post-4) 
 And always when you are at a meeting and you chat things over you 
are more likely to retain it than sending me an e-mail saying please 
use x,y,z.  So, it was useful  (Pre-7) 
 I think there is enormous value of having a meeting every so often, to 
get all the GPs and prescribers in a room and talking  (Post-11) 
 But it was good to kind of…’the Pharmacist ‘being there, we could just 
ask you questions and it was solved just there and then.  (Post 13)   
 It was great that ‘Pharmacist’ came in face-to-face and brought the 
evidence that we asked and no question was out of limits really.Post6 
 We had an opportunity to ask her areas that we were uncertain about 
and if she didn’t know, she went away and researched and came 
back with some really good answers, which was fantastic, um, that 
was really helpful actually.  (Post-7) 
 I mean it was, of course it’s easier for us if someone comes and talks 
about it and presents it, as trying to get the information on your own, 
internet.  (Post-10) 
 Therefore, we can make much rigorous action as a team to take it 
forward.  So that’s a definite, definite difference  (Post-7) 
 Yeah, I think, yeah, this is much more useful now than PQP. (Post-7) 
 
Prescribing - Data 
 
 
 this is you know how you’re doing compared to other Practices which 
is always an incentive to do more when you realise when you’re one 
of the worst in the patch at something   (Post-5) 
 Well interesting with the NSAIDs, we weren’t doing what I thought we 
were doing as much as we said we were doing.  (Post-1) 
 “Oh, no, no, we always use Naprosyn” and then he said “Well, 
actually, you know, you aren’t”  (Post-1) 
 the thing about being in a group of course is that people talk about 
their own prescribing habits and you start to understand how other 
people are prescribing and not just you as an individual, the way 
things are, are sort of done.  (Post-3) 
 So there was the data that was also quite important to know how we 
are doing because you can see, compare yourself with the other 
peers  (Post-10) 
 
Ongoing Feedback  
 
 
 It was useful when it was positive because we felt as though you were 
all doing well, you know.  It’s that pat on the back thing really  (Post-5) 
 she provided, graphs and stuff, we actually saw the impact of the 
work that she was doing within the practice.   (Post-9) 
 She went away and thought about what we needed and came back 






 she’s got a lot of information at her fingertips  (Post-7) 
 There was a very good hand-out about diabetes that he gave us.  
Yeah, that was excellent  (Post-1) 
 I think those things were useful ‘cause they were like a summary I 
think, of all the information you’d found  (Post-13)  




6.4.5 Pharmacist Support 
 
The GPs described visits as supportive and conciliatory rather than being directional 
or prescriptive.  Discussions facilitated by the pharmacists were regarded as 
informative and evidence-based, compared with traditional interactions with MMT.  
Discussions were also more clinical, which GPs felt was relevant to their actual 
prescribing function rather than focusing on cost-reduction. 
 
Meeting format was relatively informal.  GPs found the approach more personal, and 
there was reciprocal communication between them and the pharmacist who was 
helping them achieve prescribing objectives.  The pharmacists were all regarded as 
being clinically aware and, providing reasoned arguments, whilst also being 
prepared to listen and acknowledge GP concerns, which were taken seriously. 
 
The GPs felt that communications with them were on a more professional level and 
that they were working in partnership with the pharmacists rather than MMT 
adopting a ‘policing role' as in traditional interactions. 
 
Several GPs acknowledged that it had taken the pharmacist to make them realise 
and persuade them that change was required.  The pharmacist had supported and 





6.4.5.1 Pharmacists Delivering the Intervention 
 
The GPs realised that the pharmacists delivering the intervention were acting in a 
very different capacity from other MMT pharmacists with whom they had previously 
interacted.  They were perceived to be relatively senior, having influence in the 
wider medical community, and with means of instigating change at higher levels and 
across the primary/secondary care interface if necessary. 
 
The pharmacist was considered fundamental to the success and impact of the 
intervention, not just as a conduit of knowledge about drugs and therapeutics but 
also as a skilled facilitator and guide, helping the GPs to achieve their shared goals.  
 
The GPs recognised that the pharmacist had considerable expertise and knowledge 
(which they lacked) and the pharmacist became regarded as a trusted source and 
vector of reliable information, ultimately gaining considerable respect from the GPs.  
Many practices developed established relationships with their pharmacist, which 
were sustained following completion of the study.  Overall, GPs were unanimous 
that the individual delivering the intervention should be a pharmacist essentially 
because of their specialist knowledge-base which is fundamental to their expertise.   
 
Virtually all feedback regarding the pharmacists and their interactions with the GPs 
was positive and complimentary, in terms of their knowledge, skills and other 
attributes.  The pharmacists were perceived as acting with professionalism and 
dignity and were trusted in their interactions with the GPs.  
 
Although the pharmacists challenged GP prescribing practices, the outcome was a 
positive experience for GPs in terms of interactions with the pharmacists and the 
resulting impact on their prescribing behaviour. 
 
The abilities and competencies demonstrated by the pharmacists inherent in the 
intervention model are multifaceted, requiring a combination of expert knowledge, 
which is both clinical and contextual in terms of the setting in primary care.  The 
pharmacists clearly demonstrated excellent communication and facilitation skills with 
abilities to engage with clinicians in practice.  Relevant experience, expertise and 
confidence were necessary to underpin and ensure success of the intervention.  
 
A selection of interviewee comments relating to the intervention pharmacists are 












 You know, um, it was a very give and take situation and, and she was, 
you know, prepared to give you the evidence and explain to you why 
she thought these things were better um, but also listen to you when 
you expressed some of your concerns about it.  (Post-9) 
 It was much better and you felt it was more on a professional level 
rather than you’re the underdog being told what to do, does that make 
sense?  Which I know is probably a bit pathetic as GP’s but…(Post-6) 
 I think that’s absolutely fine and most of us can take it on the chin 
thinking, “Oh God, what an idiot, have I been doing that?” you know, so, 
so yeah, it’s true.  (Post-1) 
 I’ve no qualms therefore doing whatever I’m told, or working with them 






 It’s not something you can do sort of fresh out of Pharmacy 
School…and you know it takes quite an experienced person I think to be 
able to facilitate it and to help you.  (Post-5) 
 I think, from some of the other doctors, there is a realisation that, 
actually, you know these people have got something useful to say.  
(Post-7) 
 And I think because, because we were, because the partners were 
obviously hearing all this from the pharmacist they were really open to it.  






 I think having somebody there giving you that guidance it’s fantastically 
helpful.   (Post-9) 
 I found ‘the Pharmacist’ to be a very competent, helpful adviser actually  
(Post-6) 
 You know, they haven’t got all the answers, but, they can stimulate 
discussion.  They, they can help us take forward what we’re all trying to 
achieve, which is sensible prescribing.  And they’re not necessarily um, 
the enemy just beating you with a stick.  (Post-7) 
 Well they know what they’re talking about, yeah.  (Post-1) 
 And actually ‘the Pharmacist’ was great, she’s very good at what she 
did.  (Post-6)     
 Oh, she was excellent, and she was very experienced, very 
knowledgeable.  (Post-7) 
 I mean our Pharmacist was fantastic and we, you know, I think as I e-
mailed to you.  (Post-9) 
 
 
Table 6.10 Summary of GP Comments on Interactions with Intervention 






6.4.6 Value of the Intervention 
 
Overall the GPs were extremely positive about the intervention and believed that it 
was of great value to them in supporting better prescribing behaviour. 
 
All of the GPs interviewed post-intervention were receptive (if not enthusiastic) to the 
idea that intervention approach be expanded, both in terms of therapeutic areas and 
geographically.  Many GPs believed that the approach, if implemented more widely 
would add further value by promoting better prescribing practice throughout the 
PCT. (Comments summarised in Table 6.11) 
 
 
Value and Wider Implementation of the Intervention - GP Comments 
 
Value of the 
Intervention 
 
 No, I think the intervention was excellent.  (Post-6) 
 And overall I think it was quite positive, yes, I found it quite useful.  (Post-8) 
 Some people said it was really excellent, it was really useful.  I definitely 
thought it was useful.  (Post-7) 
 You know. It’s been of benefit, you know, I view any kind of education 






 I think there’s an important role personally for Medicines Management to 
come and do that and would be valuable.  (Post-1) 
 I think there’s no doubt it would be very useful.  Having a Pharmacist really 
look at our prescribing and the way it is actually matching up with the 
guidelines is very useful  (Post-8) 
 It is a service that I think, that would be good to continue, and I would have 
hoped that had shown enough benefits within the practice for it to be 
effective.  (Post-9) 
 
 
Table 6.11 Summary of GP Comments on Value and Wider Implementation of the 
        Intervention 
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The intervention model was regarded as an appropriate if not ideal format and 
structure to discuss prescribing issues.  GPs identified several elements of the 
intervention, which they had not previously experienced which they found 
particularly useful in supporting their prescribing objectives. 
 
Allocation of a dedicated Prescribing Adviser with relevant skills and knowledge 
enabling GPs to establish relationships with one key individual was deemed 
important in providing regular and consistent prescribing support.   
 
GPs envisaged regular meetings (between quarterly and annually, depending on 
practice needs) focusing on several aspects of prescribing which had been identified 
as requiring pharmacists input.  Provision of evidence-based prescribing information 
was also regarded as a key component for the GPs.  Regular meetings were 
considered important to reinforce messages, monitor prescribing activity and 
evaluate the impact of agreed actions. 
 “these are the things that I’m thinking about, then you would do a meeting and you’d have all the 
evidence, all that sort of thing ready, and then three months later, you come back  (Post-6) 
 You’d sit down at the beginning of the year, you’d say these are our areas of prescribing that we 
need to focus on and then you’d have some subsequent meetings that would drill down into those 
areas a bit more.  I like the idea of at least once a year just whizzing through a whole BNF as well 
just so everybody’s aware of what’s going on.  (Post-3) 
 
Provision of regular trend data was regarded as crucial in informing GP prescribing 
practice, to target efforts at improvement and to demonstrate prescribing change. 
Attendance by all practice GPs where possible (and other HCPs if relevant) was 
considered important to provide the opportunity to engage with and deliver key 
messages to all.  
 





6.4.7 Potential Barriers to Implementation 
 
The main potential barrier to successful implementation of the intervention identified 
by GPs was lack of engagement either by individual GPs or by complete practices.   
 
Lack of attendance by practice GPs (and other HCPs if relevant), for whatever 
reason was also believed to constitute a potential barrier.  GPs believed that 
attendance by all practice GPs where possible would provide the opportunity to 
engage and to deliver the key messages to all.  
 
Several potential ‘enhancements’ in provision of prescribing support were also 
identified during interviews and are considered further in the main Discussion.  
(Summarised in Table 6.12)   
 
 
Suggested Gaps in MMT Support for GPs 
Evidence 
Updates 
 Provision of regular pre-appraised evidence summaries 
highlighting key messages (maximum A4 sheet). 





 Address lack of GP knowledge.  Provision of  tailored sessions   
 Promote evidence awareness underpinning prescribing 
recommendations.  Improve clarity and understanding 
 Ad hoc educational support depending on practice/PCT  needs 
Trusted 
Websites  
 Develop list of trusted evidence-based resources to guide GPs 
to evidence-based sources of information on prescribing. 
Up-to-date 
MMT website  
 
 Post information on prescribing topics and recommendations.   
 Provide simple summaries with links to more in depth 
information.   
Telephone 
advice line  
 Capitalise on prescribing adviser skills in accessing and 
evaluating evidence and answers to clinical questions 
Prescribing 
Lead 
 Develop practice GP Prescribing Lead Job Description and 
Role Specification 
 
Table 6.12 Summary of Suggested Gaps in Provision of MMT Services to Support 






6.4.8 Wider Implementation 
 
Several GPs indicated that participation in the study had provided insight and an 
opportunity to consider how they might work with MMT in the future.  GPs realised 
that there was an untapped resource and expertise available within MMT which was 
not routinely being accessed to support their prescribing activities or promote 
evidence-based practice.   
 
The intervention had raised awareness of the support or ‘services’ that MMT could 
offer which had not previously been routinely provided.  Indications were that GPs 
attitudes to MMT had changed as a consequence of the intervention and that rather 
than being perceived as a barrier, MMT was regarded as a resource which could be 
accessed for support.   
 I think, as I said, I think it’s perhaps, it’s given us an idea as to how we can um, interact as a 
practice with Medicines Management in the future.  Er hopefully perhaps more fruitfully.  (Post-3) 
 I just think people are not seeing them as, er as an obstacle, as a difficulty.  They’re trying to use 
them you know.  Other partners and doctors have realised that there is someone they can call on 
for help.  (Post-7) 
 
Affordability and resources, particularly in the forthcoming era of primary care 
commissioning were considered to be factors which should be considered if such a 
‘service’ were commissioned through MMT and which may also impact on the 
frequency of meetings. It was also thought that results from the study might inform 




The GP experience of the intervention was different from traditional interactions with 
MMT in that it was regarded as supportive in helping them to achieve practice 
prescribing objectives collectively.  The approach was educational and GPs found 
several facets and elements inherent in the intervention model beneficial in 
supporting their learning needs around evidence-based prescribing. 
 
The intervention highlighted GPs lack of knowledge and understanding about 
medicines.  Virtually all expressed their belief that the intervention had influenced 
their personal prescribing behaviour and that, their basic knowledge and education 
about drugs had increased.  Importantly there became an increased awareness of 
safety and efficacy issues related to medicines use.  
 
The intervention also apparently promoted self-reflection on the principles of EBM 
and incorporation of evidence into prescribing decision-making.   
 
Overall GPs were extremely positive about the intervention which they believed was 
effective in influencing their prescribing behaviour.  It was believed to be valuable to 
them and ultimately of benefit to the patient. 
 
Several aspects of this review are explored further in the discussion section of 












The main tenet of this study concerns getting research evidence into practice 
through an intervention aimed at influencing GP prescribing behaviour.  It was 
designed primarily to demonstrate an impact on prescribing outcomes.  It was also 
intended to establish whether there were any effects on patient outcomes, as 
evidence is currently lacking for both. The qualitative evaluation explored GP 
perceptions of EBM and the impact of the intervention from their perspective. 
 
This chapter provides a summary and discussion of key study findings from both 
quantitative and qualitative evaluations.  It considers reasons why the intervention 
was successful with reference to the current literature and known strategies 
(including several conceptual models) on getting research findings into practice.   
 
This section also reflects on study strengths and limitations and considers how the 
intervention might be implemented more widely. 
 
 
7.2 Key Findings 
 
This study has demonstrated that implementation of the intervention using a 
multifaceted approach consisting of strategies which are known to work in changing 
healthcare professional behaviour has resulted in a change in GP prescribing 
practice and promoted the uptake of research evidence into practice. 
 
7.2.1 Quantitative Evaluation 
 
7.2.1.1 Prescribing Data – Outcome Measures 
 
The most important finding based on quantitative evaluation of prescribing data 
demonstrated statistically significant differences in prescribing and achievement of 
primary outcome measures (defined prospectively and which determined the power 
of the study) aimed at improving uptake of evidence-based prescribing by GPs in 
the intervention group compared with control.  This finding provides evidence for the 
impact of primary care pharmacists in promoting the uptake of research evidence 




Results clearly demonstrated statistically significant differences between 
intervention and control groups in the prescribing of NSAIDs.   
 
A statistically significant difference in the primary outcome measure of a reduction in 
diclofenac (p<0.05, Mann Whitney U test) was demonstrated.  Additionally, there 
was a statistically significant reduction in prescribing of COX-2 Inhibitors (p<0.001) 
and a corresponding and statistically significant increase in the prescribing of 
naproxen and ibuprofen combined (p<0.05).  Effect sizes for each indicator were 
either medium or large.  Naproxen and ibuprofen were recommended alternatives to 
diclofenac and COX-2 Inhibitors.  However, naproxen appears to have been the 




Individual and aggregated practice trend data graphs also demonstrate that there 
was a widespread reduction in the prescribing of diclofenac in the majority of 
intervention practices with a corresponding increase in naproxen. 
 
Differences in the prescribing of total NSAIDs almost reached statistical significance 
(p=0.057, Mann-Whitney U test).  The overall results, (from ePACT, individual 
practice data and GP feedback) also indicate a general downward trend in total 




Statistically significant differences for the primary and secondary outcome 
prescribing measures for T2DM prescribing (increase in metformin and reduction in 
glitazones respectively) from ePACT data were not demonstrated.    
 
One factor which affected glitazone prescribing and potentially the study results was 
the withdrawal of one of only two licensed glitazones (rosiglitazone) during the 
intervention period, for safety reasons.  This event was obviously outside control of 
the study and would have necessitated review of individual patients and 
consideration of alternative therapeutic options which ultimately may have 
influenced prescribing patterns across the PCT.  
 
Lack of major differences in prescribing of oral medications for T2DM may also 
reflect the long term nature of the condition and/or external influences on prescribing 
in T2DM such as diabetes specialist nurse and hospital prescribing. 
 
Prescribing trend data presented in graph format also reflect results from statistical 
analysis of prescribing data. 
 
 
7.2.1.2 Patient Related Outcome Measures 
 
The results from the patient-oriented outcomes data also demonstrated statistically 
significant differences between intervention and benchmark groups.  This finding 
challenges one of the main criticisms of EBM, which is that evidence is lacking to 
demonstrate that incorporation of evidence-based research into clinical decision-
making improves outcomes for patients.8,25,38  
 
Although a statistically significant difference in prescribing of metformin was not 
detected from ePACT data, a statistically significant difference in the proportion of 
patients with T2DM prescribed metformin in the intervention group compared with 
benchmark group practices was detected from practice data (p<0.05), indicating that 
metformin prescribing had increased, (also reported by several GPs during 
interviews).  This result may have reflected more appropriate prescribing through 
initiation of metformin in newly diagnosed patients and/or possibly in previously 
diagnosed patients not already on Metformin, resulting in a greater proportion of 
patients being prescribed metformin overall.  This trend is also reflected in individual 
practice data where prescribing of metformin increased in the majority of 
intervention practices. 
 
There was also a statistically significant difference in the proportion of patients with 
T2DM prescribed a Renin-Angiotensin drug (p<0.05), an important (evidence-
based) clinical intervention for patients with microalbuminuria.  This trend was also 
reflected in individual practice data where there was a relative increase in the 
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prescribing of RAS drugs in the majority of intervention practices and relative 
decrease in benchmark practices with a tendency to increased use of ACE-I 
compared with A-II-A in intervention practices.  Importantly, higher proportions of 
patients with microalbuminuria were also achieving tighter blood pressure targets in 
intervention group practices compared with benchmark practices.   
 
These results therefore indicate that GPs had internalised key messages about 
holistic management of T2DM and were focusing on aspects of care which impact 
on patient outcomes, in this case, conserving renal function.  The results also signify 
that clinical decision-making in this situation was underpinned by the evidence-base. 
 
Not only were statistically significant differences in prescribing in patients with T2DM 
detected from practice data, importantly there were also statistically significant 
differences in proportions of patients achieving, HbA1c targets ≤7.5% (p<0.01) and 
≤9.0% (p<0.05) in the intervention group compared with benchmark.  Again 
individual practice data also indicates clear improvement compared with benchmark 
practices. 
 
Ironically, the key messages delivered by pharmacists, intended to improve 
cardiovascular risk focussed on management of blood pressure in particular rather 
than intensive management of blood glucose.  No statistically significant differences 
were detected in cardiovascular parameters although the practice data suggested 
that there was a tendency towards better management of blood pressure in 
individual practices compared with benchmark practices, particularly in patients with 
microalbuminuria.   
  
Nevertheless, HbA1c is the key clinical outcome measure used to monitor disease 
progression in T2DM as well as treatment efficacy and the results indicate that this 
aspect of care was being managed better and in line with evidence-based treatment 
recommendations.    
 
Interestingly, there were no statistically significant differences detected between 
intervention and benchmark practices for NSAIDs patient-orientated outcome 
indicators (i.e. clinical risk factors).  The main reason is believed to relate to small 
sample sizes in data sub-sets for patients receiving NSAID medication compared for 
example with patients with T2DM.   
 
The proportion of patients receiving NSAIDs in most practices is generally lower 
than the proportion of patients diagnosed with T2DM (approximately half).  NSAID 
prescribing also reflects acute as well as repeat prescriptions whereas most 
prescribing in T2DM consists of several repeat prescriptions for what is a long term 
condition.  Therefore, the overall volume of NSAID prescribing is likely to be lower 
than prescribing for patients in T2DM and differences in patient sub-sets harder to 
detect from practice data. 
 
Conversely, NSAID patient-orientated prescribing outcome indicators do suggest an 
increase in prescribing of PPIs and a reduction in prescribing of concomitant aspirin 









7.2.2 Qualitative Evaluation 
 
7.2.2.1 Pre-Intervention Interviews 
 
The main finding arising from the exploration of perceptions, attitudes and beliefs 
regarding EBM suggests that the majority of GPs consider application of EBM as a 
model of practice to be applied in the clinical encounter, equated with ‘best practice’ 
in clinical decision-making.  Results also indicated that despite enthusiasm to 
practice as evidence-based practitioners, GPs do not generally possess the skills to 
access or evaluate the evidence to inform their clinical decision-making and that 
RCGP curriculum competencies, aimed at ensuring evidence-based decision-
making in everyday practice are not routinely applied or consistently demonstrated 
by GPs. 
 
7.2.2.2 Post-Intervention Interviews 
 
The main findings arising from post-intervention semi-structured interviews with GPs 
were that the intervention educated and supported GPs in improving prescribing 
practice in line with the EBM paradigm.   GP knowledge and understanding of the 
evidence-base underpinning prescribing decisions increased and they became more 
confident in their prescribing decisions.  Virtually all believed that the intervention 
had influenced their personal prescribing behaviour and additionally, promoted self-
reflection on the principles of EBM and incorporation of evidence into prescribing 
decision-making.  Overall GPs welcomed the intervention and were keen to receive 





















7.3 Translating Research Evidence into Practice 
 
Until recently, the spread of evidence was regarded as a linear process involving 
changes in individual clinicians behaviour in line with evidence-based 
guidelines.214,227  However the notion that research packaged as guidelines and the 
assumption it will be automatically used is now outdated.221  Evidence indicates that 
getting research into practice involves significant and planned change involving 
individuals, teams, organisations and systems.214,221,227  
 
One of the more recent advances in EBM is the emergence of Implementation 
Science, a movement dedicated to the study of methods to promote the integration 
of research findings and evidence into healthcare policy and practice (or knowledge 
translation).226,227,228,229  Various models have been used to reflect translation of 
research into practice.  
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7.3.1 Evaluating Implementation of the Intervention 
 
One such model, The PARiHS framework (Promoting Action in Research 
Implementation in Health Services) is a conceptual framework considered useful for 
researchers in framing their research or knowledge translation endeavours.227,230  
 
The framework proposes that successful research implementation (SI) is a function 
(f) of the relation between the nature of the evidence (E), the context in which the 
change is implemented (C) and the mechanism by which the change is facilitated 
(F), expressed as: SI = f(E,C,F).  
 
Each element is positioned on a low to high (or weak to strong) continuum.  Most 
successful implementation occurs when evidence is scientifically robust and 
matches professional consensus and patient preferences (high evidence), the 
context is receptive to change with sympathetic cultures, strong leadership and 
appropriate monitoring and feedback systems (high context) and where there is 
appropriate facilitation of change, with input from skilled facilitators.227,231  
Key features of the framework are summarised in Table 7.1. 
 
 
Main Features and Assumptions of the PARiHS Framework 
 
 Evidence comprises codified and non-codified sources of knowledge, including 
research evidence, patient factors, clinical expertise 
 Melding and implementing evidence in practice requires negotiation, developing 
shared understanding about benefits, disbenefits, risk and advantages of the 
new over the old 
 Some contexts are more conducive to successful implementation of evidence in 
practice than others.  These include contexts that have transformational leaders 
appropriate monitoring, evaluative and feedback mechanisms. 
 There is an emphasis on the need for appropriate facilitation to improve the 
likelihood of success.  The type of facilitation, the role and skill of the facilitator 
that is required is determined by the state of preparedness of the team in terms 
of acceptance and understanding of the evidence, receptivity of their place of 
work or context in terms of  resources, culture and values, leadership style and 
evaluation activity.  Facilitators work with individuals and teams to enhance the 
process of implementation. 
 
 
Table 7.1 Main Features and Assumptions of the PARiHS Framework (Kitson)227 
 
The framework may be applied retrospectively as here to assess interactions 
between evidence, context and facilitation in implementation settings.  The 
(therapeutics-related) evidence presented to the GPs through the intervention 
constituted high quality research, critically appraised through robust and transparent 
methodologies, thus fulfilling the criteria for ‘strong’ evidence.  With respect to 
Medicines Management, GPs were dissatisfied with the existing culture (suggesting 
weak context) although were ultimately receptive to change moving to strong 
context.   
 









                 
F1 = facilitation method for transforming weak context and strong evidence to highly receptive context 
F2 = facilitation method to manage weak context and weak evidence situation – (most challenging) 




Figure 7.1 The PARiHS Diagnostic Evaluation Grid. (Kitson)227 
 
 
The study results demonstrate successful implementation of the intervention.  When 
evaluated against the PARiHS Framework, each individual element (evidence, 
context, facilitation) achieves a high rating.  Monitoring and feedback systems 
(prescribing trends) were most appropriate for the intervention intended to influence 
prescribing (therefore also ‘high context’).  When combined, the overarching output 
suggests successful implementation against all criteria and, according to the 
framework indicates an ideal situation for implementation of evidence into practice.  
Importantly application of the model supports study results in that the means of 





Facilitation, the process of enabling (making easier) the implementation of evidence 
into practice is central to the PARiHS framework.227,231  It was also central to delivery 
of the intervention. 
 








Features of Facilitation – The PARiHS Framework 
 
 
 Facilitation is a process that depends on the person (the facilitator) carrying out 
the role with the appropriate skills, personal attributes and knowledge 
 The purpose of facilitation varies from providing help and support to achieve a 
goal to  enabling individuals and teams to analyse, reflect, and change their own 
behaviours and ways of working 
 A ‘facilitation continuum’ has been described, which distinguishes between a 
‘doing for others’ role (more discrete, practical and task driven) on one side to an 
‘enabling and empowering’ role which is more developmental, seeking to 
mentor, guide and support staff within the system to take control of their own 
learning and change processes (holistic).  
 Facilitation skills are developed through experiential learning, and more recently 
through the acquisition of key facilitation competencies 
 Facilitation as a discrete intervention has been described in the practice 
development movement in nursing and in the quality improvement literature 
 
 
Table 7.2 Features of Facilitation within the PARiHS Framework227  
 
Facilitators require appropriate skills and knowledge to help individuals, teams and 
organisations apply evidence in practice, and to make sense of the evidence being 
implemented in the context in which the change is occurring.  Depending on the 
level of facilitation required, (from task-based to holistic change), skills and attributes 
required of facilitators may vary.231  Where implementation encompasses 
counselling and experiential learning, the facilitator’s role involves enabling 
development of reflective learning by helping to identify learner needs, guiding group 
processes, encouraging critical thinking and assessing achievement of learning 
goals.231   
 
Within the intervention, the prescribing advisers were clearly fulfilling a complex, 
multifaceted role as part of a holistic process aimed at changing prescribing 
behaviour and which, as confirmed in GP feedback, undoubtedly encouraged 
reflective learning and critical thinking by the GPs.  The pharmacists also guided 
group interactions and processes, and supported and assessed achievement of 
agreed actions and (prescribing) goals. 
 
Skilled facilitators may adjust their role and style depending on circumstances. 
A facilitator who elicits respect, is credible and empathic with a personal style 
characterised by flexibility and consistence also gives strong support for 
implementation.11,231  GP feedback indicated that the pharmacists demonstrated all 
of these attributes during their interactions with them.  
 
Within the Framework, ‘high’ facilitation (or strong support for implementation) 
relates to the presence of appropriate facilitation.  Study results and GP feedback 
indicate that the pharmacists (with underpinning therapeutics knowledge and 
expertise), demonstrated well-developed facilitation skills in influencing prescribing 
behaviour and encouraging the adoption of evidence in practice, therefore 
supporting a ‘high facilitation’ score within the Framework. 
 
The facilitator role, is fundamental to the success of implementation of the 
intervention.  Not only do the study results suggest that the intervention as facilitated 
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by the pharmacists was successful, evaluation against the PARiHS framework also 
infers that they were operating at ‘high’ level and as effective facilitators in 
implementing evidence in practice. 
 
 
7.3.3 Stages in the Intervention Process  
 
Translation of research evidence into practice encompasses three major stages.229  
 
 Knowledge creation and distillation 
 Diffusion and dissemination 
 Adoption, implementation and institutionalisation 
 
In addition to deploying facilitation skills, preparation and delivery of the intervention 
to promote uptake of evidence-based prescribing by GPs, involved appropriately 














































Translation of Evidence into Practice - Stages in the Intervention Process 
 
Knowledge creation and distillation 
 
 Utilising mainly pre-synthesised evidence-based information accessed from 
reliable sources.   
 Key evidence-based messages further ‘repackaged’ for presentation to GPs as 
detail aids.   
 Prescribing data, tailored to each practice for monitoring and feedback prepared 
on a regular basis.   
 A ‘library’ of relevant evidence-based supplementary materials collated centrally 
for both GPs and pharmacists use.   
 All of these activities were co-ordinated centrally by the CI. 
 
 
Diffusion and Dissemination 
 
 Primary care pharmacists delivering and facilitating delivery of the multifaceted 
intervention through practice visits.   
 Pharmacists acting in an educative role based on an academic detailing 
approach.   
 Dependent on pharmacists understanding the evidence and its relevance in the 
context of clinical decision-making and GP prescribing.   
 Dependent on pharmacists ability to manage a complex array of information 
which they were able to convey to GPs in promoting uptake of best available 
evidence into decision-making. 
 
 
Adoption, Implementation and Institutionalisation 
 
 Provision of dedicated and tailored support to each practice by the allocated 
pharmacists.   
 Pharmacist required appropriate facilitation skills  
 Resulted in  
o collective decision-making and  
o commitment to agreed actions by GPs  
o agreed actions contributing to impact of the intervention.    
 
 





7.3.4  The Intervention as an Innovation 
 
The term ‘Innovation’ may be used to encompass a set of activities and behaviours 
aimed at translating research findings into practice.214,232  
  
An extensive literature review of the uptake of research innovations defines the 
three principle means of spreading research findings in practice as diffusion, 
dissemination and implementation.  Diffusion and implementation may be regarded 
as being situated at opposite ends of a continuum with dissemination being 
positioned somewhere between the two.214  
 ‘Diffusion’ is passive, unpredictable, uncertain, in effect, ‘letting it happen’.  
 ‘Implementation’ is scientific, orderly, planned, properly managed and requires 
active efforts to ‘make it happen’ by mainstreaming or embedding innovation 
within organisational systems and structures.  Its influence is top down and 
takes much effort at a higher level to bring about. 
 ‘Dissemination’ involves ‘helping it happen’ using active and planned efforts to 
persuade target groups to adopt the innovation.  It is negotiated, influenced and 
enabled. 
 
Pre-intervention feedback from GPs indicated that they primarily regarded uptake of 
evidence in practice occurring through either Diffusion or Implementation.  However 
the intervention tested in this project, clearly falls into the category of ‘Dissemination’ 
or ‘helping it happen’.  By raising awareness of evidence-based prescribing, and by 
facilitating and supporting change, GPs were persuaded (and convinced) of the 
evidence to inform decision-making and consequently the benefits both in terms of 
its application in clinical practice, and related benefits for patients. 
 
In this context, by spreading research findings into practice through ‘dissemination’ 
the intervention may be described as an ‘innovation’.  It also fulfils the criteria under 







Definition of an Innovation in Health Service Delivery and Organisation 
 
An innovation in health service delivery and organisation may be defined as ‘ a set 
of behaviours, routines and ways of working, along with any associated 
administrative technologies and systems’  which are: 
 Directed at improving health outcomes, efficiency, cost-effectiveness or the user 
experience 
 Implemented by means of planned and co-ordinated action by individuals, teams 
or organisations. 
 Perceived as new by a proportion of stakeholders 
 Linked to the provision of healthcare 
 Discontinuous with previous practice 
 
Attributes of an Innovation 
 
An innovation is more likely to be adopted if possesses six key attributes. 
 Relative advantage over current practice which is clear and unambiguous 
 Lack of complexity (is simple to ‘use’ or can be broken down into simple 
components) 
 Compatibility (is compatible with the adopters values, beliefs, perceived needs 
and ways of working) 
 Trialability (Intended users can experiment on a limited basis before committing) 
 Observability (the impact is visible and obvious to intended adopters) 
 Re-invention.  The innovation can be adapted to suit local needs and services 
 
Adoption of Innovation at an Organisational Level 
At an organisational level an innovation is more likely to be adopted if 
 There is a tension for change (staff feel that the current situation is intolerable) 
 The innovation is congruent with the organisational values, norms and ways of 
working  
 The innovation is supported 
 Implications have been carefully considered and planned for 
 Resources have been allocated 
 Monitoring systems are in place to evaluate its impact 
 
 
Table 7.4 Summary of ‘Innovations’ Adapted from ‘Getting a better grip on research: 
      the organisational dimension’232 
 
 
The intervention tested aimed to improve patient health outcomes by means of 
planned and co-ordinated action from within the medicines management service to 
promote evidence-based prescribing practice.  It was new (certainly very different), 
and hence discontinuous with previous practice as GPs confirmed.   
 
The intervention also possesses attributes which are more likely to promote its 
adoption in practice.  Clear and unambiguous advantages to GPs, patients and to 
the organisation were demonstrated by both quantitative and qualitative study 
evaluations.  Although the intervention is by definition ‘complex’, considerable effort 
was expended in clearly defining the component parts to ensure consistency of 
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approach and reproducibility.   It is compatible with ‘adopters’ values and beliefs as 
GPs wished to practice in an evidence-based manner and appreciated the principles 
of incorporating research evidence into their clinical decisions.  This study itself was 
an opportunity to pilot the intervention, providing evidence of its impact which is 
visible and obvious to intended adopters.  GP feedback confirmed flexibility and 
tailoring to meet individual practice needs. 
 
GPs expressed dissatisfaction with established arrangements for influencing 
prescribing practice and enthusiasm for receiving more support based on the 
intervention model.  They were also positive and enthusiastic about adopting the 
intervention more widely.  If the intervention were to be formally adopted at 
organisational level, it would be necessary to convince commissioners of its benefits 
including completing a cost-analysis and demonstration of cost-effectiveness. 
 
 
7.3.5 Supporting Adoption of Evidence into Practice 
 
Adoption of evidence into practice ultimately depends on decisions to change made 
by individual people.  Adopting a strategic approach to introducing evidence and 
changing practice is recommended.224  As with many ‘innovations’, development and 
implementation of this intervention required significant preparation and planning and 
consistent effort involving, individuals, teams, organisations and systems.214,221,227  
 
Seven key principles which support adoption of evidence in practice have been 
identified for people whose job involves introducing evidence-based changes to 
practice.224,233  It is argued that the intervention as employed also conforms to these 




Seven Principles for More Successful Implementation of Evidence into 
Practice 
 
1. Aim for adoption of the change in practice, not its imposition 
 The intervention clearly promotes adoption of change in prescribing, by using 
a targeted multifaceted approach to ‘help it happen’ by influencing behaviour 
rather than making it happen.  
 
2.   Consider the concerns and questions of potential adopters 
 Pharmacists supporting GPs in building on prior knowledge and developing 
understanding were able to address concerns and questions of potential 
adopters.   
  
3.   Make it easier for people to do the right thing 
 GPs realised that changing ways of doing things and breaking habits is 
difficult, even if individuals are motivated to do so.  The intervention 
supported GPs in ‘doing the right thing’ by adopting several approaches 
known to influence behaviour within the multifaceted approach. The 
intervention also capitalised on GP motivations to practice as evidence-
based practitioners within their practice environment. 
 
4.   Support effective foraging, hunting and hot-synching 
 The intervention supported effective foraging, hunting, hot-synching and 
information mastery primarily on behalf of GPs, also making it easier for 
them to implement change. 
 
5.   Recognise and support the communities of practice in which potential 
adopters work 
 By providing continuing support and facilitation, pharmacists assigned to 
individual practices were able to tailor support to GP communities of 
practice. 
 
6.   Allow potential adopters to experiment with and adapt the change in 
practice to their situation 
 The targeted intervention approach enabled potential adopters (GPs) and 
pharmacists to adapt change in practice to their situation. 
 
7.  Plan carefully but be flexible and adaptable 
 The intervention as a whole was carefully planned with discrete components 
defined, resulting in a consistent approach across the participating practices.  
However, there was flexibility in approach which was largely due to 
pharmacist skills in tailoring input with their allocated practices. 
  
 













7.4  Clinical Reasoning How People Make Decisions 
 
Understanding how people learn and make decisions is also relevant in translating 
research evidence into practice, and using approaches which include measures to 
support personal adoption of evidence, as in this intervention, may be 
advantageous.224  
 
Healthcare professionals need to be good decision makers.  Recent work suggests 
that if students understood the importance of reasoning processes in clinical 
decision-making they might be better equipped to adapt their reasoning strategies 
as the situation demands.234  Better understanding of reasoning and decision-
making processes ought also help reduce errors and increase proportion of 
decisions which are better.226,235  Unfortunately, learners are rarely exposed to the 
evidence that describes how humans make decisions.222,226   
 
 




Cognitive processes which underlie clinical reasoning, are complex and multifarious. 
Dual Process Theory is a model of reasoning and decision-making which applies to 
all types of decisions including medical decision-making. 236,237  The theory 
characterises two systems of acquiring information and reaching a decision.  




Dual Process Theory in Clinical Decision-Making 
 
 System 1 is based on intuitive reasoning and is reflexive, fast, frugal and 
effortless, with low to variable reliability. 
o Relies heavily on the experience of the decision-maker.  Experienced 
decision-makers recognise overall patterns (Gestalt effects). 
o Characterised by heuristics and other mental shortcuts.  Many diagnostic 
decisions often based on this type of pattern recognition.237  
 
 System 2 is based on analytical reasoning and is deliberate, rule-based, time 
consuming with high and consistent reliability.  
o Takes place under more ideal conditions where there are fewer 
boundaries and greater availability of resources, resulting in less 
uncertainty.   
o Engaged when patient’s signs and symptoms not readily recognised or 
do not follow a particular script (illness script).237  
 









Traditional learning and development of expertise is essentially based on System 2 
reasoning.  It is logical, linear and largely hypothetico-deductive.  As experience 
grows, a System 1 approach starts to dominate as pattern recognition develops.223   
 
Development of new skill (e.g. prescribing particular drug) can also be illustrated by 
dual process theory in combination with the conscious competence model.226,235  
Summarised in Table 7.7 
 
Development of Clinical Expertise 
 
 Initially, learner knows they are not able to do it (consciously incompetent) 
 
 Purposeful and conscious learning is required (using system 2 processes) to a 
state of conscious competence 
 
 With further practice, actions may become automatic, moving towards 
unconscious competence.  System 2 learning has become embedded in System 
1 process. 
 
 If person stays in System 1, errors may occur (a state of) unconscious 
incompetence. By effortful System 2 assessment, can realise this and become 
consciously incompetent, again using System 2 as a check on system 1. 
 
 A fifth stage is proposed whereby an unconsciously competent practitioner can 
toggle into System 2 and perform an internal assessment using reflection or 
metacognition to correct activity. 
 
 Development of expertise and traditional learning is almost all System 2 
 
 
Table 7.7 Development of Clinical Expertise based on Dual Process Theory and the 
    Conscious Competence Model 
 
System 2 reasoning might be anticipated to underpin most healthcare decisions.   
However, clinical-decision-making requires recall and interpretation of large volumes 
of information.  Because there is a limit to the amount of information which humans 
can process, it becomes truncated so as to make ‘good enough’ decision 
(satisficing).  The tendency is therefore for the system to default to that requiring the 
least cognitive effort, that is, System 1 (the ‘cognitive miser’ function).  This 
approach may carry risks if the relevant information is not incorporated.  Most 
decision errors occur in System 1.238  
 
Clinicians mainly access information to inform decision-making through reliance on 
mindlines, informed by brief reading, and developed and reinforced through 
experience, repetition and interactions with others in the community of practice. 
4,40,41,224  This approach relies on System 1 processing.   
 
Gaps between evidence and practice can occur when clinicians develop a pattern of 
knowledge which is relied upon for decisions using System 1 without the activation 
of System 2 check.  Metacognition, the ability to step back and reflect on what is 
going on in a clinical situation is essentially System 2 monitoring in action and is not 




In most areas of therapeutics, it is possible to identify a difference in patterns of 
prescribing by UK GPs based on System 1 processing and what the System 2 




Results from semi-structured interviews indicate that with respect to prescribing 
decisions, GPs prefer to ‘stick with what they know’ favouring and relying on a 
largely System 1 decision-making mode.   
 
Dual Process Theory may therefore offer some explanation as to why GPs prefer 
not to move from their ‘comfort zone’ into an analytical System 2 approach which 
requires careful rational analysis (including metacognition), evaluation of all the 
information, and which takes much effort and time.  Instead, relying on 
predominantly System 1 processing for most prescribing decision-making.224  
 
It is believed that Dual Process Theory, may also go some way to explaining the 
effectiveness of the intervention.  It is hypothesised here therefore that through the 
intervention model, patient-centred decision-making based on best quality evidence 
is promoted by supporting a combination of System 2 processing (by pharmacists) 
for incorporation into System 1 decision-making (by GPs). 
 
Evidence indicates that GPs rely on System 1 processes in prescribing decision-
making. One component of the intervention depends on assimilation and evaluation 
of the relevant evidence using System 2 processes by suitably qualified 
pharmacists.    Additionally, pharmacists delivering the intervention in practices, 
promoted evidence uptake by facilitating and in effect enabling System 2 learning by 
GPs, which ultimately became embedded in their System 1 processing, the GP 
preferred decision-making style.   
 
It is proposed that this process of GP learning, as facilitated within the intervention 
by individual pharmacists is not only effective, it is also more efficient as it is 
conducted with groups of GPs in their ‘community of practice’.  
 
Understanding how people learn and make decisions and better manage 
information may help in developing strategies for implementing the adoption of 
evidence and changing practice.214  Acquisition of knowledge in traditional teaching 
and learning, occurs where the learner gains knowledge in the teacher approved 
form (‘push’ approach).  In contrast, adult learning theory encourages a ‘pull’ 
approach where learners are more in control of the learning process and teachers 


















7.5 Learning as a Community of Practice 
 
Learning can also occur through participation, which may be defined as a process of 
becoming a member of and contributing to the development of a ‘community of 
practice’.  The community of practice is also seen as having similar thinking, values, 
behaviours and expectations which are associated with its particular culture.  A 
group of GPs in a practice would characteristically constitute ‘a community of 
practice’. Learning in this model, enables creation of knowledge at the level of both 
the individual and the system in which they practice.224  In this model, individuals 
engage in and contribute to the communal development of these concepts and the 
community’s sense-making of new information or circumstances.  
 
The idea of community of practice collectively making sense of new information and 
refining group characteristics can help explain complex behaviours of its member 
and its interpersonal influences within it. 
 
The intervention model also facilitated GPs learning as a community of practice.  It 
facilitated group decision-making, enabling pooling of intellect, expertise, and GP 
perceptions and fostering communication between participants so that all were 
involved and ultimately accountable for the group actions.  ‘Mindlines’ are also 
developed and reinforced through experience, repetition and interactions with others 
in the community of practice.  Interaction with GPs through the intervention 
approach also capitalises on the ‘mindlines’ model of learning by functioning in an 
environment where discussion and joint decision-making is based on accurate 
information and robust evidence (rather than unreliable sources). 
 
 
7.6 Awareness of the Evidence 
 
In the absence of a mechanism to raise awareness of new and relevant evidence, 
GPs relying on System 1 processing are only ever likely to become aware by talking 
to colleagues or from brief reading which may ultimately serve to reinforce 
‘mindlines’, which may reflect inappropriate practice rather than best evidence.223  
Such an approach constitutes a high-risk strategy as study results demonstrate that 
GPs do not have time or more importantly, the skills to evaluate information 
themselves which has mostly reached them opportunistically, rather than through a 
robust process to deliver high-quality evidence-based information.  It is also unlikely 
to result in implementation of best evidence in clinical practice.   
 
Better Information Management skills might offer individual GPs an alternative 
approach to access evidence-based information.216,222  Ideally clinicians need to 
adopt a more systematic approach to knowing or being able to find the best 
available evidence on which to base practice. In many areas of medicine, evidence 
is already synthesised.217  Unbiased summaries from trustworthy sources are widely 
available with information translated in a format that GPs and patients can 
understand. 
 
Unfortunately, not only are GPs not skilled in formulating questions, literature search 
and critical appraisal, (hunting) which is System 2 processing, feedback indicated 
that neither are they skilled in managing information to ensure filtering and receipt of 
relevant and valid evidence which may influence practice (foraging).  Consequently, 
GPs are unlikely to keep up-to-date and incorporate evidence into prescribing 




None of the GPs indicated that they received regular alerts from trustworthy 
sources.  Techniques such as hunting, foraging and ‘hot-synching’ were not 
apparently part of their routine clinical practice.   
 
The results suggested that there remains a major challenge for GPs in identifying 
and accessing important new evidence to incorporate into prescribing-decision-
making and in highlighting information which is out of date and no longer 
appropriate.  
 
In an environment of information overload therefore, one question is whether 
practitioners recognise when they do not have the best evidence for clinical 
decision-making?   Research findings presented to GPs may be incorrect, review 
articles often fail to mention important advances and harmful treatments continue to 
be used.222  
 
The GPs interviewed believed that they practiced in an evidence-based manner, 
which despite some evidence to the contrary, indicated that they might prefer that 
their clinical-decisions be made on a System 2 approach.  However they indicated 
that they did not have the time or the relevant skills and reverted to System 1 
processing, based on unstructured reading, professional networks and expert 
opinion. 
 
Without an active strategy, relevant evidence to inform clinical decision-making is 
unlikely to reach GPs indicating that a different approach is required.  The process 
of adoption of evidence into practice is a complex one and careful planning involving 
individuals, teams, organisations and systems is essential when promoting evidence 
uptake. 
 
The intervention as described here is believed to constitute an effective strategy 
comprising an appropriate approach (or combination of approaches) to support 
adoption of evidence into prescribing practice in primary care and which is tailored 
to the environment in which adoption of evidence into practice is being promoted.   
 
 
7.7 How the Intervention may Support Evidence-Based Decision-Making  
 
Study results indicate that GPs do not have the skills nor apparently the inclination 
to access robust evidence to answer clinical questions and inform clinical decision-
making in routine practice.  Neither are they skilled in managing information to find 
best available evidence on which to inform practice. 
 
The RCGP curriculum requires that GPs base their treatment decisions on best 
available evidence.  However, the fact remains that for whatever reason, many GPs 
did not demonstrate required EBP competencies, which appeared to be more 
aspirational than a reality.  GPs still failed to find or incorporate the best available 
evidence into their prescribing decision-making.  Results also indicated that GPs are 
unlikely to address these responsibilities if left to their own devices.  GPs were 
however keen to practice EBM and were enthusiastic about the intervention which 
supported them in promoting evidence uptake into prescribing decision-making and 
in becoming better prescribers.  For organisations and individuals wishing to support 
best quality patient-centred decision-making in prescribing, then an effective 
process is clearly required.  It is proposed therefore that the intervention which has 
been described here and shown to work, provides an effective means of promoting 




Accessing and evaluating evidence is a highly skilled job.  It is also the most difficult 
and time-consuming part of EBM.  GPs are not equipped with relevant skills and 
their time might be better spent seeing patients.  Medicines Management functions 
within primary care organisations typically employ pharmacists in distinct and 
specialist roles.  Many primary care pharmacists are equipped with skills in critical 
appraisal, accessing evidence and answering clinical questions.  Many also have 
developed information mastery skills enabling access to high quality evidence 
syntheses produced by organisations with robust and transparent methodologies 
such as Cochrane, NICE, SIGN, CKS and the NPC.  Consequently, they are 
consistently aware of relevant information which they are also able to communicate 
to GPs and who might otherwise not receive the benefit of this expertise.226  
 
In addition to dissemination of relevant evidence-based prescribing information to 
GPs, appropriately skilled primary care pharmacists may confidently challenge 
inaccurate knowledge and GP misconceptions which may have evolved through 
reliance on informal networks and their own inability to assess the value of 
information presented to them.   
 
Delivery of this intervention would not have been possible without pharmacists with 
traditional EBM and information mastery skills as well as those with relevant skills, 
experience and expertise in facilitating delivery of the intervention.  Clinical primary 
care pharmacists can fulfil functions in accessing finding the best available evidence 
and advice to inform prescribing decision-making.  Importantly primary care 
pharmacists can support GPs in bringing about prescribing change as demonstrated 
in this study.  
 
It is believed therefore that the intervention constitutes an effective means of 
promoting and influencing evidence-based prescribing with primary care 




7.8 Study Strengths  
 
The purpose of the intervention was to promote evidence-based prescribing practice 
by adopting a number of (evidence-based) approaches known to be effective in 
influencing behaviour change.   
 
Several aspects of the study design and implementation are believed to have 
contributed to the impact of the intervention in influencing GP prescribing behaviour.  
Study design and development took into consideration MRC recommendations on 
design and development of complex interventions.  These included standardisation 
of design and delivery of the intervention, and identification of its components.  
Although the main evaluation to demonstrate efficacy was quantitative, qualitative 
evaluation was incorporated to add depth and gain insight of the recipients of the 
intervention.  
 
Cochrane recommendations were also addressed by utilising effective strategies 
(multifaceted approach, interactive educational meetings, audit, feedback, key 
messages summaries, clearly defined type of visitor and visit content) and by 
employing sustained efforts to improve prescribing behaviour.  The study was 
powered to detect significant differences in prescribing and patient outcomes were 
also included as an evaluation measure.  The qualitative evaluation also included a 
process review.  Consequently, it is believed that study design and evaluation 
complied with robust, evidence-based recommendations to support adoption of 
evidence in practice and to address evaluation of a complex intervention. 
 
The intervention constitutes a clearly defined consistent and reproducible approach, 
(component parts described) for promotion and implementation of evidence-based 
prescribing in practice and had produced evidence to demonstrate that such an 
evidence-based approach when adopted, works in influencing prescribing 
behaviour. 
 
Importantly, the quantitative evaluation has provided robust evidence which was 
previously lacking to demonstrate the impact of prescribing advisers on GP 
prescribing by promoting incorporation of evidence into the prescribing decision-
making process.  Most significantly, evidence for an effect on patient outcomes 
which was also lacking (and which was one of the major criticisms of EBM) has also 
been demonstrated. 
 
Several other aspects of the multifaceted approach inherent within the intervention 
strategy are also believed to have contributed to the overall effect in influencing 
prescribing behaviour in practice.    
 
Changes in clinical practice are generally triggered by personal contact as in 
‘academic detailing’, the approach which was employed within the intervention.232  
Interpersonal influence was fundamental to the intervention and pharmacists were 
central to its delivery.  
 
Importantly, the intervention aimed for adoption of change, not its imposition.  GPs 
were clearly persuaded and ultimately convinced to change prescribing behaviour.  
The AIDA adoption framework explains how clinicians may adopt an MMT agenda 
and describes four stages in the process:11  
 raising Awareness of issues, evidence and potential changes to practice which  
 leads to Interest to make some sort of change and engage with the process 
 then making a Decision to change 




Whilst this framework was not adopted prospectively as a strategy for GPs to 
conform to a predefined agenda, the process through which the GPs and the 
pharmacists progressed in achieving change within the intervention was similar, 
starting by raising awareness of the evidence and practice prescribing patterns, 
followed by discussion, decision and action to bring about change. 
 
Building relationships is also an extremely important factor with prescribing advisers 
ideally striving to become a trusted adviser.  The core of any such relationship must 
be based on trust and communication should not simplify and shift the argument in 
MMT favour by representing only half the evidence or guidance.11 
  
The GPs believed that building a relationship was important and reported that 
relationships based on trust were established between them and the pharmacists.  
Feedback also indicated that this was a major difference between traditional 
interactions with MMT (which focused on cost-based arguments) and delivery of the 
intervention which was clearly evidence-based.  Several GPs also noted that their 
pharmacist was empathic, acknowledging their concerns, without trivialising them, 
also important factors in interactions with clinicians.11 
 
Gaining agreement was also an important factor in obtaining GP commitment to 
change.  Clear and concise written feedback summarised as visit reports following 
all visits and regular and follow-up communications involving reinforcement of key 
messages and agreed actions and review of progress were also documented in visit 
reports.  Employing sustained efforts (as recommended by Cochrane) to improve 
prescribing behaviour, rather than individual visits (as for APMs) was also believed 
to have been an important factor in achieving change.  Clear communication 
materials, including concise detail aids and provision of prescribing data throughout 
the intervention period as part of the comprehensive evidence-based package 




7.9 Study Limitations  
 
Ideally a randomised controlled trial would have been preferred to evaluate the 
impact of the intervention.  However, because of the small sample size, this was not 
feasible.  Instead, the preferred most robust alternative design, a pre-test, post-test 
study was adopted whereby a control (business as usual), non-intervention group 
with the same characteristics as the study population was identified for comparison 
and where observed differences are assumed to be due to the intervention.  
 
The fact that the study was conducted in one PCT is also a potential limitation as a 
larger study involving other PCOs might reflect a wider more generalisable picture.   
 
Potential limitations to success of the intervention if implemented more widely could 
include lack of engagement either by individual GPs or practices as a whole.  
Difficulties in getting all GPs together for practice visits could impact on the 
effectiveness of the intervention.  Flexibility and tailoring intervention visits to GP 
availability would help address this potential problem.   
 
If participating practices failed to engage, lack of commitment to prescribing change 
and ultimately wasted MMF resources could occur.  Lack of practice engagement 
may require intervention from the MMF lead and if necessary, GP leads within the 




7.10 Policy Implications 
 
Following completion of this study, significant restructuring of the NHS has occurred. 
PCTs have been abolished and the majority of commissioning functions are being 
delivered through commissioning consortia or Clinical Commissioning Groups 
(CCGs).  During transfer of responsibilities from PCTs, medicines management 
functions were required to be actively integrated into existing or new commissioning 
organisations.126  The NHS was expected to make the safe, legal and effective use 
of medicines a priority and ensure that evidence-based approaches to safe and 
effective use of medicines were not lost but strengthened.126  
 
Commissioning consortia are advised that medicines management is not just about 
controlling prescribing costs but about realising the full benefits that optimal 
medicines use can deliver for patients and the NHS.127  CCGs are required to fulfil a 
set of organisational medicines management competencies and must have 
medicines management expertise to optimise medicines usage and improve patient 
outcomes in all the services that they commission on behalf of their patients.127    
 
CCGs should recruit and retain individuals with the appropriate skill mix and 
competencies.  This includes individuals with the necessary skills to access and 
utilise quality summaries of evidence and who know how to interpret and where 
appropriate challenge, the evidence base underpinning the use of medicines.127  
Several Key Medicines Management Functions expected of CCGs based on 
principles consistent with the intervention approach are summarised in Table 7.8. 
 




 Ensure that evidence informed decision-making underpins the 
development of locally approved guidelines and commissioning 
agreements  on the use of medicines 
 Ensure that individuals and teams have the appropriate 
education, training and developments necessary to ensure the 
safe, legal and effective use of medicines 
 Ensuring effective practice in the use of medicines in and across 
pathways and across a health economy including  
o development of joint robust processes and policies to 




 Provision of advice on medicines and medicines related issues 
to the organisation and externally. 
Workforce 
Development 
 Ensuring that local healthcare teams have appropriate skills 
through education, training and development including GPs, 




 Has the skills necessary to access and utilise quality summaries 
of evidence  
 Knows how to interpret and where appropriate challenge, the 
evidence base underpinning the use of medicines.  
 Recruits, retains, or accesses the appropriate skill mix which 
takes account of emerging roles and organisations. 
 
Table 7.8 Medicines Management Competencies Expected of Commissioning 




Despite DoH policies and priorities intended to improve patient care, and 
requirements that comprehensive medicines management services are embedded 
within the new commissioning organisations, evolution of the revised NHS structure 
within the PCO has resulted in significant reduction in pharmacist skills base.  
Reduction in staffing levels to approximately 35% of previous capacity suggests that 
commissioning and funding of MMT services might not be a priority function for the 
new organisation as strategies intended to reduce staff costs were implemented.   
 
Government commitment to utilise pharmacist skills in primary care more effectively 
and acknowledgement that prescribing advisers are increasingly active in promoting 
cost effective use of medicines may not necessarily have been considered within the 
emerging organisation.  Local policy indicates a trend towards the dismantling of the 
established Medicines Management service, albeit one which has not traditionally 
focussed on influencing prescribing behaviour as implemented through the 
intervention model.  This approach is inconsistent with study findings which have 
demonstrated the impact of skilled pharmacists on GP prescribing decision-making 
and the promotion of evidence-based practice through the intervention model. 
 
Evidence-based prescribing is an essential component of good quality, effective and 
safe healthcare for patients which underpins national healthcare policy.1,2,3  Many 
primary care pharmacists are highly skilled professionals possessing significant 
expertise in managing medicines.9  They are also arguably the only qualified 
healthcare professionals equipped to support delivery of this agenda within the 
NHS.11  It is suggested that a more appropriate and effective approach to supporting 
safe, effective and cost-effective prescribing and which would also support CCG and 
national policy objectives would involve adoption and implementation of the 
intervention. 
 
The intervention is regarded as a ‘package’ or programme of support provided from 
within the Medicines Management function aimed at improving prescribing practice 
by facilitation of evidence-based prescribing.   
 
Any such programme would need to sustainable and cost-effective and be part of a 
more comprehensive MMT strategy.  However, based on study results it is believed 
that provision of such a service would improve prescribing practice, making it both 
evidence-based and more cost-effective.  It is also believed that such a service 
supported with appropriate resources would also improve engagement with MMT 
and persuade GPs to prescribe more effectively and safely to the benefit of patients.  
A more comprehensive service would however need to be costed, marketed and 
fronted by a senior person with relevant knowledge and skills.  If adopted more 
widely, the intervention would need to be appropriately monitored and evaluated.   
 
Implementation of the intervention in the organisation is perceived as just one 
aspect of a formal structured Medicines Management function.  As part of a wider 
and more comprehensive approach to promoting evidence-based prescribing, it 
would also be appropriate to identify and map out barriers to implementation of EBM 
in prescribing practice at micro, meso, and macro level.  Possible solutions to 
overcome identified barriers could then be explored, and where feasible considered 
further to promote uptake of evidence in practice. 
  
Promotion and adoption of evidence-based prescribing according to the model 
should support best quality patient-centred prescribing decision-making to the 
ultimate benefit of patients, healthcare professionals and the organisation as a 
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Questions have arisen from this study regarding the role and functions of MMT 
within the organisation and GPs perceptions of it.  Therefore several 
recommendations are specifically aimed at improving provision of prescribing 
support to GPs within the organisation where the study was conducted.  It is 
believed that GPs would become better engaged with MMT and more involved in 
achieving clear and agreed prescribing objectives across the PCO. 
 
 Reformat and restructure annual prescribing meetings to the intervention model.  
Where necessary, and if funds allow, schedule more frequent meetings. 
 Discuss and agree annual prescribing objectives with GPs.  Tailor to individual 
practices rather than implement generic audits which do not necessarily reflect 
true prescribing activities. 
 Realign MMT data management resources to prepare relevant prescribing data 
including prescribing trends to support achievement of individual practice 
prescribing objectives and to inform intervention-type visits.  
 Allocate a suitably qualified pharmacist to each practice to support GPs in 
achieving relevant and evidence-based prescribing objectives. 
 Develop a GP Prescribing Lead Job Description and Role Specification to 
formalise and clarify the function and improve understanding of GP Prescribing 
Lead and MMT responsibilities. 
 
Expansion of the intervention and wider implementation could significantly influence 
prescribing behaviour across the whole organisation. 
 
 Offer the intervention to all practices within the PCO. 
 Develop the intervention to cover other therapeutic areas within the BNF. 
 Tailor practice visits and prescribing adviser input to individual practice needs. 
 
Several additional activities were identified which, resources permitting might 
provide more comprehensive support in addressing GP prescribing information 
needs. 
 
 Implement formal mechanism to raise GP awareness of new evidence/evidence-
based guidance when available. 
 Provide regular easily-digested pre-appraised evidence summaries/updates of 
evidence to help GPs keep up-to-date and overcome barriers in accessing 
evidence.  
 Disseminate list of trusted evidence-based website resources to guide GPs to 
appropriate sources of prescribing-related information.   
 Develop an educational role within the Medicines Management function to 











7.11.1 Areas for Future Research 
 
 Conduct an economic analysis of proposed future service based on 
implementation of the intervention model. 
 Identify and map out barriers to implementation of EBM in prescribing at micro, 
meso, and macro level. 
 Conduct a study (preferably an RCT) with a larger sample size to further 
investigate the impact of the intervention and to contribute to the evidence base 








The hypothesis that implementation of an intervention utilising a multifaceted 
approach, adopting strategies known to influence healthcare professional behaviour 
will affect GP prescribing behaviour according to the EBM paradigm is verified. 
 
Recommendations to influence healthcare professional behaviours were addressed 
by utilising effective strategies to promote uptake of evidence (multifaceted 
approach, interactive educational meetings, audit, feedback, key messages 
summaries, clearly defined type of visitor and visit content) and by employing 
sustained efforts to improve prescribing behaviour.   
 
The intervention tested constitutes a clearly defined, consistent and reproducible 
approach, (with component parts described) which was shown to be effective in 
promotion and implementation of evidence-based prescribing in practice.  This study 
provides evidence to demonstrate that such an evidence-based approach when 
adopted is effective in influencing prescribing behaviour. 
 
The study also demonstrated feasibility and delivery of the intervention in everyday 
practice and that the intervention can be delivered as intended and implemented 
more widely.  Its impact on and acceptability to participants was also demonstrated.  
 
Qualitative evaluation indicated that the intervention was successful in influencing 
the way GPs worked.  GPs valued the intervention overall and many evidently 
developed as a result by becoming more reflective about their prescribing decisions 
and internalising key evidence-based prescribing messages.   
 
The premise for this study was that there was very little evidence to demonstrate 
incorporation of evidence into the decision-making process and of its translation into 
routine practice, or that incorporation of evidence-based information into decisions 
improves patient care or patient outcomes.  Not only has an effect on influencing 
uptake of evidence into prescribing decisions been confirmed, an effect on 
measurable patient-oriented outcomes has also been demonstrated.  This finding 
addresses one of the key criticisms in that EBM lacks evidence to demonstrate its 
effect on patient-orientated outcomes. 
 
 




Literature Review - Methodology 
 
Electronic database searches were conducted in EMBASE (Drugs and 
Pharmacology and other aspects of Human Medicine) and Medline (General 
Medical Database) using the National Electronic Library for Health (NeLH) database 
searching facility.  (More recently accessible via the NICE website using the 
Healthcare Database Advanced Search).   
 
The literature search question was structured according to the PICO Model 
whereby, the population of interest, the intervention of interest, comparator (if there 
is one) and the outcome are defined.  The different components of the question 
were combined using Boolean Operators (AND and OR) 
 
In this instance, the population of interest was GPs, the main intervention was 
centred on pharmacists using an academic detailing or educational outreach 
approach and the outcome was impact on prescribing.  In this case, there was no 
specific comparator.   
 
Search terms were derived from keywords indicated below, using truncation to 
refine textword searching.  Search terms were also ‘Mapped to Thesaurus’ to 
access relevant subject headings.  The search was based on key words or phrases 
appearing in Title or Abstracts.  Limits were applied to published articles from ‘1988 
to Current’ 
 
The literature search was structured as follows:   
 
((GENERAL PRACTICE/) OR (("general practice" OR "family practice").ti,ab) OR  
(GENERAL PRACTITIONER/) OR (("general practitioner*" OR gp*).ti,ab) OR (("family 
physician*" OR "primary care physician*").ti,ab))  
AND 
(((PHARMACIST/) OR (pharmacist*.ti,ab) OR (("prescribing advis*" OR " pharmac* 
advis*").ti,ab))  
AND  
(((advice OR education* OR inform* OR feedback OR audit).ti,ab) OR  
((intervention* OR meeting* OR visit* OR outreach OR detail*).ti,ab))  
AND  
((PRESCRIPTION/) OR ((prescrib* OR prescrip*).ti,ab))) 
AND 
(EBM OR EBP OR "Evidence-Base*" OR "evidence base*" OR evidence*).ti,ab [Limit to: 
Publication Year 1988-Current] 
 
Abstracts of all publications identified in the searches were scanned for suitability 
and if relevant, full text articles were accessed. 
 
NB: Broad (higher) searches were conducted to ensure that relevant articles were 
not missed.  Abstracts identified from these searches were all scanned for suitability.  
The additional searches combining search terms relating to EBM were conducted to 
identify if there were any specific articles which incorporated interventions based on 
delivery of evidence based interventions.  No articles with EBM as the basis of 
interventions to change behaviour were identified following review of abstracts. 
 





NICE Recommendations for Management of OA  
 
 Exercise should be a core treatment for people with OA irrespective of age, 
comorbidity, pain severity or disability. Paracetamol and/or topical NSAIDs 
should be considered ahead of oral NSAIDs or COX-Inhibitors.  (Ref NICE)   
 
 NSAIDs or COX-2 Inhibitors should only be used when other safer treatments 
are ineffective or not tolerated and should be prescribed at the lowest effective 
dose for the shortest period of time owing to potential gastrointestinal, 
cardiorenal, and liver toxicity.  (NICE, MeReC) 
 
 Individual patient risk factors should be taken into account when prescribing 
NSAIDs.   
 
 Where necessary, a proton pump inhibitor (PPI) should be offered for GI 
protection.   
 
 Other drugs such as aspirin and SSRI antidepressants increase GI risk.   
 
 NSAIDs should not be prescribed for patients with active peptic ulcer disease, 
past history of GI bleed, renal or heart failure.  “At risk” groups also include those 
with established CVD disease, smokers, people with diabetes, and age  > 65 
years. (Ref CG 59) 
 
 
NICE Recommendations for Management of RA  
 
NICE Guidance recommends that patients are offered disease modifying anti-
rheumatic drugs (DMARDs) as the mainstay of their management.  (Ref CG 79) 
 
 For symptom control, NICE recommends analgesics.  If NSAIDs or COX-
Inhibitors are offered, they should be prescribed with a PPI for gastro-protection.   
 
 Because of potential gastrointestinal, liver and cardio-renal toxicities individual 
patient risk factors including age and individual patient risk factors should be 
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Appendix 3 
 
Therapeutic Topics for EBM Prescribing Intervention - Key Messages, Outcomes and Data Source  




Topic Key Messages / 
Rationale 
Outcome - ePACT Outcome - Clinical Data sources / 
Evaluation 
      
Cardiovascular/ 
Endocrine 
 Type 2 diabetes 
 Oral Hypoglycaemic 
agents 
 Glitazones  
 Metformin 














Appropriate use of 
medication in T2DM 
 




 Importance of use of 




Importance of managing 
cardiovascular risk, 
specifically hypertension 
in patients with T2DM 
Primary outcome 





 Reduction in 
prescribing of 
Glitazones 
 Overall reduction in 




Proportion of T2DM patients 
achieving target 
 HbA1c 7.5%, 9.0% 
 BP 
 Total cholesterol 






Renal targets   
 Increase in prescribing 
of ACE-I/A-II-As for 
T2DM patients with m/a 
 Proportion of T2DM 
patients achieving BP 
<140/80mmHg 
 Proportion of T2DM 




ADQ / ASTRO PU for 
quarter immediately 
before intervention 









Data from practice 
system 
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BNF Chapter 
 
Topic Key Messages / 
Rationale 
Outcome - ePACT Outcome - Clinical Data sources / 
Evaluation 
 
Musculoskeletal NSAIDs Safety issues relating to 
use of NSAIDS 
 
Safety issues relating to 
Diclofenac 
 
Safety issues relating to 
Coxibs 
Primary outcome 





 Reduction in overall 
prescribing of NSAIDs 
(including COX-II 
Inhibitors) 
 Relative increase in 






 Reduction in proportion 
of elderly patients (>65) 
on NSAID repeats 
 Proportion of patients 
with risk factors on 
NSAIDs 
 ePACT Data 
ADQ / ASTRO PU for 
quarter immediately 
before intervention 




Data from practice 
system 
      
  











Post Graduate Qualifications * 
 
Years Registered ** 
(Pharmaceutical Register) 
Ph 1  PG Diploma - 
      Community Pharmacy 
19 
Ph 2  PG Certificate –  
      Clinical Pharmacy 
23 
Ph 3  PG Diploma – 
Pharmacy Practice 
 M.Sc.  - Safety and Quality, 
Healthcare 
 M.Ed.  
15 
Ph 4  PG Diploma – 
      Clinical 
22 
Ph 5  M.Sc. –  
Pharmaceutical Sciences 
 Independent Prescriber 
21 
 
*    Highest Level Post-Graduate Qualifications Achieved Indicated 
**  Years Qualified and Registered as a Pharmacist 
 
 
Pharmacist PCT Roles included: 
 Principal Pharmacist Clinical Services Lead (3) 
 Specialist Pharmacist (Area Prescribing Committee and Formulary) 
 Consultant Pharmacist (DoH Defined Role) 
 




NPC Training Lesson Plan Template 
 





Session Title NPC Plus Type 2 Diabetes and NSAIDs 
No of Students 20 
Time 10.00a.m. – 4.00p.m.     Duration 6 hours 
  
Session Title  
Aims of Session  To review the key principles of NICE guidance on Type 2 diabetes 
and best practice around NSAIDs. 
 Using the principles of information mastery, review the key 
therapeutic principles of an evidence based approach in the 
management of Type 2 diabetes and use of NSAIDs. 
 To apply the evidence base through review of case studies. 
Specific Learning 
Outcomes  
 Describe the key principles of evidence based prescribing in the 
management of Type 2 diabetes including: 
o The benefits of tight blood pressure control vs tight blood 
glucose control 
o Management of cardiovascular risk 
o Management of blood glucose 
 Describe the key principles of evidence based prescribing of NSAIDs 
including: 
o The NICE guidance on the management of osteoarthritis 
o cardiovascular and gastrointestinal risk 
o the three steps to appropriate NSAID use 
 Apply the key therapeutics in the clinical management of patients 









 Lesson plan and facilitators notes. internet access 
 Projector, laptop, slides and handouts 
 Register of students 
 Pens, markers 
 Flipchart, smiley facts 




Case Study worksheets 
Feedback 
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Appendix 5 (Cont) 
 
Lesson Plan Template 
 
Session Plan for NPC Plus LTC Update 
 
 
























Quiz on arrival 
 
 
Flip Chart – 
What want to 































Benefits of tight 
blood pressure 






















































































Materials to take 
with you 
Selling messages 
















                                                                  203 













Intro – What are 
NSAIDS used for? 










Topicals – short 
bursts 
Paracetamol – good 
for mild to 
moderate 





































































is there a problem? 
Heart failure – 
increased risk if 
predisposition 













study -  
Individual 
participation  






practice – Summary 
Tool 5 
Action Plans 



























Reinforce learning – 
identify key learning 
points for 
implementation 
Juggling ball Facilitate group 
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NPC Pharmacist Training 
 





The aims of the session were: 
  
 To review an evidence based approach to clinical practice and decision making 
 Understanding of common terms and techniques used in published research 
 Asking of relevant questions when presented with published research  - especially 
in relation to new medicines 
 Raise awareness of skills required to interpret absolute benefits from data, and use 
summaries of evidence in decision making 
 Accessing useful and easily available evidence when faced with an information 
need. 
 Communicating the evidence.     
 
 
Therapeutics Update - T2DM 
 
The Aims of the session were: 
 
 To review the key principles of NICE guidance on Type 2 diabetes and best 
practice in management of Type 2 diabetes 
 Using the principles of information mastery, review the key therapeutic principles of 
an evidence based approach in the management of Type 2 diabetes 
 To apply the evidence base through review of case studies. 
 
Specific Learning Outcomes: 
 
 Describe the key principles of evidence base prescribing in the management of 
Type 2 Diabetes including: 
o The benefits of tight blood pressure control vs tight blood glucose 
control 
o Management of cardiovascular risk 
o Management of blood glucose 
 Apply the key therapeutic principles in the clinical management of patients 
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NPC Pharmacist Training 
 
Aims, Learning Objectives and Expected Outcomes 
 
 
Therapeutics Update - NSAIDs 
 
The Aims of the session were: 
 
 To review the key principles of NICE guidance and best practice around use of 
NSAIDs 
 Using the principles of information mastery, review the key therapeutic principles of 
an evidence based approach in the management of Type 2 Diabetes and use of 
NSAIDs 
 To apply the evidence base through review of case studies. 
 
Specific Learning Outcomes: 
 
 Describe the key principles of evidence based prescribing of NSAIDs including: 
o The NICE guidance on the management of osteoarthritis 
o Patient risk factors and the use of NSAIDs 
o Evidence relating to cardiovascular and gastrointestinal risk 
o The three steps to appropriate NSAID use 
 Apply the key therapeutic principles in the clinical management of patients 




Therapeutics Update – RAS Drugs 
 
Key Aims of the session were: 
 
 To review factors guiding choice of RAS drug (efficacy, safety, patient factors, cost) 
 Evidence based practice – Review evidence for recommended ACE-I first line 
 Evidence based practice – Review evidence for recommendation for appropriate 
use of A-II-As if ACE-I discontinued 
 Therapeutic dilemmas (1)  Combination Therapy 
Therapeutic dilemmas (2): 
o Recommendations for RAS drugs in pregnancy/breast feeding? 
o Risk of MI with A-II-As? 
o Place in therapy of new direct renin inhibitor, aliskiren? 








Academic Detail Training 
 
 
Key Aims of the training - To cover: 
 
 An overview of what works in effective communication and influencing effectively.  
 How to deliver a consistent, clear and compelling message.  
 Principles of effective face to face and group communication  
 “Detailing skills” 
o Questioning techniques 
o Identifying needs  
o Summarising techniques  
o Gaining agreement  
o Action planning 
 Development of detail aids and delivery of key messages 
 Breaking down the communication/detailing task into manageable chunks  
 Influencing Skills 
o Influencing Behaviour 
 Presentation skills  
 Use of visual aids  
 Pre detailing activities:  
o Choosing what messages to use, with whom and when  
o Defining objectives 
 How to follow up and reinforce face to face communication  
 Embedding and applying the training  
 Measuring progress 
 Opportunity to implement and  practice techniques 
 
 
Specific Learning Outcomes: 
 
For each participant: 
 Gaining an understanding of communication styles,  
 Confident use of the detailing structure (story board),  
 Skilled use of questioning techniques.  
 Ability to manage and handle clinician raised objections. 
 Ability to draw the detail to a close with an agreed “call to action” by the clinician.  
 Structuring a discussion and presenting reference material. 
 Provision of an effective framework for group presentation - delivering effective 
presentations, tackling objections, challenging current practice, and group 
discussion management.  
 
 
                                                                  207 
 
Appendix 8  
 
Academic Detailing - Training Approach  
 
The detailing methodology, adapted to the project, focussed on the principles and 
processes to enable clear and compelling communication within the professional 
setting.  
 
Aim:  To reflect the approach known to be successful within the pharmaceutical sector 
by adopting structured methodologies and which were anticipated to be most effective 
when all aspects are addressed.   
 Identification and targeting (segmentation) of the detail audience  
 Preparation of the detailing message  
 Support materials (detailing aids, slide presentations, reference material etc.)  
 Skill learning for those undertaking the “Academic detailing”  
 Follow-up and assessment of success  
 
The course was structured to develop detailing skills for application in both one-to-one 
and group meeting situations.  
 
 
Detailing Skills  
 
Principles of Academic Detailing Approach: 
 
 Focused, directed discussions which follow a planned approach (as determined in 
the detail planning matrix). 
 Identification of needs and issues of the participants and presentation of cohesive 
arguments backed up by referenced facts.  
 The conclusion of the detail is to agree a “call to action”. i.e. to agree that the 
clinician take a course of action.  
 The agreed course of action may then be followed up and confirmation of the action 
having been completed will form the start of the next “detailing” visit.   
 
The training therefore focussed on development of the pharmacists skills to achieve the 
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Pharmacist participation in pre-workshop training in order to consider the objectives 
and desired outcomes of the intervention and to start to structure their thinking and 
approach to delivering the intervention utilising detailing techniques. 
 
Format: 
 Two pre-workshop group sessions involving all pharmacists involved in delivering 
the intervention.  
 Teleconference discussion with the trainers in the form of a structured workbook 




 To provide an introduction to the process and principals of academic detailing 




 Principles of communication 
 Technique of developing an influential detail and detail structure.  
 Participants introduced to the concepts of an adoption ladder, a tool which may be 
used in communication and driving change in behaviour and which assists the 
person conducting the presentation to structure detailing tasks and measure 
progress towards their desired outcome.    
 Participants introduced to the concept of a questions / issue bank which may be 
used to anticipate and identify four categories of questions or opinion which may 
constitute diversion by the meeting participants and in order to be able to challenge 
such diversion or objection  
 In between the two sessions, the pharmacists worked together on development of a 
written adoption ladder and suggested question bank, based on their experiences 




At the end of the sessions the participants should be prepared in advance of the main 
training with: 
 An understanding of the detail communication process and structure 
 An adoption ladder 
 An objection/ question bank 
 Knowledge of the four categories of diversion, and how to handle them 











Evidence Based Prescribing Support from Primary Care Prescribing Advisers 
Academic Detailing – Review Session 
 
Date:   24th August 2010 
Time:  1.00 - 5.00pm 
Venue:  PHN Conference Room, Hunts Area Office  
A G E N D A  
 
 
1.  Introduction       MW 
 - Study Aims and Objectives 
 - Detail Aids, Data 
 
2. Academic Detailing      MW 
 
3. Review        TY / MW 
 - Change Theory 
 - Openings 
 - Questions and Listening 
 - Obstacles ans Obstructions 
 - Getting Agreements 
 - Record Keeping / Reflection 
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Summary of Academic Detailing Review Session  
 
We reviewed techniques used in ‘academic detailing’ also known as ‘educational 
outreach’.  This involved exploring the needs and wants of the clinicians involved.   
 
As we have discussed previously, the principles of educational outreach are based on 
the following: 
1. Investigate baseline knowledge 
2. Focus on specific categories of prescribers 
3. Define clear educational and behavioural objectives 
4. Establish trust and credibility 
5. Encourage doctor/prescriber participation 
6. Provide concise graphic materials 
7. Highlight and repeat key messages 
8. Reinforce with follow up visits 
 
Essential elements -  Keep to time…..ensure it’s well targeted 
Practice; practice; practice ……………………  
 
Application of the approach is also summarised in slides in the presentation 
 Preparation 
o Key Messages 
o Features 
o Benefits 
o Trust / Credibility 
o Suitable Questions 
 
 The visit 
o Aim of session 
o Areas of controversy 
o Mandatory literature 
o Possible ‘Starters for 10’ 
o Questions to ascertain closure 
o Materials to take with you 
 
As discussed, the Planning Matrix for NSAIDs and T2DM should provide the 
information you need based on the above headings.  These have been forwarded 
already and any revised versions will be forwarded to you when and if updated. Copies 
will also be in your individual folders with information on the outcomes being measured 
and a copy of the brief presentation. 
 
Important: Copies of the attached (NAO) document have been provided to you all 
previously. Please read Chapter 1, ie the Introduction (Pages 6,7) and Chapters 6 and 
7 before you go on the visits.  This should help put the visit (and the project) in context 
and why the approach using detail aids, prescribing data and our own expertise and 
clinical knowledge etc. is adopted.  It clearly identifies the principles which we have 
covered in the training but not at the exclusion of other aspects of the package.  
The above report can be accessed using the following link:  
http://www.nao.org.uk/publications/0607/prescribing_costs_in_primary_c.aspx 
If you have any questions or require further clarification, please do not hesitate to ask. 
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Aim
To have a basic 
understanding of Academic 






The ‘selling’ of ideas as opposed to 
physical products to achieve health and 
social solutions
Kotler P, Roberto E, Social Marketing.  Strategies for changing public behaviour. New 
York: Free Press 1989
        
Some key ideas/terms approaches
• ‘push’ or ‘pull’
- You can only push the change principles
- Sell the benefits of the change
- You want people to pull the idea towards        
themselves
- People need to adopt the idea themselves so 
that they have ownership






The delivery of educational messages about 
how to achieve better health outcomes in the 
patient’s interest
• One to one communication
• Uses the principles of Social Marketing
• Not driven by commercial interest
• Focused on achieving behavioural change
• Delivered in the prescriber’s own time and 
practice area
        
Academic Detailing is . . . 









‘An evidence base exists supporting the 
impact of academic detailing on 
behavioural change, particularly 
prescribing behaviour’.
        
Principles of Academic Detailing
1. Investigate baseline knowledge
2. Focus on specific categories of prescribers
3. Define clear educational and behavioural objectives
4. Establish trust and credibility
5. Encourage doctor/prescriber participation
6. Provide concise graphic materials
7. Highlight and repeat key messages
8. Reinforce with follow up visits
Essential elements
Keep to time…..ensure it’s well targeted








– Trust / Credibility
– Suitable Questions
        
The Package
• Academic detailing  - The visit
– Aim of session
– Areas of controversy
– Mandatory literature
– Possible ‘Starters for 10’
– Questions to ascertain closure
– Materials to take with you
 
       
Distil the aim into key messages
• Choose 4/5 key messages
• Repeat throughout the session
• Use adult learning theory – i.e. account for 
different learning styles
• Address deep learning and surface 
learning
        


































Which means that . .
        
Group feedback?
• Summary 
• Potential benefits / pitfalls?
• Next steps?
Academic Detailing ‘techniques have been 
shown to reduce inappropriate prescribing as 
well as unnecessary health care expenditures’.
Soumerai S, B and Avorn J (1990) Principles of Educational Outreach (‘Academic Detailing’) to 









Key Messages in Development of Detail Aids - NSAIDs 
 
Therapeutic Topic – NSAIDs and Musculoskeletal Pain   
Key Messages for Pharmacists Delivering the Intervention 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) including COX-Inhibitors carry the 
risk of side effects, which can be serious and life-threatening.  Important side effects 
include gastrointestinal (GI) complications (e.g. perforation, ulcer, bleeding) and 
cardiovascular (CV) (e.g. stroke, myocardial infarction). 
  
 COX-II inhibitors and NSAIDs have similar analgesic effects and do not differ in 
efficacy for pain relief. 
 The level of risk varies between individual NSAIDs 
 COX-II inhibitors have reduced risk of causing GI ulcers than older NSAIDs, 
however, they increase cardiovascular risk 
 Diclofenac is associated with a similar cardiovascular risk as COX-II inhibitors 
 
NICE Guidance on management of osteoarthritis – largely supports the evidence 
base. 
 Exercise should be a core treatment for people with OA irrespective of age, 
comorbidity, pain severity or disability. 
 Healthcare professionals (HCPs) should consider offering paracetamol for pain 
relief  
 Healthcare professionals (HCPs) should consider offering topical NSAIDs for 
pain relief. 
 Paracetamol and/or topical NSAIDs should be considered ahead of oral 
NSAIDs, COX-Inhibitors or opioids 
 It is particularly important to use NSAIDs or COX-II inhibitors only when other 
safer treatments are ineffective or not tolerated 
 When offering treatment with an NSAID or COX-II inhibitor, these should be 
prescribed with a PPI choosing one with the lowest acquisition cost.   
 Prescribe at lowest effective dose for shortest possible period of time 
 Owing to potential GI, cardio-renal and liver toxicity 
o Take into account individual risk factors including age when choosing 
NSAID/COX-II and dose to be prescribed 
o Assess/monitor patient risk factors 
o Consider alternative analgesic if patient already taking low-dose aspirin 
 
What does the evidence say?   
 
Cardiovascular risk  
 Although risk to individual patient is small, CV risks are important a population 
level because of the volumes in which they are prescribed. 
 Estimated risk 
o Coxibs account for approximately 6% items in England. – potentially 
responsible for 240 additional/premature CV events per year 
o Diclofenac accounted for 46% NSAID prescriptions (2007/2008) – 
potentially equating to 2000 additional/premature CV events per year 
 Coxibs (celecoxib, etoricoxib▼),  are associated with a small excess risk of 
thrombotic events compared with no treatment (about three per 1000 users 
treated for one year). 
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 Two coxibs have already been withdrawn from worldwide markets because of 
unacceptable risks (rofecoxib, lumaricoxib). 
 All coxibs are contraindicated in patients with established CV disease (IHD, 
PVD, CVD). 
 Coxibs have a higher CV risk than ibuprofen ≤1200mg per day or naproxen 
1000mg. 
 Traditional NSAIDs may be associated with an increased risk of thrombotic 
events. Diclofenac 150mg/day appears to be associated with a similar excess 
risk to that of coxibs. 
 Low-dose ibuprofen (≤1200mg/day) and naproxen 1000mg/day do not carry the 
same CV risks and should be first line choice for most patients (taking into 
account GI risks and interpatient variability in response)  
 The evidence suggests that there is no safe period over which there is no risk of 
events.  Risk increases with dose and persists throughout treatment. 
 Cardio-renal effects are not affected by COX-selectivity and contribute to CV 
risk.  (Heart failure, oedema, hypertension). 
 
GI Risk 
 GI risk increases with age of patient, co-morbidities (including cardiovascular 
disease, diabetes, smokers) 
 Coxibs, are associated with a lower GI risk than traditional NSAIDs. However, 
their GI-safety advantage is diminished when co-administered with aspirin. 
 Of the traditional NSAIDS, low-dose ibuprofen is associated with a lower GI risk 
than diclofenac and naproxen. 
 Use of a proton pump inhibitor (PPI) with any NSAID reduces the risk of GI side 
effects. 
 Benefits from gastroprotection largely depend on the individual patient’s baseline 
risk of GI complications.  
 There is, as yet, no good evidence that adding a PPI to a coxib is more 
beneficial, equivalent or a worse option than adding a PPI to a traditional NSAID. 
 There is an increased GI risk with co-prescription of aspirin. 
 
What does this mean in practice? 
 Prescribing of NSAIDs should be based on the safety profiles of individual 
NSAIDs and on individual patient risk factors.  
 NSAIDs should be used at the lowest effective dose and for the shortest period 
of time necessary to control symptoms. 
 Low-dose ibuprofen (≤1200mg per day) is an appropriate first choice NSAID in 
view of its low risk of GI and CV side effects. 
 Low-dose ibuprofen or naproxen 1000mg would appear more appropriate than 
other NSAIDs for patients in whom CV risk is a significant consideration in 
decision making. 
 Consider prescribing a PPI with any NSAID to reduce the risk of adverse GI 
effects, particularly in those who are at high GI risk (includes anybody aged 65 
years or older) and long-term NSAID users. 
 Although coxibs are associated with a lower risk of GI side effects than 
traditional NSAIDs, there is no good evidence to support the use of coxibs alone 
ahead of traditional NSAIDs co-prescribed with a PPI.  
 Medication reviews of NSAIDs should consider: 
o Whether the NSAID is necessary 
o When reviewing the treatment of patients receiving diclofenac, some 
cases it may be appropriate to consider alternatives(especially in patients 
with significant risk factors for CV disease): 
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o Patients who change from diclofenac 150mg/day to 1200mg ibuprofen/day 
would probably reduce both GI and CV thrombotic risk. 
Patients who change from diclofenac 150mg/day to naproxen 1000mg/day 
would reduce their CV thrombotic risk, but may slightly increase their risk of GI 
complications. However, if PPI is introduced, the GI risks may also be reduced.  
 
NSAID Initiation – Points for consideration 
 
Is the NSAID needed? 
 Is paracetamol an appropriate first line analgesic choice? 
 What about topical NSAIDs first line / in combination with paracetamol?  
 Is the NSAID prescribed appropriate based on the patients CV risk? 
 Is the NSAID prescribed the one with the lowest GI risk suitable for that patient? 
 Should a PPI be co-prescribed to reduce the risk of adverse GI effects?  (high 
risk) 
 When should treatment / dose next be reviewed? 
 Consider NSAID switch to lower risk choice 
 Remove from repeat 
 
Points for Good Practice / Audit 
 
 Is the indication for NSAID recorded 
 No prescribing for patients with 
o Active PUD 
o Past history of GI bleed 
o Renal or heart failure 
 “At risk” groups should have risk assessment documented 
 Review to address continued need and whether still appropriate 
 Who should be prioritised for review? 
o Those with established CVD risk  
 On aspirin 
 Smokers 
 People with diabetes 
o Those at high GI risk 
 Age >65 years 
 History of GI bleeding 
 On medicine which increase risk of GI bleed warfarin, aspirin, 
corticosteroids 
 Serious co-morbidity eg CV, renal hepatic, diabetes, hypertension 
 Prolonged use or high doses of NSAIDs 
 Excessive alcohol 
 Heavy smokers 
 
What is the evidence for other medications? 
 
o Both paracetamol and NSAIDs (including coxibs) have a small to moderate 
effect in reducing pain. (Cochrane, 2006). 
o Evidence for the use of glucosamine and chondroitin is not robust 
o Tramadol.  Tramadol is no more effective than other weak opioid analgesics and 
its safety profile is problematic. (Cochrane, 2006, CSM, 2006) 
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Key Messages in Development of Detail Aids - T2DM 
 
Therapeutic Topic – Management of Type 2 Diabetes (T2DM)   
Key Messages for Pharmacists Delivering the Intervention 
 
T2DM is a long term conditions associated with increasing obesity and an aging 
population.  Although characterised by raised blood glucose, it is essentially a 
cardiovascular disease associated with increased morbidity and mortality.  People 
with T2DM are at almost twice the risk of dying from any cause than those without 
diabetes.  There is evidence that effective management of the disease and 
associated risk factors increases quality of life and life expectancy. 
 
 Lifestyle interventions are key in the prevention and treatment of type 2 
diabetes.  Dietary interventions and exercise aim to correct obesity, improve 
glycaemic control, blood pressure and blood lipid control.  
 The single most effective intervention in those who smoke is smoking cessation. 
 After stopping smoking, successful management of blood pressure is the most 
effective means of reducing cardiovascular risk in T2DM.   
 Lipid management and use of aspirin are the next most effective interventions.   
 Aims of treatment 
o Manage symptoms 
o Reduce life threatening or disabling complications (MI, stroke) 




Three main components 
 Blood glucose (BG)  
Intensive BG control with sulphonylureas/insulin vs conventional BG control 
 Metformin 
Intensive BG control with metformin (or SU/insulin) vs conventional control in 
obese/overweight patients 
 Blood Pressure (BP) 
Tight BP control vs less tight BP control (ACE-I and ß-blocker comparisons) 
 
Results 
 Intensive BG control by either SUs or insulin decreased risk of microvascular 
problems but not macrovascular disease. 
 Metformin reduced the risk for any diabetes related end-point (32%, p=0.002), 
diabetes related death(42%, p=0.021) and all cause mortality (36%, p=0.011) 
(Despite similar reductions in HbA1c for metformin compared with SUs/insulin) 
NNTs for aggregate endpoints and overall mortality were 10 and 14 respectively 
 Risk reductions for tight BP control were 24% for any diabetes related end-
points (p=0.0046), 32% for diabetes related death(p=0.019), 44% in strokes 
(p=01013) and 37% in microvascular endpoints (p=0.0092). 
 
Conclusions 
 Tight control of blood glucose  
 Important in terms of symptoms and microvascular complications 
 Benefit on microvascular problems not proven 
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 Metformin has an effect on macrovascular complications that is independent of 
its blood glucose lowering effect.  Metformin is the hypoglycaemic drug of choice 
in T2DM 
 Management of BP is as if not more important than tight control of BG 
 
Questions 
Does this support the high profile given the need for tight control of BG? 
Think about the priorities for patients  - The Diabetes Hand 
 
Why are the following statements repeatedly quoted? 
‘Good glycaemic control significantly reduces risk of long term complications in 
T2DM’ 
‘A 1% reduction in HbA1c reduces diabetes related deaths  by 21%, risk of 
microvascular complications by 37% and risk of MI by 14%’ 
 
 All based on observational data from UKPDS 35 (Stratton et al and EPIC 
Norfolk) 
 The papers generate a hypothesis based on epidemiological data.  
 As yet there is no prospective RCT evidence to support this 
 In fact, UKPDS results from SU/insulin arm refute this.  Also Stettler meta-
analysis 
 
Conclusion: Managing BG is important but in isolation is not the key to reducing 





 Metformin first line choice oral hypoglycaemic agent (OHA) overweight and 
non-overweight 
 SU second line or if metformin contraindicated  





 Importance of aiming to put all on metformin because of cardiovascular 
protective effects 
 Step up dose gradually to reduce GI effects 
 Use MR only after adequate trial of normal release (no evidence of beneficial 
effect of MR compared with NR 
 
Glitazones 
 Safety issues 
 First drug in class, troglitazone was withdrawn (1997) after a few months 
because of hepatotoxicity.   
 Both rosiglitazone and pioglitazone were introduced on the basis of their 
blood glucose lowering ability rather than ability to reduce complications of 
T2DM 
 Only one published study specifically designed to evaluate secondary 
prevention of macrovascular events with a glitazone - PROactive Study. No 
significant difference in primary end-point. Statistically significant difference 
when analysis was restricted to the secondary endpoint.  The number 
needed to treat was 48.  NNH 63 for heart failure requiring hospitalisation. 
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 No definitive evidence that glitazones are associated with significant 
reduction in the long term microvascular or macrovascular complications of 
T2DM. 
 Controversy regarding safety of glitazones, in particular rosiglitazone 
 The evidence is now indicating that rosiglitazone is associated with 
cardiovascular morbidity and mortality.  Conversely, pioglitazone appears to 
have better cardiovascular safety (excluding HF) 
 Midlands Therapeutic Review and Advisory Committee reviewed the 
evidence for glitazones (April 2008).  Concluded that Rosiglitazone cannot 
be recommended for prescribing based on current concerns about potential 
CV adverse effects and lack of evidence for improved patient-orientated 
outcomes and pioglitazone is suitable for use in primary care by a prescriber 
with a particular interest in T2DM.  There is conflicting evidence regarding 
long term clinical benefits or harms on cardiovascular outcomes which 
dictates caution in its use.  
 Fluid retention, heart failure are well known adverse events of glitazones.  
Effects on bone density and fracture risk and macular oedema are more 
recently reported concerns.  The SPCs for both products now also carry 
warnings regarding all of these adverse effects. 
 
Tight BG control 
 Recently evidence from ACCORD and ADVANCE demonstrates that 
intensive BG lowering failed to show any reduction on cardiovascular events 
compared with standard treatment. 
 Now concerns that that intensive BG control is actually harmful.  ACCORD 
study (target HbA1c <6%, mean achieved target was 6.4%) was stopped 
early because of higher incidence in all-cause mortality in the intensive arm. 
 
Self-monitoring of Blood Glucose 
Two studies recently been published in the BMJ, ESMON and DiGEM trials.  Both 
studies were funded independently without industry sponsorship. 
 ESMON Study    
o No difference in HbA1c 
o Increase in depression and anxiety 
 
 Economic Evaluation of DIGEM 
o Decreased QoL 
o Evaluation of cost in monitoring 
o Diabetes UK changed stance 
 
 
Management of Hypertension –  
 
Summarised in MeReC bulletin.  Focussing on updated NICE Guidance 
 
Drug Choice - Specified in algorithm 
Step 1  <55 years  ACE-I 
>55 years or black CCB or diuretic (D) 
Step 2   A+C   or  A+D 
Step 3    A+ C + D 




                                                                  219 
 
 
 In general however no compelling evidence of any clinically significant, drug 
specific effects to distinguish between drugs in terms of efficacy when BP 
lowering effect is taken into account. 
 May be benefits for specific classes in specific patient groups 
 
ALLHAT  
 ALLHAT is one of the most important trials of hypertensive therapy. 
 For primary end-points of fatal CHD or non-fatal MI there was no difference 
between chlorthalidone, amlodipine and lisinopril.   
 There were some differences in secondary end-points.  Amlodipine had a higher 
risk of heart failure and lisinopril had higher risk for combined CVD, stroke, heart 
failure and angina than chlorthalidone 
 Diuretics are the preferred initial treatment for hypertension including in people 
with diabetes. Endorsed by JNC7. 




 If CV risk low, assess using UKPDS risk engine.  (NICE). 
 Initiate simvastatin 40mg for most people aged 40 or over unless risk low 
(younger if CV risk high).  Consider increasing dose to simvastatin 80mg 
unless TC less than 4mmol/l or LDL less than 2mmol/l.  (NICE). 
 For people with T2DM with established or newly diagnosed CV disease or 
raised ACR, initiate simvastatin 40mg.  Consider changing statin or add 
ezetimibe (NICE). 
 If either figure is below level, dose increase is not recommended 
 NICE does not set lipid targets which patients are expected to achieve 
 Single cholesterol levels may vary.  HCPs should be aware of making 
treatment decision based on one reading 
 The only published RCT of ezetimibe plus simvastatin did not produce 
beneficial effects compared with double placebo but raised safety concerns 
relating to cancer. 




 Use aspirin in higher risk patients and those aged 50 or older as long as BP 
is <145/90mmHg. 
 Clopidogrel is alternative on those with clear aspirin intolerance 
 POPADAD Trial.  Study too small and underpowered to rule out benefit of 
aspirin in T2DM patients at risk of CV disease. 
 
 




Typical Evidence Based Resources Utilised in the Development of Detail Aids  
 
Included the following (the list is not exhaustive):  
 
NICE Guidance 
Current NICE Guidance documents relating to T2DM and NSAIDs were key 
evidence based references utilised in the therapeutics training. 
  
MeReC Publications 
MeReC publications are high quality resources issued by NPC useful to a wide 
range of healthcare professionals.  They provide concise pre-appraised evidence 
based information about medicines and prescribing related issues.  Rapid Reviews 
are produced in response to requests for evaluation of key clinical trials or guidance 
as soon as they are published whereas MeReC bulletins focus on key therapeutic 
dilemmas – collating and summarising evidence and guidelines.   
MeReC may produce drug specific and drug class focussed reviews as well as 
disease focussed reviews.  The resources accessed provided and reinforced 
consistent key messages which are supported by high quality evidence based 
studies and other evidence based sources.   
 
NPCi e-Learning 
These resources are available for healthcare professionals through NPCi and are 
frequently used by primary care pharmacist prescribing advisers.  A number of these 
are intended to be used as educational tools and may be used to promote behaviour 
change in prescribing.   
 
 ‘Key Slides’ 
The ‘Key Slides’ are most akin to detail aids.  They constitute are a limited set of 
slides summarising key messages relating to specific therapeutic topics.  They are 
provided as PowerPoint presentations for discussions about the therapeutic topic.  
Key slides are accompanied by extensive notes for each slide, available as Word 
files and providing supporting evidence and discussion points.  The slides and 
accompanying notes enable individuals to explain key messages and discuss 
important therapeutic issues with colleagues.  
 
 Data Focussed Commentaries 
Data focussed commentaries accompany the key slides.  They consist of a short 
report comparing prescribing and other data with the evidence-base, highlighting 
areas where the evidence may not have been fully implemented. They also provide 
















    
Targeting Treatment in OA





Background – It’s about Safety
 All NSAIDs including Coxibs carry risk of side effects.  
Potentially serious and life threatening
● GI (perforation, ulcer, bleeding)
● CV (stroke, MI)
● Renovascular (fluid retention, hypertension, HF) 
 Need to review our NSAID prescribing to minimise risk 
to patients 
 Thrombotic risk concern
● 2 coxibs withdrawn because of unacceptable risk
● Evidence suggests Coxibs and diclofenac have similar 
thrombotic risk
● 3 additional events / 1000 patients / year
    





















● COX-II inhibitors may 
cause 240 additional or 
premature CV events per 
year in England alone 
● Diclofenac may cause 
2000 additional or 
premature CV events per 
year
NSAID prescribing in England 





CV Risk - Overview
 Coxibs cause an increased risk of thrombotic events 
c.f. placebo (3 additional events / 1000 patients / year)
 Coxibs are contraindicated in patients with CV disease
 Risk increases with dose & persists throughout 
treatment
 Diclofenac 150mg/day has similar excess risk to 
coxibs
 Cardio renal effects apply to all NSAIDs including 
coxibs and contribute to CV risk
 Low dose ibuprofen (≤1200mg/day) and naproxen 
1000mg/day have a lower thrombotic risk
    
GI Risk - Overview
 All NSAIDs (including coxibs) carry a risk of GI side effects
 GI risk increases with age, co-morbidities (eg CV disease, 
diabetes, smoking)
 Concomitant aspirin greatly increases the GI risks of NSAIDs and
reduces any GI safety advantages of coxibs
 Dyspepsia as common with coxibs as with traditional NSAIDs
 No good evidence that addition of PPI to coxib is more beneficial 
than adding PPI to traditional NSAID
 Low dose ibuprofen (≤1200mg/day) is associated with lower GI 
risk than diclofenac or naproxen
 Evidence suggests there is no safe period of ‘no risk’ Risk 
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 Established CV 
disease
 Taking CV 






High GI risk 
 Age >65 years
 History of GI bleeding, ulcer 
or perforation
 Taking medicines that 
increase risk of upper-GI AEs
(warfarin, aspirin and 
corticosteroids)
 Co-morbidity: CV disease, 
renal or hepatic impairment, 
diabetes or hypertension
 Prolonged duration or 
maximum doses of NSAID
 Excessive alcohol use
 Heavy smokers
    
What does this mean in practice?
 Base prescribing on safety profiles of individual NSAIDs 
and on individual patient risk factors
 Consider Paracetamol and topical NSAIDs first line
 Use NSAIDs at the lowest effective dose and for shortest 
period of time
 Low dose ibuprofen is an appropriate first line choice as 
lower risk of GI and CV side effects
 Low dose ibuprofen or naproxen would appear appropriate 
for patients where CV risk is a consideration
 Consider PPI with NSAID especially in those at high GI risk 





Best Practice for NSAID prescribing
Don’t use NSAIDs unless you have to
● non-drug interventions should be considered in every case
● Consider topical NSAIDs ahead of oral NSAIDs for OA
● Paracetamol can be effective
If you have to use NSAIDs, use them wisely
● assess benefits and risks; consider CV, GI and renal issues
● Use a safer drug (ibuprofen, then naproxen) 
● lowest effective dose for the shortest period 
Gastroprotection for patients at high risk
● Options are PPIs, double-dose H2RAs, misoprostol
● Co-prescribe PPI with NSAID for OA
Medication reviews for all NSAID users
● are NSAIDs effective/needed? 
● drug holiday? 
● no repeat prescriptions without review
    
Practice Audit for NSAIDs
 Identify patients with active NSAID Rx
 Identify patients with contraindications for 
NSAIDs
● Active peptic ulceration
● Previous GI bleed
● Renal failure
● Heart failure
 Identify patients with





 Is NSAID still necessary?
 Does the NSAID prescribed have the 
lowest CV risk?
 Does the NSAID prescribed have the 
lowest GI risk?
 Should PPI be co-prescribed? 
 When should the patient be reviewed 
again?
    
For patients on higher CV risk NSAIDs
Consider switching them to 
 Paracetamol 4g / day
● Reduces CV 
● Reduces GI risk
 Ibuprofen 1200mg / day 
● Reduces CV 
● Reduces GI risk (PPI reduces risk further)
 Naproxen 1g / day
● Reduces CV risk
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Burden of Type 2 Diabetes
 T2DM reduces life expectancy by about 7 – 10 years
 Macrovascular disease 
 causes  > 70% of deaths (CHD, CVA, PVD)
 Microvascular disease causes disability and suffering
 retinopathy, renal disease, neuropathy, feet
 Metabolic complications
 Potential huge economic burden of treatment in terms of
 lost earnings 





Death by Cause – T2DM 
Laing et al (1999) Diabetic Medicine
16: 466 – 471
Office for National Statistics (2000)








CVD Cancer Respiratory disease









Respiratory disease Renal disease
Accidents and violence Diabetes
All other causes
    












Laing et al (1999) Diabetic Medicine; 16: 466 – 471
Office for National Statistics (2000)




Background – Key Issues
 Risk factors for T2DM - Cardiovascular
 Type 2 diabetes is essentially a cardiovascular 
disease associated with obesity and insulin resistance
 Characterised by raised blood glucose
 How to prioritise treatment and target drug therapy
 Evidence shows that more effective management of the 
disease and its associated risk factors increases quality of life 
and life expectancy
 Choice of medications to manage CV risk (BP, lipids) 
blood glucose and microvascular complications
 Role of old and newer drug therapies
    
Evidence for Intervention
 UKPDS provides compelling evidence for approach to 
management
 Recruited 5,102 newly diagnosed diabetics, (FBG > 6mmol/l)
 Initially treated for 3 months with diet and advice
 Three main components:
- Blood glucose - intensive BG vs conventional BG  
(+ insulin and sulphonylurea comparisons)
- Metformin - intensive BG control in overweight patients 
metformin vs SU / insulin
- Blood pressure - tight BP vs less tight control 
(+ ACE-I and ß-blocker comparisons)
UKPDS 33. Lancet 1998;352:837–853
UKPDS 34. Lancet 1998;352:854–865 
UKPDS 38. BMJ 1998;317:703–713  
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What did UKPDS show us?
Take 100 people as in UKPDs - Over 10 years
 Intensive control of BG using sulphonylurea / insulin
 Prevents about 3 people developing microvascular
complications
(mainly because they don’t need retinal photocoagulation) 
 Do not prevent deaths, strokes or probably heart attacks
 Use metformin to control BG
 Prevents about 7 heart attacks, 5 people from dying from 
diabetes complications and 8 from dying of any cause
 Intensive control of BP (over 8 years)
 Prevents about 4 people having a stroke, 5 deaths from 
diabetes complications and about 5 from having 
microvascular problems
    
1. Lifestyle 





3. Add Stain 4. Add metformin
(and aspirin if appropriate)







 Lifestyle interventions are key in prevention and 
treatment of Type 2 diabetes
 Diet and exercise to manage weight, correct obesity 
and to improve:
 blood pressure, glycaemic control and blood lipids
 The most effective intervention to reduce CV risk in 
smokers is smoking cessation
 Structured education should be seen as an integral 
component of diabetes care
 Health care professionals passing on the same messages 
repeatedly
 Management of depression
    
2. Control Blood Pressure
 Successful management of blood pressure is the most 
effective means of reducing cardiovascular risk (after 
smoking cessation). Which Antihypertensive?





3. Role of Statins in T2DM
 Next most effective intervention to reduce CV risk after control of 
blood pressure (and smoking cessation)
 Benefits approximately 2030% relative risk reduction regardless 
of age, gender, lipid levels.
 Baseline risk is the key to the size of the absolute risk reduction
 Evidence is for simvastatin 40mg/day or atorvastatin 10mg/day
 Consider for all > 40 years and those <40 years with high CV risk
 Offer generic simvastatin
 Local and national policy – simvastatin 40mg/day
 Assess lipids and modifiable risk factors 1-3 months after starting
 Titrate to simvastatin 80mg if
 Cholesterol >4.0mmol/l
 LDL >2mmol/l
 NB: Safety concerns with rosuvastatin (don’t forget cerivastatin)
    
4. Metformin / Aspirin
 Using metformin first line to control BG
 Prevents about 7 heart attacks, 5 people from dying from 
diabetes complications and 8 from dying of any cause 
(UKPDS)
 Metformin has an effect in reducing cardiovascular 
risk which is independent from its glucose lowering 
ability
 Intensive control of blood glucose with SU / insulin 
does not demonstrate CV risk reduction shown by 
metformin
 Low dose aspirin
 Evidence supports use in patients with high CV risk and 
those with existing CV disease (but control BP < 145/90mg)
1. UKPDS 34. Lancet 1998;352:854–865
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 Setting a target
 Involve the patient in setting an individual HbA1c target
 Avoid very intensive management 
 Evidence from studies assessing intensive glucose 
lowering strategies ADVANCE, ACCORD, VADT
 First line metformin followed by sulphonylurea
 Self-monitoring of blood glucose
 Only offer as integral part of self-management plan
 Make available to those on insulin, on medication likely to 
cause hypoglycaemia and to monitor medication lifestyle 
changes and/or illness
    
Glucose Control
UKPDS 33. Lancet 1998;352:837–853






 Lifestyle modification is key to management - to be 
maintained
 Reducing cardiovascular risk is the main objective
 Reducing BP is more important than worrying about drug 
choice
 ACE-Is are acceptable first choice with thiazides good 
addition for most
 Many will need combinations to achieve target
 Avoid ARBs and doxazosin if possible
 Statins are appropriate for most patients 
 Simvastatin 40mg first line
    
Summary (2)
 Is the emphasis on tight BG control justified by the 
evidence?
 Metformin for everyone with T2DM?
 Consider need for and frequency of self-monitoring BG 
Set realistic HbA1c target.
 Manage overall risk which is similar to that in patients 
with established CHD.
 Remember – Polypharmacy is the norm
















Aims of Treatment for Type 2 Diabetes
 Manage symptoms
 Reduce risk of major life-threatening or 
disabling complications (MI/stroke)
 Manage diabetic renal disease, retinopathy 
and foot disease
Note:
 Targets set by NICE can be demanding to reach
 Targets should be agreed with individuals as 










3. Add statin 4. Add metformin
(and aspirin if appropriate)




Algorithm for BP Control (1)
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
Algorithm  for BP Control (2)
Type 2 diabetes: the management of type 2 diabetes.  NICE Clinical Guideline 87;May 2009
 
*-Features of metabolic syndrome, strong early family history of CV disease, smoking, hypertension, existing 
CV disease, microalbuminuria
But see new evidence from POPADAD trial in primary prevention of people with 
diabetes
Anti-thrombotic therapy
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
 
Management of Blood Glucose 
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
Management of Blood Glucose 2
 




Management of Blood Glucose 4
 
Management of Blood Glucose 5
 
NICE Clinical Guideline: 
the management of type 2 diabetes
 Partial update of CG 66 (May 2008) to address role of 
newer drugs.  Most remains unchanged
 Monitoring of BP, lipids and BG
 Diabetes Education programmes
 Use of medications to manage BP, lipids and BG
 Ongoing management and monitoring of microvascular effects 
and depression
 What has changed?
 New recommendations on medications to control BG
 GLP-1 mimetic (exenatide), DPP-4 inhibitors (sitagliptin, vildagliptin) 
and glitazones (rosiglitazone and pioglitazone)
NICE Clinical Guideline 87;May 2009 Type 2 diabetes: the management of type 2 diabetes  
 
Key Priorities for Implementation
 Patient Education – Offer structured education around time of 
diagnosis.  
 Dietary Advice – Provide individualised and ongoing nutritional 
advice from a HCP with specific expertise and competencies in 
nutrition
● Lifestyle management remains key to management of T2DM
 Setting a Target HbA1c
● Involve person in decisions re target level (may be higher than 
6.5%)
● Avoid pursuing highly intensive management to less than 6.5%
 Self monitoring of Blood Glucose (SMBG)
● Offer to newly diagnosed only as part of self management 
education
 
Management of Blood Glucose
Glucose Control Strategy
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
Setting a Target HbA1c 
 Involve person in decisions about their individual target level 
which may be above that set for people with T2DM in general
 HbA1c value of 6.5% (or other higher level agreed with the 
individual) for diet controlled and people on one glucose 
lowering drug
 HbA1c value of 7.5% (or other higher level agreed with the 
individual) for people on two or more oral glucose lowering 
drugs
 Avoid pursuing highly intensive management to less than 6.5%
Measure HbA1c every 2-6 months (according to need) until 
stable on unchanging therapy then every 6 months
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Glitazones (1)
 Increase insulin sensitivity + glucose uptake, reduce gluconeogenesis
 Known safety concerns – MHRA/CSM advice
 Contraindicated in heart failure or history of HF
 Incidence of HF increased when combined with insulin
.
 Cautions and safety concerns
 Fluid retention and heart failure
 Bone density loss and fracture risk
 Macular oedema
 Cause increase in body weight, peripheral oedema
 Rosiglitazone may be associated with increased risk of cardiac 
ischaemia
 Not recommended for use in patients with IHD, PAD, contraindicated in ACS
 May increase the likelihood of MI or cardiovascular disease
 Rosiglitazone associated with dislipidaemia, (raised LDL, TGs)
DTB 2008;46: (4)25-29  
Summary - Recommendations for BG 
Control (NICE) - 2
 Are there alternatives to insulin therapy?
 Sitagliptin ▼ or a glitazone can be considered for triple therapy 
with Metformin plus SU if insulin unacceptable or inappropriate
 Exenatide may be considered for triple therapy in addition 
to metformin and SU (if HbA1c > 7.5% or higher agreed 
level) where
 BMI>35kg/m2 and specific psychological or medical problems 
with high weight
 BMI>35kg/m2 and therapy with insulin would have significant 
occupational implications or weight loss would benefit other 
significant obesity related co-morbidities
 Exenatide should only be continued if there is a reduction in 
HbA1c of at least 1% and a weight loss of 3% of initial body 
weight at 6 months
 
Starting Insulin Therapy (NICE)
 If other measures do not keep HbA1c <7.5% (or 
agreed target) discuss benefits and risks of insulin
 Initiate with structured programme
 Begin with human NPH (isophane) insulin at bedtime 
or b.d. depending on need
Ref: Type 2 diabetes: the management of type 2 diabetes.  NICE Clinical Guideline 87;May 2009   
 
Self-monitoring of blood glucose
Make available to:
●Those on insulin
● Those on oral medication to provide information on hypoglycaemia
● Assess changes during medication or lifestyle changes, or illness
● Ensure safety during activities, including driving
Assess at least annually in a structured way:
● Self-monitoring skills
● Quality and appropriate frequency of testing
● The use made of results obtained
● The impact on quality of life
● The continued benefit
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 66;May 2008  
Self Monitoring of Blood Glucose (SMBG)
 Two new studies suggest that newly diagnosed people with T2DM are 
unlikely to gain any benefit from monitoring blood glucose themselves.  
SMBG may result in lower quality of life.
 O’Kane M et al Efficacy of self monitoring of BG in patients with newly 
diagnosed T2DM (ESMON Study BMJ April 2008)
 Adding SMBG structured education did not produce greater reductions in 
HbA1c cf education alone
 No differences in reported hypoglycaemia, OHA use or BMI
 Patients in SMBG gp were significantly more depressed than control gp
 Simon J et al Cost effectiveness of SMBG in patients with non insulin 
treated T2DM economic evaluation from DiGEM trial (BMJ April 2008)
 SMBG was associated with reduced health related QoL thought to be due to 
increased levels of depression and anxiety
 
Glitazones (1)
 Increase insulin sensitivity + glucose uptake, reduce gluconeogenesis
 Known safety concerns – MHRA/CSM advice
 Contraindicated in heart failure or history of HF
 Incidence of HF increased when combined with insulin
.
 Cautions and safety concerns
 Fluid retention and heart failure
 Bone density loss and fracture risk
 Macular oedema
 Cause increase in body weight, peripheral oedema
 Rosiglitazone may be associated with increased risk of cardiac 
ischaemia
 Not recommended for use in patients with IHD, PAD, contraindicated in ACS
 May increase the likelihood of MI or cardiovascular disease
 Rosiglitazone associated with dislipidaemia, (raised LDL, TGs)
DTB 2008;46: (4)25-29  
 
Glitazones (2) 
 Only one glitazone study– PRO-ACTIVE deigned to assess 
cardiovascular outcomes (pioglitazone)
 No statistically significant difference between groups for primary 
endpoint
 No convincing evidence for improved clinical outcomes
 If glitazone thought to be appropriate, pioglitazone appears to be 
safer
 Recommended preferred choice – Pioglitazone (formulary choice)
 Combination products  - No evidence for improved compliance or 
HbA1c
 Removes capacity to titrate maximise metformin concentration
 Not licensed for initiation
DTB 2008;46: (4)25-29  
PRO-Active Study
 Average observation was 35.4 months
 Primary endpoint – Composite of all-cause mortality, non-
fatal MI, stroke, ACS, endovascular/surgical intervention
● no significant difference between groups
 Main secondary endpoint – Composite of all-cause 
mortality, non-fatal MI, stroke
 NNT= 48 over 34.5 months
 p = 0.27
 but no difference in those taking statins
 Heart Failure requiring hospital admission
 NNH= 62 over 34.5 months
 p = 0.007
Dormandy JA et al.  Lancet 2005;366:1279-1289  
Oral Hypoglycaemics: Old vs. new drugs
● Systematic review of 216 studies and 2 earlier SRs of oral 
hypoglycaemics to January 2006 concluded that older 
agents have similar or superior effects to newer, more 
expensive agents on glycaemic control, lipids and other 
intermediate endpoints (body weight, BP, adverse effects, 
etc.)





– Gliptins sitagliptin, vildagliptin ~ 0.7%
– GLP agonists (exenatide) ~1.0%
Bolen S, et al. Ann Intern Med 2007;147:386–99  
 
Incretin Therapy
 GLP-1 agonists (Exenatide, liraglutide)
 Stimulate glucose dependent insulin secretion
 Glucagon Suppression
 Delays gastric emptying
 GLP-agonists rapidly inactivated by the enzyme dipeptidyl
dipeptidase 4
 DPP-4 inhibitors (Gliptins – Sitagliptin, vildagliptin)
 Inhibit dipeptidyl dipeptidase - 4
 Enhance levels of incretin hormones (eg GLP1)
 Enhance insulin, reduce glucagon




 Licensed in combination with metformin and / or SUs
 Twice daily s.c. injection within 60min of main meal
 HbA1c reduction approx 0.9 – 1.0%
 Currently secondary care prescribing only
 Once weekly preparation in development
 Liraglutide
 Licensed in combination with metformin and / or SUs
 Licensed in combination with metformin and glitazone
 Once daily 
 Currently red listed
 
DPP-4 Inhibitors - Gliptins
 Possibly weight neutral
 Increase ß-cell activity
 No evidence more effective than current options
 No outcome, morbidity or mortality data
 Long term adverse event profile not known
 No effect on insulin resistance
 Key interventions lifestyle, metformin




DPP-4 Inhibitors - Gliptins
 Sitagliptin
 Licensed in combination with metformin or 
glitazone or SU or metformin and SU
 Oral 100mg od
 HbA1c reduction approx 0.7%
 Vildagliptin
 Licensed in combination with metformin or 
glitazone or SU (not triple therapy) 
 HbA1c reduction approx 0.7%
 
DPP-4 Inhibitors - Gliptins
 Sitagliptin
 Licensed in combination with metformin or 
glitazone or SU or metformin and SU
 Oral 100mg od
 HbA1c reduction approx 0.7%
 Vildagliptin
 Licensed in combination with metformin or 
glitazone or SU (not triple therapy) 
 HbA1c reduction approx 0.7%
 
Management of Cardiovascular Risk
 Blood pressure management
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Algorithm  for BP Control (1)
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  NICE guideline 34. 2006




First-line BP lowering therapy should be a once-
daily, generic ACE inhibitor
●Exceptions to this are:
● People of African-Caribbean descent, who should 
receive an ACE inhibitor plus either a diuretic or a 
generic calcium-channel blocker (CCB)
● Women for whom there is a possibility of becoming 
pregnant, who should receive a CCB
● For a person with continuing intolerance to an ACE 
inhibitor (other than renal deterioration or 
hyperkalaemia), substitute an angiotensin-II receptor 
antagonist (A2RA)* for the ACE inhibitor 
* Also called an angiotensin-II receptor blocker (A2RB)
NICE Diabetes Clinical Guideline 87;May 2009. NICE Full Diabetes Guideline;2009  
 
Evidence from ALLHAT
The Antihypertensive and Lipid Lowering treatment to Prevent Heart attack  Trial –
ALLHAT
●33,357 people aged >55 with hypertension and at least one other CHD risk factor - randomised to chlorthalidine, 
amlodipine or lisinopril (mean follow up 4.9 years)
● Target BP, 140/90mmHg.  Titration of study drug and added open label therapy
●No significant differences between treatments for primary outcome (combined fatal CHD or non- fatal MI).
● First line use of thiazides, ACE inhibitor, or CCB were similarly effective in reducing the risk of major CV 
events
● There was no evidence of superiority for CCBs or ACE inhibitors compared with a thiazide-type diuretic in 
patients with diabetes or IFG
●Differences in secondary outcomes – Diuretic superior to CCB and ACE-I
● Amlodipine had higher 6 year rate of HF than chlorthalidone
● Lisinopril had higher 6 year rate of stroke, combined CVD  and HF than chlorthalidone
● NB: Fourth treatment arm with doxazosin was stopped prematurely (median 3.3 years) because of adverse CV rate (stroke, 
CVD and HF)
●Concluded that chlortalidone was unsurpassed in lowering BP and reducing CV outcomes
●Thiazides in patients with diabetes are safe and well tolerated
● If there are no compelling reasons to favour one recommended second line therapy over one another, a 
thiazide diuretic is an appropriate choice in  most
JAMA 2002;288:2981–2997. Whelton P, et al. Arch Intern Med 2005;165:
1401–1409,  MeReC Extra No. 27;March 2007  
Evidence from ALLHAT
 Over 30,000 patients (excluding doxazosin arm)
 First line use of thiazides, ACE-I or CCB were similarly effective in 
reducing the risk of major CV events
 There was no evidence of superiority for CCBs or ACE-I compared 
with thiazide-type diuretic in patients with diabetes or IFG
 No differences in fatal or non-fatal CHD between lisinopril (ACE) and 
chlortalidone (diuretic) groups.  Patients taking amlodipine had higher 
risk of fatal or non-fatal CHD, and higher risk of heart failure, than 
those taking chlortalidone (2º outcomes)
 More cases of diabetes (FG>6.9mmol/l) detected in chlorthalidone
group – however absolute differences were small 
 Patients randomised to chlortalidone were not disadvantaged for any 
other outcomes compared to those in other treatment arms
 The authors concluded that thiazide diuretics are unsurpassed for 
lowering blood pressure and reducing CV outcomes
Whelton P, et al. Arch Intern Med 2005; 165: 140109
 
Further Evidence
 BPLTTC - Blood Pressure Lowering Treatment Trialists Collaboration  - Meta-
analysis of 27 trials
 Included 158,709 participants, 33,395 with diabetes
 Found that CV events reduced to a similar extent by regimes based on diuretic, ß-
blocker, ACE-I, A-II-A or CCB
 Chlorthalidone, amlodipine and lisinopril similarly effective in reducing BP
 HF more common in patients with t2DM than chlorthalidone
 ADVANCE BP Study – RCT 
 11,140 patients >55 with T2DM plus CV disease or at least one risk factor
 Perindopril and indipamide vs placebo (concurrent medications continued)
 Combined major macrovascular and microvascular events reduced by 1.3%,             
NNT=77, RRR 9%, p=0.04
 No significant differences when macro and micro events analysed separately
 Death from CV disease and from any cause reduced by 0.8% (NNT= 25, RRR18%, 
p=0.03) and 1.2% respectively
 STUDY CONFIRMS THAT
 lowering BP in patients with T2DM reduces CV complications and death
 Thiazide remains good first choice in most
BPLTTC.  Arch Intern Med 2005;165:1410-1419 Lancet 2007; Ref  
 
ACE-Is vs A-II-As 
Two new studies
ONTARGET Study
 No significant difference in primary outcome (CV death, 
MI, stroke or hospitalisation for HF) with between 
telmisartan, ramipril or the combination
● Compared with telmisartan alone, more ramipril patients discontinued due cough (NNH 
32) or angiodema (NNH 500)
● Compared with ramipril alone, more telmisartan patients discontinued because of 
hypotensive symptoms (NNH 100)
TRANSCEND Study (Patients intolerant of ACE-Is)
 No significant reduction in the primary outcome (CV 
death, MI, stroke or hospitalisation for HF) with 
telmisartan compared with placebo
N Eng J Med 2008;358:1547-1549, Lancet 2008;372:1174-1183  
ACE-Is vs A-II-As - Summary
 ACE-Is remain first choice
 A-II-As are an alternative if ACE-I not tolerated 
because of cough
 A-II-As not supported by outcome evidence
 Combination treatment (RAS drugs) is not appropriate 
for the prevention of CV events in people with T2DM
 It is no more effective and is associated with more 
adverse events (hypotension, syncope, renal 
dysfunction and hyperkalaemia
 
Role of Statins in Type 2 Diabetes
 After symptom control (smoking cessation if relevant) and 
control of blood pressure
 Benefits appear to be around a 2030% relative risk 
reduction regardless of age, gender, lipid levels.
 Baseline risk is the key to the size of the absolute benefits
 Should all those with type 2 diabetes be on a statin?
 Which statin:
 Evidence is for simvastatin 40mg/day or atorvastatin
10mg/day
 Local and national policy – simvastatin 40mg/day




Management of Blood Lipids (1)
 Offer generic simvastatin (to 40mg) or a statin of similar efficacy + cost
 For people:
 Aged 40+ years and normal to high CV risk for someone with type 2 
diabetes
 Aged 40+ years and low CV risk for someone with type 2 diabetes 
but CV risk >20%/10 years when assessed using UKPDS risk engine 
 Aged under 40 years and poor CV risk factor profile
 High serum triglycerides (may be necessary to offer fibrate if 
>4.5mmol/l
 Assess lipid profile and modifiable risk factors 1–3 months after starting 
therapy.  Continue to monitor annually
 If possibility of becoming pregnant, discuss issues around statin use and 
agree next step with patient. 
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
Management of Blood Lipids (2)
 Increase to simvastatin 80mg daily unless total cholesterol 
<4.0mmol/L or LDL-cholesterol <2.0mmol/L
 The health economic analysis suggested titration to simvastatin 80mg was highly cost 
effective in those whose lipid-levels were not controlled to target levels of 4.0/2.0mmol/L 
irrespective of presence or absence of diagnosed CVD
 If there is existing or newly diagnosed CV disease or increased 
albumin excretion rate, consider intensifying therapy (with a more 
effective statin or ezetimibe)* to achieve a total cholesterol level 
below 4.0mmol/L or LDL-cholesterol level below 2.0mmol/L
 In those with CVD the health economic analysis suggested that uptitration from 
simvastatin 80mg to a more efficacious statin (modelled as atorvastatin 80mg) was cost-
effective if the titration targets were not met on simvastatin
*In line with NICE TAG 94: statins for prevention of CV events and NICE 
TAG 132: ezetimibe for primary hypercholesterolaemia
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
When to Initiate Fibrates
 Offer a fibrate (fenofibrate as first-line) if TG levels remain above 
4.5 mmol/L despite attention to other causes (optimised
glycaemic control)
 In some circumstances, this will be before a statin has been started 
because of acute need (i.e. risk of pancreatitis) and because of the 
undesirability of initiating two drugs at the same time
 If cardiovascular risk is high (as is typical in people with type 2 
diabetes), consider adding a fibrate to statin therapy if TG 
levels remain in the range 2.3–4.5 mmol/L despite statins
But safety issues with fibrates…
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
 
Antithrombotic Therapy
 Current NICE Guideline recommends in people with T2DM –
Offer low dose aspirin (75mg) daily
 for >50 years as long as BP controlled (<145/90)
 Age < 50 and significant other CV risk factors
 There is good evidence that aspirin is effective for the prevention of 
secondary events, including those with T2DM Low dose aspirin is 
established in the secondary prevention of cardiovascular disease
What about primary prevention?
 More recent evidence from meta-analyses and the POPADAD trial suggest 
that in primary prevention, the benefits and harms from aspirin in this setting 
may be more finely balanced than was previously thought even in those 
estimated to be at higher risk of CV events (eg diabetes , raised BP).
 Low dose aspirin is not therefore routinely recommended for primary 
prevention
DTB 2009; Vol 47 (11):122-124   
Kidney Damage 
If diabetic nephropathy confirmed, offer ACE-I with dose 
titration to maximum dose (unless not tolerated)
●Substitute A-II-A if ACE-I not tolerated
●Maintain BP < 130/80mmHg if abnormal ACR (renal 
damage)
● Or if retinopathy or cerebrovascular damage
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009
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Neuropathic Pain Management
 Offer tricyclic drug (amitriptyline) starting at low 
dose, titrate as tolerated
 If uncontrolled offer trial (to max dose) of gabapentin
If uncontrolled offer alternative therapy (pregabalin
or duloxetine) according to CPCT guideline
 Stop if ineffective at maximally tolerated dose
 Try another drug if SEs limit dose titration
 If uncontrolled, consider trial of opiate analgesia
 If uncontrolled discuss with person and seek 
assistance of local chronic pain management team if 
agreeable.
 If any of the above treatments are effective, 
consider reducing dose/stopping therapy following 
discussion and agreement with person concerned.
Type 2 diabetes: the management of type 2 diabetes. NICE Clinical Guideline 87;May 2009  
Glucose Control




















6.2% upper limit of normal range
UKPDS 33. Lancet 1998;352:837–853;  
Intensive BG control in T1DM 
 Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications DCCT/EDIC 
Research Group
 Observational Data – Frequencies of serious complications 
in patients with T1DM are lower than reported historically.  
 Incidence of complications appears to be substantially 
lower than those who started intensive BG control early on 
in their treatment
 Paper reinforces the current approach of aiming for 
intensive BG control in patients with T1DM
 In contrast to the evidence around T2DM
Arch Intern Med 2009; 169:1307-16  
 
 
10-year follow-up of UKPDS 
● Observational follow-up of the blood glucose part of the study
● Baseline differences in mean HbA1c levels lost by 1 year, but despite this…
There was a continued reduction in microvascular risk and emergent reduction in 
macrovascular risk seen with intensive vs. conventional therapy
● Significant risk reductions also persisted with metformin, in the sub-study of 
overweight patients
● BUT these are observational data
● Needs comparison with original UKPDS RCT data
● Does not provide evidence for early, very intensive glucose-lowering 
treatment for all patients with type 2 diabetes
There is still no convincing evidence that tight control of blood glucose in type 2 
diabetes reduces CV risk 
And we now have ACCORD, ADVANCE and VADT
Holman RR, et al. N Engl J Med 2008;359:1577–89. www.npci.org.uk/blog  
ACCORD, ADVANCE and VADT
 Three large RCT set up to assess whether intensive 
glucose control strategies offered any advantage over 
standard therapies with regard to major CV events 
 Found no significant improvements in macrovascular 
events with intensive glucose control
 In ACCORD, intensive BG lowering therapy was 
associated with an increased risk of death
 
The ACCORD Study 
Randomise Controlled Trial - 10,251 patients (mean age 62 years) with T2DM and 
elevated CV risk.   Set up to assess effects of intensive BG, BP and lipid lowering
Blood Glucose Lowering Arm
● Randomised to intensive glucose-lowering (target HbA1c <6.0%) or standard therapy 
(target HbA1c 7.0–7.9%)
● Primary endpoint (MI, stroke or CV death) did not differ between groups







Hazard Ratio (95% CI)
Stable median HbA1c at 1 
year
6.4% 7.5% -
Primary endpoint (MI, 
stroke or CV death)
6.9% 7.2% 0.90 (0.78-1.04); P=0.16 Not 
significant
All-cause mortality 5.0% 4.0% 1.22 (1.01-1.46); P=0.04; NNH=95




 10,251 patients with type 2 diabetes
 Average age 62
 Diabetes present for an average of 10 years
 Participants randomly assigned to treatment with any 
number of glucose lowering therapies
 Target HbA1c 6% or less
 All-cause mortality (5%v4%) and cardiovascular mortality 
(2.6%v1.8%) were higher in the intensive group of the 
study
 Study stopped early, after 3.5 years of follow up
 
What about ADVANCE?
 RCT of 11,140 patients (mean age 66 years) with T2DM and elevated CV risk
 Randomised to intensive treatment with gliclazide-based regime (target 
HbA1c<6.5% or less) or standard therapy (target based on local guidelines)
 Median follow-up 5 years
 Intensive therapy showed no significant effect on macrovascular events or all-





Hazard Ratio (95% CI)
Mean HbA1c 6.5% 7.3% -
Macrovascular primary endpoint (MI, 
stroke or CV death)
10.0% 10.6% 0.94 (0.84–1.06); P=0.32 Not 
significant
Microvascular primary endpoint (new 
or worsening nephropathy or 
retinopathy)
9.4% 10.9% 0.86 (0.77–0.97); P=0.01; NNT=67
All-cause mortality 8.9% 9.6% 0.93 (0.83–1.06); P=0.28 Not 
significant
N Engl J Med 2008;358:2560–2572. www.npci.org.uk/blog  
ADVANCE
 11,140 participants
 Mean age 66, diabetes for 8 years
 Randomly assigned to intensive treatment with modified 
release gliclazide or standard therapy
 Target HbA1c 6.5% or less
 After 5 years follow up HbA1c 6.5% in intensive group 
and 7.3% in control group
 No difference in all-cause mortality, cardiovascular 
mortality or major cardiovascular events





The Veterans Affairs Diabetes Trial (VADT)
 Open-label RCT -1,791 people (mean age 60 years) with T2DM
 Most did not smoke, had well-controlled BP and were taking a statin
 Randomised to intensive or standard glucose control with oral hypoglycaemic
drugs (including rosiglitazone) plus insulin if necessary. Other CV risk factors 
were treated uniformly
 Over median follow-up of 5.6 years - intensive treatment to achieve a median 
HbA1c of 6.9% compared with standard control to a median of 8.4% did not 
statistically significantly reduce the risk of:
 Major CV events (MI, stroke, death from CV causes, CHF, surgery for 
vascular disease, inoperable coronary disease, amputation for ischaemic
gangrene), HR 0.88; 95% CI 0.74 to 1.05, P=0.14
or any of these component endpoints
 All-cause mortality, HR 1.07; 95% CI 0.81 – 1.42; P=0.62
 Any microvascular outcomes (ophthalmic, nephropathic or neuropathic)
 Patients in the intensive treatment arm were more likely to experience 
hypoglycaemic episodes
N Engl J Med 2009;360:129–39.  www.npci.org.uk/blog  
Managing blood glucose is important 
but, in isolation it is not the key to 
preventing morbidity and mortality
MeReC Bulletin 2004; 15: 1-4
 
What is basis of this?
 
 
Evidence base for the factsheet
 Stems from observational data 
 UKPDS35 – Stratton et al, BMJ 2000; 321: 405-412
 Also EPIC Norfolk – Khaw KT et al, Ann Intern Med 
2004; 141: 413-420 (TYPE 1 diabetes study)
 So what?
 These papers generate a hypothesis – that reducing 
HbA1c results in reductions in CV events and 
mortality in type 2 diabetes
 The UKPDS refutes this hypothesis, as it found little 
evidence for insulin/SU-based tight control of blood 
glucose
 
Targets in Type 2 Diabetes
7%, 8%, 9%Monotherapy -6.5%
Dual therapy -7.5% 
HbA1c
TC <5TC < 4
LDL < 2








When setting a target HbA1c …..
 Involve the person in decisions about their individual HbA1c 
target which may be above that set for patients with T2DM in 
general
 Encourage person to a maintain individual target unless SEs
impair quality of life
 Offer therapy (lifestyle and medication) to help achieve and 
maintain target HbA1c
 Inform person with higher Hba1c that any reduction towards 
agreed target is advantageous to future health
 Avoid pursuing highly intensive management to levels of  < 6.5%
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Appendix 14 
 
Academic Detailing: Planning Matrix T2DM 
 Key Message              Features Benefits (which 
Means that…) 
Trust / Credibility Suitable  Questions 
1  
Although characterised by raised BG, T2DM is a 
cardiovascular disease associated with 
increased morbidity and mortality  
 
 there is inherently a higher cardiovascular 
risk in patients with T2DM 
 associated with  overweight / obesity  
 
Generally associated 
with obesity and insulin 
resistance c.f. T1DM 
where there is an 
absence of insulin 
 
Can target therapeutic 
and non therapeutic 
interventions more 
effectively to reduce 
morbidity and mortality. 
 
Evidence eg UKPDS 
Increasing awareness that 
cardiovascular risk is key 
in improving outcomes 
 
What are the most 
important things to 
consider in 
management of 
patients with T2DM  
2  
Prioritisation of treatment is key to targeting the 
specific aspects of care and reducing morbidity 
and mortality associated with T2DM.   
 
T2DM is a long term 
condition associated 
with poor long term 
outcomes if not 
managed 
 
Can target therapeutic 
and non therapeutic 
interventions more 
effectively to reduce 






How would they 




Aggressive management of cardiovascular risk 
is the most effective intervention in reducing 
more serious complications, morbidity and 
mortality rather than tight control of glucose.  
 
Tight control (intensive management) of blood 





of a number of aspects 
of care for each 
individual.   
 
Aim to manage so have 




Prevent / delay avoidable 





  Human 










Renal Studies  
(ACE-I / A-II-A) 
 
 
What sources of 
information would they 
access to support their 
education in managing 
aspects of T2DM 
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 Key Message              Features Benefits (which 
Means that…) 





Use to prioritise / remember approach to 
management in terms of most effective 
interventions – Lifestyle interventions are key 
and underpin management 
 Lifestyle interventions are key in prevention 
and treatment – Needs to be maintained 
 Stopping smoking 
 Management of BP most effective means of 
reducing CV risk after stopping smoking 
 Management of BP as if not more important 
then tight control of BP in reducing events 
 Stormin Metformin 
 
Provides aide memoire 
to prioritise approach to 
management of 
individual patients  
 
Improved patient care, 
reduction in complications 





Have they a different 
aide memoire eg 
ABCDEFG? 
5  
Guidance to GPs on most appropriate first line 








Knowledge, expertise  
and advice on evidence 
based medication 
choices.  To achieve 
best clinical outcomes 
for patients 
 




GPs can use prescribing 





Provision of further 
information/background  
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 Key Message              Features Benefits (which 
Means that…) 
Trust / Credibility Suitable  Questions 
6 How can practice improve? 
 Follow best practice advice  
 Audit of patients outcomes to support 
decision making in concentrating efforts for 
management of various aspects of therapy.  
MRW can provide information / support 
 
 Get commitment from practice to 
 
o Increase prescribing of metformin 
o Reduce rosiglitazone.  Initiate 
pioglitazone / managed switch to 
pioglitazone (reduce overall 
glitazones) 
o Cautious use of new drugs – 
starting/stopping criteria 
o Increase ratio metformin:metformin 
MR 
 
 Increase in prescribing of ACE-I/A-II-As 
for T2DM patients with m/a 
 Proportion of T2DM patients achieving 
BP <140/80mmHg 
 Proportion of T2DM patients with m/a 
achieving BP <130/80mmHg 
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Academic Detailing: Planning Matrix T2DM 
Aim of Session Areas of Controversy Mandatory Literature 
 
To discuss approach to management of T2DM  
 
To promote better management (if possible) of T2DM by 
prioritisation of effort in managing various aspects of the 
disease to prevent progression and reduce complications 
of diabetes. 
 
To consider the most effective and evidence based 
therapeutic (and non-therapeutic) interventions to reduce 




Blood Glucose or Blood Pressure? 
 
ACE-I versus A-II-As 
 
NICE Guideline on T2DM  




Detail Aid, Support Slides 
Access to original sources 
 
MHRA/FDA (Glitazones) 
DTB - Glitazones 
Possible ‘Starters for 10’ Questions to Ascertain Closure Materials to Take With You 
 
What do you consider as the most important factors in 
managing patients with T2DM. 
 
Does the practice have a specific approach?  Eg 
Nominated GP, PN 
 









Do they think that this approach differs from their 
current approach? 
 




 Increase use of metformin 
 1st, 2nd and 3rd line choice of antihypertensive 
 Switch/reduce glitazone prescribing 
 
How could we support them in any agreed actions?  
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Appendix 15 
 
Academic Detailing: Planning Matrix  NSAIDs 







The key and most important message relates to Safety 
 

























How does this 
fit in with the 
NICE guidance? 
3 Need to consider approach to NSAID prescribing to 
minimise patient risk 
 
High volume prescribing – More attributable events 
To prevent adverse 
events,  SUEs 
Minimise risk to patient  
population 
 




  Human 
  Financial / NHS 








4 Need to assess the risk for individual patients and tailor 
drug choice / treatment Including non-NSAID options to 
individual patient to minimise risk 
To prevent adverse 
events,  SUEs 
Minimise risk to individual 
patient   
Prevent avoidable clinical 
problems,  suffering, 
admissions 
 How do they 
approach 
management of 
risk in individual 
patients?   
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5 Best Practice Points – List 
 Copy of list for each GP 
 Steps to ‘NSAID heaven’ 
 
 










6 Anticipated Outcome / Objective 
 
How can practice improve? 
 
 Follow best practice advice 
 Audit  patients on NSAIDS (and COX-IIs) As defined in 
presentation 
 If appropriate get commitment from practice to perform 
audit to reduce NSAID prescribing  
 Expect 
o ↓ Diclofenac prescribing 
o ↓ COX-II prescribing 
o ↓ Overall NSAID prescribing  
o If NSAID has to be used, reflected by  relative 
↑ in proportion of ibuprofen, naproxen c.f. 
diclofenac 
o Increase in prescribing of topical NSAIDs 
o If NSAID has to be used, reflected by 
increased proportion of gastroprotection 
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Academic Detailing: Planning Matrix  NSAIDs 
 
Aim of Session Areas of Controversy Mandatory Literature 
 
To discuss approach to management of OA and 
related conditions where prescribing of an NSAID 
might be an option. 
 
To raise awareness of risk and safety issues around 
the use of NSAIDs. 
 
To promote safer prescribing of NSAIDs and use of 






Alleged improved safety of COX-IIs  
 






NICE CG 59 Feb 2008 
 
MHRA 
Possible ‘Starters for 10’ Questions to Ascertain Closure Materials to Take With You 
  
Do they think that there are changes that they could 
make 
 
Would it be an idea to review patients according to the 
audit criteria? 
 
Before next visit 
 
Could do it for them? 
 
 










Recruitment Process - Summary Flowchart  
 
Study Title - An Evaluation of Evidence-Based Prescribing Support from Primary Care 
Prescribing Advisers on GP Prescribing Behaviour. 
 
Recruitment -   
Study details sent to GP Practices in Cambridgeshire PCT  
- Letter of invitation to participate in study 
- Study Information Sheet (1) 
- Expression of interest to participate 
- Chief Investigator contact details 
 
      
 








Intervention     
       
       
 
Practice Outreach Visits by Primary Care Pharmacists    
    - Baseline Visit       
   - Follow Up Visits (3)      
  
Visit content includes; 
   Provision of evidence-based prescribing support 
   Written educational support materials 
   Audit and feedback on prescribing 
Study duration ~ 12 months 
 
Qualitative Evaluation 





Recruitment of GP participants 
from intervention practices 




Pre-intervention     Post-intervention 
Study Details (information sheet (2))   Study details(information sheet(2)) 
provided to individual GPs prior to provided to individual GPs 
baseline visit post intervention   
(~ 12 months after baseline visit) 
 
   
Interested GPs Interested GPs 
 Consent        Consent 




Medicines Management Newsletter –  ‘Prescribing Matters’ 
 





EB or not EB 
What is the question? 
 
There are a number of questions regarding evidence based practice – for example: 
 What does evidence based practice mean to you?   
 How does it inform your decision making in relation to prescribing? 
 
Participation in a local research study could help provide the answers.  
The study will investigate how evidence based prescribing support provided by clinical 
pharmacist prescribing advisers may inform GP decision making and influence prescribing 
behaviour. 
 
Invitation letters and Study Information Sheets will shortly be distributed to GP Prescribing 
Leads, Senior Partners and Practice Managers for information. 
If you think you may be interested in taking part in the study, please look out for the study 
details.  
 
If you have any queries or require further information, please do not hesitate to contact 
Melanie Whittick , Consultant Pharmacist, NHS Cambridgeshire.  
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  Appendix 18     Hunts Area Offices  
California Road 
         Huntingdon 
Cambridgeshire 
                                                           PE29 1BN 
                   01480 354360 





Dear Senior Partner 




Re: Research Project: Evidence-Based Prescribing Support from Primary Care 
       Prescribing Advisers 
 
 
I am writing to invite you to take part in a research study.  The study is investigating 
how prescribing support by primary care prescribing advisers may influence the 
prescribing behaviour of GPs and promote incorporation of the evidence-based 
information into the clinical decision-making process. 
 
The project is being carried out as part of a Professional Doctorate being 
undertaken at the School for Health, University of Bath.  
 
Please find enclosed an information sheet which describes why the research is 
being done and what it would involve for you and your practice.  If you would like the 
opportunity to discuss the project further and what it would mean for the practice, I 
would be happy to meet with you 
 
Please also feel free to contact me on the above number or by e-mail to ask me if 
there is anything that is not clear or if you would like more information about the 
study. 
 
If you are interested in taking part, please complete the enclosed an ‘Expression if 












Cc:  Practice Manager 
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Study Information Sheet (1)    Version 1, 30.11.08 
 
 
Information About the Research 
 
 
Study Title:  An Evaluation of Evidence-Based Prescribing Support from 
Primary Care Prescribing Advisers on GP Prescribing Behaviour. 
 
 
Researcher:  Melanie Whittick, Cambridgeshire PCT 
 
Supervisor:  Marjorie Weiss 
  Professor of Pharmacy Practice & Medicine Use, University of Bath 
 
Your practice is being invited to take part in a research study.  The study is 
investigating how prescribing support by primary care prescribing advisers may 
influence the prescribing behaviour of GPs and promote incorporation of the 
evidence-based information into the clinical decision-making process. 
 
Before you decide, you need to understand why the research is being done and 
what it would involve for you and your practice.  Please take time to read the 
following information carefully and discuss with other members of your practice.  
Please ask me if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part.  
 
 
What is the purpose of the study?  
 
The purpose of the study is to investigate whether dedicated evidence-based 
prescribing support delivered by primary care clinical pharmacists (prescribing 
advisers) to GP practices can influence prescribing behaviour and promote uptake 
of evidence-based information into the clinical decision-making process by GPs.  In 
order to gain an understanding of the impact of the prescribing support and its 
potential value in practice, GP perceptions, attitudes and beliefs will also be 
explored.  The results of the study may have implications for the way primary care 
medicines management services are delivered in the future. 
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The project is being carried out as part of a Professional Doctorate being 
undertaken at the School for Health, University of Bath.  
 
 
Why have I been invited?  
 
You have been invited to take part in the study because you represent a 




Does the practice have to take part?  
 
Participation is voluntary.  It is up to you and your partners to decide.  Details of the 
study are included in this information sheet, which you may keep.  Please read and 
share the information about the study with your partners.  If you do decide to take 
part, you or another nominated GP will be asked to sign a consent form on behalf of 
the practice.  You are free to withdraw at any time, without giving a reason.  This 
would not affect your relationship with the PCT (or service you receive from the 
Medicines Management Team) in the future.  
 
 
What will happen to the practice if we take part?  
 
Participation in the study will involve the following: 
 
Randomisation to ‘the intervention’ or control (no intervention) groups.   
 




GPs and healthcare professionals in the practice will be invited to attend a practice-
based meeting at which the evidence-base relating to two pre-specified therapeutic 
topics will be presented and discussed.  Succinct summaries on the therapeutic 
topics will be disseminated as handouts to practice GPs and other HCPs involved in 
the visits.  Additional copies will be provided for members of the practice not able to 
attend the visit meeting.  Prescribing data reflecting current prescribing trends for 
the therapeutic topics containing anonymised comparative data for practices in the 




Practices will receive three follow-up visits 4 months apart.  Meeting agendas will be 
based on the predetermined therapeutic topics.  Updated evidence-based materials 
will be prepared for each visit if new information is available.  Updated prescribing 
data reflecting current prescribing trends will be provided to inform discussion.  
Additional copies of therapeutic topic summaries will be available.  Audit and 
feedback reflecting prescribing volume in relation to the therapeutic topics during the 
study period will be based on PACT data. 
 
The prescribing adviser will summarise discussions, document any agreed actions 
and send a summary to the practice after baseline and follow-up visits 
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It is anticipated that the baseline visit may take between 1-1½ hours with follow-up 
visits lasting up to an hour.  Participating practices will be involved in the study for 
12 months.  It is anticipated that the overall study timeframe will be 18-24 months.  
 
Non-intervention practices (control) will receive written materials only. 
 
Participating practices will continue to receive usual medicines management support 
and communications from the Medicines Management Team.  No element of the 






In order to assess the impact of the intervention on patient outcomes, pre- 
intervention (baseline) and post-intervention audit on patient data will be performed 
for a number of pre-specified patient outcomes, which relate to the therapeutic 
topics.  Individual patient notes will not be accessed for the purposes of this study 
and no patient identifiable data will be removed from practices.  Practice permission 
will however be sought from intervention and non-intervention practices for access 
to audit data.  (NB: Members of the Medicines Management Team currently 
supporting prescribing initiatives in practices routinely access patient notes in the 
course of their work and are bound by a contractual confidentiality clause as 





The clinician perspective in terms of delivery of the intervention to improve uptake 
and incorporation of evidence into the clinical decision-making process and the 
feasibility of the intervention in practice will also be sought through qualitative 
methodologies both before and after the intervention.   
 
The qualitative evaluation will involve semi-structured interviews with individual GPs.  
Details are provided in the accompanying ‘Participant Information Sheet – 




What will the practice have to do? 
 
Participating practices will be asked to commit to the four visits as described 
previously.  All GPs and other healthcare professionals working in the practice who 
may influence prescribing behaviour will be invited to attend.  Although it may not be 
possible for all GPs to attend on a particular occasion, it is intended that the majority 
will be available to participate in each meeting. 
 
Research suggests that short (lunchtime) meetings may be an appropriate 
circumstance in which to engage with practitioners on such topics.  Practices may 
chose to have a lunchtime meeting or arrange an alternative time.   
 
Practices will be asked to consent for the researcher (member of the Medicines 
Management Team) to access the practice system to collect audit data pre-
intervention and post-intervention. 
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What is the intervention that is being tested?  
 
The intervention is a complex intervention that is, an intervention that contains 
several interacting components.  It will consist of a number of known approaches for 
influencing healthcare professional behaviour.  It will be centred on interactive 
practice meetings based on face-to-face communication (academic detailing) with 
clinical pharmacists and incorporate additional approaches including audit and 
feedback and provision of supporting education materials. A key component of this 
study is that the therapeutic messages are evidence-based. 
 
The pharmacist prescribing advisers will be trained in detailing techniques and will 




What are the possible benefits of taking part? 
 
You will have the opportunity as a group to discuss up to date evidence-based 
therapeutics with prescribing advisers who will be able to communicate pre-
appraised evidence-based information thus removing the burden for GPs of seeking 
evidence at the point of prescribing.  It is anticipated that there may be an 




What are the possible disadvantages and risks of taking part? 
 
There are no perceived disadvantages of taking part. 
 
 
What will happen to the results of the study? 
 
The results of the study will be written up as part of my doctoral thesis.  Results will 
be shared with participating practices and more widely within the PCT.  The results 
of the research may be published in peer reviewed scientific journals and 
disseminated through conference presentation. 
 
 
Who is organising and funding the research? 
 
The project is being led by Melanie Whittick as part of her Professionals Doctorate 
at Bath University.  An application for separate funding may be sought through the 
National Institute for Health Research, Research for Patient Benefit Scheme. 
 
Who has reviewed the study? 
 
The study has been reviewed by the following authorities: 
 
Ethical Approval has been given by the Cambridgeshire 4 Research Ethics 
Committee. 
 
CamSTRAD.  The study meets the Research Governance Requirements for 
Peterborough and Cambridgeshire NHS Trusts (Primary Care). 
 
University of Bath, School for Health School Research Ethics Approval Panel 




Further information and contact details 
 
If you wish to discuss the study in more detail or require further information, please 
contact the researcher. 
 
Researcher Melanie Whittick 
  Medicines Management 
  Cambridgeshire PCT 
  Hunts Area Offices 
  California Road 
  Huntingdon 
  Cambs. 
  PE29 1BN 
  e-mail: melanie.whittick@cambridgeshire.nhs.uk 
 
Thank you for taking the time to read this information sheet.  If you are interested in 
taking part in the research project, please fill in the attached ‘Expression of Interest’ 









Expression of Interest 
 
Re: Research Study 
 
 
I / We are interested in taking part in the research Study: Evidence-Based 







Name     ………………………………… 
 
 













Please return to: 
 Melanie Whittick 
 Consultant Pharmacist 
 Medicines Management  
 Hunts Area Offices 
 California Road 
 Huntingdon 
 Cambridgeshire 
 PE29 1BN 
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Appendix 20 
                   
 
Hunts Area Offices 
California Road 
        Huntingdon 
         Cambridgeshire 
                                                             PE29 1BN 
      




Title of Project:   An Evaluation of Evidence-Based Prescribing Support from 
Primary Care Prescribing Advisers on GP Prescribing 
Behaviour. 
 
Name of Researcher: Melanie Whittick 
 
To be completed on behalf of Practice by senior partner or nominated GP. 
 
                        Please initial box 
 
1. I confirm that I have read and understand the information sheet 
    dated...................   (version..............) for the above study on behalf of  
    ……………… Practice. 
 
2. I confirm that I have discussed the study with my partners who have also had  
    the opportunity to consider the information, ask questions and have  
    had these answered satisfactorily.  
 
3. I understand that participation of the Practice is voluntary and that as a  
    practice we are free to withdraw at any time without giving any reason and the 
    practice relationship with the PCT will not be affected in any way.  
 
4. I understand that audit data relating to patient outcomes will be accessed and 
    collected during the study and may be looked at by individuals from the PCT  
    Medicines Management Team where it is relevant to the practice taking part in  
    this research.  No patient identifiable data will be removed from the practice. 
    I give permission for these individuals to access practice data.   
 
5. I confirm that my practice colleagues have delegated authority to me to  
    consent to participation in this study on behalf of the practice under the terms  
    specified above. The Practice consents to participation in the above study.  
 
_________ ________________  ___________ __________________  
Name of Signatory     Date    Signature  
On behalf of participating practice 
 
_________________ ___________             ___________             ______ 
Name of Person taking consent  Date    Signature  
On completion, one copy to be held in research study files and one copy for practice files 




        Hunts Area Offices  
California Road 
      Huntingdon 
Cambridgeshire 
                                                           PE29 1BN 
                   01480 354360 





Re: Research Study:  An Evaluation of Evidence-Based Prescribing Support 




As you are aware, your practice has agreed to participate in the above study.  
Baseline practice visits are currently being arranged for intervention practices with 
allocated pharmacists.   The practice visits are centred on your practice GP team 
meetings.  All GPs are invited to attend the meetings and participate as part of the 
study.  Practice nurses and the practice manager are also invited to attend. 
 
In addition to the quantitative evaluation, I will be carrying out a qualitative 
evaluation which is embedded in the main study.  I am therefore seeking individual 
GP participants to take part in a semi-structured interview before the study 
intervention starts.  (I will also seek additional GPs to participate in a semi-structured 
interview at study completion). 
 
Please find attached the information sheet for the qualitative evaluation.  I would be 
grateful if you would read the information and if possible discuss with / circulate to 
your GP colleagues.  I will contact you in the near future to discuss possible 
participation in the qualitative evaluation. 
 
I will also contact you before baseline visits to confirm that arrangements are in 
place for the baseline visit. 
 











Cc: Practice Manager / Study Contact 
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Appendix 22 
            
                                  
     Hunts Area Offices 
California Road 
                 Huntingdon 
Cambridgeshire 









Information About the Research – Qualitative Evaluation 
 
 
Study Title:  An Evaluation of Evidence-Based Prescribing Support from 




Your practice has agreed to take part in a research study.  The study is investigating 
how prescribing support by primary care prescribing advisers may influence the 
prescribing behaviour of GPs and promote the incorporation of the evidence-based 
information into the clinical decision-making process. 
 
Details of the study are provided in Study Information Sheet (1)  
 
The study is employing a mixed methods approach.  Within the main study is a 
qualitative evaluation of the intervention delivered in practice.  You are being invited 
to take part in this part of the study. This information sheet provides details of this 
aspect of the study. 
  
Before you decide, you need to understand why the research is being done and 
what it would involve for you.    Please take time to read the following information 
carefully and discuss with other members of your practice.  Please ask me if there is 
anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part.  
 
 
What is the purpose of this study?  
 
The purpose of the qualitative evaluation is to explore GP perceptions, attitudes and 
beliefs before and after delivery of the intervention and to gain an understanding of 
the impact and feasibility of the intervention and its potential value in practice.  The 
clinician perspective in terms of delivery of the intervention to improve uptake and 
incorporation of evidence into the clinical decision-making process will be sought.   
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Why have I been invited?  
 
You have been invited to take part in this part of the study because you are a GP 
based in one of the practices participating in the study allocated to receive the 
intervention.   
 
 
Do I have to take part?  
 
Participation is voluntary.  It is up to you to decide.  Details of the study are included 
in this information sheet, which you may keep.  If you do decide to take part, you will 
be asked to sign a consent form.  You are free to withdraw at any time, without 
giving a reason.  This would not affect your relationship with the PCT or service you 
receive from the Medicines Management Team in the future.  
 
 
What will happen to me if I take part?  
 
Participation in the study will involve participation in a semi-structured interview with 
a researcher trained in conducting interviews either before or after implementation of 
the intervention in the practice.  The interview will last up to one hour and take place 
at a suitable time and date in your preferred location in the practice.   
 
The researcher will ask you about your experience of the intervention and your 
views on evidence-based practice.  The interview will be tape-recorded and 
subsequently transcribed.  You will be asked to sign a consent form for permission 
to tape record the interview.  Anonymised excerpts of transcripts may be quoted in 
any potential publications or presentations arising from the study for which your 
permission will also be sought. 
 
 
Will my taking part in the study be kept confidential? 
 
Information obtained from the interview will not be identifiable.  The interview tapes 
and transcripts will be identified by a study code.  Your name and any other 
identifying information will not be used.  Interview tapes and transcripts will be 
stored securely in a locked cabinet.  Interview tapes will be destroyed once data has 
been transcribed and verified.   
 
 
What are the possible benefits of taking part? 
 
There are no direct benefits to you in taking part.  However, it may lead to a greater 
understanding of the prescribing support needs of GPs in practice and development 
of the role of the prescribing adviser in practice. 
 
What are the possible disadvantages and risks of taking part? 
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What will happen to the results of the study? 
 
The results of the study will be written up as part of my doctoral thesis.  Results will 
be shared with participating practices and more widely within the PCT.  The results 
of the research may be published in peer reviewed scientific journals and 





Who has reviewed the study? 
 
The study has been reviewed by the following authorities: 
 
Ethical Approval has been given by Cambridgeshire 4 Research Ethics Committee. 
 
CamSTRAD.  The study meets the Research Governance Requirements for 
Peterborough and Cambridgeshire NHS Trusts (Primary Care). 
 




Further information and contact details 
 
If you wish to discuss the study in more detail or require further information, please 
contact the researcher. 
 
Researcher Melanie Whittick 
  Medicines Management 
  Cambridgeshire PCT 
  Hunts Area Offices 
  California Road 
  Huntingdon 
  Cambs. 
  PE29 1BN 
  e-mail: melanie.whittick@cambridgeshire.nhs.uk 
 
Thank you for taking the time to read this information sheet.  If you are interested in 
taking part in this part of the research project, please fill in the attached ‘Expression 




                                                                  251 
Appendix 23 
Hunts Area Offices 
                             California Road 
        Huntingdon 
Cambridgeshire 
                                                             PE29 1BN 
 





Title of Project:  An Evaluation of Evidence-Based Prescribing Support from 
Primary Care Prescribing Advisers on GP Prescribing Behaviour. 
 
Name of Researcher: Melanie Whittick 
Please initial box  
 
 
1. I confirm that I have read and understand the information sheet 
    dated....................  (version............) for the above study. I have had  
    the opportunity to consider the information, ask questions and have had  
    these    answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to 
    withdraw at any time without giving any reason and without my rights being  
    affected. 
 
3. I understand that the interview will be tape-recorded and transcribed  
    and excerpts may be looked at by responsible individuals from the  
    research team.  I give permission for the interview to be tape recorded. 
 
4. I understand that anonymised excerpts may be quoted in the resulting 
    thesis and possibly included in written documents including publications 
    in peer reviewed journals.  I give permission for direct quotations to be  
    published where it is relevant to my taking part in this research. 
 




________________________             ______________     _______________________ 




__ _______________ _______   ______________ _______________ 
Name of Person taking consent   Date    Signature   
 
On completion, one copy to be held in research study files and one copy for participant 
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        Hunts Area Offices  
California Road 
      Huntingdon 
Cambridgeshire 
                                                           PE29 1BN 
                   01480 354360 
        March 2012 
 
To: GP Prescribing Lead 





Re: Research Study:  An Evaluation of Evidence-Based Prescribing Support 
from Primary Care Prescribing Advisers on GP Prescribing Behaviour. 
 
 
As you are aware, your practice took part in the intervention phase of the above 
study which involved practice visits with a nominated primary care pharmacist which 
were centred on your practice GP team meetings.    
 
The practice visits are now complete.   I am writing therefore to thank you and your 
partners for participating in the study.  I am grateful for your time and commitment to 
the study objectives and I would also be grateful if you will pass on my thanks to 
your partners and other staff who may have been involved in the study. 
 
I am currently embarking on the process of analysing both the quantitative and 
qualitative data collected as part of the evaluation, then progress to write up the 
project.  I anticipate that this will take some time and hope to be able provide formal 
feedback to your practice once this is complete. 
 
Once I have completed the data analysis, I should be able to provide interim 
feedback, particularly on the quantitative elements of the study, including e-PACT 
data which demonstrates some interesting trends, particularly in the use of NSAIDs.  
Please let me know if you would be interested in such feedback. 
 
Thankyou again for your participation. 
 







Melanie Whittick BSc, MSc, MRPharmS 
Consultant Pharmacist 
 
Cc: Practice Manager 








NHS Cambridgeshire (All practices) - Oral NSAIDs



























etodolac + meloxicam 
others  
                                                                  254 




July 2009 – June 2010 
    
** Health Centre          
                        
  Practice        PCT  Average     
  
Variation from PCT Average 
                 
  % Items  % Cost % ADQ   % Items % Cost % ADQ   % Items % Cost % ADQ 
                        
DRUG GROUP - BNF 
chapter                       
Muscoskeletal                       
10.1.1 NSAIDs                       
                        
  Diclofenac 55.7% 40.2% 59.1%   32.2% 23.1% 34.8%    23.5%   17.1%  24.3% 
  Ibuprofen 20.1% 9.7% 14.5%   20.8% 7.9% 14.8%   - 0.8%    1.8% - 0.3% 
  Naproxen 13.3% 11.9% 14.2%   24.6% 17.5% 22.9%   -11.3% - 5.6% - 8.7% 
  Coxibs 2.8% 17.1% 3.0%   6.2% 28.0% 7.9%   - 3.4% -10.9% - 4.9% 
  Etodolac + meloxicam 3.0% 13.2% 4.2%   10.2% 15.2% 14.2%   - 7.2% - 2.0% -10.0% 
  Others  5.2% 7.9% 4.9%   5.9% 8.2% 5.4%   - 0.7% - 0.3%  0.5% 
Total 100.0% 100.0% 100.0%   100.0% 100.0% 100.0%         
                        
                        
                        
MR NSAIDs / Oral NSAIDs Practice 23.5%     PCT 29.1%           
                       
                       
10.3.2 Topical NSAIDs Practice 21.9%     PCT  20.6%           
                       




Visit Summary Example (Anonymised) 
 
 
** Practice – Visit Four ** 08.11 
 
Summary of Previous Visit Report 
 
Actions from Previous Meeting: 
 
 The partners had agreed to check the practice database and review patients with 
diclofenac on repeat.  
 The partners had received prescribing data before the previous meeting to 
establish whether the change in prescribing habits which had been agreed to 
implement had happened.         
 
Actions for next meeting: 
 
 Review how the prescribing had changed for both NSAIDs and anti-diabetic agents.  
Provision of ePACT trend data.  (NSAID report already sent to GPs) 
 Agree main focus of next meeting with GP lead.  Topics to be finalised to meet 
practice objectives and needs. 
 
Information required for Practice 
 Provision of ePACT trend data on drugs used in T2DM. 






Prescribing Data Included for Visit 4 
 
Summary of Prescribing Trends for NSAIDs and drugs in T2DM over study period. 
 
This information has been updated with Data to May 2011 
 
The partners had indicated that prescribing practice has changed and naproxen or 
ibuprofen is now used in preference to diclofenac in acute conditions.   




























Diclofenac 136 97 123 86 117 92 93 102 96 97 91 
Ibuprofen 44 59 53 45 41 46 40 55 50 58 47 
Naproxen 25 38 30 39 38 37 38 43 49 65 57 
Coxibs 5 5 7 3 4 3 5 3 7 4 6 
Etodolac 5 6 5 5 6 8 4 6 7 3 4 
Others 6 8 5 3 3 5 6 10 5 4 3 
Mefenamic Acid 5 4 4 7 12 9 8 9 5 3 8 
Total 226 217 227 188 221 200 194 228 219 234 216 
 



























Diclofenac 60.2 44.7 54.2 45.7 52.9 46.0 47.9 44.7 43.8 41.5 42.1 
Ibuprofen 19.5 27.2 23.3 23.9 18.6 23.0 20.6 24.1 22.8 24.8 21.8 
Naproxen 11.1 17.5 13.2 20.7 17.2 18.5 19.6 18.9 22.4 27.8 26.4 
Coxibs 2.2 2.3 3.1 1.6 1.8 1.5 2.6 1.3 3.2 1.7 2.8 
Etodolac 2.2 2.8 2.2 2.7 2.7 4.0 2.1 2.6 3.2 1.3 1.9 
Others 2.7 3.7 2.2 1.6 1.4 2.5 3.1 4.4 2.3 1.7 1.4 
Mefenamic Acid 2.2 1.8 1.8 3.7 5.4 4.5 4.1 3.9 2.3 1.3 3.7 
Total 100 100 100 100 100 100 100 100 100 100 100 
 
Table 3.  % Prescription Main NSAID Items (Monthly) July 2010 to May 2011 

















































Graph 1. Overall NSAID Trend  - % prescription NSAID Items April 2010 – May 2011 
 
 
The trend data suggests that overall 
 The decrease in diclofenac prescribing continues and is now levelling off 






The updated data is based on currently available ePACT data to May 2011.   
The data indicates that the anticipated trends based on change in NSAID prescribing 
choice by the GPs continues.  
 
There is a reduction in diclofenac with a corresponding increase in naproxen and a 
small increase in ibuprofen.  
 
Updated information can be made available as more ePACT data becomes available. 
 
 
Further actions for  Visit 4 - Suggestions 
 Discuss prescribing data for NSAIDs and fact that GP actions are resulting in 











 Table 1.  Prescription Items (Monthly) April 2010 to May 2011 
 Table 2.  Summary Main Prescription Items (Monthly) April 2010 - May 2011 
 Table 3.  % Prescription Items (Monthly) April 2010 to May 2011 
 Graph 1.  Diabetes Drugs Trend  - % Prescription Items  
 
These tables and graph demonstrate the prescribing trends over 14 months for OHA 
items prescribed and percentage of overall OHAs.  The data demonstrates that 
prescribing of metformin, sulphonylureas and glitazones has remained relatively stable 
during the timescale covered.  
 
The practice has not generally prescribed any of the following: 
 Combination metformin / glitazone products 
 Newer drugs in diabetes 
o Exenatide, liraglutide 
o Gliptins 
NB: In addition to a single prescription for sitagliptin in December 2010, a further 
prescription has been dispensed in April 2011.  ? Regular patient on gliptin 
 
The data demonstrates compliance with local recommendations around the newer 
drugs in diabetes and clinical recommendation not to use combination products which 
limit ability to titrate metformin.  It is relatively unusual in practices and demonstrates a 
clear approach to the use of medication in the management of T2DM adopted by the 
whole practice. 
 
There are a few regular prescriptions for glibenclamide and the partners may wish to 
review these patients and consider a shorter acting sulphonylurea.  
 
Table 4.  Glitazone Prescription % Items April 2010 to May 2011 
Graph 4.  Glitazone Trend  - % prescription Items (Data from Table 4) 
 
This data and graph show generally stable prescribing of glitazones although suggest 




Further actions for next meeting - Suggestions 
 
General discussion regarding data – Positive feedback! 
 
Are there any areas of T2DM prescribing that the partners wish to address? 
 
Are there any aspects of care that the partners would like to address? 
 
eg Discussion around management of BP and lipids, ACE-I vs A-II-A, renal care, 
neuropathic pain. 
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  Items                           



























Acarbose 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Exenatide 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Glibenclamide 0 5 1 4 3 2 4 3 3 2 2 2 4 4 
Gliclazide 53 65 61 60 57 63 55 60 61 51 53 63 54 65 
Glimepiride 2 3 1 2 0 3 0 3 1 2 0 3 0 3 
Glipizide 2 1 0 1 1 0 1 0 2 0 0 0 1 1 
Liraglutide 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Metformin 160 182 176 182 159 189 175 164 186 182 150 200 170 185 
Metformin/Pioglitazone 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
Metformin/Rosiglitazone 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Metformin/Sitagliptin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Metformin/Vildagliptin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Nateglinide 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Pioglitazone 21 15 21 18 13 24 22 26 23 27 19 29 30 25 
Repaglinide 1 2 1 1 0 1 1 1 1 2 0 1 1 2 
Rosiglitazone 3 5 4 2 4 2 0 0 0 0 0 0 0 0 
Saxagliptin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sitagliptin 0 0 0 0 0 0 0 0 1 0 0 0 1 0 
Tolbutamide 14 21 28 21 14 19 16 16 19 13 19 22 13 15 
Vildagliptin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
  256 299 293 291 251 303 274 273 298 279 243 320 274 300 
 
Table 1.  Prescription Items (Monthly) April 2010 to May 2011 
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  Items                           



























Sulphonylureas  71 95 91 88 75 87 76 82 86 68 74 90 72 88 
Metformin 160 182 176 182 159 189 175 164 186 182 150 200 170 185 
Metformin/Pioglitazone 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
Pioglitazone 21 15 21 18 13 24 22 26 23 27 19 29 30 25 
Repaglinide 1 2 1 1 0 1 1 1 1 2 0 1 1 2 
Rosiglitazone 3 5 4 2 4 2 0 0 0 0 0 0 0 0 
Sitagliptin 0 0 0 0 0 0 0 0 1 0 0 0 1 0 
  256 299 293 291 251 303 274 273 298 279 243 320 274 300 




Items                           



























Sulphonylureas  27.7 31.8 31.1 30.2 29.9 28.7 27.7 30.0 28.9 24.4 30.5 28.1 26.3 29.3 
Metformin 62.5 60.9 60.1 62.5 63.3 62.4 63.9 60.1 62.4 65.2 61.7 62.5 62.0 61.7 
Metformin/Pioglitazone 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 
Pioglitazone 8.2 5.0 7.2 6.2 5.2 7.9 8.0 9.5 7.7 9.7 7.8 9.1 10.9 8.3 
Repaglinide 0.4 0.7 0.3 0.3 0.0 0.3 0.4 0.4 0.3 0.7 0.0 0.3 0.4 0.7 
Rosiglitazone 1.2 1.7 1.4 0.7 1.6 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Sitagliptin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.0 
  100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Table 3.  % Prescription Items (Monthly) April 2010 to May 2011 
 
  Apr 10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11 
Pioglitazone 8.2 5.0 7.2 6.2 5.2 7.9 8.0 9.5 8.0 9.7 7.8 9.1 10.9 8.3 
Rosiglitazone 1.2 1.7 1.4 0.7 1.6 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Table 4.  Glitazone Prescription % Items April 2010 to May 2011 
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Graph 2.  Diabetes Drugs Trend  - % Prescription Items  
 






















































Study Specific Reference Documents 
 
An individual folder was prepared for each pharmacist containing core study 
reference materials.   
 
These included copies of:  
 T2DM Academic Detail Matrix  
 NSAIDs Academic Detail Matrix 
 Table of Outcome Measures (ePACT and practice patient orientated outcomes) 
 Powerpoint Presentation from Academic Detailing Revision Session 
 NAO Report: Influencing Prescribing Cost and Quality in Primary Care 
 
 




Individual pharmacist folders contained key references for each therapeutic topic. 
 
The key references included: 
 Mandatory literature identified in the Detail Aid Matrices 
 NICE guidance,  
 MeReC publications 
o In particular pre-appraised summaries focusing on management of 
T2DM and NSAIDs  
 Additional copies of pre-appraised summaries for distribution to GPs if required 
during the practice visits were also included in each folder. 





A central repository containing key references, and supporting evidence based 
information was maintained by the Chief Investigator.  Its purpose was to: 
 
 Facilitate pharmacist access to information to support knowledge and learning 
objectives around the evidence base and key messages.   
 Provide support materials in anticipation of questions and requests for evidence 
based reference sources as a result of discussion with GPs (including original 
references).   
 
The central repository also included copies of: 
 Therapeutics and Information Mastery training slides  
 NPC key slides and data focussed commentaries. 
 National Guidelines (including NICE) e.g. T2DM, Management of hypertension, 
management of renal insufficiency 
 Original references   
 
 




Visit Report Examples (Anonymised) 
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Dr **, GP, Senior Partner   **, Nurse Practitioner 
Dr **, GP     **, Practice Nurse  
Dr **, GP, Prescribing Lead   **, Pharmacist (MMT) 
 
Purpose of the Visit 
 
This was the second study visit as part of a research study evaluating the impact of 
prescribing support/advice on GP prescribing behaviour.  The study topics are focussing on 




T2DM.  The baseline visit focussed on management of various aspects of T2DM and the 
evidence behind recommendations around approach to management.   
 
The group had discussed prioritisation of treatments in managing T2DM and cardiovascular 
risk utilising the ‘diabetes hand’ approach.  ‘Pharmacist’ reviewed the evidence from UKPDS 
relating to  management of blood pressure and blood glucose and the importance of 
metformin in reducing CV risk.  Pharmacist used PDAs to demonstrate relative benefits of 
the different interventions in UKPDS. 
 
The group discussed the more recent evidence for use of aspirin in primary prevention and 
for sequence of antihypertensive choice in the management of hypertension.  
 
There was some discussion on the use of oral hypoglycaemic agents (glitazones) and the 
newer drugs in diabetes.  The practice had relatively high use of metformin combination 
products and this was an area where they may consider preferential use of the individual 
drugs. 
 
The focus of this meeting was also on aspects of care in T2DM as agreed with Dr 3 (PL).  
Pharmacist had also brought some trend data on prescribing of NSAIDs which had not been 




 Diclofenac and coxibs are associated with higher CV risk than other NSAIDs.  Low dose 
ibuprofen and naproxen are associated with lower thrombotic risk.   
 All NSAIDs carry risk of GI side effects 
 When prescribing NSAIDS it is important to assess cardiovascular, cardiorenal and GI 
risk according to individual patient factors. 
 Baseline data (pie charts) indicate that as a practice, prescribing of diclofenac is lower 
than the PCT averages which is appropriate in order to limit / reduce diclofenac 
associated CV risk. 
 Use of COX-II inhibitors is slightly higher than PCT average and this may be an area for 
the partners to consider in the future. 
 The group discussed the fact that both CV and GI risk are cumulative, increasing with 
length of treatment and dose. 
 The partners recommend NSAIDs on a p.r.n. basis where possible 
 The NICE recommended approach to management of musculoskeletal disorders was 
reviewed.  In addition to core treatments, first line therapeutic options are paracetamol 
and topical NSAIDs. 
 CPCT formulary suggests ketoprofen as a first line topical preparation (based on cost 
effectiveness).  Ketoprofen is also more potent than other options.  The partners are 
aware that ketoprofen is associated with a higher risk of photosensitivity about which 
there are concerns.  Therefore other first line options may be more appropriate.    
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 The partners were reminded that topical application of NSAIDs (particularly large 
amounts) may result in systemic side effects eg asthma. 
 The practice has a template in place on its computer system which considers risk 
associated with prescribing of NSAIDs. 
 Dr 1 considered that review of patients on long term diclofenac might be an appropriate 
subject for one of the practice quality projects.  To consider associated risks eg CVD, 
CKD, GI and concomitant use of other drugs which can exacerbate adverse events eg 
SSRIs and GI bleeds.  Pharmacist is happy to provide support the practice where 
appropriate.   




Previous discussion with Dr 3 suggested focus of meeting on  
 New diabetes drugs 
 ACE-I vs A2RA  (particularly re. proven benefits of ACE-I) 
 BP control in CKD (focus on T2DM) 
 
Aspirin 
 Pharmacist had brought a number of evidence based updates questioning the use of 
aspirin for primary prevention in T2DM as an action from the previous visit.  This 
included summary details from POPADAD and recent meta-analysis (six studies). 
 There was further discussion on the lack of evidence for the benefit of aspirin in primary 
prevention.  A key factor is the fact that benefit of reduction in CV risk needs to be 
balanced against the increased risk of a major bleed. 
 The more recent evidence contradicts the current NICE guidance recommendation to 
prescribe for patients over 50 years (with BP <145/90mmHg) 
 Currently patients with T2DM (primary prevention) are having aspirin actively stopped by 
the GPs. 
 In some cases it may be appropriate to consider prescribing aspirin depending on the 
patients individual risk factors.  If aspirin is prescribed, it is important to ensure BP is 
controlled. 
 Pharmacist also brought copies of the Antiplatelet PDAs on aspirin for primary 
prevention of cardiovascular disease for the GPs and PNs to review and use when 
discussing with patients if appropriate. 
 A copy of the whole NPC PDA folder had been left previously with the practice. 
 
Drugs in T2DM  
 Prescribing trend data shows no prescribing of the newer drugs exenatide, liraglutide. 
There appears to be one recent repeat for sitagliptin. 
 The practice is relatively high prescriber of metformin (reduces CV risk).  
 Overall use of glitazones is below PCT average and has decreased recently.   
 Since baseline, use of metformin combination products has virtually ceased.   
 GP1 tends to be more cautious in use of glitazones in view of continuing concerns and 
adverse effects attributable to glitazones.  
 There is currently less experience with the use of gliptins. 
 Sequence of antihypertensive following ACE-I was briefly discussed.  Although either 
thiazide or CCB are recommended as second line add in options, there is strong 
evidence that a thiazide is an appropriate and cost effective second choice.  (ALLHAT 




Pharmacist had agreed with GP 3 (prescribing lead) to cover the evidence relating to use of 
RAS drugs ie ACE-Inhibitors and Angiotensin Antagonists.   
 Current NICE guidance advocates use of RAS drugs in  
o Hypertension 
o Heart failure 
o Post MI 
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o T2DM 
o CKD 
 For each of these indications NICE recommends ACE-Is first line where RAS drugs are 
recommended. 
 A2RAs should be reserved for patients where ACE-Is have to be discontinued because 
of intractable cough.  (A2RAs cause less cough than ACE-I) 
 There is no evidence that A2RAs are superior to ACE-I in any indication 
 There is no evidence that A2RAs are safer than ACE-I in any indication 
 Incidence of cough may be less than generally thought 
Evidence from ONTARGET,  
o Incidence of cough 4.2% (ramipriil) vs 1.1% (telmisartan) 
o Absolute difference 3.1% (possibly underestimate but not high as thought) 
 
Combination therapy with ACE-I and A2RA. 
 No more effective than either treatment alone (ONTARGET study)  
 Associated with more discontinuations due to hypotension, syncope, diarrhoea and renal 
impairment 
 There is considerable concern regarding renal deterioration with combination  
 The combination is not recommended except by specialists (renal care) 
 Bottom line 
o Hypertension – No benefit, worse outcomes 
o Renal disease – No benefit, worse outcomes 
 If specialist using in minority of patients with proteinuria not responding 
to monotherapy, requires very careful monitoring 
o Post MI  - Not recommended 
o Heart Failure – Possible specialist option.  However, concerns regarding renal 




 Dr 2 asked about use of Calcium and Vitamin D in combination for patients with Vitamin 
D deficiency (eg elderly, inflammatory conditions, anaemia).  Are there implications 
associated with possibly too much calcium eg increased CV risk in using the available 




There was not enough time to cover all of the topics previously discussed with Dr ** (PL)  
Eg New drugs for management of blood glucose.   
 
As the second visit had been postponed, the option of carrying out one further visit or 
whether to squeeze two further visits was discussed.  It was agreed to complete two more 
shorter visits as part of the next two practice nurse meetings.   
Dates of next meetings: 
 ** June 2011 12.30pm 
 ** July 2011  12.30pm 
 
Pharmacist to confirm focus of meeting with Dr 3, Practice Lead prior to the next visit. 
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Practice Visit ** Medical Practice    Date: ** February 2011  
 
Present: 





The pharmacist summarised the purpose of the visit (2nd) and how it related to the research 
study which is to evaluate the impact of prescribing support /advice on GP prescribing 
behaviour  it is intended to follow up the baseline visit with further visits. Prescribing data will 
be used to examine to assess change in prescribing patterns in the use of anti-diabetic 
medicines and NSAIDs.  Two further meetings would follow during the year to re-enforce the 
messages relating to NSAID and diabetes prescribing, and to feedback on prescribing 
trends.  
 
Topic Discussion points Actions  
Prescribing 
NSAIDs  
 Pharmacist confirmed how the use of non-pharmacological 
approaches such as weight management and exercises 
would be considered first, and use of paracetamol and topical 
NSAIDs as the first step pharmacological treatment for the 
management of osteoarthritis 
 Pharmacist revisited previous discussed area: GI related risks 
and the use of NSAIDs, and stated that patients that are over 
65 years old, with a history of GI problems such as bleeding 
and ulceration would be at high risk of GI side effects relating 
to the use of NSAIDs 
 From the data available for the first meeting it was noted that 
the practice were high users of naproxen.   
 Pharmacist presented the previously shared epact data. The 
practice at November were prescribing 32.2% diclofenac 
items, 17% Ibuprofen, 36% naproxen, 2.9% Coxibs and 5.9% 
Etodolac and Meloxicam. The practice would like to become 
a higher user of Naproxen, and has agreed to review patients 
currently on Diclofenac with a view to switch patients to 
Naproxen if appropriate.  
 The pharmacist commented that the Practice has a higher 
than PCT average use of Naproxen (12.6% higher than PCT 
average), which is commendable.  
 As previously discussed, Coxibs and Diclofenac exhibited 
similar CVD risk profile in causing an extra 3 CVD events per 
1000 patients per year. There are no direct risk data for 
Meloxicam, but the PCT do not advocate it’s use. Pharmacist 
shared that Meloxicam may have a similar CVD risk profile, 
but there are not data at hand to demonstrate this. There is 
also weaker evidence to support its use.   
 The practice requested further practice data on the 
prescribing of NSAIDs, relating to patient number and their 
current renal status.  
 Discussed 2 trials, MELISSA and SELECT and the lack of 
evidence to support the use of meloxicam. For Melissa, there 
was no significant difference between the groups in the 
occurrence of perforations, ulcers or bleeds (five patients with 
meloxicam and seven with diclofenac), but the study was only 
short-term and was not powered to show this.  
 The practice has agreed that reviewing Meloxicam could be a 
further action point, e.g. at visit three. The GPs felt that the 
use of Meloxicam is mainly secondary care led.  


























stop and switch 
to ibuprofen or 
Naproxen if 
appropriate.  
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and how GI protection is important for patients using a PPI 




 Pharmacist discussed again the importance of managing 
CVD risks in type 2 diabetic patients, by showing that that 
63% of diabetic patients died from CV causes, which is twice 
the percentage of normal population (33% of non-diabetic 
patients died of CV causes) 
 As per discussion at the last practice visit, the practice is 
currently managing its diabetic patients using QOF indicators 
and are achieving good results according to QOF 
requirements, this include BP control in diabetic patients 
 Pharmacist discussed that the cornerstone of evidence in 
managing type two diabetic is the UKPDS study, which 
shows that managing patients BP and using metformin were 
associated with much better outcomes for patients 
 Pharmacist revisited the use of the ‘Diabetic Hand’ in the 
management of type two diabetic patients. Both GPs 
remembered the points well.  
 The practice is currently exhibiting ‘clean’ data for the 
prescribing for type two diabetic medications. 66.2% on 
Metformin, which is 11% higher than PCT average, 32.3% 
patients on Gliclazide. The practice has discontinued the only 
one patient prescribed a gliptin and has make changes to all 
patients prescribed Rosiglitazone to an appropriate agent. 
Pharmacist commented that Glitazones and Gliptins should 
be third line treatments.  
 Pharmacist confirmed that all diabetics should be using ACE 
inhibitors across all ages due to better evidence in preventing 
cardiovascular events. Pharmacist also mentioned a recent 
BMJ meta-analysis that showed that A2RAs has no evidence 
in preventing stroke when compared to placebo 
 Pharmacist showed the scatter plot of Law and Morris et al 
1999, and explained that there is no evidence of AII in 
preventing stroke and much weaker evidence in the 
prevention of cardiovascular events.  
 Pharmacist also demonstrated using the same graph that 
prescribing of beta blockers causes excess risk in causing 
stroke, hence this is not recommended in NICE guidance.  
 Pharmacist showed data collated by CI, and showed that 
there was a patient being prescribed two calcium channel 
blockers. Dr. ** will review the patient.  
 Pharmacist discussed that simvastatin 40mg remains to be 
the first line treatment for controlling cholesterol levels even in 
type two diabetic patients with CVD risk of >20%. 
 The practice observed from the practice data that 8 patients 
with microalbuminuria not prescribed an angiotensin drug, the 
practice has agreed to review these patients and treat 
appropriately.    
 The practice also noted that 19 patients on AII, and has 
agreed to check if these patients were prescribed ACE as a 
first line agent.  
 The practice was provided with the printed spreadsheet with 
patients renal status and medication histories.  
The practice will 
review all type 
two diabetics on 
AIIs and check if 
ACE are used 










































patients on AII 
(19) and assess 
if patients were 
prescribed an 





 The practice is aware of current process of requesting 
consultant opinion prior to the initiation of gliptins and the 
process of delegating prescribing of Exanetide to primary 
care.  
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 The practice is reminded that all relevant paperwork can be 
accessed via the CJPG website 
 The practice is not aware of any difficulties or problems to 
date. 
 Pharmacist showed that the HbA1c lowering power of newer 
diabetic drugs are not as potent as Metformin and Gliclazide, 
0.5-1.5% for Glitazones, up to 0.7% for Gliptins and up to 1% 
for Exanetide. Both Metformin and Gliclazide could lower 
HBA1c to up to 2%.   
 
 The meeting was closed and then all four actions reviewed.   
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Feedback from Practice Visit 2 




GPs –  Dr 1, Dr 2, Dr 3, Dr 4, Dr 5, Dr 6, Dr 7 
Practice Nurse (Diabetes) 
Pharmacist, PCT Medicines Management Team 
 
 
Topic Discussion points Action for next 
meeting 
Introduction  Pharmacist reminded GPs of the research project – 
effect of 4 visits by pharmaceutical adviser to be 
assessed (on 2 subject areas- type 2 diabetes/NSAIDs) 
spread over 1 year 
 At the previous visit, the practice had expressed interest 
in comparisons with neighbouring practice (NPS) where 
the population was deemed “similar” to this practice. 
Pharmacist produced comparative data on both 
NSAIDs and diabetes treatments. NP Surgery had 
agreed to share with this practice and, and GPs present 
also indicated willingness for data to be shared with 
NPS.  
‘Electronic link to Word document containing 
comparative data inserted here’ 
 The practice had also suggested that deprivation played 
a part. Pharmacist confirmed prevalence is definitely 
higher than average (LISI deprivation weighting 9.3 
compared to PCT average 6.2). 
 GPs had previously asked if new Medicines 
Management Solutions Audit tool would help identify 
which GP in a practice had initiated a treatment. GP4 
had found that it would. Pharmacist had no further 
information as to whether this tool was to be 
implemented. 
 Pharmacist to 
send 
comparative 






 Comparative data with NPS showed both practices had 
higher-than-average prescribing rates for oral 
antidiabetic drugs, metformin, insulin and blood glucose 
test strips (BGTS).  
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 Higher-than-average prescribing of BGTS was found to 
correlate with higher-than-average insulin costs, but NPS 
insulin costs were higher than Practice (with lower BGTS 
costs). Unclear whether this might be due to particularly 
expensive forms of insulin used at NP, or inappropriately 
low testing of BG at that practice. GPs confident that 
testing at this practice is only undertaken if appropriate. 
 Pharmacist provided trend data for prescribing of BGTS. 
This did show the work the practice had put in to reduce 
prescribing, but also showed a subsequent rise again. 
    ‘Electronic link to Excel document containing prescribing 
trend data inserted here’ 
 Practice felt that remaining prescribing was probably 
appropriate (considerable input already from medicines 
management team on this topic). 
 GPs suggested it would be helpful to compare numbers 
of patients instead of costs. 
 Pharmacist to 
investigate 
data further, to 
find whether 
type of insulin 
or volume was 
influencing 
high costs at 
NPS.  
 Pharmacist to 
ask NPS 








 Practice aware that this was to be discontinued shortly. 
 All 18 patients to be reviewed and changed by Diabetes 
Specialist Nurse. (Patients have sufficient Mixtard to last 
until the change-over effected). 
 
Glitazones  Pharmacist confirmed latest data (September 2010) still 
showed 17 prescriptions for rosiglitazone issued. 
 Practice staff were confident that October data would 
show zero. (Patients would not have been able to 
accumulate prescriptions to obtain supplies after the 
withdrawal of rosiglitazone.) 
 Pharmacist to 
check later 






 Pharmacist advised new guidance on exenatide was 
imminent.  
 Consultants would retain prescribing for 6 months, at the 
end of which period, the patient would be assessed for 
compliance with NICE criteria for continuing treatment 
(required weight loss and HbA1C change). If continuing 
treatment appropriate, consultant to write to GP with 
details, and GP to continue. 
 Patients started on treatment to be given a leaflet 
explaining that treatment will be stopped if NICE criteria 
not met. 
 Pharmacist confirmed practice would need to monitor to 
ensure weight loss etc maintained 
 
Gliptins  Pharmacist advised new guidance on gliptins was 
imminent.  
 GP would need to contact consultants before prescribing 
– patient to be seen as outpatient or GP to telephone 
consultant to discuss. DH confirmed cost of telephone 
consultation would be lower than cost of out-patient 
appointment. 
 If consultant agreeable, GP can initiate. (Contact must be 
between GP and consultant – not diabetes specialist 
nurses). 
 Checklist of information will be provided to GPs.  
 Patients started on treatment to be given a leaflet 
explaining that treatment will be stopped if NICE criteria 
not met. 
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 Pharmacist had researched current guidance on use 
of aspirin in diabetics. 
 Aspirin is still recommended in secondary prevention 
patients (existing CV disease). Practice confirmed 
these are still being prescribed. 
 Advised that, for primary prevention, latest guidance 
from NPCi suggested that, in all age groups, this was 
no longer routinely recommended (but that it might be 
appropriate to continue in patients where 
cardiovascular risk deemed to be particularly high in a 
primary prevention patient) – see 
http://www.npci.org.uk/blog/?p=995 . 
 Practice had taken all patients under the age of 50 off 
aspirin if primary prevention, but was still prescribing 
for over 50’s. All agreed probably appropriate now to 
review these individually (but concerned about 
workload). Pharmacist suggested that it might be more 
manageable to flag the notes to ensure use of aspirin 
reviewed at annual/6-month review in practice (i.e. at a 
scheduled appointment). This would stagger workload. 
 Discussed use of CV risk tool – GPs tend to use 
QRISK assessment for diabetics (as available on 
computer system). Pharmacist not sure whether 
QRISK accounted fully for the risk from diabetes, and 
suggested UKPDS assessment tool might be more 
appropriate. 
 Unclear whether there might be a code for using the 
UKPDS tool in the computer system. 
























 Briefly noted that the comparative data with NP 
Surgery did not appear to correlate with that from 
Practice (NSAIDs prescribed per patient in Practice 
appeared higher-than-average, but lower-than-
average in NP Surgery). 
 Due to shortage of time, discussion of the data (and 
follow-up on NSAID points from last meeting) deferred 
to next session. 
 Pharmacist  to 
bring data 
again to 
discuss at next 
meeting. 






Topic Discussion points Action for next 
meeting 
Next meeting  Date to be booked as soon as possible. 
 To cover topics highlighted above, and any other 
related issues that arise in the meantime.  







File ref: R:\Pharmaceutical\ ** \visit2.doc  
 




Review of Baseline Visits - Meeting 4th November 2010 
Agenda / Discussion Points 
 
1. Baseline Visits. 
 Experiences so far 
 Analysis and interpretation of the data to steer conversation and influence 
prescribing at each meeting. 
 Use of Detailing / Educational Outreach Techniques 
 Background Information / Training 
o NPC 
o NAO Report 
o Presentation 
o Detailing: Planning Matrix / Key Messages 
o Outcomes being measured 
 Presentation Materials – Detail Aids 
 Folders, Sticks, Data, Information 
 Support Materials 
 
2. Summary of Visit Reports 
 
3. Visit Reports 
 Visit Report Format 
 Visit Report Timeframe  Within 1 week Maximum 2 weeks 
 Agreed Actions 
 Timeframe – Agree with Practice 
 SMART 
 Provision of additional information eg clinical, ePACT 
 
5. ePACT Data 
 Provision of ePACT data following visit as result of agreed actions 
 Use of additional graphs for the practice visits 
 Preparation? 
 Preparation of data for next round of visits 
 
6. Detail from outcome data to inform visits? 
 
7. Follow up visits 
 Booking Next Visits  ASAP ie First follow up 
 Arrangements to determine  
content , structure, attendance 
Information requirements for next round of visits 
Suggest - Contact practice in advance of following visit to discuss 
 




9. Housekeeping - Folders / files on system 
Visit Reports  
Data –  
 e-PACT Data – downloaded / graphs for visits / additional 
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Appendix 29 (Cont.) 
 
Review of Baseline Visits - Meeting 4th November 2010 
 
Discussion Points and Actions 
 
 
1. Baseline Visits. 
 
There was a general discussion of individual experiences so far 
 
 Approach to visits – 
 
 Use of Detailing / Educational Outreach Techniques 
o There is clearly a variation in approach which may be partly due to 
experience – As indicated earlier, it is important to use and develop the 
techniques we already have and learned. 
o MW summarised key points regarding academic detailing in a short 
presentation (attached).   
 
 Presentation Materials – Detail Aids 
o Again, there is a range of approaches with some individuals using detail 
aids more than others 
o Some people are using it more as a formal presentation, others less so. 
o A number of visit reports are very similar, reflecting standard approach.  
Whilst it is accepted that the topics covered may be similar and overlap, 
it is important to utilise and develop the techniques we already have and 
have learned during training and re-iterating the detail aid messages. 
o A reminder, we can aim for consistency by focusing on the key 
messages and lead into the detail based on discussion with the GPs and 
nurses. 
  
 Presentation Materials 
o Memory Sticks – General agreement that not particularly practical and 
may have possible time constraints.   
o Folders - Everyone generally comfortable with hard copies of detail aids.  
(Remember - A4 folder each and two A3 folders for those who prefer to 
use larger folder). 
 
 Analysis and interpretation of the data to steer conversation and influence 
prescribing at each meeting 
o Did not discuss and obtain individual feedback regarding this point. 
o However, point made that some GPs are resistant to sharing their data.  
Please note that GPs can be reassured that data is confidential and not 
shared without agreement or is anonymised. 
 
Background Information / Training 
 MW reminded everyone that there is a considerable amount of background 
information which has been prepared and provided for the project which 
everyone should be familiar with.  This ranges from information about the study 
such as to reference sources relating to detailing techniques and clinical 
references / resources intended to support the information presented in the 
detail aids. 
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MW reminded everyone about the NAO Report ‘Influencing Prescribing Cost and 
Quality in Primary Care’ which has previously been forwarded and circulated as a 
link and which contains a really useful summary of the practical application of 
detailing techniques and including planning, targeting and communication with 
clinicians.   MW requested that please can everyone read the sections that she has 
highlighted previously.  MW will also provide further copies of the protocol for 
pharmacists. 
 
 In addition, everyone has been given a folder which contains: 
o Academic Detailing Planning Matrix for T2DM 
o Academic Detailing Planning Matrix for NSAIDs 
o Outcomes being monitored and measured for the study ie 
 Prescribing Data - ePACT 
 Outcome Data – Practice level 
The detailing matrices provide details on the aims of the sessions, key messages, 
possible areas of controversy.  Please can everyone ensure that they have 
familiarised themselves with these documents as they are intended to guide and 
support pharmacists in conducting the practice visits.  They also contain the 
information which is intended to promote consistency when conducting the visits.  
Knowledge of the outcome measures should also help pharmacists focus on the 
required changes when directing discussions with the GPs.  
 
 Support Materials 
o Additional materials include NPC training materials, references quoted 
on the slides including original references, MeReC summaries (eg RAS 
Drugs, NSAIDs).  These are filed in a box in MW’s office.  So far not 
aware that these have been accessed although MW has used some of 
this information when responding to queries raised by other pharmacists 
resulting from practice visits.  NB: Dealing with queries covered later in 
these notes. 
o Please note that there are copies of the current NICE guidance for T2DM 
and NSAIDs.  There are enough copies for each GP in study practices 
and nurses.  It was intended that the NICE guidance (and MeReCs for 
example) are available for distribution during/following practice visits. 
 
 
2. Visit Reports 
 
 Visit Report Format 
 
o In general, most pharmacists have adopted the study report format that ** 
had shared before the study visits started and this appears to be the 
preferred approach.  As indicated earlier, it is acceptable for individuals to 
use the template or adapt to suit their style.  It was confirmed that a 
standardised report format is not crucial.  The most important aspect is to 
ensure that the discussion points from the visit are documented accurately, 
action points noted and feedback is provided to the practice in a timely 
manner. 
o There was some discussion on content of report.  It is not intended that 
feedback is uniform (ie same content/actions for all practices).  Not possible 
to be prescriptive about content.  More that visit report and resulting actions 
reflects discussion topics addressed during individual visit. 
o There is a variation in timing of writing up and dissemination of feedback 
between pharmacists.  It is most important to ensure that the visit and 
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discussion details are documented quickly so that accurate notes can be 
made.  Agreed data and information requirements can be followed up 
accordingly. 
o SU suggested blocking time in the calendar immediately after practice visit to 
write up.  This will require commitment to the process.  It was agreed that 
this approach be implemented by all members of the study team in order to 
ensure consistency and timely feedback.  
o NB: If it is not possible to write up immediately after the visit, it is suggested 
that preliminary notes and actions at least are written up within two days to 
capture the main discussion points and actions. This could be in bullet form 
initially.   
o Visit Report Timeframe - Please stick to original request to feedback full 
report to practice preferably within one week, maximum two weeks. 
o Please forward copy of each visit report to MW 
 
 Visit reports should document 
o Agreed Actions 
o Timeframe for Actions – Agree with Practice 
o SMART 
o Requirements for provision of additional information eg clinical, ePACT 
 
 MW presented a summary of actions from the baseline visits disseminated so far 
to practices.  Pharmacists are able to follow up queries with individual practices.  
Some of the actions resulting from different practice visits are similar.  If 
pharmacists are struggling to follow up actions, where possible, MW will follow 
up the queries to support the other pharmacists particularly for clinical queries. 
o NB: Please d/w MW as soon as possible following visits if there are 
actions that she may be able to help other pharmacists with.  
 
 MW will prepare a FAQ sheet from the visit reports.  This will be accessible by 
everyone and will help reduce duplication of effort if similar queries are raised. 
 
3. Visit Summaries  
 
It has been requested that each pharmacist will provide a written feedback following 





 Provision of ePACT data following visit as result of agreed actions 
o It was agreed that it is not appropriate to pull off the same data for the 
next round of visits as for the baseline visits.  Because of the delay in 
ePACT data it will not be possible to provide comparative data to detect 
a difference at this stage. 
o Next set of routine data will need to be pulled off for third visits to 
feedback to GPs and detect whether any change in prescribing. 
 
 Preparation of ePACT data for next round of visits - MW to address 
 
 Preparation of additional data/graphs as a result of actions from practice visits 
o One pharmacist is pulling off her own additional data based on visit 
discussions.  If other pharmacists are able to do this then this is fine as it 
will be tailored to the practice’s needs. 
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o MW to negotiate for others.  Please advise data requirement if you are 
not able to pull off information from agreed actions. 
 
5. Outcome Data to Inform Visits? 
 
 For information – The outcome data MW is collecting from practice searches is 
primarily intended to enable a before and after comparison to assess whether 
there has been an impact as a result of the intervention. 
o It was not originally intended to utilise the data within the practice visits.  
However, it has become apparent that some of the information collected 
at baseline might actually inform the discussions around prescribing and 
be useful in the communications with the partners.  MW has already 
offered to share this information with one of her practices.  One 
pharmacist had a query from PH Surgery for which MW’s data may 
provide an answer. 
o From a practical perspective, the practices could extract the information 
themselves following on from discussions with the pharmacists.  
However, as the data is available MW is happy for pharmacists to share 
information with the practices if appropriate. 
o The type of data includes  
 proportions of patients on ACE-Is versus A-II-As 
 HbA1c levels 
 BP levels 
 Drugs prescribed for blood glucose lowering, BP 
 Patients on NSAIDs also on aspirin, PPIs, SSRIs plus much more 
o MW will provide details of data available and information which can be 
extracted from it.  MW will feedback to other pharmacists. 
o Please ask Melanie if you think that any of this information will support 
pharmacists in delivering the intervention in individual practices. 
 
 
7. Follow up visits 
 
 Booking Next Visits  MW will ask Sec to book the next visits which are due in 
December  
o MW and one other pharmacist will be contacting practices direct to set up 
the meetings.  The other pharmacists may wish to consider this 
approach. 
 
 Arrangements to determine content , structure, attendance, information 
requirements for next round of visits 
o MW is also planning to contact the GP prescribing lead / GP study 
contact to discuss and confirm the content of the next visits in advance of 
the visit.  MW requested that this approach be considered by the other 
pharmacists.  Ie  Contact practice in advance of following visit to discuss.  
This may also help focus on visit content and aid preparation. 
 
 It will be necessary to review individual actions prior to the next visit to ensure 
that they have been addressed. 
 
 Topics for next meeting 
o Some individuals are not sure what topics to cover at the next meeting.  
Hence, review of actions and encouragement to contact PL in advance to 
tailor to practice requirements.  (Direct communication will also promote 
engagement with the practice that we are trying to develop). 
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o If only one topic covered in baseline visit, other topic should be 
addressed in next visit (plus re-iteration of initial topic as appropriate). 
o It is anticipated that by the time the next meeting is due, the PCT 
guidance on newer drugs should be available.  This will be a hot issue 
and practices will be keen to find out what the requirements are.  
Therefore, suggest that this is a topic may be suggested to practices a as 
an option if pharmacists feel appropriate.  Obviously it addresses PCT 
policy, however, the recommendations are essentially based on the 
evidence presented in the NICE guidance which is the subject of the 
detail aids. 
 
8. Sharing Information 
 
 It is really important that as a team working on the project together, we share 
information both 
o Clinical 
o Relating to experiences 
 
Please can we keep each other informed and share information relation relating to 
the study and its progress, issues etc. – As we do in real practice. 
 
 MW will prepare a FAQ sheet from the visit reports.  This will be accessible by 
everyone and will help reduce duplication of effort if similar queries are raised. 
 
 
9. Housekeeping - Folders / files on system 
 
 The main study files are in a folder ‘Project EBH. 
o Visit Reports  
o Practice Data  
o e-PACT Data – downloaded / graphs for visits / additional 
o Detail Aids 
o Additional Slides 
o Evidence 
 






 COX-II Selectivity slide useful.  To be shared and added to ‘Additional Slides’ 
folder in ‘Detail Aids’ folder in Study folder (Prescribing/Project EBP/Detail Aids) 
 MW will prepare other additional slides as necessary and forward to everyone as 
well as filing in ‘Additional Slides folder. 
 




Practice Searches – Data Collection Requirements Type 2 Diabetes 
 
Search:  Current Registered Practice Population with T2DM 
 
Report: Practice T2DM population (eg Korner bands, capitation report) as 
proportion of current practice population.  
 
Build up report containing data listed: 
 
 Patient ID 
 Age in years 
 Gender M/F 
 
 Current Blood Glucose Lowering Medication 
o Insulins 
o Metformin 
o Sulphonylureas and related drugs group 
o Rosiglitazone 
o Rosiglitazone and Metformin 
o Pioglitazone 








o Liraglutide   
 
NB: All but insulins, metformin and sulphonylureas may be also extracted under 
‘other’ drugs used in diabetes 
 
Latest recorded value: 
 
 HbA1c    Previous 2 years Latest, date and value 
 SBP    Previous 2 years Latest, date and value 
 DBP    Previous 2 years Latest, date and value 
 Urine Albumin:Creatinine Ratio Previous 2 years Latest, date and value 
 
 
 Current Antihypertensive Medication: 
 







o Centrally Acting Antihypertensive 
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Appendix 30 (Cont.) 
 
 
Practice Searches – Data Collection Requirements Type 2 Diabetes (Cont.) 
 
 
 Current Aspirin / Antiplatelet 
 
 Current Lipid Lowering Therapy (Drugs used to treat hyperlipidemia) 
 
Latest recorded value 
 
 Total (serum)cholesterol  Previous 2 years Latest, date and value 
 Serum LDL   Previous 2 years Latest, date and value 







NB: Read Codes on Torex may be different from those on EMIS or System One 
 
 





Practice Searches – Data Collection Requirements 
Non-Steroidal Anti-inflammatory Drugs 
 
Search:  Current Practice Population on NSAID (excluding Aspirin) 
 
Report: Practice population on NSAID (eg Korner bands, capitation report) as 
proportion of current practice population.  
 
 
Build up report containing data listed: 
 
 Patient ID 
 Age in years 
 Gender M/F 
 










 Read Code for 
o Peptic Ulcer   J130   Latest 
 
o CKD 5    1z14   Latest 
o CKD 4    1z13   Latest 
o CKD 3    1z12   Latest  
 
o Heart Failure   G58   Latest 
o Hypertension   G20   Latest 
o Ischaemic Heart Disease G3    Latest 
o Myocardial Infarction  G30   Latest 
o Peripheral Vascular Disease G73   Latest 
o Stroke / CVA   G66   Latest 





NB: Read Codes on Torex may be different from those on EMIS or System One 
 
 





EMIS Search Strategy for Type 2 Diabetes Data Collection 
 
Building up the search requires a methodical and stepwise approach.  The EMIS 
search methodology and subsequent preparation of the Excel spreadsheets is 
described here.  
 
The first step is to build a simple search of the practice population of interest as 
follows: 
 
From the main menu select ST (Search and Statistics) 
Select B (Patient searches) 
Select A (Build and perform new search) 
Select A (Add a feature) and proceed to build up a simple search on todays practice 
population.  In this case All Type 2 diabetics currently on the practice register.   
When no more features are required, enter ‘Return’ and at the prompt ‘Are the 
features correct?’ Enter ‘Yes’ 
Name the search and store in an appropriate area of the search directory. 
At the prompt ‘Run the search now?’ enter ‘Yes’ 
 
When notified that the search is complete, go to ‘Search Results’.  Access the table 
showing distribution by age and sex (Korner bands).  Details relating to practice 
population and percentages of patients with T2DM are provided and documented. 
 
This search may now be used to build up a report containing data on all of the 
parameters required for export to excel. 
 
Building the Export Report  
 
Enter S (Search results) and access the basic search 
Enter F (Report names and Addresses and Aspects of Patient Records) 
Enter A (Add a new report) 
The search can now be built up in a stepwise manner from the following screen: 
 
Add Aspect to Collection 
A.  Registration details B.  Registration status 
C.  Diary or recall dates D.  Clinical aspect of record 
E.  Present Medication F.  Past Medication 
G. Patient Number H.  GP National Code 
I.  Consultation P.  Problem Titles 
J.  Age T.  Temporary Number 
 
The patient number, age and gender (from registration details) are included.  All 
other aspects of the search relate to present or past medication and clinical aspects 
of the patient record (ie E, F and D). 
 
When each aspect of the record is accessed, the user is prompted and given the 
option to include associated information in the report.  These include date range, 
whether latest value only is require, date of entry, Read Code, code description, 
numerical value.  For parameters such as whether HbA1c, BP and lipids have been 
measured within a specified time period, it is necessary to define a date range.  It is 
also necessary to ensure that data on recorded values is collected.  The code 
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description and term used is not necessary in terms of data collection.  However, it 
is necessary to ensure that the terms and codes used in the search extract the data 
required.  It is possible to enter dates in the future so if running the same audit 
elsewhere or again, the appropriate information can be picked op over the time 
period of the data collection.  Ideally, the ‘latest only’ function is specified in order to 
obtain single entries in line for each patient.  
 
Once collected, the search is saved (F8) and named appropriately.  The attached 
EMIS screen dump is an example of how the search is displayed from the pilot data 
collection (prior to finalisation of the parameters required).  It provides a view of the 
EMIS screen including a summary of search strategy and detail relating to each 
parameter which will be reported.  The search can now be exported to Excel using 
the ‘P’ function (Print, view or export report) 
 
The report destination is Microsoft Excel (Excel must be the default spreadsheet).  
EMIS will create a spool file.  Once complete, Search and Statistics module is exited 
by returning to the main menu.  Once the search and report has been created and 
saved, it can be exported to a floppy disk and shared with other practices.  However, 
once completed, it is not possible to alter the pre-determined dates. 
 
The Excel spread sheet must now be tidied.  A single row is inserted at the top and 
each column given an appropriate title referring to the data in it.  Duplicate patients 
are deleted.  (EMIS may export data relating to individual patients more than once 
for example when entering past medication data as in this audit).  It is extremely 
important at this stage to check that all or the columns have data entered (if 
available) as some practices may use different Read Codes or different descriptors 
(terms) for the same parameter.  If not, it is necessary to amend the report using the 
relevant Read Code or descriptor used by the practice and rerun the report and re-
export the data into Excel.  The file is then saved as an excel workbook for the 









EMIS Search Strategy for NSAIDs Data Collection 
 
Building up the search requires a methodical and stepwise approach.  The EMIS 
search methodology is described here.  
NB: EMIS NSAID search detects all patients on low dose aspirin which need to be 
excluded (unless on NSAID) 
The first step is to build a simple search of the practice population of interest as 
follows: 
 
First EMIS Search 
From the main menu select ST (Search and Statistics) 
Select B (Patient searches) 
Select A (Build and perform new search) 
Select A (Add a feature) and proceed to build up a simple search on todays practice 
population.   
Select E Present Medication NSAIDs 
All Drugs    
Current/Past/Both  C 
Acutes/Repeats/Autos/All A 
Issued Between  01.09.09 – 01.09.10 (1 Year, to date) 
 
Continue 
Name the search and store in an appropriate area of the search directory. 
At the prompt ‘Run the search now?’ enter ‘Yes’ 
 
First Report 
When search complete, go to ‘Search Results’ 
Select search 
F report names and addresses plus aspect of patient record 
A Add new report 
E present medication: G drug group NSAIDs  
P print  
Export to excel.  In Excel sort NSAIDs alphabetically  
Highlight products containing low dose aspirin 
 
 
Second EMIS Search 
Return to build and perform new search on todays practice population 
Select E Present Medication - NSAIDs 
All Drugs   N 
(Do not select All Drugs. Scroll down, use the space bar to exclude low dose 
aspirin products highlighted above from search)  
Current/Past/Both  C 
Acutes/Repeats/Autos/All A 
Issued Between  01.09.09 – 01.09.10 (1 Year, to date) 
Continue 
Name the search and store in an appropriate area of the search directory. 
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When search complete 
Select F  - Report names and addresses plus aspect of patient record 
Add new report 
Add the following aspects 
: 
G  Patient ID 
A  Sex M/F 
J Age in years 
E  Present medication: NSAID do not include drug group 
    Aspirin (G) (T) 
PPI 
Compound antidepressants  
D Clinical aspect (select only latest) 
 
  Read Code    
Peptic Ulcer   (J130)    Latest  
 
MI  (G30)    Latest 
    IHD   (G3)    Latest 
 Heart Failure (G58)    Latest 
 
CKD3  (1z12)    Latest 
CKD4  (1z13)    Latest 
  CKD5  (1z14)    Latest 
   
Peripheral vascular disease (G73)  Latest 
 Stoke & CVA   (G66)  Latest 
  Cerebrovascular disease  (G6)  Latest 
 
 
Save and export to Excel 
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Appendix 34 (Cont.) 
 
Sample Search Outputs – Torex (Rep Aid) 
 
1,"1Rep-D1825E5D-8879-F44D-852B-631C68522CF6",1,"N",,"New Report","Last run:  Tue 16 November 2010 14:00:24 
Run time:  2 m : 3 s 
Patients:  687 
 
Last run:  Tue 16 November 2010 14:51:57 
Run time:  5 m : 36 s 
Patients:  685 
 
Last run:  Fri 23 September 2011 11:10:19 
Run time:  8 m : 41 s 
Patients:  241","Tue   16/11/10",#FALSE#,"",#FALSE#,"","",#TRUE#,,,,,,1,#TRUE#,,,,,,,"",,#TRUE#," Patient ID",#FALSE#,#FALSE#,,,#FALSE# 
2,"2ID-378F8F5A-7DEF-514E-BAE0-081315021D26",2,1,"1Rep-D1825E5D-8879-F44D-852B-631C68522CF6","2ID","Full 
GMS","0","either",120,0,0,0,"","","",#FALSE#,#FALSE#,"False",#FALSE#,"",#FALSE#,#FALSE#,"",#FALSE#,0,0,,,#TRUE#," first name",#FALSE#,18366,,#FALSE#,"" 
3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2",4,2,"2ID-378F8F5A-7DEF-514E-BAE0-081315021D26","NSAIDS L12M",#FALSE#,"j2, j2, j21, j211, j211, j212, j21y, j21z, j22, 
j221, j222, j223, j224, j225, j226, j227, j228, j229, j22A, j22B, j22C, j22D, j22E, j22F, j22G, j22H, j22I, j22J, j22K, j22L, j22M, j22N, j22O, j22P, j22Q, j22R, j22S, j22T, j22U, j22V, j22W, j22X, 
j22X, j22X, j22Y, j22Z, j22a, j22b, j22c, j22d, j22e, j22f, j22g, j22h, j22i, j22j, j22k, j22l, j22m, j22n, j22o, j22o, j22p, j22q, j22r, j22s, j22t, j22u, j22v, j22w, j22x, j22y, j22z, j22z, j23, j231, j232, 
j233, j234, j24, j241, j242, j243, j244, j245, j246, j247, j248, j249, j24A, j24B, j24C, j24D, j25, j251, j252, j253, j254, j255, j256, j257, j258, j259, j25A, j25B, j25y, j25z, j26, j261, j262, j263, 
j264, j27, j271, j272, j273, j274, j275, j27x, j27y, j27z, j28, j281, j282, j283, j284, j285, j286, j287, j288, j289, j28A, j28B, j28C, j28D, j28E, j28F, j28G, j28H, j28I, j28J, j28K, j28M, j28N, j28O, 
j28O, j28P, j28R, j28S, j28T, j28U, j28V, j28V, j28W, j28X, j28Y, j28Y, j28Y, j28Z, j28a, j28b, j28c, j28d, j28e, j28f, j28g, j28h, j28i, j28j, j28k, j28l, j28m, j28n, j28o, j28p, j28q, j28r, j28s, j28t, 
j28u, j28v, j28w, j28w, j28w, j28x, j28y, j28z, j28z, j29, j29, j291, j291, j292, j292, j293, j293, j293, j294, j295, j296, j297, j298, j299, j29A, j29A, j29A, j29B, j29B, j29B, j29C, j29C, j29C, j29D, 
j29D, j29D, j29E, j29E, j29E, j29F, j29G, j29H, j29J, j29K, j29a, j29b, j29c, j29d, j29e, j29f, j29g, j29h, j29i, j29j, j29k, j29l, j29m, j29n, j29o, j29p, j29p, j29p, j29q, j29r, j29s, j29t, j29u, j29v, 
j29v, j29w, j29y, j29y, j29z, j29z, j29z, j2a, j2a1, j2a2, j2a3, j2a4, j2a5, j2a6, j2a7, j2a8, j2a9, j2aA, j2aB, j2aC, j2aD, j2aE, j2aF, j2aG, j2aH, j2aI, j2aJ, j2aK, j2aL, j2aM, j2aO, j2aP, j2aQ, 
j2aQ, j2aR, j2aR, j2aa, j2ab, j2aw, j2ax, j2ay, j2az, j2b, j2b1, j2b2, j2b3, j2b4, j2b5, j2b6, j2b7, j2b8, j2b9, j2bA, j2bB, j2bC, j2bD, j2bx, j2by, j2bz, j2c, j2c1, j2c2, j2c3, j2c4, j2c5, j2c6, j2c7, 
j2c8, j2c9, j2cA, j2cB, j2cC, j2cD, j2cE, j2cF, j2cG, j2cH, j2cI, j2cJ, j2cK, j2cL, j2cM, j2cN, j2cO, j2ca, j2cb, j2cc, j2cd, j2ce, j2cf, j2cg, j2ch, j2ci, j2cj, j2ck, j2cl, j2cm, j2cn, j2co, j2cp, j2cq, 
j2cr, j2cs, j2ct, j2cu, j2cv, j2cw, j2cx, j2cx, j2cy, j2cz, j2d, j2d1, j2d2, j2d3, j2d4, j2d5, j2d6, j2d7, j2d8, j2e, j2e1, j2e2, j2e3, j2e4, j2e5, j2e6, j2e7, j2e8, j2e9, j2eA, j2eB, j2ea, j2eb, j2ec, j2ed, 
j2ee, j2ef, j2ev, j2ew, j2ex, j2ey, j2ez, j2f, j2f1, j2f2, j2fy, j2fz, j2g, j2g1, j2g2, j2g3, j2g4, j2g5, j2gx, j2gy, j2gz, j2h, j2h1, j2h2, j2h3, j2hy, j2hz, j2i, j2i, j2i1, j2i1, j2i1, j2i1, j2i2, j2i2, j2j, j2j1, 
j2j2, j2k, j2k, j2k1, j2k2, j2k3, j2k4, j2k5, j2k6, j2l, j2l1, j2l2, j2l3, j2l4, j2l5, j2l6, j2l7, j2l8, j2m, j2m1, j2m2, j2n, j2n1, j2n2, j2n3, j2n4, j2n5, j2n6, j2n7, j2n8, j2o, j2o1, j2o2, j2o3, j2o4, j2o5, 
j2o6, j2o6, j2o7, j2o8, j2o9, j2oA, j2oB, j2oC, j2oD, j2oE, j2oF, j2oG, j2oH, j2oJ, j2oK, j2oK, j2oL, j2oM, j2oN, j2oO, j2ol, j2om, j2oo, j2op, j2oq, j2or, j2os, j2ot, j2ou, j2ov, j2ow, j2ox, j2oy, 
j2oz, j2p, j2p1, j2p2, j2p3, j2p3, j2p3, j2p4, j2p5, j2p6, j2p6, j2p7, j2p8, j2p9, j2pA, j2pB, j2pC, j2pD, j2pE, j2pF, j2pG, j2pH, j2pI, j2pJ, j2pK, j2pL, j2pM, j2pN, j2pO, j2pP, j2pQ, j2pR, j2pS, 
j2pT, j2pU, j2pV, j2pW, j2pX, j2pY, j2pZ, j2pa, j2q, j2q1, j2qz, j2r, j2r1, j2r2, j2r3, j2rx, j2ry, j2rz, j2s, j2s1, j2s2, j2s3, j2sx, j2sy, j2sz, j2t, j2t1, j2t2, j2ty, j2tz, jA2, jA2y, jA2z, jA5, jA51, jA52, 
jA53, jA58","","NON-STEROIDAL ANTI-INFLAMM NOS and others","",0,"","Thu 30/9/2010","Sat 
1/10/2011","True",#TRUE#,#FALSE#,"","True","False","False","False",#TRUE#,#TRUE#,"Authorisation","True",,2,#TRUE#," surname",#FALSE#,241,"",#FALSE#,#FALSE# 
4,"4Drug-16931555-8894-4E4C-813E-6D9AD6C7E6F3",4,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","Aspirin",#FALSE#,"bu23, bu24, bu25, bu2A, bu2B, bu2D, bu2E, bu2F, 
bu2G, bu2H, bu2K, bu2c","","ASPIRIN 75mg disp tabs         and 
others","",0,"","","","True","True","False","","True","False","False","False",#TRUE#,#TRUE#,"Authorisation","True",,3,#TRUE#," sex",#FALSE#,25,"",#FALSE#,# FALSE# 
5,"5Drug-04D32D0E-FF61-FE44-82D5-A42B0D5950FB",4,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","PPI",#FALSE#,"a6b, a6b1, a6b1, a6b2, a6b3, a6b4, a6b5, a6b5, 
a6b6, a6b7, a6b7, a6b8, a6b9, a6bA, a6bB, a6bC, a6bD, a6bE, a6bF, a6bG, a6bH, a6bI, a6bJ, a6bK, a6bL, a6bM, a6bN, a6bO, a6bP, a6bu, a6bv, a6bw, a6bx, a6by, a6bz, a6c, a6c1, 
a6c2, a6c3, a6c4, a6c5, a6c6, a6c7, a6c8, a6c9, a6cA, a6e, a6e1, a6e2, a6e3, a6e4, a6e5, a6e6, a6f, a6f1, a6f2, a6f3, a6f4, a6h, a6h1, a6h2, a6h3, a6hx, a6hy, a6hz","","OMEPRAZOLE                     
and others","",0,"","","","True","True","False","","True","False","False","False",#TRUE#,#TRUE#,"Authorisation","True",,3,#TRUE#," age",#FALSE#,74,"",#FALSE#,#FALSE# 
6,"6Drug-4C21C26E-D15E-2843-8FE1-4B2302665BC1",4,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","SSRI",#FALSE#,"da4, da41, da42, da43, da44, da45, da46, da47, 
da48, da49, da4A, da4B, da5, da51, da52, da53, da54, da6, da61, da62, da63, da64, da65, da66, da67, da68, da7, da71, da72, da73, da74, da75, da76, da77, da78, da79, da7A, da7B, 
da7C, da7D, da7E, da7F, da7G, da7H, da7I, da7J, da7K, da7L, da7M, da7N, da7O, da7P, da7Q, da7R, da7S, da7T, da7U, da7V, da7W, da7X, da7Y, da7Z, da7a, da7b, da7c, da9, da91, 
da92, da93, da94, da95, da96, da97, da98, da99, da9A, da9z, daC, daC1, daC2, daC3, daC4, daC5, daC6, daC7, daC8, daC9, daCA","","FLUOXETINE HYDROCHLORIDE       and 
others","",0,"","","","True","True","False","","True","False","False","False",#TRUE#,#TRUE#,"Authorisation","True",,3,#TRUE#," road",#FALSE#,37,"",#FALSE#,#FALSE# 
7,"7Morb-4CFA0F48-74D6-FA41-9A5F-E263D82A3E22",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","PU",#FALSE#,"J13, J130, J1300, J1301, J1302, J1303, J1304, J130y, 
J130z, J131, J1310, J1311, J1312, J1313, J1314, J131y, J131z, J13y, J13y0, J13y1, J13y2, J13y3, J13y4, J13yy, J13yz, J13z","" ,"Peptic ulcer - (PU) site unsp. and 
others","",0,"","","False","False","False",#TRUE#,"True","False","False",#FALSE#,"",#FALSE#,#FALSE#,"False","",,3,#TRUE#," GP",#FALSE#,0,,#FALSE#,#FALSE# 
8,"8Morb-F8FE425C-DDD4-2D4F-88A9-CDAF4E8E2C24",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","CKD",#FALSE#,"1Z10, 1Z11, 1Z12, 1Z13, 1Z14","","Chronic kidney 
disease stage 1 and others","",0,"","","False","False","False",#TRUE#,"True","False","False",#FALSE#,"",#FALSE#,#FALSE#,"False","",,3,#TRUE#," post 
code",#FALSE#,15,,#FALSE#,#FALSE# 
9,"9Morb-61E3A627-9D85-C84E-AE53-0EA5F4ADA0C9",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","HF",#FALSE#,"G58, G58, G580, G580, G580, G580, G580, G5800, 
G5801, G5802, G5803, G5804, G581, G581, G581, G581, G5810, G582, G58z, G58z, G58z, G58z","","Cardiac failure                and 
others","",0,"","","False","False","False",#TRUE#,"True","False","False",#FALSE#,"",#FALSE#,#FALSE#,"False","",,3,#FALSE#," surgery",#FALSE#,2,,#FALSE#,#FALSE# 
10,"10Morb-CFBC0374-D4E2-9A45-B109-10AE6CBF6D28",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","Hypertension",#FALSE#,"G20, G20, G200, G201, G202, G203, 
G20z, G20z","","Essential hypertension         and others","",0,"","","False","False","False",#TRUE#,"True","False","False",#FALSE#,"",#FALSE#,#FALSE#,"False","",,3,#FALSE#," 
title",#FALSE#,23,,#FALSE#,#FALSE# 
11,"11Morb-9083A301-1F59-6441-860E-9129FB0F9555",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","MI",#FALSE#,"G30, G30, G30, G30, G30, G30, G30, G30, G300, 
G301, G3010, G3011, G301z, G302, G303, G304, G305, G306, G307, G3070, G3071, G308, G309, G30A, G30B, G30X, G30X0, G30y, G30y0, G30y1, G30y2, G30yz, G30z","","Acute 
myocardial infarction    and others","",0,"","","False","False","False",#TRUE#,"True","False","False",#FALSE#,"",#FALSE#,#FALSE#,"False","",,3,#FALSE#," 
house",#FALSE#,6,,#FALSE#,#FALSE# 
12,"12Morb-C82524FB-D6BF-8E44-980D-AD47434290C2",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","IHD",#FALSE#,"G3, G3, G3, G3","","Arteriosclerotic heart disease 
and others","",0,"","","False","False","False",#TRUE#,"True","False","False",#FALSE#,"",#FALSE#,#FALSE#,"False","",,3,#FALSE#," date of birth",#FALSE#,8,,#FALSE#,#FALSE# 
13,"13Morb-9810548F-353E-D847-8668-6C8AA6027EA0",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","PVD",#FALSE#,"G73, G73, G73, G73, G730, G7300, G7301, 
G7301, G730z, G731, G7310, G7311, G731z, G732, G7320, G7321, G7322, G7323, G7324, G733, G73y, G73y0, G73y1, G73y2, G73y4, G73y4, G73y5, G73y5, G73y6, G73y7, G73y8, 
G73y8, G73y8, G73yz, G73z, G73z0, G73z0, G73z0, G73z1, G73zz","","Ischaemia of legs              and 
others","",0,"","","False","False","False",#TRUE#,"True","False","False",#FALSE#,"",#FALSE#,#FALSE#,"False","",,3,#FALSE#," phone",#FALSE#,4,,#FALSE#,#FALSE# 
14,"14Morb-9D652D90-0173-6649-8FC3-2BCD272FAB95",3,3,"3Drug-74EA9EF2-632B-FA46-93AC-6DFC04B8EFF2","Stroke_CVA",#FALSE#,"G6, G60, G600, G601, G602, G603, G604, 
G605, G606, G60X, G60z, G61, G61, G61, G610, G611, G612, G613, G614, G615, G616, G617, G618, G61X, G61X0, G61X1, G61z, G62, G620, G621, G622, G623, G62z, G63, G63, 
G63, G630, G631, G631, G631, G632, G633, G634, G63y, G63y0, G63y1, G63z, G64, G64, G64, G64, G640, G6400, G641, G641, G6410, G64z, G64z, G64z, G64z0, G64z1, G64z1, 
G64z2, G64z3, G64z4, G65, G65, G65, G65, G650, G650, G651, G6510, G652, G653, G654, G655, G656, G65y, G65z, G65z0, G65z1, G65zz, G66, G66, G66, G66, G66, G660, G661, 
G662, G663, G664, G665, G666, G667, G668, G669, G67, G670, G670, G671, G6710, G6711, G671z, G672, G672, G673, G6730, G6731, G6732, G6733, G674, G6740, G675, G676, 
G6760, G677, G6770, G6771, G6772, G6773, G6774, G678, G679, G67y, G67z, G68, G680, G681, G682, G683, G68W, G68X, G6W, G6X, G6y, G6z","","Cerebrovascular disease        
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Baseline  Post Intervention Shift  
  
    No.  % No.  % % 
Practice     
Population 
 









ACE-I / A-II-A 
 




Clinical Outcomes  
 
Blood Glucose 
HbA1c ≤ 7.5%(58mmol/ml) 
HbA1c ≤ 9.0%(75mmol/ml) 
HbA1c ≥ 9.0%/not recorded 
 
Blood Pressure 
BP  ≤ 140/80mmHg 
 






(of those measured) 
 
Those with m/a  
on ACE-I / A-II-A 
 
Those with m/a  
with BP ≤ 135/80mmHg 
 
Blood Lipids 
TC ≤ 4mmol/l 
TC ≤ 5mmol/l 
LDL  ≤ 2mmol/l 
TGs ≤ 2.3mmol/l 
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    Data Record Form 
NSAIDs    
Practice 
 
Baseline  Post Intervention Shift  
  
    No.  % No.  % % 
Practice     
Population 
 
Patients on  
NSAID 
    Diclofenac 
    Ibuprofen 
    Diclofenac 
    Coxibs 
    Others 
Total 
Ib + Na 
 
 







Aspirin + PPI 
 
SSRI 








     3 
     4 




     IHD 
     PVD 









An Evaluation of Evidence-Based Prescribing Support from Primary Care 




Proposed Topic Guide – Pre-Intervention 
 
 
Intended to evaluate GP perspective in relation to perceptions, attitudes, knowledge 
and clinical behaviour before delivering the intervention. 
 
Tell me a little about yourself.  Experience, interests 
 
 Have you had specific training in EBM?  In curriculum at college?  Since 
college? 
 
 Has it equipped you to practice in an evidence based way? 
 What about critical appraisal? 
  
 General perceptions of EBM 
 
 Definition of EBM Defining EBM 
 Opinion of EBM 
 
 EBM and Clinical Practice 
 
 How does EBM affect your clinical practice? 
 Are you able to incorporate EBM in your prescribing practice? 
 Are there any particular triggers which might prompt you to seek evidence 
based information to inform you practice, including prescribing decisions? 
 Where would you normally access information from to inform prescribing 
decisions? 
 What do you consider as evidence-based sources of information?   Would 
you actively seek them (if at all) to inform prescribing decisions? 
 Guidelines, would you question them? 
 Pressures to prescribe 
 
 Do you perceive any barriers to incorporation of EBM into prescribing decisions 
 How overcome them? 
 
 View of prescribing advisers  Role, knowledge, experience 
 Current, previous experience 
 
 What if any expectations do you have in relation to the proposed intervention. 
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An Evaluation of Evidence-Based Prescribing Support from Primary Care 




Proposed Topic Guide – Post-Intervention 
 
Intended to evaluate GP perspective in relation to perceptions, attitudes, knowledge 
and clinical behaviour following delivery of the intervention. 
 
 Tell me a bit about yourself. 
o How long a GP?  Experience  Special Interests 
 
General perceptions of EBM 
o Do you have a view / perception on practice of evidence based medicine 
 What it is?   How would you define it? Training? 
 
EBM and Clinical Practice 
 
 Do you have a view on EBM? 
o How does EBM affect your clinical practice 
o Do you consider yourself to be an evidence based practitioner? 
o Do you incorporate EBM into your clinical decision making? 
 
 Before the prescribing adviser visits, where / how would you normally access 
information from to inform prescribing decisions? 
o Has your approach to accessing prescribing information changed since 
the intervention? 
 
 What was your personal experience of ‘prescribing advice’ before the 
intervention 
o ? Support from MMT 
o ? Support from individual pharmacists (or technicians) 
o ? Support from prescribing adviser 
 
Attitudes toward the evidence-based intervention 
 Did you have any idea / preconceptions of what the ’intervention’ was going to 
involve? 
 
 Can you tell me about the visits? 
o What happened?  Content. 
o What was your experience / view of the practice visits 
o Different from previously?  
o Is there anything that worked particularly well / not so well 
o What, if any, are the benefits of this approach?  
 
 What did you think of ‘the intervention’ itself in the practice? 
o As a means of communicating (evidence based) prescribing information 
(with MMT, with each other). 
o Facilitating discussion 
o Research into practice Was the evidence base promoted? 
o Agreed Actions 
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 What was your view of the support delivered by the prescribing adviser as 
source of information (evidence based or otherwise) 
o Is that different from your previous experience? 
o Any specific observations 
 
 View of prescribing advisers   
o Role, knowledge, experience 
o What makes a good pharmacist in fulfilling this role? 
 
 Since implementation of the intervention have your pre-intervention perceptions 
changed 
o Prescribing advisers / MMT? 
o Attitude to EBM? 
 
 What is your view of the suitability and usefulness of written information provided 
o Evidence 
o Data (feedback) 
 
 Did anything change over the intervention period ie from baseline to Visit 4? 
o Eg development of relationship between pharmacist and the partners? 
o Trust? 
o Does this role have to be carried out by a pharmacist? 
 
 
Impact of the evidence-based intervention 
 
 What impact if any do you think the intervention has had  
o On you personally 
o On your prescribing practice? 
 
 What impact if any do you think the intervention has had  
o On the Practice as a whole 
o On practice partners as colleagues and clinicians (and PNs if attended). 
o On prescribing practice. 
 
 Has the intervention added value to you and / or your practice 
o Have you become better prescribers 
o Has it reduced any perceived barriers to prescribing 
 
 Do you consider that your knowledge and education about drugs and 
therapeutics increased as a result of the intervention?   In relation to: 
o Type 2 diabetes 
o Appropriate use of NSAIDs 
 Has it made you more aware of the evidence behind prescribing 
recommendations (and its robustness) 
 
 What if this approach were rolled out more widely? 
o Would this be a good idea 
o What advice / recommendations would you give 
 
 Is there anything else you want to add? 
 










  Statistic Std. Error 
NSAIDDiff Mean   -10.823 4.088 
  95% Confidence 
Interval for Mean 
Lower Bound -19.28   
  Upper Bound -2.366   
  5% Trimmed Mean   -8.263   
  Median   -4.62   
  Variance   401.085   
  Std. Deviation   20.0271   
  Minimum   -83.3   
  Maximum   8.3   
  Range   91.5   
  Interquartile Range   21.6   
  Skewness   -2.238 0.472 
  Kurtosis   6.749 0.918 
 
Table 38.1 Summary Statistics for Total NSAIDs 
 
  
Table 38.2  Total NSAIDs Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
NSAIDDiff 0.171 24 0.067 0.79 24 0 
a Lilliefors Significance Correction     
 
Table 38.3 Total NSAIDs Tests of Normality 
 
                                                                                                                                        296 
Appendix 38 (Cont.) 
 
Prescribing Data 





  Statistic Std. Error 
DicDiff Mean   -14.079 3.6178 
  95% Confidence 
Interval for Mean 
Lower Bound -21.563   
  Upper Bound -6.595   
  5% Trimmed Mean   -12.007   
  Median   -11.705   
  Variance   314.118   
  Std. Deviation   17.7234   
  Minimum   -76.6   
  Maximum   5.2   
  Range   81.8   
  Interquartile Range   22.5   
  Skewness   -2.008 0.472 
  Kurtosis   5.872 0.918 
 





Table 38.5  Diclofenac Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
DicDiff 0.147 24 0.194 0.821 24 0.001 
a Lilliefors Significance Correction    
 
Table 38.6 Diclofenac Tests of Normality 
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Prescribing Data 





  Statistic Std. Error 
COXDiff Mean   -0.693 0.5353 
  95% Confidence 
Interval for Mean 
Lower Bound -1.801   
  Upper Bound 0.414   
  5% Trimmed Mean   -0.578   
  Median   0.115   
  Variance   6.877   
  Std. Deviation   2.6223   
  Minimum   -6.4   
  Maximum   2.9   
  Range   9.4   
  Interquartile Range   4.5   
  Skewness   -0.853 0.472 
  Kurtosis   -0.377 0.918 
 





Table 38.8  COX-2 Inhibitors Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
COXDiff 0.216 24 0.005 0.894 24 0.016 
a Lilliefors Significance Correction    
 
Table 38.9 COX-2 Inhibitors Tests of Normality 
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Prescribing Data 




  Statistic Std. Error 
IbuDiff Mean   -0.679 1.1323 
  95% Confidence 
Interval for Mean 
Lower Bound -3.022   
  Upper Bound 1.663   
  5% Trimmed Mean   -0.795   
  Median   -0.67   
  Variance   30.771   
  Std. Deviation   5.5472   
  Minimum   -10.2   
  Maximum   11   
  Range   21.2   
  Interquartile Range   6.3   
  Skewness   0.393 0.472 
  Kurtosis   0.004 0.918 
 





Table 38.11  Ibuprofen Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
IbuDiff 0.127 24 .200* 0.963 24 0.503 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction    
 
Table 38.12   Ibuprofen Tests of Normality 
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Prescribing Data 





  Statistic Std. Error 
NapDiff Mean   7.53 3.7669 
  95% Confidence 
Interval for Mean 
Lower Bound -0.262   
  Upper Bound 15.322   
  5% Trimmed Mean   7.331   
  Median   5.07   
  Variance   340.555   
  Std. Deviation   18.4541   
  Minimum   -42   
  Maximum   62.3   
  Range   104.3   
  Interquartile Range   13.8   
  Skewness   0.287 0.472 
  Kurtosis   4.314 0.918 
 






Table 38.14  Naproxen Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
NapDiff 0.214 24 0.006 0.884 24 0.01 
a Lilliefors Significance Correction    
 
Table 38.15   Naproxen Tests of Normality 
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Prescribing Data 
Summary Statistics for Non-Steroidal Anti-Inflammatory Drugs  
 
Ibuprofen and Naproxen 
 
Descriptives 
  Statistic Std. Error 
IbNapDiff Mean   6.797 3.7302 
  95% Confidence  
Interval for Mean 
Lower Bound -0.919   
  Upper Bound 14.513   
  5% Trimmed Mean   7.095   
  Median   8.425   
  Variance   333.937   
  Std. Deviation   18.2739   
  Minimum   -50.8   
  Maximum   57.6   
  Range   108.4   
  Interquartile Range   16.9   
  Skewness   -0.461 0.472 
  Kurtosis   5.644 0.918 
 






Table 38.17  Ibuprofen and Naproxen Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
IbNapDiff 0.165 24 0.088 0.854 24 0.003 
 
Table 38.18   Ibuprofen and Naproxen Tests of Normality 




Summary Statistics for Drugs used in Type 2 Diabetes 
 
Total Drugs T2DM 
 
Descriptives 
  Statistic Std. Error 
AllDiff Mean   -1.303 7.3108 
 95% Confidence 
Interval for Mean 
Lower Bound -16.427   
 Upper Bound 13.82   
  5% Trimmed Mean   4.662   
  Median   9.24   
  Variance   1282.736   
  Std. Deviation   35.8153   
  Minimum   -157.6   
  Maximum   26.8   
  Range   184.3   
  Interquartile Range   19.5   
  Skewness   -3.893 0.472 
  Kurtosis   17.105 0.918 
 





Table 39.2  Total Drugs in T2DM Histogram and Box Plot 
 
 
Tests of Normality 
  Kolmogorov-Smirnova Shapiro-Wilk 
  Statistic df Sig. Statistic df Sig. 
AllDiff 0.259 24 0 0.543 24 0 
a Lilliefors Significance Correction    
 
Table 39.3   Total Drugs in T2DM Tests of Normality 
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Prescribing Data 





  Statistic Std. Error 
MetDiff Mean   8.977 4.4386 
  95% Confidence 
Interval for Mean 
Lower Bound -0.205   
  Upper Bound 18.159   
  5% Trimmed Mean   12.611   
  Median   14.085   
  Variance   472.836   
  Std. Deviation   21.7448   
  Minimum   -87.8   
  Maximum   27.5   
  Range   115.3   
  Interquartile Range   9.8   
  Skewness   -4.128 0.472 
  Kurtosis   18.772 0.918 
 






Table 39.5   Metformin Histogram and Box Plot 
 
 
Tests of Normality 
  Kolmogorov-Smirnova Shapiro-Wilk 
  Statistic df Sig. Statistic df Sig. 
MetDiff 0.327 24 0 0.5 24 0 
a Lilliefors Significance Correction    
 
Table 39.6   Total Drugs in T2DM Tests of Normality 
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Prescribing Data 





  Statistic Std. Error 
GlitDiff Mean   -8.28 1.4505 
  95% Confidence 
Interval for Mean 
Lower Bound -11.28   
  Upper Bound -5.279   
  5% Trimmed Mean   -8.47   
  Median   -8.045   
  Variance   50.493   
  Std. Deviation   7.1058   
  Minimum   -19.5   
  Maximum   6.7   
  Range   26.2   
  Interquartile Range   8.4   
  Skewness   0.257 0.472 
  Kurtosis   -0.274 0.918 
 





Table 39.8   Glitazones Histogram and Box Plot 
 




Statistic df Sig. Statistic df Sig. 
GlitDiff 0.096 24 .200* 0.966 24 0.571 
* This is a lower bound of the true significance.   
a Lilliefors Significance Correction    
 
Table 39.9   Glitazones Tests of Normality 
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Prescribing Data 





  Statistic Std. Error 
OtherDiff Mean   0.928 0.8398 
  95% Confidence 
Interval for Mean 
Lower Bound -0.809   
  Upper Bound 2.666   
  
5% Trimmed 
Mean   1.49   
  Median   1.755   
  Variance   16.928   
  Std. Deviation   4.1143   
  Minimum   -16.4   
  Maximum   5.8   
  Range   22.2   
  
Interquartile 
Range   2.3   
  Skewness   -3.365 0.472 
  Kurtosis   14.38 0.918 
 




Table 39.11   ‘Other’ Drugs in T2DM Histogram and Box Plot 
 
Tests of Normality 
  Kolmogorov-Smirnova Shapiro-Wilk 
  Statistic df Sig. Statistic df Sig. 
OtherDiff 0.243 24 0.001 0.644 24 0 
a Lilliefors Significance Correction    
 
Table 39.12   ‘Other’ Drugs in T2DM Tests of Normality 
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Summary Statistics for Patient-Orientated Outcome Measures for Patients on 
NSAIDs 
 
Patients on NSAIDs 
 
Descriptives 
  Statistic Std. Error 
Overall NSAIDs  Mean   -0.011 0.0439 
  95% Confidence  
Interval for Mean 
Lower Bound -0.103   
  Upper Bound 0.082   
  5% Trimmed Mean   -0.001   
  Median   0   
  Variance   0.037   
  Std. Deviation   0.1912   
  Minimum   -0.4   
  Maximum   0.2   
  Range   0.6   
  Interquartile Range   0.3   
  Skewness   -0.846 0.524 
  Kurtosis   0.107 1.014 
 





Table 40.2 NSAIDs Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
Overall NSAIDs 0.206 19 0.033 0.869 19 0.014 
a Lilliefors Significance Correction 
 
Table 40.3  NSAIDs Tests of Normality 
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Summary Statistics for Patient-Orientated Outcome Measures for Patients on 
NSAIDs 
 
Patients ≥ 65 
 
Descriptives 
  Statistic Std. Error 
Over 65 Mean   -0.545 0.9721 
  95% Confidence Interval  
for Mean 
Lower Bound -2.587   
  Upper Bound 1.498   
  5% Trimmed Mean   -0.589   
  Median   0.373   
  Variance   17.956   
  Std. Deviation   4.2375   
  Minimum   -8   
  Maximum   7.7   
  Range   15.7   
  Interquartile Range   6   
  Skewness   -0.131 0.524 
  Kurtosis   -0.292 1.014 
 






Table 40.5 Patients ≥ 65 Histogram and Box Plot 
 
Tests of Normality 
  
  
Kolmogorov-Smirnova Shapiro-Wilk  
Statistic df Sig. Statistic df Sig. 
Over 65 0.112 19 .200* 0.974 19 0.855 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 40.6 Patients ≥ 65 Tests of Normality 
                                                                                                                                        307 
Appendix 40 (Cont.) 
 
Summary Statistics for Patient-Orientated Outcome Measures for Patients on 
NSAIDs 
 
Patients with Clinical (GI, CV or CKD) Risk Factor 
 
Descriptives 
  Statistic Std. Error 
Total Risk Mean   -0.647 0.8313 
  95% Confidence Interval  
for Mean 
Lower Bound -2.394   
  Upper Bound 1.099   
  5% Trimmed Mean   -0.536   
  Median   0.1   
  Variance   13.129   
  Std. Deviation   3.6234   
  Minimum   -8.1   
  Maximum   4.8   
  Range   12.9   
  Interquartile Range   3.7   
  Skewness   -0.879 0.524 
  Kurtosis   0.237 1.014 
 






Table 40.8 Patients with Clinical Risk Factor Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
Total Risk 0.175 19 0.127 0.916 19 0.095 
a Lilliefors Significance Correction 
 
Table 40.9 Patients with Clinical Risk Factor Tests of Normality 
                                                                                                                                        308 
Appendix 40 (Cont.) 
 
Summary Statistics for Patient-Orientated Outcome Measures for Patients on 
NSAIDs 
 
Patients on Proton Pump Inhibitor 
 
Descriptives 
  Statistic Std. Error 
Proportion on PPI Mean   2.474 1.0149 
  
95% Confidence Interval  
for Mean Lower Bound 0.342   
    Upper Bound 4.606   
  5% Trimmed Mean   2.332   
  Median   2   
  Variance   19.569   
  Std. Deviation   4.4237   
  Minimum   -6   
  Maximum   13.5   
  Range   19.5   
  Interquartile Range   5   
  Skewness   0.493 0.524 
  Kurtosis   1.172 1.014 
 





Table 40.11 Patients on PPI Histogram and Box Plot 
 




Statistic df Sig. Statistic df Sig. 
Proportion on PPI 0.124 19 .200* 0.964 19 0.655 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 40.12 Patients on PPI Tests of Normality 
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Summary Statistics for Patient-Orientated Outcome Measures for Patients on 
NSAIDs 
 
Patients on Aspirin 
 
Descriptives 
 Statistic Std. Error 
Proportion on 
Aspirin Mean   -1.137 0.5805 
  95% Confidence 
Interval for Mean 
Lower Bound -2.356   
  Upper Bound 0.083   
  5% Trimmed Mean   -1.102   
  Median   -1.4   
  Variance   6.402   
  Std. Deviation   2.5303   
  Minimum   -6.3   
  Maximum   3.4   
  Range   9.7   
  Interquartile Range   3.4   
  Skewness   -0.085 0.524 
  Kurtosis   -0.258 1.014 
 






Table 40.14 Patients on Aspirin Histogram and Box Plot 
 




Statistic df Sig. Statistic df Sig. 
Proportion on PPI 0.124 19 .200* 0.964 19 0.655 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 40.15 Patients on Aspirin Tests of Normality 
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Summary Statistics for Patient-Orientated Outcome Measures for Patients on 
NSAIDs 
 
Patients on SSRI 
 
Descriptives 
  Statistic Std. Error 
Proportion on 
SSRI Mean   1.037 0.5278 
  95% Confidence Interval 
for Mean 
Lower Bound -0.072   
  Upper Bound 2.146   
  5% Trimmed Mean   1.063   
  Median   0.8   
  Variance   5.292   
  Std. Deviation   2.3005   
  Minimum   -3.1   
  Maximum   4.7   
  Range   7.8   
  Interquartile Range   2.9   
  Skewness   -0.088 0.524 
  Kurtosis   -0.641 1.014 
 





Table 40.17 Patients on SSRIs Histogram and Box Plot 
 
 




Statistic df Sig. Statistic df Sig. 
Proportion on SSRI 0.087 19 .200* 0.967 19 0.722 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 40.18 Patients on SSRIs Tests of Normality 
                                                                                                                                        311 
Appendix 41 
 





  Statistic Std. Error 
Metformin Diff Mean   0.135 0.7284 
  95% Confidence 
Interval for Mean 
Lower Bound -1.395   
  Upper Bound 1.665   
  5% Trimmed Mean   0.269   
  Median   0.4   
  Variance   10.08   
  Std. Deviation   3.1749   
  Minimum   -8.2   
  Maximum   6.1   
  Range   14.3   
  Interquartile Range   3.8   
  Skewness   -0.917 0.524 
  Kurtosis   1.948 1.014 
 






Table 41.2  Metformin Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Metformin Diff 0.145 19 .200* 0.934 19 0.208 
 
Table 41.3 Metformin Tests of Normality 
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  Statistic Std. Error 
RAS-Diff Mean   -0.437 0.4075 
  95% Confidence Interval 
for Mean 
Lower Bound -1.293   
  Upper Bound 0.419   
  5% Trimmed Mean   -0.485   
  Median   -1.1   
  Variance   3.156   
  Std. Deviation   1.7765   
  Minimum   -3.8   
  Maximum   3.8   
  Range   7.6   
  Interquartile Range   2.2   
  Skewness   0.58 0.524 
  Kurtosis   0.614 1.014 
 





Table 41.5  Renin-Angiotensin Drugs Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
RAS-Diff 0.172 19 0.142 0.96 19 0.574 
 
Table 41.6 Renin-Angiotensin Drugs Tests of Normality 
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Summary Statistics for Patient-Orientated Outcome Measures in Type 2 Diabetes 
 
ACE-Inhibitors (as Proportion of RAS Drugs) 
 
Descriptives 
  Statistic Std. Error 
ACE-I Diff Mean   0.163 0.5164 
  95% Confidence Interval  
for Mean 
Lower Bound -0.922   
  Upper Bound 1.248   
  5% Trimmed Mean   0.242   
  Median   0.6   
  Variance   5.067   
  Std. Deviation   2.251   
  Minimum   -5.1   
  Maximum   4   
  Range   9.1   
  Interquartile Range   2.9   
  Skewness   -0.58 0.524 
  Kurtosis   0.78 1.014 
 






Table 41.8  ACE-Inhibitors as proportion of RAS Drugs Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
ACE-I 0.155 19 .200* 0.946 19 0.34 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 41.9 for ACE-Inhibitors as proportion of RAS Drugs Tests of Normality 
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Summary Statistics for Patient-Orientated Outcome Measures in Type 2 Diabetes 
 
Lipid Lowering Agents 
 
Descriptives  
  Statistic Std. Error 
LLA Diff Mean -1.042 0.7242 
  95% Confidence 
Interval for Mean 
Lower Bound -2.564   
  Upper Bound 0.479   
  5% Trimmed Mean   -1.025   
  Median   -1.1   
  Variance   9.964   
  Std. Deviation   3.1565   
  Minimum   -8.2   
  Maximum   5.8   
  Range   14   
  Interquartile Range   3.8   
  Skewness   -0.066 0.524 
  Kurtosis   0.94 1.014 
 






Table 41.11  Lipid Lowering Agents Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
LLA 0.12 19 .200* 0.986 19 0.988 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 41.12 Lipid Lowering Agents  Tests of Normality 
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  Statistic Std. Error 
Aspirin Diff Mean -3.784 1.0295 
  95% Confidence Interval 
for Mean 
Lower Bound -5.947   
  Upper Bound -1.621   
  5% Trimmed Mean   -3.332   
  Median   -2.1   
  Variance   20.136   
  Std. Deviation   4.4873   
  Minimum   -16.6   
  Maximum   0.9   
  Range   17.5   
  Interquartile Range   5.8   
  Skewness   -1.607 0.524 
  Kurtosis   2.734 1.014 
 






Table 41.14  Aspirin (Antiplatelet) Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Aspirin 0.173 19 0.139 0.841 19 0.005 
a Lilliefors Significance Correction    
 
Table 41.15 Aspirin (Antiplatelet) Tests of Normality 
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Summary Statistics for Patient Outcome Measures in Type 2 Diabetes 
 
Target Blood Pressure (140/80mmHg) 
 
Descriptives 
  Statistic Std. Error 
BP Target Diff Mean 0.137 1.2777 
  95% Confidence 
Interval for Mean 
Lower Bound -2.548   
  Upper Bound 2.821   
  5% Trimmed Mean   0.058   
  Median   -1.1   
  Variance   31.02   
  Std. Deviation   5.5696   
  Minimum   -9.7   
  Maximum   11.4   
  Range   21.1   
  Interquartile Range   7.8   
  Skewness   0.312 0.524 
  Kurtosis   -0.148 1.014 
 






Table 41.17 Target Blood Pressure Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
BP Target 0.141 19 .200* 0.97 19 0.771 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 41.18 Target Blood Pressure Tests of Normality 
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Summary Statistics for Patient Outcome Measures in Type 2 Diabetes 
 




      Statistic Std. Error 
Cholesterol Diff Mean   1.506 0.7607 
  95% Confidence Interval  
for Mean 
Lower Bound -0.107   
  Upper Bound 3.118   
  5% Trimmed Mean   1.44   
  Median   0.8   
  Variance   9.837   
  Std. Deviation   3.1364   
  Minimum   -2.8   
  Maximum   7   
  Range   9.8   
  Interquartile Range   5   
  Skewness   0.412 0.55 
  Kurtosis   -1.015 1.063 
 









Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Cholesterol 0.177 17 0.16 0.939 17 0.303 
a Lilliefors Significance Correction 
 
Table 41.21 Target Total Cholesterol Tests of Normality 
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Summary Statistics for Patient Outcome Measures in Type 2 Diabetes 
 




  Statistic Std. Error 
HbA1c (7.5%)Diff Mean   -1.421 0.917 
  95% Confidence 
Interval for Mean 
Lower Bound -3.348   
  Upper Bound 0.506   
  5% Trimmed Mean   -1.368   
  Median   -2   
  Variance   15.978   
  Std. Deviation   3.9973   
  Minimum   -9.3   
  Maximum   5.5   
  Range   14.8   
  Interquartile Range   6.6   
  Skewness   0.051 0.524 
  Kurtosis   -0.505 1.014 
 





Table 41.23 Target HbA1c (≤ 7.5%) Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
HbA1c (7.5%) 0.112 19 .200* 0.967 19 0.722 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 41.24 Target HbA1c (≤ 7.5%) Tests of Normality 
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Summary Statistics for Patient Outcome Measures in Type 2 Diabetes 
 
Target HbA1c (≤ 7.5%) 
 
Descriptives 
      Statistic Std. Error 
HbA1c 
(9.0%) Diff Mean   -1.432 0.9313 
  95% Confidence Interval  
for Mean 
Lower Bound -3.388   
  Upper Bound 0.525   
  5% Trimmed Mean   -1.335   
  Median   -0.6   
  Variance   16.479   
  Std. Deviation   4.0594   
  Minimum   -10.3   
  Maximum   5.7   
  Range   16   
  Interquartile Range   3.4   
  Skewness   -0.812 0.524 
  Kurtosis   1.057 1.014 
 





Table 41.26 Target HbA1c (≤ 9.0%) Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
HbA1c9 0.148 19 .200* 0.923 19 0.129 
* This is a lower bound of the true significance. 
a Lilliefors Significance Correction 
 
Table 41.27 Target HbA1c (≤ 9.0%) Tests of Normality 
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      Statistic Std. Error 
ACR Measured Diff Mean   2.974 1.926 
  95% Confidence 
Interval for Mean 
Lower Bound -1.073   
  Upper Bound 7.02   
  5% Trimmed Mean   1.615   
  Median   0.6   
  Variance   70.48   
  Std. Deviation   8.3952   
  Minimum   -5   
  Maximum   35.4   
  Range   40.4   
  Interquartile Range   6.1   
  Skewness   3.491 0.524 
  Kurtosis   13.794 1.014 
 






Table 41.29 ACR Measured Histogram and Box Plot 
 
 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
ACR Measured 0.285 19 0 0.57 19 0 
a Lilliefors Significance Correction 
 
Table 41.30  ACR Measured Tests of Normality 
                                                                                                                                        321 
Appendix 41 (Cont.) 
 





 Statistic Std. Error 
Microalbuminuria 
Detected (Diff) Mean   0.253 0.6454 
  95% Confidence 
Interval for Mean 
Lower Bound -1.103   
  Upper Bound 1.609   
  5% Trimmed Mean   0.142   
  Median   -0.4   
  Variance   7.915   
  Std. Deviation   2.8133   
  Minimum   -5.4   
  Maximum   7.9   
  Range   13.3   
  Interquartile Range   2.9   
  Skewness   0.846 0.524 
  Kurtosis   2.352 1.014 
 









Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Microalbuminuria Detected 0.195 19 0.054 0.927 19 0.15 
a Lilliefors Significance Correction 
 
Table 41.33  Microalbuminuria Recorded Tests of Normality 
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Microalbuminuria on RAS Drug 
 
Descriptives         
  Statistic Std. Error 
m/aRASDiff Mean   3.842 3.6084 
  95% Confidence 
Interval for Mean 
Lower Bound -3.739   
  Upper Bound 11.423   
  5% Trimmed Mean   2.658   
  Median   0.2   
  Variance   247.388   
  Std. Deviation   15.7286   
  Minimum   -18.1   
  Maximum   47.1   
  Range   65.2   
  Interquartile Range   12   
  Skewness   1.489 0.524 
  Kurtosis   2.549 1.014 
 










Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
m/aRASDiff 0.217 19 0.019 0.86 19 0.01 
a Lilliefors Significance Correction 
 
Table 41.36  Microalbuminuria on RAS Drug Tests of Normality 
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Microalbuminuria BP Target Achieved  
 
Descriptives 
  Statistic Std. Error 
m/a BP Diff Mean   -1.526 2.033 
  95% Confidence Interval  
for Mean 
Lower Bound -5.798   
  Upper Bound 2.745   
  5% Trimmed Mean   -1.551   
  Median   -1.5   
  Variance   78.531   
  Std. Deviation   8.8618   
  Minimum   -14.1   
  Maximum   11.5   
  Range   25.6   
  Interquartile Range   15.5   
  Skewness   -0.03 0.524 
  Kurtosis   -1.478 1.014 
 









Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
m/aBPDiff 0.174 19 0.134 0.917 19 0.1 
a Lilliefors Significance Correction 
 
Table 41.39  Microalbuminuria BP Target Achieved Tests of Normality  
 
 





1. National Service Framework for Older People: Implementing medicines-related 
aspects of the NSF for Older People.  Department of Health.  March 2001. 
 
2. Evidence-based prescribing.  BMA Board of Science Report. London. May 2007. 
 
3. How to change practice.  Understand, identify and overcome barriers to change.  
National Institute of Health and Clinical Excellence. December 2007. 
 
4. Prosser H, Almond S, Walley T.  Influences on GPs’ decision to prescribe new 
drugs-the importance of who says what.  Family Practice 2003; 20:1,61-68. 
 
5. David L Sackett, Sharon E. Straus, W. Scott Richardson, William Rosenberg, R. 
Brian Haynes. Evidence Based Medicine.  How to Teach and Practice EBM.  
Churchill Livingstone, London, 2000.  Second Edition. 
 
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research 
Group.  Major Outcomes in High-risk Hypertensive Patients Randomised to ACE-
inhibitor, Calcium Channel Blocker vs Diuretic.  The Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002; 288 2981-2997. 
 
7. UK Prospective Diabetes Study Group.  Tight Blood Pressure Control and risk of 
macrovascular and microvascular complications in type 2 diabetes.  UKPDS 38.  
BMJ 1998; 317:703-713. 
 
8. Straus E. and Jones G.  What has evidence based medicine done for us?  Editorial.  
BMJ 2004; 329: 987-988. 
 
9. National Prescribing Centre.  NPC PCT responsibilities around prescribing and 
medicines management - a scoping and support guide’.  Incorporating the second 
edition of Competencies for pharmacists working in primary care.  July 2003. 
 
10. National Prescribing Centre.  Supporting rational local decision-making about 
medicines and treatments.  A handbook of good practice guidance.  February 2009. 
 
11. National Audit Office (2007) Influencing Prescribing Cost and Quality in Primary 
Care. A suggested communication plan for prescribing advisers. May 2007. 
 
12. Evidence Based Medicine Working Group.  Evidence Based Medicine.  A New 
Approach to teaching the practice of medicine.  JAMA 1992; 268: 2420-2425. 
 
13. Dawes M, et al.  Sicily statement on evidence-based practice.  BMC medical 
education (electronic resource) 2005; 5:1 doi:10.1186/1472-6920-5-1. 
 
14. Greenhalgh T.  How to Read a Paper.  The basics of evidence based medicine. 
Second Edition Chapter 1.  2001 BMJ Books London. 
 
15. Slawson D. and Shaughnessy AF.  Becoming an Information Master.  Journal of 
Family Practice. 2000; 49:1. 
 
                                                                                                                                        325 
16. Barrie R. and Ward A. Questioning behaviour in general practice: a pragmatic 
study.  BMJ 1997 315; 7121:1512-1515. 
 
17. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence 
based medicine: what it is and what it isn’t.  BMJ 1996; 312:71-2. 
 
18. Lockwood S. “Evidence of me” in evidence based medicine?  BMJ 2004; 329:1033-
1035. 
 
19. Gray DP. Evidence-based medicine and patient-centred medicine: the need to 
harmonise. J Health Serv Res Policy 2005 10; 2:66-67. 
 
20. Straus SE, McAlister FA. Evidence-based medicine: a commentary on common 
criticisms. CMAJ 2000; 163:837-41. 
 
21. Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-
based medicine and patient choice.  Evidence Based Medicine 2002; 7:36-38. 
 
22. Straus S. What’s the E for EBM? BMJ 2004; 326:319-321. 
 
23. Ramos KD, Shafer S, Tracz SM. Validation of the Fresno test of competence in 
evidence based medicine. BMJ 2003; 328:535-536. 
 
24. Coomerasami A, Khan KS.  What is the evidence that postgraduate teaching in 
evidence based medicine changes anything? A systematic review.  BMJ 2004; 
329:1017-1021. 
 
25. Guyatt G, Cook D, Haynes B.  Evidence based medicine has come a long way. 
BMJ 2004; 329:990-991. 
 
26. National Prescribing Centre Using Evidence to Guide Practice MeReC Briefing 
2005 Issue No.30. 
 
27. National Prescribing Centre Using Evidence to Guide Practice - Supplement 
MeReC Briefing 2005 Issue No.30. 
 
28. Centre for Evidence-Based Medicine, Oxford.  EBM: Levels of Evidence – Essential 
Evidence Plus. www.essentialevidenceplus.co/product/ebm_loe.cfm?show=oxford 
Accessed 12.07.13. 
 
29. McAlister FA, van Diepen S, Padwal RS, Johnson JA, Majumdar SR. (2007) How 
Evidence Based Are the Recommendations in Evidence-Based Guidelines?  PLoS 
Med 4(8): e250 doi:10.1371/journal.pmed.0040250.  Accessed 15/05/08. 
 
30. Finkelstein A, Rao G. About levels of Evidence. Journal of Family Practice 2005; 
54(4):340. 
 
31. Montori VM, Guyatt H.  Progress in Evidence Based Medicine.  JAMA. 2008; 300 
(15):1814-1816. 
 
32. Hudson Z.  Evidence-based practice, empirical practice or personal whim? Physical 
Therapy in Sport. 2004; 5(2): 52-56. 
 
                                                                                                                                        326 
33. Walker AE, Grimshaw J, Johnston M, Pitts N, Steen N, Eccles M.  PRIME –
PRocess modelling in ImpleMEntation research: selecting a theoretical basis for 
interventions to change clinical practice.  BMC Health Services Research 2003; 
3:2. 
 
34. Grimshaw J, Eccles M, and Tetroe J.  Implementing Clinical Guidelines: Current 
Evidence and Future Implications. Journal of Continuing Education in the Health 
Professions 2004; 24:31-S37. 
 
35. Oxman A, Thompson MA, Davis DA, Haynes RB.  No magic bullets: a systematic 
review of 102 trials of interventions to improve professional practice.  CMAJ 1995; 
153:1423-1431. 
 
36. Scott I.  The Evolving Science of Translating Research Evidence into Clinical 
Practice.  EBM Feb 2007; Vol 12. www.evidence-basedmedicine.com. 
 
37. Sheikh, A Smeeth L, Ashcroft R. Randomised controlled trials n primary care: 
scope and application. British Journal of General Practice. 2002; 52: 746-752. 
 
38. Reilly BM.  The essence of EBM.  Editorial BMJ 2004; 329: 991-992. 
 
39. NHS Centre for Reviews and Dissemination. Getting Evidence Into Practice. 
Effective Health Care Feb 1999; 5:No 1. 
 
40. Gabbay J, le May A. Evidence based guidelines or collectively constructed 
‘mindlines’?  Ethnographic study of knowledge management in primary care.  BMJ 
2004; 329:1013-1017. 
 
41. Coumou HCH.  How do primary care physicians seek answers to clinical 
questions?  A literature review. Journal of the Medical Library Association 2006; 94 
(1): 55-60. 
 
42. Mason A. New medicines in primary care: a review of influences on general 
practitioner prescribing. Journal of Clinical Pharmacy and Therapeutics. 2008; 33:1-
10. 
 
43. Mears R. and Sweeney K.  A preliminary study of the decision-making process 
within general practice.  Family Practice 2000; 17:428-429. 
 
44. Hannes K, Leys M, Vermeire E, Aertgeerts B, Buntinx F, Depoorter A.  
Implementing evidence in general practice: a focus group based study.  BMC 
Family Practice 2005: 6:37-49. 
 
45. Freeman A C and Sweeney K.  Why general practitioners do not implement 
evidence: qualitative study.  BMJ 2001; 323:1100-1115. 
 
46. Putnam W, Twohig PL, Burge FI, Jackson LA, Cox JL.  A qualitative study of 
evidence in primary care: what the practitioners are saying.  Journal of the 
Canadian Medical Association. 2002; 166 (12):1525-1530. 
 
47. Haynes B. and Haines A.  Getting research findings into practice: Barriers and 
bridges to evidence based clinical practice.  BMJ 1998; 317: 273-276. 
 
                                                                                                                                        327 
48. Salisbury C, Bosanquet N, Wilkinson E, Bosanquet A. Hasler J.  The 
implementation of evidence-base medicine in general prescribing.  British Journal 
of General Practice 1998; 48:1849-1851. 
 
49. Weekes LM, Mackson JM, Fitzgerald M, Phillips SR.  National Prescribing Service: 
creating an implementation arm for national medicines policy. Br J Clin Pharmacol 
2005; 59(1):112-116. 
 
50. Hakkenes S. and Green S.  Measures for assessing practice change in medical 
practitioners.  Implementation Science 2006; 1:29. 
 
51. Shaneyfelt T, Baum K, Bell D, Feldstein D, Houston TK, Kaatz S, Whelan C, Green 
M.  Instruments for Evaluating Education in Evidence-Based Practice.  A systematic 
Review. JAMA 2006; 296:(9)1116-1127 
 
52. Tilson JK, Kaplan SL, Harris JL, Hutchinson A, Ilic D, Neiderman R, Potomkova J, 
Zwolsman SE.  Sicily statement on classification and development of evidence-
based practice learning assessment tools.  BMC Medical Education 2011; 11:78-
87. 
 
53. Greenhalgh T.  How to Read a Paper.  The basics of evidence based medicine. 
Chapter 12.  2001 Second Edition BMJ Books. London. 
 
54. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty 
P, Eccles MP, Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C.  
Effectiveness and efficiency of guideline dissemination and implementation 
strategies. Health Technology Assessment 2004; Vol 8: No. 6. 
 
55. Cabana MD et al.  Why Don’t Physicians Follow Clinical Practice Guidelines?  A 
framework for Improvement.  JAMA, 1999; 282 (15):1458-1465. 
 
56. Kawamoto K, Houlihan CA, Balas EA, Lobach DF.  Improving clinical practice using 
clinical decision support systems: a systematic review of trails to identify features 
critical to success. BMJ 2005; 330: 765-768. 
 
57. Tierney WM, Overhage JM et al.  Effects of Computerised Guidelines for Managing 
Heart Disease in Primary Care.  A Randomised, Controlled Trial.  J Gen Intern Med 
2003; 18:967-976. 
 
58. Eccles M,  McColl E, Steen N, Rousseau N, Grimshaw J, Parkin D, Purves I.  Effect 
of computerised evidence based guidelines on management of asthma and angina 
in adults in primary care: cluster randomised controlled trial.  BMJ 2002; 325 941-
944. 
 
59. Jamtvedt G, Young JM, Kristoffersen DT, O’Brien MA, Oxman AD.  Audit and 
feedback: effects on professional practice and health care outcomes.  Cochrane 
Database of Systematic Reviews 2006, Issue 2. Art. No.: CD000259. DOI: 
10.1002/14651858.CD000259.pub2. 
 
60. Majumdar SR, Soumerai SB.  Why most interventions to improve physician 
prescribing do not seem to work.  JAMC. 2003; 169 (1):30-31. 
 
                                                                                                                                        328 
61. Davis D, Thomson MA, Oxman AD, Haynes B. Changing Physician Performance. A 
Systematic Review of the Effect of Continuing Medical Education Strategies. JAMA 
1995; 274(9): 700-705. 
 
62. Shojania KG, Grimshaw JM.  Still no magic bullets: Pursuing More Rigorous 
Research in Quality Improvement.  The American journal of Medicine, 2004; 
116:778-780. 
 
63. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spielelhalter, 
Tyrer P.  Framework for design and evaluation of complex interventions to improve 
health.  BMJ 2000; 321: 694-696. 
 
64. Medical Research Council.  Developing and evaluating complex interventions: new 
guidance.  www.mrc.ac.uk/complexinterventionsguidance  Accessed October 2008. 
 
65. Soumerai SB, Avorn J.  Principles of Educational Outreach (‘Academic Detailing’) 
to Improve Clinical Decision Making.  JAMA, 1990; 263 (4):549-556. 
 
66. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational 
outreach: a randomised controlled trial of academically based ‘detailing. N Engl J 
Med. 1983; 308:1457-1463. 
 
67. Barreuther A. Academic Detailing to Influence Prescribing.  Journal of Managed 
Care Pharmacy. 1997; 3(6):631-638. 
 
68. O’Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen 
DT, Forsetlund L, Bainbridge D, Freemantle N, Davis D, Haynes RB, Harvey E. 
Educational outreach visits: effects on professional practice and healthcare 
outcomes. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: 
CD000409. DOI: 10.1002/14651858.CD000409.pub2. 
 
69. Teal S, Ricketts L, Belton A, Allsopp G, Silcock J, Wright DJ.  How effective are 
pharmacists who work with medical practitioners?  A study of interventions intended 
to influence prescribing.  International Journal of Pharmacy Practice. 2002; 10:185-
190. 
 
70. Denneboom W,  Dautzenberg MGH et al.  Treatment reviews of older people on 
polypharmacy in primary care.  British Journal of General Practice 2007; 57:723-
731. 
 
71. Bond CM, Fish A et al.  International Journal of Family Practice. 2007; 15:39-46. 
 
72. Wermeille J, Bennie M, Brown I, McKnight J.  Pharmaceutical care model for 
patients with type 2 diabetes: integration of the community pharmacist into the 
diabetes team – a pilot study.  Pharmacy World and Science 2004; 26(1):18-25. 
 
73. Gray H, McKinnon M, Townsend J.  Evaluation of a practice-based clinical 
pharmacist scheme.  Hospital Pharmacist 2001; 8:25-28. 
 
74. Rodgers S, Avery AJ, Meechan D, Briant S, Geraghty M, Doran K, Whynes DK. 
Controlled trial of pharmacist intervention in general practice: the effect on 
prescribing costs.  British Journal of General Practice. 1999; 49 717-720. 
 
                                                                                                                                        329 
75. Pottie K, Farrell B, Haydt S, Dolovich L. Sellors C, Kennie N, Hogg W Martin C. 
Integrating pharmacists into family practice teams. Physicians’ perspectives on 
collaborative care. Canadian Family Physician. 2008; 54: 1714-5e1-5. 
 
76. Farrell B, Pottie K, Haydt S, Dolovich L., Kennie N, Sellors C, Hogg W. Examining 
physicians perspectives during the integration of a pharmacist into family practice: 
Qualitative results from the IMPACT study. Canadian Pharmacists Journal. 2008; 
141:39. 
 
77. Farrell B, Pottie K, Haydt S, Kennie N, Sellors C, Dolovich L.  Integrating into family 
practice: the experiences of pharmacists in Ontario, Canada. International Journal 
of Pharmacy Practice. 2008; 16:309-315. 
 
78. Rothman RL, Malone R et al.  A randomised trial of a primary care-based disease 
management program to improve cardiovascular risk factors and glycated 
haemoglobin levels in patients with diabetes.  The American Journal of Medicine. 
2005; 118:276-284. 
 
79. Nichol A, Downs GE.  The pharmacist as physician extender in family medicine 
office practice.  Journal of the American Pharmacists Association; 2006 46: 77-83.   
 
80. Vivian EM. Improving blood pressure control in a pharmacist-managed 
hypertension clinic.  Pharmacotherapy 2002; 22:1533-1540 etc. 
 
81. Chen J, Britten N.  ‘Strong Medicine’: an analysis of pharmacist consultations in 
primary care.  Family Practice 2000; 17 (6) 480 – 483. 
 
82. Jesson JK, Wilson KA, Blenkinsopp A.  Primary Care Pharmacists: A Profile.  
Journal of Social and Administrative Pharmacy.  2002; 19 (3):99-104. 
 
83. National Prescribing Centre and NHS Executive.  Competencies for pharmacists 
working in primary care.  National Prescribing Centre. April 2000. 
 
84. National Prescribing Centre. Competencies for pharmacists working in primary 
care.  Second Edition.  July 2003. 
 
85. Braybrooke S, Walker R. Influencing prescribing in primary care using different 
feedback strategies.  Pharmacy World and Science 2000; 22 (2):39-46. 
 
86. Braybrooke S, Walker R.  Influencing prescribing in primary care: a comparison of 
two different prescribing feedback methods. Journal of Clinical Pharmacy and 
Therapeutics 1996; 21:247-254 
 
87. Walker J, Mathers N.  The impact of a general practice group intervention on 
prescribing costs and patterns.  British Journal of General Practice. 2002; 52:181-
186. 
 
88. Law J, Thompson A.  Medication prescribing advice and drug utilization: A review 
from the United Kingdom.  Pharmacy Practice Management Quarterly. 1996; 15(4): 
27-35. 
 
89. De Santis G, Harvey KJ, Howard D, Mashford ML, Moulds RFW.  Improving the 
quality of antibiotic prescription patterns in general practice.  The role of 
educational intervention.   Medical Journal of Australia 1994; 160(8)502,504-505. 
                                                                                                                                        330 
 
90. Ilett KF, Johnson S et al.  Modification of general practitioner prescribing of 
antibiotics by use of a therapeutics adviser (academic detailer).  British Journal of 
Clinical Pharmacology 2000; 49: 168-173 etc. 
 
91. Peterson GM, Sugden JE.  Educational programme to improve the dosage 
prescribing of allopurinol. Medical Journal of Australia 1995; 162:74-77. 
 
92. Peterson GM, Bergin JK, Nelson BJ, Stanton LA.  Improving drug use in rheumatic 
disorders.  Journal of Clinical Pharmacy and Therapeutics. 1996; 21:215-220. 
 
93. Peterson GM, Stanton LA et al.  Improving the prescribing of antibiotics for urinary 
tract infection.  Journal of Clinical Pharmacy and Therapeutics 1997; 22:147-153. 
 
94. Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel M.   Multifaceted 
Educational Program Increases Prescribing of Preventative Medicine for 
Corticosteroid Induced Osteoporosis.  The Journal of Rheumatology. 2004; 31 (3): 
550-556. 
 
95. Ferguson RI, Salmond CE, Maling TJB.  The Nelson Prescribing Project.  A 
Programmed Intervention in General Practice in New Zealand.  
Pharmacoeconomics 1995; 7 (6):555-561. 
 
96. McDonald P, Winkle CA, Askew D.  Evaluation of Academic Detailing Within a 
Coordinated Care Trial. Journal of Pharmacy Practice and Research.  2003; 
33:114-116. 
 
97. Zwarenstein M, Bheekie A Lombard C et al.  Educational Outreach to general 
practitioners reduces children’s asthma symptoms: a cluster randomised control 
trial.  Implementation Science 2007; 2 (3):30. 
 
98. Newton-Syms FAO, Dawson PH, Cooke J, Feeley M, Booth TG, Jerwood D, 
Calvert RT. The influence of an academic representative on prescribing by general 
practitioners. Br J Clin Pharmacol 1992; 33: 69-73. 
 
99. Watson M, Gunnell D, Peters T, Brookes S, Sharp D.  Guidelines and educational 
outreach visits from community pharmacists to improve prescribing in general 
practice: a randomised controlled trial.  J Health Serv Res Policy. 2001; 6 (4) 207-
213. 
 
100. Wood KM, Mucklow JC, Boath EH. Influencing prescribing in primary care: A 
collaboration between clinical pharmacology and clinical pharmacy.  International 
Journal of Pharmacy Practice. 1997; 5;1-5 
 
101. Patel B. Safiullah A. Effects of an educational outreach campaign (IMPACT) on 
depression management delivered to general practitioners in one primary care 
trust. Mental Health in Family Medicine 2009; 6: 155-162. 
 
102. Freemantle N, Nazareth I, Eccles M, Wood J, Haines A and the Evidence-
based OutReachTrialists.   A randomised controlled trial of the effect of educational 
outreach by community pharmacists on prescribing in UK general practice.  British 
Journal of General Practice 2002; 52:290-295. 
 
                                                                                                                                        331 
103. Nazareth I, Freemantle N, Duggan C, Mason J, Haines A.  Evaluation of a 
complex intervention for changing professional behaviour: the Evidence Based Out 
Reach (EBOR) Trial. J Health Serv Res Policy 2002; 7 (4): 230-238. 
 
104. Fretheim A, Oxman AD, Havelsrud K, Treweek S, Kristofferson DT, Bjorndal A.  
Rational Prescribing in Primary Care (RaPP): A Cluster Randomised Trial of a 
Tailored Intervention.  PLoS Medicine. 2006; 3 (6) e134. 
 
105. Fretheim A, Oxman AD, Treweek S, Bjorndal A.  Rational Prescribing in 
Primary Care (RaPP-trial).  A randomised trial of a tailored intervention to improve 
prescribing on antihypertensive and cholesterol lowering drugs in general practice.  
BMC Health Services Research 2003; 3:5. 
 
106. Fretheim A, Aaserud M, Oxman AD. Rational Prescribing in Primary Care 
(RaPP): Economic evaluation of an Intervention to Improve Professional Practice.  
PLoS Medicine 2006;3 (6) e216:792-799. 
 
107. Magrini N, Formoso G et al.  Randomised controlled trials for evaluating the 
prescribing impact of information meetings led by pharmacists and of new 
information formats, in General Practice in Italy.  BMC Health Services Research 
2007; 7:158. 
 
108. Bobbio M, Malavasi P et al.  The role of public health pharmacists in promoting 
information on benefits and risks of drugs: Evaluation of the impact of a new 
information strategy for primary care groups.  Giornale Italiano Farmacia Clinica. 
2011; 25 (1):12-24. Abstract. 
 
109. Van Eijke, Avorn J, Porsius AJ, de Boer.  Reducing prescribing of highly 
anticholinergic antidepressants for elderly people: a randomised trial of group 
versus individual academic detailing.  BMJ 2001; 322:654-659. 
 
110. Young SF, Macleod AK. Influencing Prescribing Through Effective 
Communication Skills. American Journal of Health System Pharmacy. 2005; 
62(23):2528-2530. 
 
111. Eccles MP, Steen IN, Whitty PM, Hall L. Is untargeted educational outreach 
visiting delivered by pharmaceutical advisers effective in primary care? A pragmatic 
randomised controlled trial. Implementation Science 2007; 2:23. 
 
112. Shuval K, Shachak A, Linn S, Breziz m, Feder-Bubis P, Reis S.  The Impact of 
an Evidence-Based Medicine Educational Intervention on Primary Care Physicians: 
A Qualitative Study.  Society of General Internal Medicine 2007; 22:327-331. 
 
113. Royal Pharmaceutical Society  http://www.rpharms.com/home/about-
pharmacy.asp   RPSGB accessed 22.01.12. 
 
114. National Prescribing Centre.  Maintaining Competency in Prescribing.  An 
outline framework to help pharmacist prescribers.  Second Edition October 2006. 
 
115. Royal Pharmaceutical Society of Great Britain (2009). Pharmacy Workforce 
Census 2008: Main Findings   Printed in Great Britain by the Royal Pharmaceutical 
Society of Great Britain. ISBN: 9780956332301. 
 
 
                                                                                                                                        332 
116. A Spoonful of Sugar: Medicines Management in NHS Hospitals. Audit 
Commission, 2001. London. 
 
117. Department of Health (2000). Pharmacy in the Future - Implementing the NHS 
Plan.  A Programme for Pharmacy in the National Health Service. HMSO 
http://www.webarchive.org.uk/wayback/archive/20041102120000/http://www.dh.go
v.uk/assetRoot/04/06/82/04/04068204.pdf  Accessed 12.09.12. 
 
118. Department of Health (2003).  A vision for pharmacy in the new NHS. 
http://www.webarchive.org.uk/wayback/archive/20050118120000/http://www.dh.go
v.uk/assetRoot/04/06/83/56/04068356.pdf  Accessed 12.09.12. 
 
119. Department of Health (2008). Pharmacy in England.  Building on Strengths - 
Delivering the Future.  http://www.official-
documents.gov.uk/document/cm73/7341/7341.pdf  Accessed 12.09.12. 
 
120. Chaplin S. National Audit Office calls for more cost-effective prescribing.   2007; 
18 (13):20-22.   
 
121. Cantrill J, Devlin M, Jackson C, Queenborough R. Improving Quality in 
Primary Care: supporting pharmacists working in primary care groups and 
trusts. National Primary Care Research and Development Centre and National 
Prescribing Centre, 1999. 
 
122. NHS Modernisation Agency. The National and Primary Care Trust Development 
Programme (NatPaCT 2002-2005). Competency Framework 
http://www.natpact.info/downloads/newcf/m.pdf  Accessed 12.09.12. 
 
123. Audit Commission. (2003). Primary care prescribing. A bulletin for primary care 
trusts. London. March 2003. 
 
124. Scoggins S, Tiessen J, Ling T, Rabinovich, L. Prescribing in primary care.  
Understanding what shapes GPs’ prescribing choices and how might these be 
changed. Technical Report, RAND Corporation. 2006. 
 
125. A Handbook for Local National Prescribing Centre Associates.  National 
Prescribing Centre.  First Edition: March 2010. 
 
126. Ensuring Delivery of prescribing, medicines management and pharmacy 
functions in primary and community care:  An organisational competency 
framework and key functions checklist.  Working Document.  National Prescribing 
Centre.  October 2010. 
 
127. An organisational competency framework to ensure the effective delivery of 
medicines management functions and responsibilities; A guide for Commissioning 
Consortia Boards.  Version 1.1 National Prescribing Centre.  July 2011. 
 
128. http://www.keele.ac.uk/pharmacy/npcplus/npcplusworkshops/flexibletherapeutic
workshops/Workshops%20Flyer%20Final.pdf  Accessed 6th April 2012. 
 
129. National Prescribing Centre Annual Report 2004-2005.  Editors Jackson C, 
Coppell A.  National Prescribing Centre. 2005. Liverpool. 
 
 
                                                                                                                                        333 
130. NPC Legacy Site http://www.npc.co.uk/  Accessed 29th March 2013. 
 
131. NPC Plus Important Announcement http://www.keele.ac.uk/pharmacy/npcplus/ 
Accessed 29th March 2013. 
 
132. Smith R. Editorial. Strategies for coping with information overload. BMJ 
2010;341:c7126. 
 
133. Howarth M. Coping with information overload.  MeReC Rapid Review. National 
Prescribing Centre August 2011. 
 
134. Slawson DC, Shaughnessy AF. Changing the doctor-patient relationship. Are 
we providing doctors with the training and tools for lifelong learning? BMJ 1999; 
319:1280. 
 
135. Tse J, McAvoy BR.  Information Mastery and the 21st century doctor: change 
management for general practitioners.  Medical Journal of Australia 2006; 
185(2):92-93. 
 
136. Slawson DC, Shaughnessy AF. Teaching Information Mastery: Creating 
Informed Consumers of Medical Information. Journal of the American Board of 
Family Practice 1999; 12:444-449. 
 
137. Slawson DC, Shaughnessy AF. Teaching Evidence-Based Medicine: Should 
We Be Teaching Information management Instead? Academic Medicine 2005; 
80:685-689. 
 
138. NPC eCAB Legacy Site http://www.npc.nhs.uk/ecab.php  Accessed 11.07.12. 
 
139. National electronic Library for Medicines http://www.nelm.nhs.uk/en/About-
NeLM/  Accessed 11.07.12. 
 
140. Managing Diabetes.  Improving services for people with diabetes. Service 
review. Healthcare Commission. July 2007. 
 
141. National Prescribing Centre/NICE. MeReC Bulletin. Improving outcomes in type 
2 diabetes. Vol.21 No.05 June 2011. 
 
142. UK Prospective Diabetes Study (UKPDS) Group.  Intensive blood-glucose 
control with sulphonylureas or insulin compared with conventional treatment and 
risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet 1998; 
352:837-853. 
 
143. UK Prospective Diabetes Study (UKPDS) Group.  Effect of intensive blood-
glucose control with metformin on complications in overweight patients with type 2 
diabetes (UKPDS 34).  Lancet 1998; 352:854-865. 
 
144. UK Prospective Diabetes Study (UKPDS) Group.  Tight blood pressure control 
and risk of macrovascular and microvascular complications in type 2 diabetes.  
UKPDS 38.  BMJ. 1998; 317(7160):703-713. 
 
145. McCormack, J and Greenhalgh, T.  Seeing what you want to see in randomised 
controlled trials.  BMJ 2001; 174(2): 123-127. 
 
                                                                                                                                        334 
146. Stratton IM, et al.  Association of glycaemia with macrovascular and 
microvascular complications of type 2 diabetes (UKPDS 35): Prospective 
observational study.  BMJ 2000; 321(7258) 405-412. 
 
147. Shaughnessy, A.F and Slawson, D.  What happened to the valid POEMs?  A 
survey of review articles on the treatment of type 2 diabetes. BMJ 2003; 
327(7409):266. 
 
148. Stettler C et al.  Glycaemic control and macrovascular disease in types 1 and 2 
diabetes mellitus: Meta-analysis of randomized trials.  Am Heart J. 2006; 152(1): 
27-38. 
 
149. Bailey CJ, et al.  Value of glycaemic control in diabetes.  Lancet 2008; 371:116. 
 
150. TNS Healthcare May 2006 via GSK press release 5th July 2006. 
 
151. Stewart et al. Do patients understand the importance of BP control in T2DM?     
Br J Gen Pract 2005; 55; 298-304. 
 
152. The Action to Control Cardiovascular Risk in Diabetes Study Group.  Effects of 
Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 385:2545-
2559. 
 
153. The ADVANCE Collaborative Group. Intensive blood glucose control and 
vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 
358(24):2560-72. 
 
154. The VADT Investigators. Glucose Control and Vascular Complications in 
Veterans with Type 2 Diabetes. N Engl J Med 2009; 360:129-139. 
 
155. NHS Diabetes Self monitoring of blood glucose in non-insulin treated Type 2 
diabetes.  A short report prepared by the NIHR HTA Programme Working Group. 
December 2009. 
 
156. O’Kane M. et al.  Efficacy of self monitoring of blood glucose in patients with 
newly diagnosed type 2 dibetes (ESMON Study): randomised controlled trial.  BMJ 
2008; 336:1174. 
 
157. Simon J et al. Cost effectiveness of self monitoring of blood glucose in patients 
with non insulin treated type 2 diabetes: economic evaluation from the DiGEM trial. 
BMJ 2008; 336:1177. 
 
158. National Institute for Health and Clinical Excellence.  Type 2 diabetes The 
management of type 2 diabetes (update of NICE clinical guideline 66): NICE 
Clinical Guideline 87. Quick Reference Guide. May 2009. 
 
159. Turnbull F et al. Blood Pressure Lowering Treatment Trialists’ Collaboration.  
Effects of Blood Pressure-Lowering Regimens on Major Cardiovascular Events in 
Individuals With and Without Diabetes Mellitus.  Arch Inter Med. 2005; 165 (12): 
1410-1418. 
 
160. United Kingdom Prospective Diabetes Study Group.  Efficacy of Atenolol and 
captopril in reducing risk of macrovascular and microvascular complications in type 
2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.  
                                                                                                                                        335 
 
161. Heart Protection Study Collaborative Group.  MRC/BHF Heart Protection Study 
of cholesterol lowering with simvastatin in 20,536 high risk individuals: a 
randomised placebo-controlled trial.  Lancet 2002; 360:7-22. 
 
162. Heart Protection Study Collaborative Group.  MRC/BHF Heart Protection Study 
of cholesterol lowering with simvastatin in 5,963 people with diabetes: a 
randomised placebo-controlled trial.  Lancet 2003; 361: 2005-2016. 
 
163. Colhoun HM, Betteridge DJ, Durrington PN et al.  Primary prevention of 
cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative 
atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled 
trial.  Lancet 2004; 364:685-696. 
 
164. The prevention of progression of arterial disease and diabetes (POPADAD) 
trial: factorial randomised placebo controlled trial of aspirin and antioxidants in 
patients with diabetes and asymptomatic peripheral arterial disease.  BMJ 2008; 
337:a1804. 
 
165. Strippoli GFM, et al.  Angiotensin converting enzyme inhibitors and angiotensin 
II receptor antagonists for preventing progression of diabetic kidney disease. 
Cochrane Database of Systematic Reviews 2006 Issue 4. Art. No.:CD006527. 
 
166. Chronic kidney disease in adults.  UK guidelines for identification, management 
and referral.  Joint Speciality Committee on Renal Medicine of the Royal College of 
Physicians  of London and the Renal Association. March 2006. 
 
167. National Institute for Health and Clinical Excellence.  Type 2 diabetes.  National 
clinical guideline for the management in primary and secondary care (update).  
NICE Clinical Guideline 66. May 2008. 
 
168. National Institute for Health and Clinical Excellence Chronic kidney disease. 
NICE clinical guideline 73 (2008).  Available from www.nice.org.uk/CG73. 
 
169. National Prescribing Centre/NICE. MeReC Bulletin. Implementing key 
therapeutic topics:3 Type 2 diabetes Vol.22 No.05 March 2012. 
 
170. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davies B, Day 
R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ.  Comparison of 
upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid 
arthritis: VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528. 
 
171. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch 
R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, 
Verburg KM, Geis GS.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-
inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A 
randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. 
JAMA. 2000 Sep 13; 284(10):1247-55. 
 
172. National Institute for Health and Clinical Excellence.  Guidance on the use of 
cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and 
etodolac for osteoarthritis and rheumatoid arthritis.  NICE Technology Appraisal 27. 
July 2001. www.nice.org.uk. 
 
                                                                                                                                        336 
173. National Prescribing Centre.  MeRec Briefing Issue No. 20. October 2002. 
 
174. National Prescribing Centre.  MeReC Extra Issue No. 30. November 2007. 
 
175. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C.  Do 
selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-
inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of 
randomised trials.  BMJ 2006 Jun 3; 332(7553): 1302-8. 
 
176. MHRA/CSM (2005) Duff G. Chairman Committee on Safety of Medicines.  
Updated advice on the safety of selective COX-2 Inhibitors. Health Professional 
Letter 17 February 2005  www.mhra.gov.uk. 
 
177. MHRA/CSM (2002) Non-steroidal anti-inflammatory drugs (NSAIDs) and 
gastrointestinal (GI) safety.  Current Problems in Pharmacovigilance April 2002; 
28:5. 
 
178. MHRA/CSM (2003) Reminder: Gastrointestinal toxicity and NSAIDs.  Current 
Problems in Pharmacovigilance September 2003; 29:8-9. 
 
179. MHRA/CSM. (2006a) Cardiovascular safety of NSAIDs and selective COX-2 
Inhibitors.  Current Problems in Pharmacovigilance May 2006; 31:7. 
 
180. MHRA/CHM  (2006b) Duff G. Chairman Commission on Human Medicines. 
Safety of selective and non-selective NSAIDs: Health professional letter.  24 
October 2006 www.mhra.gov.uk. 
 
181. MHRA/CHM (2007) NSAIDs and coxibs: balancing of cardiovascular and 
gastrointestinal risks.  Drug Safety Update 1(5)13. 
 
182. MHRA/CHM (2009a) Non-steroidal anti-inflammatory drugs: cardiovascular risk. 
Drug Safety Update 2(7)3. 
 
183. MHRA/CHM (2009b) Non-steroidal anti-inflammatory drugs: reminder on renal 
failure and impairment. Drug Safety Update 2(10)4. 
 
184. National Institute for Health and Clinical Excellence.   Osteoarthritis.  The care 
and management of osteoarthritis in adults. NICE Clinical Guideline 59. February 
2008.  www.nice.org.uk. 
 
185. National Institute for Health and Clinical Excellence.  Rheumatoid Arthritis.  The 
management of rheumatoid arthritis in adults.  NICE Clinical Guideline 79. February 
2009. www.nice.org.uk. 
 
186. BNF 62  British National Formulary 62nd Edition September 2011. British 
Medical Association and Royal Pharmaceutical Society of Great Britain. 
 
187. National Prescribing Centre. Using Evidence to Guide Practice - Supplement 
MeReC Briefing 2005; 30:1-7. 
 
188. Greenhalgh, T. 1997. How to read a paper: getting your bearings (deciding 
what the paper is about). BMJ 1997; 315:243. 
 
                                                                                                                                        337 
189. Anthony D. Harris, Jessina C. McGregor, Eli N. Perencevich, Jon P. Furuno, 
Jingkun Zhu, Dan E. Peterson, and Joseph Finkelstein.  The Use and Interpretation 
of Quasi-Experimental Studies in Medical Informatics.  Am Med Inform Assoc. 2006 
Jan-Feb; 13(1): 16–23. doi:  10.1197/jamia.M1749  PMCID: PMC1380192. 
 
190. Jeremy Grimshaw, Marion Campbell, Martin Eccles and Nick Steen. 
Experimental and quasi-experimental designs for evaluating guideline 
implementation strategies. Family Practice Vol. 17 Suppl. S11-S16. Oxford 
University Press. 2000. 
 
191. Web Center for Social Research Methods  Quasi-Experimental Design 
http://www.socialresearchmethods.net/kb/quasiexp.php   Accessed 14.08.12.  
 
192. NHS Business Services Authority 
http://62.164.179.2/PrescriptionServices/815.aspx  Accessed 12.07.12. 
 
193. NHS Business Services Authority 
http://www.ppa.org/uk/systems/glossary/glossary.html   Accessed 12.07.12. 
 
194. NHS Business Services Authority.  Prescription Services. ePACT.net.   
http://www.nhsbsa.nhs.uk/3230.aspx   Accessed 15th May 2013. 
 
195. Silverman D. (2010) Doing Qualitative Research. A Practical Handbook. Third 
Edition. London. Sage. 
 
196. Miles MB, Huberman AM. (1994) Qualitative Data Analysis. Second Edition. 
London. Sage. 
 
197. Bowling A.  (2002) Research Methods in Health: Investigating Health and 
Health Services. Second Edition. Open University Press. 
 
198. National Institute for Health Research. Lacey A. and Luff D. Qualitative Data 
Analysis. The NIHR RDS for the East Midlands / Yorkshire & the Humber, 2007. 
 
199. Pope C, Zeibland S, Mays N.  Analysing Qualitative Data. BMJ 2000; 320:114-
116. 
 
200. Lingard L, Albert M, Levinson W.  Grounded theory, mixed methods, and action 
research. BMJ 2008;337:459-461. 
 
201. Glaser B and Strauss A. (1967) The Discovery of Grounded Theory: Strategies 
for qualitative research. New York. Aldine de Gruyter. 
 
202. Corbin J and Strauss A. (1990) Basics of Qualitative Research. Techniques and 
Procedures for Developing Grounded Theory. London. Sage. 
 
203. McCann T, Clark E Grounded theory in nursing research: Part 2 – Critique. 
Nurse Researcher. 2003; 11(2):19-27. 
 
204. McCann T, Clark E.  Grounded theory in nursing research: Part 1 – 
Methodology.  Nurse Researcher. 2003; 11(2):7-18. 
 
205. McCann T, Clark E Grounded theory in nursing research: Part 3 – Application. 
Nurse Researcher. 2003; 11(2):29-39. 
                                                                                                                                        338 
 
206. Green J, Britten N. Qualitative research and evidence based medicine. BMJ 
1998; 316:1230-1232. 
 
207. The NHS Knowledge and Skills Framework (NHS KSF) and the Development 
Review Process.  Department of Health October 2004. 
 
208. Pallant J. SPSS Survival Manual A step by step guide to data analysis using 
SPSS.  4th Edition. 2010 Open University Press McGraw Hill. 
  
209. Pallant J. SPSS Survival Manual A step by step guide to data analysis using 
SPSS. Part 5 P204.  4th Edition. 2010a Open University Press McGraw Hill. 
 
210.  Pallant J. SPSS Survival Manual A step by step guide to data analysis using 
SPSS. P230.  4th Edition. 2010b Open University Press McGraw Hill. 
 
211. Royal College of General Practitioners. Evidence-Based Practice. Curriculum 
Statement 3.5. 2007 London. 
 
212. Dawes M, Summerskill W, Glasziou P et al. Sicily statement on evidence based 
practice. BMC Med Educ 2005; 5:1. 
 
213. Djulbegovic B, Guyatt GH, Ashcroft RE.  Epistemologic Inquiries in Evidence-
Based Medicine.  Cancer Control 2009; 16(2):158-168. 
 
214. Greenhalgh T, Robert G, MacFarlane F, Bate P, Kyriakidou O. Diffusion of 
innovations in service organisations: systematic review and recommendations. The 
Milbank Quarterley. 2004; 82(4):51-629. 
 
215. McAlister FA, Graham I, Karr GW, Laupacis A.  Evidence-Based Medicine and 
the Practicing Physician.  Journal of General Internal Medicine. 1999; 14(4):236-
242. 
 
216. Smith R.  What clinical information do doctors need? BMJ 1996; 313:1602-
1608. 
 
217. Maskray N, Hutchinson A, Underhill J. Shaughnessy A, Slawson D. Getting a 
better grip on research: the maze of the most busy life.  2010 InnovAit; 3 (3):172-
179. 
 
218. Charles C. Gafni A, Freeman E.  The evidence-based model of clinical practice: 
scientific teaching or belief-based preaching? Journal of Evaluation in Clinical 
Practice. 2011; 17:597-605. 
 
219. Eddy DM. Evidence-Based Medicine: A Unified Approach.  Two approaches to 
using evidence to solve clinical problems and how to unify them.  Health Affairs 
2011; 24(1):9-17. 
 
220. Paper - Selvaraj S, Yeshwant Kumar NNT, Elakiya M, Prarthana Saraswathi C, 
Balaji D, Nagamani P.  Evidence-based medicine - a new approach to teach 
medicine: a basic review for beginners.  Biology and Medicine 2010; 2 (1):1-5. 
 
221. Ilott I.  Evidence-based Practice: A Critical Appraisal. Occupational Therapy Int. 
2012;19:1-6. 
                                                                                                                                        339 
 
222. Maskray N, Hutchinson A, Underhill J. Shaughnessy A, Slawson D. Getting a 
better grip on research: A simple system that works.  2009 InnovAit; 2(12):739-749. 
 
223. Maskray N, Hutchinson A, Underhill J.  Getting a better grip on research: the 
comfort of opinion.  2009 InnovAit; 2(11):679-686. 
 
224. National Prescribing Centre. Supporting Adoption of Evidence into Practice.  
MeReC Bulletin 2011;22(2) 
 
225. Maskray N, Greenhalgh T. Getting a better grip on research: the fate of those 
who ignore history.  2009 InnovAit; 2(10):619-625. 
 
226. National Prescribing Centre. Making decisions better. MeReC Bulletin 
2011;22(1) 
 
227. Kitson AL, Rycroft-Malone J, Harvey G, McKormack B, Seers K, Titchen A. 
Evaluating the successful implementation of evidence into practice using the 
PARiHS framework: theoretical and practical challenges. Implementation Science 
2008; 3:1-12. 
 
228. Rycroft-Malone J, Seers K, Chandler J, Hawkes CA, Chricton N, Allen C, 
Bullock I, Strunin L.  The role of evidence, context and facilitation in an 
implementation trial: implications for the development of the PARIHS framework. 
Implementation Science 2013; 8:28 
 
229. Titler M. Translating Research into Practice. Models for changing clinician 
behaviour. American Journal of Nursing. 2007;107 (6):26-32. 
 
230. Stetler CB, Damschroder LJ, Helfrich CD, Hagedorn HJ. A Guide for applying a 
revised version of the PARIHS framework for implementation. Implementation 
Science 2011; 6:99. 
 
231. Rycroft-Malone J. The PARIHS Framework – A Framework for Guiding the 
Implementation of Evidence-based Practice Rycroft-Malone J. J. Nurse Care Qual. 
2004; 4:297-304. 
 
232. Greenhalgh T, McFarlane F, Maskray N.. 2009 InnovAit; 3 (2):102-107. 
 
233. National Prescribing Centre. Getting evidence adopted into practice: a complex 
problem not just a complicated one. NPC Rapid Review 2012. 
http://www.npc.nhs.uk/rapidreview Accessed 02.08.12 
 
234. Eva KW. What every teacher needs to know about clinical reasoning. Medical 
education 2004; 39:98-106. 
 
235. Bate L, Hutchinson A, Underhill J, Maskrey N.  How clinical decisions are made.  
British Journal of Clinical Pharmacology. 2012; 74(4):614-620. 
  
236. Croskerry P. A Universal Model of Diagnostic Reasoning.  Academic Medicine 
2009; 84 (8): 1022-1028. 
 
                                                                                                                                        340 
237. Croskerry P.  Clinical cognition and diagnostic error: applications of a dual 
process of reasoning. Advances in Health Science Education. 2009 Springer     
DOI 10.1007/s10459-009-9182-2. 
 
238. Croskerry P.  Context is Everything or How Could I have Been That Stupid?  
Healthcare Quarterly 2009; 12 :e171-e176. 
 
 
 
